

**ジブロモメタンの p53 ヘテロ欠損マウスを  
用いた吸入による中期発がん性試験報告書**

**試験番号：0944**

**CAS No. 74-95-3**

**2022 年 6 月 16 日**

**独立行政法人労働者健康安全機構  
日本バイオアッセイ研究センター**

目次

標題	.....
試験目的	.....
試験法	.....
<b>GLP 対応</b>	.....
拡散防止措置及び動物福祉	.....
厚生労働省担当課	.....
試験施設及び運営管理者	.....
試験日程	.....
試験関係者一覧	.....
試資料の保管	.....
試験責任者（最終報告書作成者）の署名、捺印及び日付	.....
陳述書	.....
信頼性保証証明書	.....
本文	.....
<b>TABLES</b>	<b>A 1 ~ A 37, B 1 ~ B 28</b>
<b>FIGURES</b>	<b>1 ~ 7</b>
<b>PHOTOGRAPHS</b>	<b>1 ~ 4</b>
<b>APPENDICES</b>	<b>1-1 ~ 14-2</b>

（ APPENDIX 5-1 ~ 14-2（個体表）は、報告書添付の CD に収録）

## 標題

ジプロモメタンの p53 ヘテロ欠損マウスを用いた吸入による中期発がん性試験

## 試験目的

本試験は、ジプロモメタンを遺伝子改変マウス (p53 ヘテロ欠損マウス) に 26 週間全身暴露 (経気道投与) し、その発がん性を検索した。

## 試験法

本試験は「遺伝子改変動物を用いたがん原性試験による調査の基準」(平成 28 年度第 3 回発がん性評価ワーキンググループ: 2017 年 3 月 1 日厚生労働省) に準拠して実施した。

## GLP 対応

本試験は、「労働安全衛生規則第 34 条の 3 第 2 項の規定に基づき試験施設等が具備すべき基準 (安衛法 GLP)」(昭和 63 年 9 月 1 日労働省告示第 76 号、最終改正平成 28 年 4 月 18 日厚生労働省告示第 208 号) に準拠し、OECD GLP (1997 年 11 月 26 日採択) を参考にして実施した。

## 拡散防止措置及び動物福祉

本試験は、「日本バイオアッセイ研究センターにおける遺伝子組換え生物使用実験安全管理規程」(平成 26 年 9 月 3 日制定、最終改正平成 28 年 4 月 1 日) 及び「実験動物の飼養及び保管並びに苦痛の軽減に関する基準」(平成 18 年 4 月 28 日環境省告示第 88 号、最終改正平成 25 年 8 月 30 日環境省告示第 84 号)、「厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針」(平成 18 年 6 月 1 日厚生労働省大臣官房厚生科学課長通知、最終改正平成 27 年 2 月 20 日厚生労働省大臣官房厚生科学課長通知) 及び「日本バイオアッセイ研究センターにおける動物実験等に関する規程」(平成 24 年 4 月 25 日制定、最終改正令和元年 7 月 11 日) を遵守して行った。

また、本試験は日本バイオアッセイ研究センターの遺伝子組換え生物使用実験安全委員会 (承認番号 2020-04) 及び日本バイオアッセイ研究センターの動物実験委員会で審査された (承認番号 0284)。

厚生労働省担当課

厚生労働省労働基準局安全衛生部化学物質対策課  
東京都千代田区霞が関 1-2-2

ジプロモメタンの p53 ヘテロ欠損マウスを用いた吸入による中期発がん性試験報告書

試験番号：0944

本文

## 本文目次

	頁
要約 .....	1
試験材料 .....	4
-1 被験物質 .....	4
-1-1 被験物質の名称等 .....	4
-1-2 被験物質の構造式及び分子量 .....	4
-1-3 被験物質の物理化学的性状等 .....	4
-1-4 被験物質の使用ロット等 .....	4
-1-5 被験物質の製造量等 .....	4
-1-6 被験物質の主な用途 .....	4
-1-7 許容濃度、発がん分類 .....	5
-1-8 被験物質の特性 .....	5
(1) 同一性 .....	5
(2) 安定性 .....	5
-2 陽性対照物質及び調製媒体 .....	5
-2-1 陽性対照物質の名称等 .....	5
-2-2 陽性対照物質の構造式及び分子量 .....	5
-2-3 陽性対照物質の物理化学的性状等 .....	6
-2-4 陽性対照物質の使用ロット等 .....	6
-2-5 陽性対照物質の調製媒体 .....	6
-2-6 陽性対照物質の特性 .....	6
(1) 同一性 .....	6
(2) 安定性 .....	6
-3 試験動物 .....	7
試験方法 .....	8
-1 投与 .....	8
-1-1 投与経路 .....	8
-1-2 投与方法 .....	8
-1-3 投与期間及び投与回数 .....	8
-1-4 投与濃度(用量) .....	8
-1-5 投与経路、投与期間及び投与濃度(用量)の設定理由 .....	8

-1-6	被験物質の発生方法と濃度調整	9
-1-7	被験物質濃度の測定	9
-1-8	陽性対照物質投与液の調製	9
-1-9	陽性対照物質投与液の濃度及び均一性確認	10
-2	動物管理	10
-2-1	群の構成及び各群の使用動物数	10
-2-2	群分け方法	10
-2-3	動物の個体識別	10
-2-4	使用飼育室及び他試験・異種動物との区別	11
-2-5	飼育条件	11
(1)	飼育環境	11
(2)	飼料	12
(3)	飲水	12
-3	観察・検査項目及び方法	12
-3-1	動物の生死及び一般状態の観察	12
-3-2	体重測定	12
-3-3	摂餌量測定	12
-3-4	血液学的検査	12
-3-5	血液生化学的検査	13
-3-6	病理学的検査	13
(1)	肉眼的観察	13
(2)	臓器重量	13
(3)	病理組織学的検査	13
-3-7	病理ピアレビュー	13
-4	数値処理と統計方法	14
-4-1	数値の取扱いと表示	14
-4-2	統計処理	14
	試験成績-1(被験物質投与群)	16
-1	生死状況	16
-2	一般状態	16
-3	体重	16
-4	摂餌量	17
-5	血液学的検査	17
-6	血液生化学的検査	18

-7 病理学的検査 .....	18
-7-1 肉眼的観察 .....	18
-7-2 臓器重量 .....	19
-7-3 病理組織学的検査 .....	19
(1) 腫瘍性病変 .....	19
(2) 非腫瘍性病変 .....	20
-7-4 死因 .....	22
試験成績-2 (陽性対照群) .....	23
-1 生死状況 .....	23
-2 一般状態 .....	23
-3 体重 .....	23
-4 摂餌量 .....	24
-5 血液学的検査 .....	24
-6 血液生化学的検査 .....	24
-7 病理学的検査 .....	25
-7-1 肉眼的観察 .....	25
-7-2 臓器重量 .....	25
-7-3 病理組織学的検査 .....	26
(1) 腫瘍性病変 .....	26
(2) 非腫瘍性病変 .....	27
-7-4 死因 .....	27
考察及びまとめ .....	28
-1 生存率、一般状態、体重等 .....	28
-2 腫瘍性病変 .....	28
-3 その他の影響 .....	29
-4 陽性対照群 ( <i>N</i> -ニトロソ- <i>N</i> -メチル尿素) の評価 .....	30
結論 .....	30
文献 .....	31
予見することのできなかつた試験の信頼性に影響を及ぼす疑いのある事態 及び試験計画書に従わなかつたこと .....	33



## 要 約

ジプロモメタンの発がん性を検索する目的で、遺伝子改変マウス(p53ヘテロ欠損マウス)を用いた26週間全身暴露(経気道投与)による中期発がん性試験を行った。

対照群1群、被験物質投与群3群及び陽性対照群の計5群を設け、対照群と被験物質投与群は1群当たり雌雄各25匹、陽性対照群は雌雄各20匹とした。ジプロモメタンの投与濃度は、0(対照群)、100、300及び1,000 ppm(体積比v/v)とし、投与期間は26週間(6時間/日、5日/週)とした。陽性対照物質(N-ニトロソ-N-メチル尿素)の投与用量は雌雄とも75 mg/kg体重とし、単回腹腔内投与した後、26週間飼育した。飼育期間中、生死及び一般状態の観察、体重及び摂餌量の測定を行い、26週間の試験終了後に動物を解剖し、血液学的検査、血液生化学的検査、肉眼的観察、臓器重量の測定及び病理組織学的検査を行った。

その結果、最終生存率は雌雄とも1,000 ppm群で対照群と比較して低下が認められた。同群の死因の多くは雌雄とも悪性リンパ腫によるものであった。一般状態は、雌雄ともすべての投与群で投与に関連した特徴的な所見はみられなかった。体重は、雄では1,000 ppm群で投与8週以降に有意な低値がみられたが、雌では各投与群とも対照群とほぼ同様の推移であった。摂餌量は、雌雄とも300 ppm以上の群で投与期間の多くの週で有意な高値が認められた。

病理組織学的検査では、腫瘍性病変として、雄で胸腺の悪性リンパ腫の発生が1,000 ppm群で有意な増加(Fisher検定)、傾向検定(Peto, Cochran-Armitage検定)で増加傾向を示した。さらに、胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生が、1,000 ppm群で有意な増加、傾向検定で増加傾向を示した。雌では、胸腺の悪性リンパ腫の発生が1,000 ppm群で有意な増加、傾向検定で増加傾向を示した。さらに、脾臓で悪性リンパ腫の発生が1,000 ppm群で2匹にみられ、傾向検定で増加傾向を示した。また、胸腺あるいは脾臓における悪性リンパ腫を合わせた発生が、1,000 ppm群で有意な増加、傾向検定で増加傾向を示した。

非腫瘍性病変では、雌雄とも生殖器系への影響が認められた。雄では、精巣の精細管萎縮が300 ppm以上の群で増加し、1,000 ppm群ではその程度が増強した。また、100 ppm以上の群で精巣重量の低値がみられた。さらに、精巣の精細管萎縮に伴って、精巣上で精子数の減少と精上皮系細胞の残屑が300 ppm以上の群で増加した。雌では、卵巣の萎縮が300 ppm以上の群で増加し、1,000 ppm群ではその程度が増強した。また、300 ppm以上の群で卵巣重量が低値を示した。さらに、子宮の萎縮及び膣の上皮萎縮が1,000 ppm群で増加した。その他、雌雄の1,000 ppm群で、前胃の過形成、唾液腺の顎下腺と舌下腺で腺房細胞の過形成の増加がみられた。

以上より、遺伝子改変マウス(p53ヘテロ欠損マウス)を用いて、ジプロモメタンの26週間の吸入による中期発がん性試験を行った結果、雄では、1,000 ppm群で胸腺の悪性リンパ腫、及び胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生増加が認められ、ジプロモメタンの雄p53ヘテロ欠損マウスへの発がん性を示す明らかな証拠が得られた(clear evidence of carcinogenic activity)と結論した。雌では、1,000 ppm群で胸腺と脾臓の悪性リンパ腫、及び胸腺あるいは脾臓における悪性リンパ腫を合わせた発生増加が認められ、ジプロモメタンの雌p53ヘテロ欠損マウスへの発がん性を示す明らかな証拠が得られた(clear evidence of carcinogenic activity)と結論した。

## ジプロモメタンの中期発がん性試験における腫瘍発生 (p53 ヘテロ欠損マウス 雄)

投与濃度 (ppm)		0	100	300	1,000	Peto 検定	Cochran- Armitage 検定
検査動物数		25	25	25	25		
鼻腔	鼻腔神経上皮腫 #	0	0	0	1		
肺	細気管支-肺胞上皮腺腫	0	0	0	1		
小腸	腺癌 #	0	0	1	0		
リンパ節	悪性リンパ腫 #	0	0	0	1		
胸腺	悪性リンパ腫 #	0	0	1	21 **	↑↑	↑↑
	組織球肉腫 #	0	0	0	1		
縦隔	組織球肉腫 #	1	0	0	0		
筋組織 (下顎)	横紋筋肉腫 #	0	0	0	1		
胸腺 + リンパ節	悪性リンパ腫 #	0	0	1	22 **	↑↑	↑↑

## ジプロモメタンの中期発がん性試験における腫瘍発生 (p53 ヘテロ欠損マウス 雌)

投与濃度 (ppm)		0	100	300	1,000	Peto 検定	Cochran- Armitage 検定
検査動物数		25	25	25	25		
皮膚/ 付属器	基底細胞癌 #	0	0	0	1		
肺	細気管支-肺胞上皮腺腫	0	0	1	0		
小腸	腺癌 #	0	0	1	0		
皮下組織	肉腫 NOS	0	0	0	1		
胸腺	悪性リンパ腫 #	1	1	0	14 **	↑↑	↑↑
脾臓	悪性リンパ腫 #	0	0	0	2	↑↑	↑
肝臓	血管腫	0	0	0	1		
脳	膠芽腫	0	0	1	0		
胸腺 + 脾臓	悪性リンパ腫 #	1	1	0	16 **	↑↑	↑↑

上段：上皮系腫瘍      中段：非上皮系腫瘍      下段：臓器合計 (非上皮系腫瘍)

#：悪性腫瘍

\*：p 0.05 で有意増加

\*\*：p 0.01 で有意増加 (Fisher 検定)

↑：p 0.05 で有意増加

↑↑：p 0.01 で有意増加 (Peto, Cochran-Armitage 検定)

↓：p 0.05 で有意減少

↓↓：p 0.01 で有意減少 (Cochran-Armitage 検定)

陽性対照物質（*N*-ニトロソ-*N*-メチル尿素）投与群における腫瘍発生  
（p53 ヘテロ欠損マウス 雄）

投与用量 (mg/kg)		対照群 0	陽性対照群 75
検査動物数		25	20
胃	扁平上皮乳頭腫	0	1
小腸	腺癌 #	0	1
	腺腫	0	1
	腺癌 #	0	15 **
	腺腫 + 腺癌 #	0	16 **
リンパ節	悪性リンパ腫 #	0	1
胸腺	悪性リンパ腫 #	0	9 **
縦隔	組織球性肉腫 #	1	0
胸腺 + リンパ節	悪性リンパ腫 #	0	10 **

上段：上皮系腫瘍      中段：非上皮系腫瘍      下段：臓器合計（非上皮系腫瘍）

陽性対照物質（*N*-ニトロソ-*N*-メチル尿素）投与群における腫瘍発生  
（p53 ヘテロ欠損マウス 雌）

投与用量 (mg/kg)		対照群 0	陽性対照群 75
検査動物数		25	20
肺	細気管支-肺胞上皮腺腫	0	1
小腸	腺癌 #	0	7 **
膵臓	導管腺癌 #	0	1
胸腺	悪性リンパ腫 #	1	18 **

上段：上皮系腫瘍      下段：非上皮系腫瘍

#：悪性腫瘍

\*：p 0.05 で有意      \*\*：p 0.01 で有意      （Fisher 検定）

## 試験材料


## -1 被験物質

## -1-1 被験物質の名称等 (文献 1, 2)

名 称 : ジブロモメタン (Dibromomethane)  
別 名 : 臭化メチレン (Methylene dibromide)  
CAS No. : 74-95-3

## -1-2 被験物質の構造式及び分子量

構造式 :

化学式 :  $\text{CH}_2\text{Br}_2$ 

分子量 : 173.83

## -1-3 被験物質の物理化学的性状等

性 状 : 透明で無色の液体  
沸 点 : 97°C  
蒸 気 圧 : 4.7 kPa (20°C)  
溶 解 性 : 水 : 11.70 g/1,000 g (15°C)、11.93 g/1,000 g (30°C)  
保 管 条 件 : 室温

## -1-4 被験物質の使用ロット等

製 造 元 : 富士フィルム和光純薬 (株)  
純 度 : 99.6% (富士フィルム和光純薬 (株) 検査成績データ)  
ロット番号 : SKG4416

## -1-5 被験物質の製造量等 (文献 3)

製造、輸入量 : 届出事業者数が 2 社以下により非公表 (2020 年度)

## -1-6 被験物質の主な用途 (文献 4)

水処理剤、医薬品等の中間体

### －1－7 許容濃度、発がん分類

許容濃度等：米国産業衛生専門家会議（ACGIH）：未設定

ドイツ研究振興協会（DFG）：未設定

日本産業衛生学会：未設定

発がん分類：国際がん研究機関（IARC）、米国国家毒性プログラム（NTP）、ACGIH、日本産業衛生学会：評価していない

### －1－8 被験物質の特性

#### （1）同一性

被験物質の同一性は、赤外吸収スペクトルを赤外分光光度計（株）島津製作所 IRAffinity-1）を用いて測定し、文献値（文献5）と比較することにより確認した。その結果は APPENDIX 1-1 に示す。

被験物質の赤外吸収スペクトルは文献値と同じ波数にピークを示したことから、被験物質はジプロモメタンであることを確認した。

#### （2）安定性

被験物質の安定性は、使用開始前及び使用終了後に赤外吸収スペクトルを赤外分光光度計（株）島津製作所 IRAffinity-1）を用いて測定し、それぞれのデータを比較することにより確認した。その結果は APPENDIX 1-2 に示す。

使用開始前と使用終了後の赤外吸収スペクトルに差はみられず、使用期間中の被験物質は安定であることを確認した。

## －2 陽性対照物質及び調製媒体

### －2－1 陽性対照物質の名称等（文献6,7）


名 称：N-ニトロソ-N-メチル尿素（N-Nitroso-N-methylurea）

別 名：MNU、N-メチル-N-ニトロソ尿素（N-Methyl-N-Nitrosourea）

CAS No.：684-93-5

### －2－2 陽性対照物質の構造式及び分子量（文献6,7）

構 造 式：



化 学 式：C<sub>2</sub>H<sub>5</sub>N<sub>3</sub>O<sub>2</sub>

分 子 量：103.08

－2－3 陽性対照物質の物理化学的性状等（文献 6, 7）

性 状 : 淡黄色固体  
融 点 : 119 ~ 124°C  
沸 点 : 193.27°C  
溶 解 性 : 水に可溶 (14.56 g/L)  
保 管 条 件 : 冷蔵 (2 ~ 8°C)

－2－4 陽性対照物質の使用ロット等

製 造 元 : Sigma-Aldrich Co. LLC.  
ロット番号 : MKBQ7120V

－2－5 陽性対照物質の調製媒体

名 称 : 0.1 M ぐえん酸緩衝液 pH4.5  
製 造 元 : 武藤化学 (株)  
ロット番号 : 201002  
保 管 条 件 : 冷蔵かつ遮光

－2－6 陽性対照物質の特性

(1) 同一性

陽性対照物質の同一性は、赤外吸収スペクトルを赤外分光光度計（(株)島津製作所 IRAffinity-1）を用いて測定し、文献値（文献 8）と比較することにより確認した。その結果は APPENDIX 2-1 に示す。

陽性対照物質の赤外吸収スペクトルは文献値と同じ波数にピークを示したことから、陽性対照物質は *N*-ニトロソ-*N*-メチル尿素であることを確認した。

(2) 安定性

陽性対照物質は、投与日に用時調製したため安定性の確認は行わなかった。

### －3 試験動物

動物は、日本チャールス・リバー (株)(筑波 SAS センター)の B6.129S2-Trp53 *tm1Tyj/J* マウス (p53 ヘテロ欠損マウス、p53 KO マウス) (SPF) の雌雄を使用した。

雌雄各 140 匹を 6 週齢で導入し、8 日間を検疫と馴化を兼ねて飼育し、その後群分けまで待機飼育した。群分け前の飼育期間中に状態異常のみられた動物を除いて、体重値の中央値に近い雌雄各 120 匹 (群分け時体重範囲、雄：23.1 ~ 27.1 g、雌：18.6 ~ 22.7 g) を選別し、試験に用いた。

中期発がん性試験に p53 ヘテロ欠損マウスを選択した理由は、中期発がん性試験としての有用性が検証されていることによる (文献 9)。

## 試験方法

### －1 投与

#### －1－1 投与経路

投与経路は全身暴露による経気道投与とした。また、陽性対照物質は腹腔内投与とした。

#### －1－2 投与方法

投与は、試験動物を収容した吸入チャンバー内に、設定濃度に調整した被験物質を含む空気を送り込み、動物に全身暴露することにより行った。

陽性対照物質は、くえん酸緩衝液（pH4.5）に溶解させたのち、27G注射針を装着したディスプレイザブル注射筒（ニプロ(株)製、1 mL）を用いて腹腔内投与した。投与液量は、10 mL/kg 体重とし、投与日の体重に基づいて個体別に算出した。

#### －1－3 投与期間及び投与回数

投与期間は26週間（2020年12月1日～2021年5月31日）とし、投与は1日6時間、1週5日、計130回とした。

陽性対照群は、群分け翌日（2020年12月1日）の12時から16時の時間帯に単回投与した。

#### －1－4 投与濃度（用量）

投与濃度は100、300及び1,000 ppm（体積比 v/v）の3段階に設定した。なお、対照群は清浄空気による換気のみとした。

陽性対照物質の投与用量は、雌雄ともに75 mg/kg 体重とした。

#### －1－5 投与経路、投与期間及び投与濃度（用量）の設定理由

投与経路は、被験物質を生産、使用する作業環境における労働者への主な暴露経路に合わせ、全身暴露による経気道投与とした。

投与期間は、「遺伝子改変動物を用いたがん原性試験による調査の基準」に準拠して26週間とした（文献10）。

投与時間はOECD 化学品テストガイドライン451（文献11）を参考に1日6時間とした。

投与濃度はC57BL/6J マウスを用いた4週間毒性試験（試験番号0937、投与濃度250、500、1,000、2,000 ppm）の結果を基に設定した（文献12）。その結果、2,000 ppm 群では暴露後に麻酔様症状が観察され、翌朝には状態回復しているものの徐々に衰弱し、投与期間途中で瀕死動物が認められたことから投与を中止した。1,000 ppm 以下の群では一般状



態や体重の推移に対照群との差はみられなかった。血液学的検査で雌雄ともに中等度の貧血と血小板数の減少が認められた。また、臓器重量では雄の全投与群で精巣の実重量と体重比の低値がみられ、雄の 500 ppm 以上の群、雌の 1,000 ppm 群で肝臓の実重量、雄の 1,000 ppm 群、雌の 500 ppm 以上の群で肝臓の体重比が高値を示した。病理組織学的検査では雌雄の 1,000 ppm 群に脾臓の髓外造血、雌の 1,000 ppm 群に骨髄の造血減少がみられ、雄の全投与群の精巣では精細管の萎縮がみられたが、これらの変化は動物の生存に影響しないと判断した。なお、肝臓では異常はみられなかった。

以上の結果から、本試験は最高投与濃度を 1,000 ppm とし、中濃度に血液学的検査、病理組織学的検査で変化がみられた 250 ppm 付近と、最低濃度にはより低い濃度が必要と判断し、以下、300 及び 100 ppm に設定した。

陽性対照物質の投与方法及び投与用量は、文献（文献 13）及び当センターにおける予備検討に基づいて、雌雄ともに 75 mg/kg 体重での単回腹腔内投与とした。

#### －1－6 被験物質の発生方法と濃度調整

ジプロモメタンの発生方法を FIGURE 1 に示す。

被験物質供給装置（柴田科学（株）特注）の発生容器内の被験物質を循環式恒温槽で加温しながら、清浄空気のバブリングにより蒸発させた。この被験物質の蒸気を循環式恒温槽で一定温度に冷却した後、清浄空気（希釈空気）と混合しながら再加温し、一定濃度にした後、流量計を用いて一定量を各吸入チャンバー上部のラインミキサーに供給した。吸入チャンバー内の被験物質濃度はガスクロマトグラフで監視し、その濃度データをもとに設定濃度になるように被験物質の吸入チャンバーへの供給量を調節した。

#### －1－7 被験物質濃度の測定

吸入チャンバー内の被験物質濃度は、自動サンプリング装置付ガスクロマトグラフ（株）島津製作所 GC-14B）により、暴露開始前から暴露終了後まで 15 分毎に測定した。濃度測定結果を TABLE A1 に示す。

各投与群の被験物質濃度は、その平均値と設定濃度の差（ $(\text{平均値} - \text{設定濃度}) / \text{設定濃度} \times 100$ ）が 0.2%以内、変動係数（標準偏差 / 平均値  $\times 100$ ）が 0.6%以内であり、吸入チャンバー内濃度は良好に管理された。

#### －1－8 陽性対照物質投与液の調製

陽性対照物質投与液は、秤量した *N*-ニトロソ-*N*-メチル尿素にくえん酸緩衝液（pH4.5）を加えて、マグネチックスターラーで攪拌・混合、または超音波処理を行うことで溶解させ、7.5 mg/mL の濃度に調製した。なお、投与液は投与日に用時調製した。

### －1－9 陽性対照物質投与液の濃度及び均一性確認

陽性対照物質投与液の濃度及び均一性確認は、調製時に調製容器内から 3 点サンプリングし、高速液体クロマトグラフ（(株)島津製作所 LC-10）を用いて濃度を測定することで確認した。

陽性対照物質投与液の濃度は APPENDIX 2-2、均一性は APPENDIX 2-3 示す。

陽性対照物質投与液の平均濃度は、設定濃度に対して 106 % であり、均一性は変動係数が 0.125 % であった。従って、陽性対照物質投与液は設定濃度に対して正確に調製されたことを確認した。

## －2 動物管理

### －2－1 群の構成及び各群の使用動物数

対照群 1 群、被験物質投与群 3 群及び陽性対照群 1 群の計 5 群を設け、1 群当たりの動物数は、対照群と被験物質投与群は雌雄各 25 匹、陽性対照群は雌雄各 20 匹の動物を用いた。

群 名 称	動物数（動物番号）	
	雄	雌
対 照 群	25 匹（1001～1025）	25 匹（2001～2025）
100 ppm 群	25 匹（1101～1125）	25 匹（2101～2125）
300 ppm 群	25 匹（1201～1225）	25 匹（2201～2225）
1,000 ppm 群	25 匹（1301～1325）	25 匹（2301～2325）
陽性対照群	20 匹（1401～1420）	20 匹（2401～2420）

### －2－2 群分け方法

群分けは、体重の重い順より各群に 1 匹ずつ割り当て、二巡目からは各群の動物の体重の合計を比較して、小さい群より順に体重の重い動物を割り当てることにより、群間の体重の偏りを小さくする群分け方法（適正層別方式）により実施した（文献 14）。

群分けにより除外された動物は、投与開始日まで飼育し、試験に使用する必要のなくなったことを確認後、本試験系より外し、他の実験に使用した。

### －2－3 動物の個体識別

動物は、導入時に尾に油性マーカーによる色素塗布をして検疫・馴化期間中の個体を識別し、群分け時には耳パンチをして以降の個体を識別した。また、ケージには個体識別番号を記したラベルを付した。

#### －2－4 使用飼育室及び他試験・異種動物との区別

動物はバリア区域内の独立した室（検疫室：雄：517室、雌：518室、飼育・吸入試験室：516室）に収容し、室の扉に試験番号、試験動物、飼育期間及び遺伝子改変動物飼育中を表示し、他試験及び異種動物と区別した。

#### －2－5 飼育条件

##### (1) 飼育環境

動物は、ステンレス製 2 連網ケージにより飼育し、吸入投与はステンレス製 5 連網ケージに動物を移して吸入チャンバーに収容し投与を行った。

検疫室、吸入試験室及び吸入チャンバー内の環境条件及び使用したケージ等を以下に示した。検疫室、吸入試験室の温度、湿度は実測値（平均値±標準偏差）を< >内に、また、吸入チャンバー内環境の測定結果は APPENDIX 3 に示した。検疫室、吸入試験室及び吸入チャンバー内の環境は、全飼育期間を通して設定条件範囲内で飼育した。

温度：検疫室； $23 \pm 2 \text{ }^{\circ}\text{C}$  < 517室： $23.1 \pm 0.2 \text{ }^{\circ}\text{C}$  >  
< 518室： $23.4 \pm 0.0 \text{ }^{\circ}\text{C}$  >

吸入試験室； $22 \pm 2 \text{ }^{\circ}\text{C}$  < 516室： $22.1 \pm 0.4 \text{ }^{\circ}\text{C}$  >  
吸入チャンバー内； $23 \pm 2 \text{ }^{\circ}\text{C}$

湿度：検疫室； $55 \pm 15 \%$  < 517室： $52 \pm 1 \%$  >  
< 518室： $50 \pm 1 \%$  >

吸入試験室； $30 \sim 70 \%$  < 516室： $50 \pm 2 \%$  >  
吸入チャンバー内； $30 \sim 70 \%$

明暗サイクル：12 時間点灯 (8:00 ~ 20:00) / 12 時間消灯 (20:00 ~ 8:00)

換気回数：検疫室；15 ~ 17 回 / 時

吸入試験室；8 ~ 10 回 / 時

吸入チャンバー内； $6 \pm 0.5$  回 / 時

圧力：吸入チャンバー内； $0 \sim -15 \times 10 \text{ Pa}$

ケージへの動物の収容方法：個別飼育

ケージの材質・形状・寸法等：

飼育用；ステンレス製 2 連網ケージ (112(W) × 212(D) × 120(H) mm/区画)

投与用；ステンレス製 5 連網ケージ (100(W) × 116(D) × 120(H) mm/区画)

巣材：Enviro-dri (SSP 社製) 投与中は使用しない。

飼育器材 (ラック、ケージ、餌箱、給水ノズル、作業台車、巣材等) の滅菌：

オートクレーブを用いて滅菌 (約 120、15 分以上)

## (2) 飼料

飼料は、全飼育期間を通して、オリエンタル酵母工業(株) 製造の CRF-1 固型 (30 kGy- $\gamma$  線照射滅菌飼料) を固型飼料給餌器により自由摂取させた。投与中及び定期解剖前日の夕方からは絶食させた。

試験に使用した飼料中の栄養成分と夾雑物については、オリエンタル酵母工業(株) から分析データを入手し、確認後保管した。

## (3) 飲水

飲水は、全飼育期間を通して、フィルターろ過した市水(神奈川県秦野市水道局供給) を自動給水ノズルから自由摂取させた。ただし、投与中は絶水させた。

飲水の水質は、動物試験施設として定期的(年2回)に実施している水道水の検査において、水道法に定められている水質基準に適合していることを確認した。

### －3 観察・検査項目及び方法

#### －3－1 動物の生死及び一般状態の観察

全動物について、週1回、投与前の一般状態を詳細に観察した。その他の日は、投与日は投与前後に、非投与日は1日1回、一般状態を観察した。瀕死状態または著しい苦痛を呈した動物は速やかに安楽死させた。

#### －3－2 体重測定

全動物について、週1回、投与前に体重測定を行った。また、定期解剖日には絶食後の体重(搬出時体重)を測定した。

飼育期間中に死亡、瀕死または切迫屠殺した動物は、飼育室からの搬出時に体重を測定した。

#### －3－3 摂餌量測定

全動物について、週1回、給餌量及び残餌量を測定し、その値から1匹1日当たりの摂餌量を算出した。

#### －3－4 血液学的検査

定期解剖時に生存していた採血可能な動物について、剖検直前にイソフルラン麻酔下で開腹し、腹大動脈から EDTA-2 カリウム入り採血管に採血した全血を用いて、下記の項目について検査を行った。検査方法は APPENDIX 4 に示す。

検査項目：赤血球数、ヘモグロビン濃度、ヘマトクリット値、平均赤血球容積(MCV)、平均赤血球ヘモグロビン量(MCH)、平均赤血球ヘモグロビン濃度(MCHC)、血小板数、網赤血球比、白血球数、白血球分類

### －3－5 血液生化学的検査

定期解剖時に生存していた採血可能な動物について、剖検直前にイソフルラン麻酔下で開腹し、腹大動脈よりヘパリンリチウム入り採血管に採血した血液を遠心分離し、得られた血漿を用いて、下記の項目について検査を行った。検査方法は APPENDIX 4 に示す。

検査項目：総蛋白、アルブミン、A/G 比、総ビリルビン、グルコース、総コレステロール、トリグリセライド、リン脂質、AST、ALT、LDH、ALP、 $\gamma$ -GTP、CK、尿素窒素、ナトリウム、カリウム、クロール、カルシウム、無機リン

### －3－6 病理学的検査

#### (1) 肉眼的観察

全動物について肉眼的に観察を行った。なお、定期解剖動物はイソフルラン麻酔下で腹大動脈より採血後、腹大動脈を切断し、放血することで安楽死させた。

#### (2) 臓器重量

定期解剖時まで生存していた動物について、下記に示した臓器の湿重量(臓器実重量)を測定した。また、各臓器の湿重量の搬出時体重に対する百分率(臓器重量体重比)を算出した。

測定臓器：副腎、精巣、卵巣、心臓、肺、腎臓、脾臓、肝臓、脳

#### (3) 病理組織学的検査

全動物について下記に示した器官、組織を摘出し、10%中性リン酸緩衝ホルマリン溶液で固定後、パラフィン包埋、薄切、ヘマトキシリン・エオジン染色を行い、光学顕微鏡で病理組織学的に検査した。

なお、鼻腔については切歯の後端(レベル1)、切歯乳頭(レベル2)、第一臼歯の前端(レベル3)の3ヶ所(文献15)で切り出し(横断)、検査した。

検査器官・組織：皮膚、鼻腔、鼻咽頭、喉頭、気管、肺、骨髓(胸骨、大腿骨)、リンパ節(腋窩、鼠径等)、胸腺、脾臓、心臓、舌、唾液腺、食道、胃、小腸(十二指腸を含む)、大腸、肝臓、胆嚢、膵臓、腎臓、膀胱、下垂体、甲状腺、上皮小体、副腎、精巣、精巣上体、精嚢、前立腺、卵巣、子宮、膣、乳腺、脳、脊髄、末梢神経(坐骨神経)、眼球、ハーダー腺、筋肉、骨(胸骨、大腿骨)、肉眼的に変化のみられた器官及び組織

### －3－7 病理ピアレビュー

病理組織診断の最終化後に外部専門家2名による病理ピアレビューを実施し、被験物質及び陽性対照物質投与による腫瘍性病変及び非腫瘍性病変について組織標本の確認を行った。その結果、以下の死因及び所見名の追加、訂正を行った。

1) 雌雄の投与群(雄16匹、雌13匹)及び陽性対照群(雄8匹、雌17匹)で、死因を「腫

瘍死：白血病」からすべて「腫瘍死：悪性リンパ腫」に変更。

- 2) 雄の 1,000 ppm 群の 1 匹で「筋組織の横紋筋肉腫」に、部位として「下顎」を追加。
- 3) 雌の 1,000 ppm 群の 1 匹を「筋組織の平滑筋肉腫」から「皮下組織の肉腫 NOS」に変更し、死因を「腫瘍死：筋組織」から「腫瘍死：皮下組織」に変更。
- 4) 雌の陽性対照群の 1 匹を「リンパ節の悪性リンパ腫」から「著変なし」に変更、「骨髄・卵巣・胸腺の白血病細胞浸潤」を削除し「胸腺の萎縮・肺の炎症性細胞浸潤」を追加、死因を「腫瘍死：白血病」から「組織学的確診なし」に変更。

#### －4 数値処理と統計方法

##### －4－1 数値の取扱いと表示

各数値データは測定機器の精度に合わせて表示した。

吸入チャンバー内の被験物質濃度は ppm を単位として、小数点以下第 3 位まで測定し、小数点以下第 2 位を四捨五入して小数点以下第 1 位までを表示した。

体重は g を単位とし、小数点以下第 1 位まで測定し、表示した。

摂餌量は g を単位とし、給餌量及び残餌量を小数点以下第 1 位まで測定し、給餌量値から残餌量値を減じて摂餌量とした。この値を測定期間の日数で除し、1 日当たりの平均摂餌量を算出し、小数点以下第 2 位を四捨五入して小数点以下第 1 位までを表示した。

臓器実重量は g を単位とし、小数点以下第 3 位まで測定し、表示した。臓器重量体重比は臓器実重量値を搬出時体重で除し、パーセント単位で小数点以下第 4 位を四捨五入し、小数点以下第 3 位までを表示した。

血液学的検査、血液生化学的検査は APPENDIX 4 に示す単位と桁数により表示した。

なお、各数値データの平均値及び標準偏差は、上記に示した桁数と同様になるよう四捨五入を行い表示した。

##### －4－2 統計処理

各群の有効動物数は、供試動物より事故等の理由で外された動物数を減じた数とした。

病理組織学的検査は、臓器ごとに検査不能臓器を除いた臓器数、その他の検査及び測定は、実施できた動物数を検査（測定）数とした。

体重、摂餌量、血液学的検査、血液生化学的検査及び臓器重量の測定値は、対照群を基準群として、まず Bartlett 法により等分散の予備検定を行い、その結果が等分散の場合には一元配置分散分析を行い、群間に有意差が認められた場合は、Dunnett の多重比較によって対照群と被験物質投与群間での有意差検定を行った。また、分散の等しくない場合には、各群を通して測定値を順位化して、Kruskal-Wallis の順位検定を行い、群間に有意差が認められた場合には、Dunnett 型の多重比較を行った。なお、対照群と陽性対照群間の有意差検定は、まず F 検定を用い、等分散である場合は Student の *t* 検定を行い、等分散でない

場合は **Aspin-Welch** の  $t$  検定を行った。

病理組織学的検査のうち非腫瘍性病変については、所見のみられなかった動物をグレード 0、所見のみられた動物は、その所見の程度及び範囲などを基準にしてグレード 1~4 に分け、 $\chi^2$  検定を行った。

腫瘍性病変については、各臓器の腫瘍ごとに、各群の総担腫瘍臓器数について、**Peto** 検定 (文献 16)、**Cochran-Armitage** 検定、**Fisher** 検定を行った。なお、対照群と陽性対照群間は、各群の総担腫瘍臓器数について **Fisher** 検定を行った。

各検定は 5% の有意水準で、**Peto** 検定、**Fisher** 検定は片側検定、その他の検定は両側検定を行い、検定結果を表示する場合には 5% 及び 1% の有意水準の表示を行った。なお、有効検査数が 2 以下の群の項目は検定より除外した。

## 試験成績-1 (被験物質投与群)

## -1 生死状況

生存率を TABLE A 2, 3 及び FIGURE 2, 3 に示す。

-雄-

1,000 ppm 群で切迫屠殺あるいは死亡動物が多く、最終生存率の低下が認められた。

各群の生存動物数(生存率)は、対照群：25 匹(100%)、100 ppm 群：24 匹(96%)、300 ppm 群：22 匹(88%)、1,000 ppm 群：8 匹(32%)であった。

-雌-

1,000 ppm 群で切迫屠殺あるいは死亡動物が多く、最終生存率の低下が認められた。

各群の生存動物数(生存率)は、対照群：23 匹(92%)、100 ppm 群：24 匹(96%)、300 ppm 群：25 匹(100%)、1,000 ppm 群：10 匹(40%)であった。

## -2 一般状態

一般状態の観察結果(週1回の投与前の詳細観察)を TABLE A 4, 5 に示す。なお、個体表は APPENDIX 5-1, 5-2 に示す。

-雌雄-

すべての投与群で被験物質投与に関連した特徴的な所見はみられなかった。

## -3 体重

体重の推移を TABLE A 6~9 及び FIGURE 4, 5 に示す。なお、個体表は APPENDIX 6-1, 6-2 に示す。

-雄-

1,000 ppm 群では、投与 8 週以降に有意な体重の低値が認められた。

最終計測日の各投与群の体重は、対照群に対して、100 ppm 群：102%、300 ppm 群：101%、1,000 ppm 群：84%であった。

-雌-

各投与群とも対照群とほぼ同様な推移を示した。

最終計測日の各投与群の体重は、対照群に対して、100 ppm 群：102%、300 ppm 群：102%、1,000 ppm 群：104%であった。



#### －4 摂餌量

摂餌量の推移を TABLE A 10～13 及び FIGURE 6, 7 に示す。なお、個体表は APPENDIX 7-1, 7-2 に示す。

－雄－

**300 ppm** 以上の群では、投与期間の多くの週で摂餌量の有意な高値が認められた。また、**100 ppm** 群でも高値が散見された。

投与期間を通した 1 匹当たりの 1 日平均摂餌量は、対照群：**3.8 g**、**100 ppm** 群：**4.0 g**、**300 ppm** 群：**4.1 g**、**1,000 ppm** 群：**4.0 g** であった。

－雌－

**300 ppm** 以上の群では、投与期間の多くの週で摂餌量の有意な高値が認められた。また、**100 ppm** 群でも高値が散見された。

投与期間を通した 1 匹当たりの 1 日平均摂餌量は、対照群：**3.7 g**、**100 ppm** 群：**3.8 g**、**300 ppm** 群：**3.9 g**、**1,000 ppm** 群：**4.1 g** であった。

#### －5 血液学的検査

血液学的検査の結果を TABLE A 14, 15 に示す。なお、個体表は APPENDIX 8-1, 8-2 に示す。

雌の対照群及び **1,000 ppm** 群の各 1 匹で、採血時に血管破綻による出血あるいは採血前の死亡により、血液学的検査データが欠落となった。

－雄－

**100 ppm** 以上の群でヘモグロビン濃度、ヘマトクリット値、**MCV**、**MCH** 及び **MCHC** の有意な高値、並びに網赤血球比の低値が認められた。

**300 ppm** 以上の群で血小板数の有意な低値が認められた。

**1,000 ppm** 群で好中球比の有意な高値、並びに白血球数及びリンパ球比の低値が認められた。なお、白血球数は **300 ppm** 群では高値を示した。

その他、**300 ppm** 群で赤血球数が高値を示したが、軽度の変化であった。また、好酸球比が高値を示したが、個体間のばらつきも大きく投与濃度に対応した変化ではなかった。

－雌－

**100 ppm** 以上の群で **MCV**、**MCH** 及び **MCHC** の有意な高値が認められた。

**300 ppm** 以上の群で単球比の有意な高値、並びに血小板数の低値が認められた。

**1,000 ppm** 群で白血球数及び好塩基球比の有意な高値、並びに赤血球数の低値が認められた。

**100 ppm** 及び **300 ppm** 群でヘモグロビン濃度の有意な高値、並びに網赤血球比の低値、**300 ppm** 群でヘマトクリット値の高値が認められた。

## －6 血液生化学的検査

血液生化学的検査の結果を TABLE A 16, 17 に示す。なお、個体表は APPENDIX 9-1, 9-2 に示す。

雌の対照群及び 1,000 ppm 群の各 1 匹で、採血時に血管破綻による出血あるいは採血前の死亡により、血液生化学的検査データが欠落となった。

－雄－

100 ppm 以上の群で尿素窒素の有意な低値が認められた。

300 ppm 以上の群で総ビリルビン及びクロールの有意な高値が認められた。

1,000 ppm 群で AST、ALT 及び LDH の有意な高値が認められた。

その他、300 ppm 群でグルコースの高値、並びにナトリウムの低値、100 及び 300 ppm 群でトリグリセライドが高値を示したが、投与濃度に対応した変化ではなかった。

－雌－

300 ppm 以上の群で ALT、LDH 及びクロールの有意な高値、並びにナトリウムの低値が認められた。

1,000 ppm 群でトリグリセライドの有意な高値が認められた。

その他、300 ppm 群で無機リンが低値を示したが、投与濃度に対応した変化ではなかった。

## －7 病理学的検査

### －7－1 肉眼的観察

解剖時の剖検観察所見を TABLE A 18, 19 に示す。なお、個体表は APPENDIX 10-1, 10-2 に示す。

－雄－

胸腺の腫大が 1,000 ppm 群に 20 匹認められ、うち 14 匹は胸腔内に胸水貯留、5 匹は胸膜の肥厚を伴っていた。

精巢の小型化が 300 ppm 及び 1,000 ppm 群に各 24 匹認められた。

前胃の白色斑が 1,000 ppm 群に 5 匹、結節が 1 匹に認められた。

－雌－

胸腺の腫大が 1,000 ppm 群に 13 匹認められ、うち 10 匹は胸腔内に胸水貯留を伴っていた。

脾臓の腫大が 1,000 ppm 群に 12 匹認められた。

前胃の白色斑が 1,000 ppm 群に 5 匹、潰瘍が 1 匹に認められた。

## －7－2 臓器重量

定期解剖時に測定した臓器の実重量を TABLE A 20, 21、体重比を TABLE A 22, 23 に示す。なお、個体表は実重量を APPENDIX 11-1, 11-2、体重比を APPENDIX 12-1, 12-2 に示す。

雌の対照群の 1 匹で、先天異常（奇形）による左腎の欠損により、腎臓の実重量と体重比データが欠落となった。

－雄－

100 ppm 以上の群で精巣の実重量及び体重比の有意な低値が認められ、300 ppm 以上の群で顕著であった。

300 ppm 以上の群で脾臓の実重量及び体重比の有意な高値が認められた。

その他、1,000 ppm 群で、脳の実重量の低値、並びに体重比の高値、心臓、肺、腎臓及び肝臓の体重比の高値がみられたが、1,000 ppm 群の搬出時体重の低値に起因するものと考えた。

－雌－

300 ppm 以上の群で脾臓の実重量及び体重比の有意な高値、卵巣の体重比の低値、肝臓の実重量の高値、脳の体重比の低値が認められた。

1,000 ppm 群で心臓、腎臓の実重量及び体重比の有意な高値、副腎の実重量及び体重比の低値、卵巣及び脳の実重量の低値、肝臓の体重比の高値が認められた。

## －7－3 病理組織学的検査

腫瘍性病変は、腫瘍の種類別の発生数を TABLE A 24, 25 に、統計解析（Peto 検定、Cochran-Armitage 検定、Fisher 検定）の結果を TABLE A 26, 27 に、担腫瘍動物数と発生腫瘍数を TABLE A 28, 29 に、転移性病変を TABLE A 30, 31 に示す。本項で取り上げた腫瘍について、日本バイオアッセイ研究センターにおける p53 ヘテロ欠損マウスのヒストリカルコントロールデータ（4 試験、雌雄各 100 匹）を TABLE A 32, 33 に示す。また、非腫瘍性病変は TABLE A 34, 35 に示す。さらに、病理組織所見の代表例を PHOTOGRAPH 1～4 に示す。なお、病理組織所見の個体表は APPENDIX 13-1, 13-2 に示す。

### （1）腫瘍性病変

－雄－

< 胸腺 >

悪性リンパ腫の発生は、対照群及び 100 ppm 群で 0 匹（0%）、300 ppm 群で 1 匹（4%）、1,000 ppm 群で 21 匹（84%）に認められ、Fisher 検定では 1,000 ppm 群で有意な増加を示し、Peto 検定（死亡率法、有病率法、死亡率法+有病率法）及び Cochran-Armitage 検定で増加傾向を示した。

## &lt;リンパ節&gt;

悪性リンパ腫の発生は、対照群、**100 ppm** 及び **300 ppm** 群で **0 匹 (0%)**、**1,000 ppm** 群で **1 匹 (4%)** にみられた。

なお、胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生は、対照群及び **100 ppm** 群で **0 匹 (0%)**、**300 ppm** 群で **1 匹 (4%)**、**1,000 ppm** 群で **22 匹 (88%)** であり、**Fisher** 検定では **1,000 ppm** 群で有意な増加を示し、**Peto** 検定 (死亡率法、有病率法、死亡率法+有病率法) 及び **Cochran-Armitage** 検定で増加傾向を示した。

雄の担腫瘍動物数は、対照群で **1 匹 (4%)**、**100 ppm** 群で **0 匹 (0%)**、**300 ppm** 群で **2 匹 (8%)**、**1,000 ppm** 群で **25 匹 (100%)** であった。

—雌—

## &lt;胸腺&gt;

悪性リンパ腫の発生は、対照群及び **100 ppm** 群で各 **1 匹 (4%)**、**300 ppm** 群で **0 匹 (0%)**、**1,000 ppm** 群で **14 匹 (56%)** に認められ、**Fisher** 検定では **1,000 ppm** 群で有意な増加を示し、**Peto** 検定 (死亡率法、有病率法、死亡率法+有病率法) 及び **Cochran-Armitage** 検定で増加傾向を示した。

## &lt;脾臓&gt;

悪性リンパ腫の発生は、対照群、**100 ppm** 及び **300 ppm** 群で **0 匹 (0%)**、**1,000 ppm** 群で **2 匹 (8%)** に認められ、**Peto** 検定 (死亡率法+有病率法) 及び **Cochran-Armitage** 検定で増加傾向を示した。

なお、胸腺あるいは脾臓における悪性リンパ腫を合わせた発生は、対照群及び **100 ppm** 群で各 **1 匹 (4%)**、**300 ppm** 群で **0 匹 (0%)**、**1,000 ppm** 群で **16 匹 (64%)** であり、**Fisher** 検定では **1,000 ppm** 群で有意な増加を示し、**Peto** 検定 (死亡率法、有病率法、死亡率法+有病率法) 及び **Cochran-Armitage** 検定で増加傾向を示した。

雌の担腫瘍動物数は、対照群で **1 匹 (4%)**、**100 ppm** 群で **1 匹 (4%)**、**300 ppm** 群で **2 匹 (8%)**、**1,000 ppm** 群で **18 匹 (72%)** であった。

## (2) 非腫瘍性病変

—雄—

## &lt;胃(前胃)&gt;

前胃で過形成が **1,000 ppm** 群 (**11 匹**: 軽度から中等度) で増加した。また、前胃の潰瘍が **300 ppm** 群で **1 匹**、**1,000 ppm** 群で **3 匹** みられた。

## &lt;精巣&gt;

精細管萎縮が **300 ppm** 群 (**25 匹**: 軽度から重度) 及び **1,000 ppm** 群 (**25 匹**: 重度) で増加し、**1,000 ppm** 群ではその程度が増強した。

<精巣上体>

精子数減少が **300 ppm** 群 (24 匹：軽度から中等度) 及び **1,000 ppm** 群 (25 匹：軽度から中等度) で増加し、**1,000 ppm** 群ではその程度が増強した。また、精上皮系細胞の残屑が、**300 ppm** 群 (25 匹：軽度) 及び **1,000 ppm** 群 (21 匹：軽度) で増加した。

<唾液腺>

顎下腺及び舌下腺の腺房細胞過形成が **1,000 ppm** 群 (各 25 匹：軽度) で増加した。

<骨髄>

ヘモジデリン沈着が **1,000 ppm** 群 (17 匹：軽度) で増加した。

<脾臓>

髄外造血が **1,000 ppm** 群 (8 匹：軽度から中等度) で増加した。また、ヘモジデリン沈着が **1,000 ppm** 群 (6 匹：軽度) で増加した。

—雌—

<胃(前胃)>

前胃の過形成が **1,000 ppm** 群 (20 匹：軽度から重度) で増加した。

<卵巣>

萎縮が **300 ppm** 群 (6 匹：軽度) 及び **1,000 ppm** 群 (25 匹：軽度から中等度) で増加し、**1,000 ppm** 群ではその程度が増強した。

<子宮>

萎縮が **1,000 ppm** 群 (21 匹：軽度) で増加した。

<膣>

上皮萎縮が **1,000 ppm** 群 (19 匹：軽度) で増加した。

<唾液腺>

顎下腺及び舌下腺の腺房細胞過形成が **1,000 ppm** 群 (各 25 匹：軽度) で増加した。

<骨>

骨硬化症が **1,000 ppm** 群 (23 匹：軽度から中等度) で増加した。

<脾臓>

髄外造血が **1,000 ppm** 群 (7 匹：軽度から中等度) で増加した。また、ヘモジデリン沈着が **1,000 ppm** 群 (10 匹：軽度) で増加した。

－7－4 死因

病理学的にみた死亡／瀕死の原因を **TABLE A 36, 37** に示す。なお、個体表は **APPENDIX 14-1, 14-2** に示す。

－雄－

**1,000 ppm** 群では死亡が **17** 匹認められ、そのうち **15** 匹の死因は胸腺またはリンパ節の悪性リンパ腫であった。

－雌－

**1,000 ppm** 群では死亡が **15** 匹認められ、そのうち **11** 匹の死因は胸腺または脾臓の悪性リンパ腫であった。

## 試験成績-2 (陽性対照群)

### －1 生死状況

生存率を **TABLE B 1, 2** に示す。

－雄－

陽性対照群の死亡/切迫屠殺動物は **10** 匹みられ、対照群と比較して生存率の低下が認められた。

生存動物数 (生存率) は、対照群 : **25** 匹 (**100** %)、陽性対照群 : **10** 匹 (**50** %) であった。

－雌－

陽性対照群の死亡/切迫屠殺動物は **18** 匹みられ、対照群と比較して生存率の低下が認められた。

生存動物数 (生存率) は、対照群 : **23** 匹 (**92** %)、陽性対照群 : **2** 匹 (**10** %) であった。

### －2 一般状態

一般状態の観察結果 (週 **1** 回の投与前の詳細観察) を **TABLE B 3, 4** に示す。なお、個体表は **APPENDIX 5-1, 5-2** に示す。

－雄－

陽性対照群の死亡/切迫屠殺動物 **10** 匹中、貧血が **5** 匹、不整呼吸及び深呼吸が各 **3** 匹に観察された。

－雌－

陽性対照群の死亡/切迫屠殺動物 **18** 匹中、貧血が **5** 匹、不整呼吸が **2** 匹、深呼吸が **6** 匹に観察された。

### －3 体重

体重の推移を **TABLE B 5, 6** に示す。なお、個体表は **APPENDIX 6-1, 6-2** に示す。

雌の陽性対照群は、投与後 **23** 週から **26** 週にかけて測定動物数が **2** 匹となったため、その期間は統計検定を実施しなかった。

－雄－

陽性対照群では、投与後 **16** 週以降に体重の有意な低値が認められ、最終体重は対照群に対して **86** %であった。

－雌－

陽性対照群では、投与後 **21** 週以降に体重の有意な低値ないし低値傾向が認められ、最終体重は対照群に対して **83** %であった。

#### －4 摂餌量

摂餌量の推移を **TABLE B 7, 8** に示す。なお、個体表は **APPENDIX 7-1, 7-2** に示す。

雌の陽性対照群は、投与後 23 週から 26 週にかけて測定動物数が 2 匹となったため、その期間は統計検定を実施しなかった。

－雄－

陽性対照群では、投与後 16 週までは摂餌量の有意な低値が散見されたが、投与後 23 週以降は高値を示した。1 匹当たりの 1 日平均摂餌量は、対照群 3.8 g に対して陽性対照群 3.8 g であった。

－雌－

陽性対照群では、飼育期間を通して対照群とほぼ同様の推移を示した。1 匹当たりの 1 日平均摂餌量は、対照群 3.7 g に対して陽性対照群 3.6 g であった。

#### －5 血液学的検査

血液学的検査の結果を **TABLE B 9, 10** に示す。なお、個体表は **APPENDIX 8-1, 8-2** に示す。

雌の陽性対照群は測定動物数が 2 匹となったため、統計検定を実施しなかった。

－雄－

陽性対照群では、赤血球数、ヘモグロビン濃度、ヘマトクリット値、**MCH**、**MCHC**、リンパ球比及び好酸球比の有意な低値、並びに **MCV**、網赤血球比、白血球数、好中球比及び好塩基球比の高値が認められた。

－雌－

陽性対照群では、赤血球数、ヘモグロビン濃度、ヘマトクリット値、**MCH**、**MCHC** 及びリンパ球比が低値傾向、網赤血球比及び好中球比が高値傾向であった。

#### －6 血液生化学的検査

血液生化学的検査の結果を **TABLE B 11, 12** に示す。なお、個体表は **APPENDIX 9-1, 9-2** に示す。

雌の陽性対照群は測定動物数が 2 匹となったため、統計検定を実施しなかった。

－雄－

陽性対照群では、総コレステロール、尿素窒素、カリウム、クロール及び無機リンの有意な高値、並びに総蛋白、アルブミン、**A/G** 比及び **ALP** の低値が認められた。

－雌－

陽性対照群では、総コレステロール、リン脂質、**ALT**、ナトリウム、カリウム及び無機リ



ンが高値傾向であった。また、総蛋白、アルブミン、A/G 比、グルコース及び ALP が低値傾向であった。

## －7 病理学的検査

### －7-1 肉眼的観察

解剖時の剖検観察所見を TABLE B 13, 14 に示す。なお、個体表は APPENDIX 10-1, 10-2 に示す。

－雄－

脾臓の腫大が 13 匹認められ、うち 8 匹は貧血を伴っていた。

胸腺の腫大が 9 匹認められ、うち 6 匹は胸腔内に胸水貯留、3 匹は胸膜の肥厚を伴っていた。

－雌－

脾臓の腫大が 14 匹認められ、うち 7 匹は貧血を伴っていた。

胸腺の腫大が 17 匹認められ、うち 11 匹は胸腔内に胸水貯留を伴っていた。

### －7-2 臓器重量

定期解剖時に測定した臓器の実重量を TABLE B 15, 16 に、体重比を TABLE B 17, 18 に示す。なお、個体表は実重量を APPENDIX 11-1, 11-2、体重比を APPENDIX 12-1, 12-2 に示す。

雌の陽性対照群は測定動物数が 2 匹となったため、統計検定を実施しなかった。

－雄－

心臓、脾臓、肝臓の実重量及び体重比の有意な高値が認められた。

その他、脳の実重量の低値、並びに体重比の高値、副腎、精巣及び腎臓の実重量の低値、肺の体重比の高値がみられたが、搬出時体重の低値に起因するものと考えた。

－雌－

脾臓及び心臓の実重量と体重比が高値傾向、副腎及び卵巣が低値傾向であった。

また、脳の実重量の低値傾向と体重比の高値傾向、肺、腎臓及び肝臓の体重比の高値傾向が示されたが、搬出時体重の低値に起因するものと考えた。

### －7－3 病理組織学的検査

腫瘍性病変は、腫瘍の種類別の発生数を **TABLE B 19, 20** に、統計解析 (**Fisher** 検定) の結果を **TABLE B 21, 22** に、担腫瘍動物数と発生腫瘍数を **TABLE B 23, 24** に示す。また、非腫瘍性病変は **TABLE B 25, 26** に示す。なお、病理組織所見の個体表は **APPENDIX 13-1, 13-2** に示す。

#### (1) 腫瘍性病変

－雄－

##### < 小腸 >

腺癌の発生は、対照群で **0 匹 (0%)**、陽性対照群で **15 匹 (75%)** に認められ、**Fisher** 検定で有意な増加を示した。また、腺腫の発生は、対照群で **0 匹 (0%)**、陽性対照群で **1 匹 (5%)** にみられた。さらに、腺腫と腺癌を合わせた発生は、対照群で **0 匹 (0%)**、陽性対照群で **16 匹 (80%)** に認められ、**Fisher** 検定で有意な増加を示した。

##### < 胸腺 >

悪性リンパ腫の発生は、対照群で **0 匹 (0%)**、陽性対照群で **9 匹 (45%)** に認められ、**Fisher** 検定で有意な増加を示した。

##### < リンパ節 >

悪性リンパ腫の発生は、対照群で **0 匹 (0%)**、陽性対照群で **1 匹 (5%)** に認められた。

なお、胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生は、対照群で **0 匹 (0%)**、陽性対照群で **10 匹 (50%)** であり、**Fisher** 検定で有意な増加を示した。

雄の担腫瘍動物数は対照群 **1 匹 (4%)** に対し、陽性対照群 **20 匹 (100%)** であった。

－雌－

##### < 小腸 >

腺癌の発生は、対照群で **0 匹 (0%)**、陽性対照群で **7 匹 (35%)** に認められ、**Fisher** 検定で有意な増加を示した。

##### < 胸腺 >

悪性リンパ腫の発生は、対照群で **1 匹 (4%)**、陽性対照群で **18 匹 (90%)** に認められ、**Fisher** 検定で有意な増加を示した。

雌の担腫瘍動物数は対照群 **1 匹 (4%)** に対し、陽性対照群 **18 匹 (90%)** であった。

(2) 非腫瘍性病変

—雄—

<胸腺>

陽性対照群で萎縮（5匹：軽度）が増加した。

<脾臓>

陽性対照群で随外造血（16匹：軽度から重度）が増加した。

<胃（前胃）>

陽性対照群で前胃の過形成（9匹：軽度から中等度）が増加した。

<精巣上体>

陽性対照群で精上皮系細胞の残屑（8匹：軽度）が増加した。

その他、肝臓で炎症性細胞集簇巣が対照群で7匹にみられたが、陽性対照群での発生はなかった。

—雌—

<脾臓>

陽性対照群で随外造血（14匹：軽度から重度）が増加した。

<胃（前胃）>

陽性対照群で前胃の過形成（11匹：軽度から中等度）が増加した。

<子宮>

陽性対照群で萎縮（8匹：軽度）が増加した。

その他、肝臓で炎症性細胞集簇巣が対照群で11匹にみられたが、陽性対照群での発生はなかった。

—7—4 死因

病理学的にみた死亡／瀕死の原因を TABLE B 27, 28 に示す。なお、個体表は APPENDIX 14-1, 14-2 に示す。

—雄—

陽性対照群の死亡動物 10 匹の死因は、悪性リンパ腫（8匹）または小腸腫瘍（2匹）であった。

—雌—

陽性対照群の死亡動物 18 匹の死因は、ほとんどが悪性リンパ腫（17匹）であった。

## 考察及びまとめ

ジプロモメタンの発がん性を検索する目的で、遺伝子改変マウス(**p53**ヘテロ欠損マウス)を用いた26週間全身暴露(経気道投与)による中期発がん性試験を行った。

対照群1群、被験物質投与群3群及び陽性対照群の計5群を設け、対照群と被験物質投与群は1群当たり雌雄各25匹、陽性対照群は雌雄各20匹とした。ジプロモメタンの投与濃度は、0(対照群)、100、300及び1,000 ppm(体積比v/v)とし、投与期間は、1日6時間、1週5日間の投与で26週間とした。陽性対照物質(*N*-ニトロソ-*N*-メチル尿素)の投与用量は雌雄とも75 mg/kg体重とし、単回腹腔内投与した後、26週間飼育した。飼育期間中、生死及び一般状態の観察、体重及び摂餌量の測定を行い、26週間の試験終了後に動物を解剖し、血液学的検査、血液生化学的検査、肉眼的観察、臓器重量の測定及び病理組織学的検査を行った。

### －1 生存率、一般状態、体重等

最終生存率は雌雄とも1,000 ppm群で対照群と比較して低下が認められた。同群の死因の多くは雌雄とも悪性リンパ腫によるものであった。一般状態は、雌雄ともすべての投与群で投与に関連した特徴的な所見はみられなかった。体重は、雄では1,000 ppm群で投与8週以降に有意な低値がみられたが、雌では各投与群とも対照群とほぼ同様の推移であった。摂餌量は、雌雄とも300 ppm以上の群で、投与期間の多くの週で有意な高値が認められた。

### －2 腫瘍性病変

雄では、悪性リンパ腫の発生が胸腺とリンパ節でそれぞれ認められた。悪性リンパ腫の発生は、胸腺では1,000 ppm群においてFisher検定で有意な増加を示し、Peto検定とCochran-Armitage検定で増加傾向を示した。リンパ節においては、1,000 ppm群で1匹に発生がみられた。さらに、胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生は、1,000 ppm群においてFisher検定で有意な増加を示し、Peto検定とCochran-Armitage検定で増加傾向を示した。なお、当センターのp53ヘテロ欠損マウスのヒストリカルコントロールデータ(4試験、雄100匹)では、悪性リンパ腫の発生はリンパ節で1匹(発生率1%)にみられたのみである。胸腺の悪性リンパ腫は、剖検観察では胸腺の腫大としてみられ、これに伴って胸水の貯留や胸膜の肥厚が認められた。

以上の結果から、雄p53ヘテロ欠損マウスの胸腺及びリンパ節における悪性リンパ腫の発生増加は、発がん性を示す明らかな証拠と判断した。

雌では、悪性リンパ腫の発生が胸腺と脾臓でそれぞれ認められた。悪性リンパ腫の発生は、胸腺では1,000 ppm群においてFisher検定で有意な増加を示し、Peto検定とCochran-

Armitage 検定で増加傾向を示した。脾臓においても **1,000 ppm** 群で 2 匹に発生がみられ、Peto 検定と Cochran-Armitage 検定で増加傾向を示した。さらに、胸腺あるいは脾臓における悪性リンパ腫を合わせた発生は、**1,000 ppm** 群において Fisher 検定で有意な増加を示し、Peto 検定と Cochran-Armitage 検定で増加傾向を示した。なお、当センターのヒストリカルコントロールデータ（4 試験、雌 100 匹）では、悪性リンパ腫の発生はリンパ節で 1 匹（発生率 1%）にみられたのみである。胸腺の悪性リンパ腫は、剖検観察では胸腺の腫大としてみられ、これに伴って胸水の貯留や脾臓の腫大が認められた。

以上の結果から、雌 p53 ヘテロ欠損マウスの胸腺及び脾臓における腫瘍の発生増加は、発がん性を示す明らかな証拠と判断した。

### －3 その他の影響

非腫瘍性病変として、雌雄とも生殖器系への影響が認められた。雄では、精巣の精細管萎縮が **300 ppm** 以上の群で増加し、**1,000 ppm** 群ではその程度が増強した。また、精巣重量は **100 ppm** 以上の群で低値を示し、**300 ppm** 以上の群の重量低下は顕著であった。さらに、精巣の精細管萎縮に伴って、精巣上体で精子数の減少と精上皮系細胞の残屑が **300 ppm** 以上の群で増加した。なお、本試験の用量設定試験として実施した、C57BL/6J マウスを用いた 4 週間毒性試験（文献 12）（投与濃度 0、250、500、**1,000** 及び **2,000 ppm**）でも、精巣の精細管萎縮と精巣重量の低下（**250 ppm** 以上の群）、精巣上体の精子減少及び精上皮系細胞の残屑（**500 ppm** 以上の群）がみられた。雌では、卵巣の萎縮が **300 ppm** 以上の群で増加し、**1,000 ppm** 群ではその程度が増強した。また、卵巣重量は **300 ppm** 以上の群で低値を示した。さらに、子宮の萎縮及び膈の上皮萎縮が **1,000 ppm** 群で増加した。なお、4 週間毒性試験（文献 12）では、瀕死動物（**2,000 ppm** 群）で卵巣の卵胞数減少がみられたのみであった。

前胃の過形成が雌雄とも **1,000 ppm** 群で増加した。この変化は前腫瘍性変化と考えられるが腫瘍の発生はみられなかった。なお、4 週間毒性試験（文献 12）では、雌の瀕死動物（**2,000 ppm** 群）で前胃の過形成がみられた。

唾液腺の顎下腺及び舌下腺で腺房細胞の過形成が雌雄とも **1,000 ppm** 群で増加した。この変化は、顎下腺及び舌下腺で一様にみられる変化であることから前腫瘍性の変化とは考えなかった。

骨の骨硬化症が雌の **1,000 ppm** 群で増加した。これは性ホルモンのバランスの乱れによる変化と関連づけられ、卵巣等の変化に対応したものと考えた（文献 17）。

脾臓のヘモジデリン沈着と髄外造血が雌雄の **1,000 ppm** 群で増加した。この変化は異常な赤血球の処理やそれに伴う造血と考えた。

#### －4 陽性対照群（*N*-ニトロソ-*N*-メチル尿素）の評価

陽性対照物質として、*N*-ニトロソ-*N*-メチル尿素を単回腹腔内投与（雌雄 20 匹、75 mg/kg 体重）し、動物を 26 週間飼育した。

腫瘍性病変の発生は、雄では、小腸で腺癌の発生が有意な増加を示し、腺腫の発生が 1 匹にみられた。さらに、腺腫及び腺癌を合わせた発生も有意な増加を示した。また、胸腺で悪性リンパ腫の発生が有意な増加を示し、リンパ節でも発生が 1 匹にみられた。さらに、胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生も有意な増加を示した。

雌では、小腸で腺癌の発生が有意な増加を示した。また、胸腺で悪性リンパ腫の発生が有意な増加を示した。

以上より、雌雄とも陽性対照物質投与による腫瘍性病変の明らかな発生増加が認められたことから、p53 ヘテロ欠損マウスを用いた 26 週間全身暴露による中期発がん性試験の有効性が確認された。

#### 結論

遺伝子改変マウス（p53 ヘテロ欠損マウス）を用いて、ジプロモメタンの 26 週間の吸入による中期発がん性試験を行った結果、雄では、1,000 ppm 群で胸腺の悪性リンパ腫、及び胸腺あるいはリンパ節における悪性リンパ腫を合わせた発生増加が認められたことから、ジプロモメタンの雄 p53 ヘテロ欠損マウスへの発がん性を示す明らかな証拠が得られた（**clear evidence of carcinogenic activity**）と結論した。

雌では、1,000 ppm 群で胸腺と脾臓の悪性リンパ腫、及び胸腺あるいは脾臓における悪性リンパ腫を合わせた発生増加が認められたことから、ジプロモメタンの雌 p53 ヘテロ欠損マウスへの発がん性を示す明らかな証拠が得られた（**clear evidence of carcinogenic activity**）と結論した。

## 文献

- 1) **International Programme on Chemical Safety (IPCS). 2013. International Chemical Safety Cards (ICSC) 0354, DIBROMOMETHANE. Accessed on 01 May 2020.**  
<http://www.inchem.org/documents/icsc/icsc/eics0354.htm>
- 2) **Jon B Reid, Custodio V Muianga, ed. 2012. Methylene Bromide. In: Patty's Toxicology. 6th edition. (Eula Bingham, Barbara Cohrssen, ed.) New York, NY: John Wiley and Sons, Volume 3; 25-27.**
- 3) **経済産業省. 2022. 一般化学物質等の製造・輸入数量（2020年度実績）について、メチレンジブロマイド. Accessed on 06 April 2022.**  
[https://www.meti.go.jp/policy/chemical\\_management/kasinhou/information/volume\\_index.html](https://www.meti.go.jp/policy/chemical_management/kasinhou/information/volume_index.html)
- 4) **化学工業日報社. 2022. メチレンジブロマイド 17322 の化学商品. 東京: 化学工業日報社, 981-982.**
- 5) **国立研究開発法人 産業技術総合研究所. 2020. 有機化合物スペクトルデータベース (SDBS), Dibromomethane. Accessed on 27 April 2020.**  
[http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre\\_index.cgi](http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre_index.cgi)
- 6) **シグマ アルドリッチ ジャパン合同会社. 2020. N-Nitroso-N-methylurea 安全データシート**
- 7) **Chemical Book. 1,3,5-トリアザペンタン-2,5-ジオン. Accessed on 25 September 2020.**  
[https://www.chemicalbook.com/ChemicalProductProperty\\_JP\\_CB5109704.htm](https://www.chemicalbook.com/ChemicalProductProperty_JP_CB5109704.htm)
- 8) **National Institute of Standards and Technology (NIST). NIST Chemistry WebBook, SRD 69: Urea, N-methyl-N-nitroso-. Accessed on 22 October 2020.**  
<https://webbook.nist.gov/cgi/cbook.cgi?Name=684-93-5&Units=SI&cIR=o n#IR-Spec>
- 9) **Robinson DE, MacDonald JS. 2001. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. Toxicol Pathol 29 (Suppl.): 13-19.**

- 10) 平成 28 年度第 3 回発がん性評価ワーキンググループ(平成 29 年 3 月 1 日開催) 2017. 遺伝子改変動物を用いたがん原性試験による調査の基準.
- 11) **Organisation for Economic Co-operation and Development (OECD). 2018. OECD Guideline for Testing of Chemicals 451: "Carcinogenicity Studies". Adopted 25 June 2018. Paris: OECD.**
- 12) 日本バイオアッセイ研究センター. 2021. ジプロモメタンの C57BL/6J マウスを用いた吸入による 4 週間毒性試験(中期発がん性試験予備試験)報告書(試験番号 0937).
- 13) **Morton D, Bailey KL, Stout CL, Weaver RJ, White KA, Lorenzen MJ, Ball DJ. 2008. N -Methyl-N -Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies. Toxicol Pathol 36(7): 926-931.**
- 14) 阿部正信 . 1986 . 長期毒性試験に用いるラット、マウスの体重変化の解析による群分けの適正層別方式の確立. 薬理と治療 14: 7285-7302.
- 15) **Nagano K, Katagiri T, Aiso S, Senoh H, Sakura Y, Takeuchi T. 1997. Spontaneous lesions of nasal cavity in aging F344 rats and BDF1 mice. Exp Toxic Pathol. 49: 97-104.**
- 16) **Peto R, Pike MC, Day NE, Gray RG, Lee PN, Parish S, et al. 1980. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. Lyon: International Agency for Research on Cancer (IARC). IARC Monographs Suppl 2: 311-426.**
- 17) 山崎寛治. 2017. 新毒性病理学 (日本毒性病理学会編) 各論 第 11 章 運動器系 2 骨・関節, 東京: 西村書店, 607-626.



予見することのできなかつた試験の信頼性に影響を及ぼす疑いのある事態及び試験計画書に従わなかつたこと

(1) 群分け時の事故による動物の差し替え

群分け作業時(2020年11月30日)の事故により、雌100 ppm群の1匹が死亡したため、群分け除外動物から体重値の近い動物を選択し、動物番号の差し替えを行った。これに伴い摂餌量の計測値も差し替え後の動物のものに訂正した。本操作は試験結果に影響を及ぼすものではないと判断した。

(2) 吸入チャンバー内濃度の欠落

以下の吸入チャンバー内濃度データが欠落した。

データの欠落については、濃度測定結果の集計に影響を及ぼすものではないと判断した。

測定日(時間)	データ欠落吸入 チャンバー番号	理由
2021年1月20日 (15:30:30~17:37:30)	CH-3, CH-5, CH-7	データ処理装置のプリンタの紙詰まり及びデータ伝送不良による欠落
2021年1月25日 (10:45:00, 11:00:00)	CH-1	データ処理装置の停止による欠落
2021年2月10日 (15:30:00, 15:37:30)	CH-3, CH-5, CH-7	データ処理装置の停止による欠落
2021年3月16日 (15:30:00~16:00:00)	CH-7	濃度測定装置の不具合により、リテンションタイムが測定バンドから逸脱したため正確な濃度測定ができず、データを削除したことによる欠落

)吸入チャンバー番号: CH-1(対照群)、CH-3(100 ppm群)、CH-5(300 ppm群)、CH-7(1,000 ppm群)

(3) 血液学的検査及び血液生化学的検査データの欠落

以下の動物について、血液学的検査及び血液生化学的検査を実施せず、データが欠落となった。

検査日	データ欠落動物番号	理由
2021年6月1日	2001	採血時に血管破綻による出血のため検査血液の採取ができなかつたため
2021年6月2日	2311	採血時に動物が死亡していたため

血液学的検査及び血液生化学的検査データの欠落については、評価に必要な検査動物数が確保されたことから、試験結果の評価に影響を及ぼすものではないと判断した。

## (4) 臓器重量データの欠落

以下の動物について先天異常(奇形)による左腎の欠損があり、右腎のみ重量測定をした。腎臓重量は左右の合計重量で評価しているため、本動物の腎臓実重量データは欠落となった。併せて腎臓重量体重比データも欠落となった。

検査日	データ欠落動物番号
2021年6月4日	2021

腎臓重量データの欠落については、評価に必要な検査動物数が確保されたことから、試験結果の評価に影響を及ぼすものではないと判断した。

## (5) 試験計画書の誤記載について

試験計画書の誤記載のため、「13-3-7 病理学的検査 (3) 臓器の採取保存、(4) 病理組織学検査」項で、採取及び検査器官に胸腺が記載されていなかった。

本試験では、胸腺の採取及び病理組織学的検査を実施するとともに、報告書中の「-3-6 病理学的検査 (3) 病理組織学的検査」の項で検査器官・組織に胸腺の記載を明記した。

ジブロモメタンの p53 ヘテロ欠損マウスを  
用いた吸入による中期発がん性試験報告書

試験番号：0944

# TABLES

## TABLES

### (Test substance-treated groups)

TABLE	A 1	CONCENTRATIONS OF DIBROMOMETHANE IN THE INHALATION CHAMBER
TABLE	A 2	SURVIVAL ANIMAL NUMBERS: MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 3	SURVIVAL ANIMAL NUMBERS: FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 4	CLINICAL OBSERVATION : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 5	CLINICAL OBSERVATION : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 6	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 7	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 8	BODY WEIGHT CHANGES: MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 9	BODY WEIGHT CHANGES: FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 10	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 11	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 12	FOOD CONSUMPTION CHANGES: MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 13	FOOD CONSUMPTION CHANGES: FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 14	HEMATOLOGY : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 15	HEMATOLOGY : FEMALE (Control, 100, 300 and 1,000 ppm groups)

**TABLES (CONTINUED)**  
**(Test substance-treated groups)**

TABLE	A 16	BIOCHEMISTRY : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 17	BIOCHEMISTRY : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 18	GROSS FINDINGS : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 19	GROSS FINDINGS : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 20	ORGAN WEIGHT, ABSOLUTE : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 21	ORGAN WEIGHT, ABSOLUTE : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 22	ORGAN WEIGHT, RELATIVE : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 23	ORGAN WEIGHT, RELATIVE : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 24	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 25	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 26	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 27	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : FEMALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 28	NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED : MALE (Control, 100, 300 and 1,000 ppm groups)
TABLE	A 29	NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED : FEMALE (Control, 100, 300 and 1,000 ppm groups)

**TABLES (CONTINUED)**  
**(Test substance-treated groups)**

- TABLE A 30 HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR  
: MALE  
(Control, 100, 300 and 1,000 ppm groups)
- TABLE A 31 HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR  
: FEMALE  
(Control, 100, 300 and 1,000 ppm groups)
- TABLE A 32 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC  
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER  
: B6.129S2-Trp53 tm1Tyj/J MALE MICE
- TABLE A 33 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC  
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER  
: B6.129S2-Trp53 tm1Tyj/J FEMALE MICE
- TABLE A 34 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: MALE  
(Control, 100, 300 and 1,000 ppm groups)
- TABLE A 35 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: FEMALE  
(Control, 100, 300 and 1,000 ppm groups)
- TABLE A 36 CAUSE OF DEATH : MALE  
(Control, 100, 300 and 1,000 ppm groups)
- TABLE A 37 CAUSE OF DEATH : FEMALE  
(Control, 100, 300 and 1,000 ppm groups)

## TABLES

### (Positive control group)

TABLE	B 1	SURVIVAL ANIMAL NUMBERS: MALE (Control and Positive control groups)
TABLE	B 2	SURVIVAL ANIMAL NUMBERS: FEMALE (Control and Positive control groups)
TABLE	B 3	CLINICAL OBSERVATION: MALE (Control and Positive control groups)
TABLE	B 4	CLINICAL OBSERVATION: FEMALE (Control and Positive control groups)
TABLE	B 5	BODY WEIGHT CHANGES: MALE (Control and Positive control groups)
TABLE	B 6	BODY WEIGHT CHANGES: FEMALE (Control and Positive control groups)
TABLE	B 7	FOOD CONSUMPTION CHANGES: MALE (Control and Positive control groups)
TABLE	B 8	FOOD CONSUMPTION CHANGES: FEMALE (Control and Positive control groups)
TABLE	B 9	HEMATOLOGY: MALE (Control and Positive control groups)
TABLE	B 10	HEMATOLOGY: FEMALE (Control and Positive control groups)
TABLE	B 11	BIOCHEMISTRY: MALE (Control and Positive control groups)
TABLE	B 12	BIOCHEMISTRY: FEMALE (Control and Positive control groups)
TABLE	B 13	GROSS FINDINGS: MALE (Control and Positive control groups)
TABLE	B 14	GROSS FINDINGS: FEMALE (Control and Positive control groups)
TABLE	B 15	ORGAN WEIGHT, ABSOLUTE: MALE (Control and Positive control groups)
TABLE	B 16	ORGAN WEIGHT, ABSOLUTE: FEMALE (Control and Positive control groups)

**TABLES (CONTINUED)**  
**(Positive control group)**

- TABLE B 17 ORGAN WEIGHT, RELATIVE: MALE  
(Control and Positive control groups)
- TABLE B 18 ORGAN WEIGHT, RELATIVE: FEMALE  
(Control and Positive control groups)
- TABLE B 19 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS:  
MALE  
(Control and Positive control groups)
- TABLE B 20 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS:  
FEMALE  
(Control and Positive control groups)
- TABLE B 21 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL  
ANALYSIS: MALE  
(Control and Positive control groups)
- TABLE B 22 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL  
ANALYSIS: FEMALE  
(Control and Positive control groups)
- TABLE B 23 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF  
TUMORS - TIME RELATED: MALE  
(Control and Positive control groups)
- TABLE B 24 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF  
TUMORS - TIME RELATED: FEMALE  
(Control and Positive control groups)
- TABLE B 25 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: MALE  
(Control and Positive control groups)
- TABLE B 26 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: FEMALE  
(Control and Positive control groups)
- TABLE B 27 CAUSE OF DEATH : MALE  
(Control and Positive control groups)
- TABLE B 28 CAUSE OF DEATH : FEMALE  
(Control and Positive control groups)



TABLE A 1

CONCENTRATIONS OF DIBROMOMETHANE  
IN THE INHALATION CHAMBER

TABLE A1 CONCENTRATIONS OF DIBROMOMETHANE IN THE INHALATION CHAMBER

Group Name	Concentration(ppm) Mean $\pm$ S.D.
Control	0.0 $\pm$ 0.0
100 ppm	100.2 $\pm$ 0.6
300 ppm	300.5 $\pm$ 1.2
1000 ppm	1001.4 $\pm$ 4.2

TABLE A 2

SURVIVAL ANIMAL NUMBERS : MALE

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 1

Group Name	Animals At start	Administration (Days)													
		0-0	1-1	1-2	1-3	1-4	1-5	1-6	1-7	2-1	2-2	2-3	2-4	2-5	2-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 2

Group Name	Animals At start	Administration (Days)													
		2-7	3-1	3-2	3-3	3-4	3-5	3-6	3-7	4-1	4-2	4-3	4-4	4-5	4-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		4-7	5-1	5-2	5-3	5-4	5-5	5-6	5-7	6-1	6-2	6-3	6-4	6-5	6-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 4

Group Name	Animals At start	Administration (Days)													
		6-7	7-1	7-2	7-3	7-4	7-5	7-6	7-7	8-1	8-2	8-3	8-4	8-5	8-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		8-7	9-1	9-2	9-3	9-4	9-5	9-6	9-7	10-1	10-2	10-3	10-4	10-5	10-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)



STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 6

Group Name	Animals At start	Administration (Days)													
		10-7	11-1	11-2	11-3	11-4	11-5	11-6	11-7	12-1	12-2	12-3	12-4	12-5	12-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 7

Group Name	Animals At start	Administration (Days)													
		12-7	13-1	13-2	13-3	13-4	13-5	13-6	13-7	14-1	14-2	14-3	14-4	14-5	14-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 8

Group Name	Animals At start	Administration (Days)													
		14-7	15-1	15-2	15-3	15-4	15-5	15-6	15-7	16-1	16-2	16-3	16-4	16-5	16-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 9

Group Name	Animals At start	Administration (Days)													
		16-7	17-1	17-2	17-3	17-4	17-5	17-6	17-7	18-1	18-2	18-3	18-4	18-5	18-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		18-7	19-1	19-2	19-3	19-4	19-5	19-6	19-7	20-1	20-2	20-3	20-4	20-5	20-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
1000 ppm	25	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 11

Group Name	Animals At start	Administration (Days)													
		20-7	21-1	21-2	21-3	21-4	21-5	21-6	21-7	22-1	22-2	22-3	22-4	22-5	22-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
1000 ppm	25	23/25 92.0	22/25 88.0	21/25 84.0	20/25 80.0	20/25 80.0	20/25 80.0	20/25 80.0	19/25 76.0	19/25 76.0	19/25 76.0	19/25 76.0	19/25 76.0	19/25 76.0	19/25 76.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		22-7	23-1	23-2	23-3	23-4	23-5	23-6	23-7	24-1	24-2	24-3	24-4	24-5	24-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
1000 ppm	25	18/25 72.0	17/25 68.0	16/25 64.0	15/25 60.0	15/25 60.0	15/25 60.0	15/25 60.0	14/25 56.0	13/25 52.0	13/25 52.0	13/25 52.0	13/25 52.0	13/25 52.0	13/25 52.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		24-7	25-1	25-2	25-3	25-4	25-5	25-6	25-7	26-1	26-2	26-3	26-4	26-5	26-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0
1000 ppm	25	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	11/25 44.0	10/25 40.0	10/25 40.0	9/25 36.0	9/25 36.0
		Number of survival/ Number of effective animals Survival rate(%)													



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

SURVIVAL ANIMAL NUMBERS

---

Group Name	Animals At start	Administration (Days) 26-7
Control	25	25/25 100.0
100 ppm	25	24/25 96.0
300 ppm	25	22/25 88.0
1000 ppm	25	8/25 32.0

---

Number of survival/ Number of effective animals  
Survival rate(%)

**TABLE A 3**

**SURVIVAL ANIMAL NUMBERS : FEMALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 15

Group Name	Animals At start	Administration (Days)													
		0-0	1-1	1-2	1-3	1-4	1-5	1-6	1-7	2-1	2-2	2-3	2-4	2-5	2-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		2-7	3-1	3-2	3-3	3-4	3-5	3-6	3-7	4-1	4-2	4-3	4-4	4-5	4-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
Survival rate(%)

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 17

Group Name	Animals At start	Administration (Days)													
		4-7	5-1	5-2	5-3	5-4	5-5	5-6	5-7	6-1	6-2	6-3	6-4	6-5	6-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		6-7	7-1	7-2	7-3	7-4	7-5	7-6	7-7	8-1	8-2	8-3	8-4	8-5	8-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
Survival rate(%)

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 19

Group Name	Animals At start	Administration (Days)													
		8-7	9-1	9-2	9-3	9-4	9-5	9-6	9-7	10-1	10-2	10-3	10-4	10-5	10-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 20

Group Name	Animals At start	Administration (Days)													
		10-7	11-1	11-2	11-3	11-4	11-5	11-6	11-7	12-1	12-2	12-3	12-4	12-5	12-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6



STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 21

Group Name	Animals At start	Administration (Days)													
		12-7	13-1	13-2	13-3	13-4	13-5	13-6	13-7	14-1	14-2	14-3	14-4	14-5	14-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 22

Group Name	Animals At start	Administration (Days)													
		14-7	15-1	15-2	15-3	15-4	15-5	15-6	15-7	16-1	16-2	16-3	16-4	16-5	16-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 23

Group Name	Animals At start	Administration (Days)													
		16-7	17-1	17-2	17-3	17-4	17-5	17-6	17-7	18-1	18-2	18-3	18-4	18-5	18-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 24

Group Name	Animals At start	Administration (Days)													
		18-7	19-1	19-2	19-3	19-4	19-5	19-6	19-7	20-1	20-2	20-3	20-4	20-5	20-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 25

Group Name	Animals At start	Administration (Days)													
		20-7	21-1	21-2	21-3	21-4	21-5	21-6	21-7	22-1	22-2	22-3	22-4	22-5	22-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	22/25 88.0	21/25 84.0	21/25 84.0	21/25 84.0	21/25 84.0	21/25 84.0	21/25 84.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		22-7	23-1	23-2	23-3	23-4	23-5	23-6	23-7	24-1	24-2	24-3	24-4	24-5	24-6
Control	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	21/25 84.0	21/25 84.0	21/25 84.0	21/25 84.0	20/25 80.0	20/25 80.0	19/25 76.0	19/25 76.0	19/25 76.0	17/25 68.0	17/25 68.0	17/25 68.0	17/25 68.0	17/25 68.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 27

Group Name	Animals At start	Administration (Days)													
		24-7	25-1	25-2	25-3	25-4	25-5	25-6	25-7	26-1	26-2	26-3	26-4	26-5	26-6
Control	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
100 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
300 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1000 ppm	25	17/25 68.0	16/25 64.0	16/25 64.0	16/25 64.0	15/25 60.0	15/25 60.0	15/25 60.0	15/25 60.0	14/25 56.0	13/25 52.0	12/25 48.0	12/25 48.0	10/25 40.0	10/25 40.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

---

Group Name	Animals At start	Administration (Days) 26-7
Control	25	23/25 92.0
100 ppm	25	24/25 96.0
300 ppm	25	25/25 100.0
1000 ppm	25	10/25 40.0

---

Number of survival/ Number of effective animals  
Survival rate(%)



**TABLE A 4**

**CLINICAL OBSERVATION : MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-7 1	2-7 1	3-7 1	4-7 1	5-7 1	6-7 1	7-7 1	8-7 1	9-7 1	10-7 1	11-7 1	12-7 1	13-7 1	14-7 1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	1	1	1	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	24	25
	100 ppm	25	25	25	25	25	25	25	25	25	25	24	24	24	24
	300 ppm	25	25	25	25	25	25	25	25	25	25	25	25	24	24
	1000 ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	2	2	2	2
MORBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1
	300 ppm	0	0	0	1	1	1	1	2	2	2	3	3
	1000 ppm	0	0	2	2	2	2	5	7	8	10	12	14
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	1	0	0	0	0
M. HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	1	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	1	1	1	1	1	1	1	1	1	1
	300 ppm	1	1	1	1	1	1	1	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0
IRRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	2	2	1	1	0	3
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25
	100 ppm	24	24	23	23	23	23	23	23	23	23	23	23
	300 ppm	24	24	24	23	23	23	23	23	23	23	22	22
	1000 ppm	25	25	23	23	23	23	18	16	14	12	11	6

**TABLE A 5**

**CLINICAL OBSERVATION : FEMALE**

**(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	1	1	1	1	2	2
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	1	1	1	2	2	2	2	3	5	7	9	14
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	1	1
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	1	1	1	1	1	1	1	1	1	1	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	1	1	1	1	1	0	1	1	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	1	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	1	1	1	1	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	1	1	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	1

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day														
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7	
		1	1	1	1	1	1	1	1	1	1	1	1	1	1	
EROSION	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOOSE STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	24	24	24	24	24	24
	100 ppm	25	25	25	25	25	24	24	24	24	24	24	24	24	24	24
	300 ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	1000 ppm	24	24	24	24	24	23	23	23	23	23	23	23	22	22	22

(HAN190)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
EROSION	Control	1	1	1	1	1	1	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	0	0	0	2	0	1	1
LOOSE STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	300 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1000 ppm	0	0	0	0	0	3	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	23	23
	100 ppm	24	24	24	24	24	24	24	24	24	24	24	24
	300 ppm	25	25	25	25	25	25	25	25	25	25	25	25
	1000 ppm	22	22	22	20	20	18	20	19	16	15	12	8

(HAN190)

BAIS 6



**TABLE A 6**

**BODY WEIGHT CHANGES AND  
SURVIVAL ANIMAL NUMBERS : MALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week-Day on Study	Control		100 ppm		300 ppm		1000 ppm				
	Av. Wt.	No. of Surviv. <25>	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.
0-0	25.2 (25)	25/25	25.2 (25)	100	25/25	25.2 (25)	100	25/25	25.2 (25)	100	25/25
1-7	25.5 (25)	25/25	25.9 (25)	102	25/25	25.8 (25)	101	25/25	25.7 (25)	101	25/25
2-7	25.9 (25)	25/25	26.4 (25)	102	25/25	26.6 (25)	103	25/25	26.5 (25)	102	25/25
3-7	26.7 (25)	25/25	27.0 (25)	101	25/25	27.4 (25)	103	25/25	26.8 (25)	100	25/25
4-7	27.4 (25)	25/25	27.7 (25)	101	25/25	28.0 (25)	102	25/25	27.1 (25)	99	25/25
5-7	27.8 (25)	25/25	28.4 (25)	102	25/25	28.7 (25)	103	25/25	27.5 (25)	99	25/25
6-7	28.3 (25)	25/25	29.0 (25)	102	25/25	29.2 (25)	103	25/25	27.8 (25)	98	25/25
7-7	28.8 (25)	25/25	29.2 (25)	101	25/25	29.7 (25)	103	25/25	28.0 (25)	97	25/25
8-7	29.3 (25)	25/25	29.7 (25)	101	25/25	30.1 (25)	103	25/25	28.1 (25)	96	25/25
9-7	29.7 (25)	25/25	30.3 (25)	102	25/25	30.5 (25)	103	25/25	28.4 (25)	96	25/25
10-7	30.1 (25)	25/25	30.6 (25)	102	25/25	30.7 (25)	102	25/25	28.7 (25)	95	25/25
11-7	30.7 (25)	25/25	31.4 (25)	102	25/25	31.1 (25)	101	25/25	29.1 (25)	95	25/25
12-7	30.8 (25)	25/25	31.3 (25)	102	25/25	31.7 (25)	103	25/25	29.1 (25)	94	25/25
13-7	31.4 (25)	25/25	32.2 (24)	103	24/25	32.1 (25)	102	25/25	29.1 (25)	93	25/25
14-7	31.6 (25)	25/25	32.5 (24)	103	24/25	32.5 (25)	103	25/25	29.3 (25)	93	25/25
15-7	32.0 (25)	25/25	33.0 (24)	103	24/25	32.7 (25)	102	25/25	29.4 (25)	92	25/25
16-7	32.4 (25)	25/25	33.1 (24)	102	24/25	32.9 (25)	102	25/25	29.3 (25)	90	25/25
17-7	32.6 (25)	25/25	33.4 (24)	102	24/25	32.8 (25)	101	25/25	29.5 (23)	90	23/25
18-7	32.9 (25)	25/25	33.8 (24)	103	24/25	33.6 (24)	102	24/25	29.6 (23)	90	23/25
19-7	33.1 (25)	25/25	33.9 (24)	102	24/25	33.7 (24)	102	24/25	29.4 (23)	89	23/25
20-7	33.2 (25)	25/25	34.4 (24)	104	24/25	34.1 (24)	103	24/25	29.4 (23)	89	23/25
21-7	33.8 (25)	25/25	34.3 (24)	101	24/25	34.6 (24)	102	24/25	29.3 (19)	87	19/25
22-7	34.0 (25)	25/25	34.7 (24)	102	24/25	35.0 (23)	103	23/25	29.0 (18)	85	18/25
23-7	34.4 (25)	25/25	35.0 (24)	102	24/25	35.2 (23)	102	23/25	30.2 (14)	88	14/25
24-7	34.6 (25)	25/25	35.5 (24)	103	24/25	35.1 (22)	101	22/25	29.9 (11)	86	11/25
25-7	35.1 (25)	25/25	35.7 (24)	102	24/25	35.3 (22)	101	22/25	29.7 (11)	85	11/25
26-7	35.2 (25)	25/25	36.0 (24)	102	24/25	35.7 (22)	101	22/25	29.5 ( 8)	84	8/25

< >:No. of effective animals, ( ) :No. of measured animals Av. Wt. : g

**TABLE A 7**

**BODY WEIGHT CHANGES AND  
SURVIVAL ANIMAL NUMBERS : FEMALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week-Day on Study	Control		100 ppm		300 ppm		1000 ppm				
	Av. Wt.	No. of Surviv. <25>	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.
0-0	20.6 (25)	25/25	20.7 (25)	100	25/25	20.6 (25)	100	25/25	20.6 (25)	100	25/25
1-7	21.0 (25)	25/25	21.7 (25)	103	25/25	21.4 (25)	102	25/25	20.7 (24)	99	24/25
2-7	21.6 (25)	25/25	22.0 (25)	102	25/25	21.9 (25)	101	25/25	21.4 (24)	99	24/25
3-7	22.1 (25)	25/25	22.4 (25)	101	25/25	22.3 (25)	101	25/25	22.2 (24)	100	24/25
4-7	22.5 (25)	25/25	22.7 (25)	101	25/25	22.8 (25)	101	25/25	22.7 (24)	101	24/25
5-7	23.1 (25)	25/25	23.6 (25)	102	25/25	23.4 (25)	101	25/25	23.2 (24)	100	24/25
6-7	23.7 (25)	25/25	24.3 (24)	103	24/25	24.0 (25)	101	25/25	23.6 (24)	100	24/25
7-7	24.2 (25)	25/25	24.4 (24)	101	24/25	24.2 (25)	100	25/25	23.8 (24)	98	24/25
8-7	24.1 (25)	25/25	24.5 (24)	102	24/25	24.4 (25)	101	25/25	24.1 (24)	100	24/25
9-7	24.3 (25)	25/25	24.8 (24)	102	24/25	24.4 (25)	100	25/25	24.2 (24)	100	24/25
10-7	24.3 (25)	25/25	25.0 (24)	103	24/25	24.8 (25)	102	25/25	24.7 (24)	102	24/25
11-7	24.5 (25)	25/25	25.0 (24)	102	24/25	24.7 (25)	101	25/25	24.8 (24)	101	24/25
12-7	24.8 (25)	25/25	25.2 (24)	102	24/25	25.1 (25)	101	25/25	25.1 (24)	101	24/25
13-7	24.8 (25)	25/25	25.4 (24)	102	24/25	25.0 (25)	101	25/25	25.1 (23)	101	23/25
14-7	25.0 (25)	25/25	25.7 (24)	103	24/25	25.4 (25)	102	25/25	25.5 (23)	102	23/25
15-7	25.3 (25)	25/25	25.8 (24)	102	24/25	25.7 (25)	102	25/25	25.8 (23)	102	23/25
16-7	25.3 (25)	25/25	26.1 (24)	103	24/25	25.7 (25)	102	25/25	25.9 (23)	102	23/25
17-7	25.6 (25)	25/25	26.3 (24)	103	24/25	25.9 (25)	101	25/25	26.2 (23)	102	23/25
18-7	25.6 (25)	25/25	26.5 (24)	104	24/25	26.4 (25)	103	25/25	26.6 (22)	104	22/25
19-7	26.2 (25)	25/25	26.8 (24)	102	24/25	26.7 (25)	102	25/25	26.9 (22)	103	22/25
20-7	26.3 (25)	25/25	26.7 (24)	102	24/25	26.9 (25)	102	25/25	27.2 (22)	103	22/25
21-7	26.4 (24)	24/25	27.2 (24)	103	24/25	26.8 (25)	102	25/25	27.7 (22)	105	22/25
22-7	26.5 (24)	24/25	27.1 (24)	102	24/25	26.9 (25)	102	25/25	27.6 (21)	104	21/25
23-7	26.7 (24)	24/25	27.2 (24)	102	24/25	27.0 (25)	101	25/25	27.5 (19)	103	19/25
24-7	26.5 (24)	24/25	27.3 (24)	103	24/25	27.4 (25)	103	25/25	27.6 (17)	104	17/25
25-7	26.7 (23)	23/25	27.5 (24)	103	24/25	27.1 (25)	101	25/25	27.8 (15)	104	15/25
26-7	27.1 (23)	23/25	27.7 (24)	102	24/25	27.7 (25)	102	25/25	28.2 (10)	104	10/25

< >:No. of effective animals, ( ):No. of measured animals Av. Wt. : g

**TABLE A 8**

**BODY WEIGHT CHANGES : MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	0-0	1-7	2-7	3-7	4-7	5-7	6-7
Control	25.2± 1.0	25.5± 1.1	25.9± 1.1	26.7± 1.1	27.4± 1.2	27.8± 1.3	28.3± 1.4
100 ppm	25.2± 1.0	25.9± 1.1	26.4± 1.2	27.0± 1.1	27.7± 1.1	28.4± 1.3	29.0± 1.4
300 ppm	25.2± 1.0	25.8± 1.2	26.6± 1.3	27.4± 1.3	28.0± 1.3	28.7± 1.4	29.2± 1.5
1000 ppm	25.2± 1.0	25.7± 1.1	26.5± 1.3	26.8± 1.5	27.1± 1.4	27.5± 1.4	27.8± 1.5

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	28.8± 1.5	29.3± 1.6	29.7± 1.7	30.1± 1.6	30.7± 1.9	30.8± 1.9	31.4± 2.2
100 ppm	29.2± 1.5	29.7± 1.6	30.3± 1.7	30.6± 2.0	31.4± 2.3	31.3± 2.7	32.2± 2.3
300 ppm	29.7± 1.5	30.1± 1.6	30.5± 1.8	30.7± 1.7	31.1± 2.0	31.7± 1.7	32.1± 1.9
1000 ppm	28.0± 1.4	28.1± 1.5*	28.4± 1.4*	28.7± 1.6*	29.1± 1.5*	29.1± 1.5**	29.1± 1.6**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-7	15-7	16-7	17-7	18-7	19-7	20-7
Control	31.6± 2.3	32.0± 2.3	32.4± 2.4	32.6± 2.4	32.9± 2.5	33.1± 2.5	33.2± 2.4
100 ppm	32.5± 2.3	33.0± 2.5	33.1± 2.5	33.4± 2.7	33.8± 2.8	33.9± 3.0	34.4± 3.0
300 ppm	32.5± 2.1	32.7± 2.2	32.9± 2.2	32.8± 3.0	33.6± 2.6	33.7± 2.4	34.1± 2.6
1000 ppm	29.3± 1.4**	29.4± 1.3**	29.3± 1.4**	29.5± 1.4**	29.6± 1.3**	29.4± 1.5**	29.4± 1.7**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day					
	21-7	22-7	23-7	24-7	25-7	26-7
Control	33.8 ± 2.4	34.0 ± 2.7	34.4 ± 2.5	34.6 ± 2.6	35.1 ± 2.7	35.2 ± 2.8
100 ppm	34.3 ± 3.2	34.7 ± 3.4	35.0 ± 3.4	35.5 ± 3.7	35.7 ± 3.7	36.0 ± 3.7
300 ppm	34.6 ± 2.7	35.0 ± 2.7	35.2 ± 2.7	35.1 ± 3.3	35.3 ± 3.1	35.7 ± 3.2
1000 ppm	29.3 ± 2.7**	29.0 ± 2.8**	30.2 ± 1.5**	29.9 ± 1.4**	29.7 ± 1.5**	29.5 ± 2.2**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE A 9**

**BODY WEIGHT CHANGES : FEMALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day							
	0-0	1-7	2-7	3-7	4-7	5-7	6-7	
Control	20.6± 1.0	21.0± 1.2	21.6± 1.1	22.1± 1.1	22.5± 1.1	23.1± 1.2	23.7± 1.2	
100 ppm	20.7± 1.0	21.7± 1.1	22.0± 1.2	22.4± 1.2	22.7± 1.2	23.6± 1.3	24.3± 1.3	
300 ppm	20.6± 1.0	21.4± 0.9	21.9± 1.0	22.3± 1.0	22.8± 1.1	23.4± 1.2	24.0± 1.3	
1000 ppm	20.6± 1.0	20.7± 1.4	21.4± 0.8	22.2± 0.8	22.7± 0.8	23.2± 0.7	23.6± 0.8	

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	24.2± 1.3	24.1± 1.0	24.3± 0.9	24.3± 0.9	24.5± 1.0	24.8± 1.3	24.8± 0.9
100 ppm	24.4± 1.3	24.5± 1.4	24.8± 1.2	25.0± 1.4	25.0± 1.2	25.2± 1.3	25.4± 1.5
300 ppm	24.2± 1.2	24.4± 1.1	24.4± 1.1	24.8± 1.0	24.7± 1.2	25.1± 1.4	25.0± 1.2
1000 ppm	23.8± 0.8	24.1± 0.8	24.2± 0.9	24.7± 0.9	24.8± 0.7	25.1± 0.9	25.1± 0.9

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-7	15-7	16-7	17-7	18-7	19-7	20-7
Control	25.0± 1.4	25.3± 0.9	25.3± 1.1	25.6± 1.1	25.6± 1.0	26.2± 1.3	26.3± 1.1
100 ppm	25.7± 1.5	25.8± 1.3	26.1± 1.2	26.3± 1.4	26.5± 1.4	26.8± 1.3	26.7± 1.6
300 ppm	25.4± 1.4	25.7± 1.2	25.7± 1.3	25.9± 1.5	26.4± 1.5	26.7± 1.2	26.9± 1.6
1000 ppm	25.5± 1.0	25.8± 0.9	25.9± 1.0	26.2± 1.0	26.6± 1.1*	26.9± 0.9	27.2± 1.4

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day					
	21-7	22-7	23-7	24-7	25-7	26-7
Control	26.4 ± 1.3	26.5 ± 1.6	26.7 ± 1.2	26.5 ± 1.6	26.7 ± 1.4	27.1 ± 1.4
100 ppm	27.2 ± 1.7	27.1 ± 1.5	27.2 ± 1.7	27.3 ± 1.9	27.5 ± 1.7	27.7 ± 2.0
300 ppm	26.8 ± 1.3	26.9 ± 1.5	27.0 ± 1.7	27.4 ± 1.6	27.1 ± 1.6	27.7 ± 1.7
1000 ppm	27.7 ± 2.0*	27.6 ± 1.6	27.5 ± 1.4	27.6 ± 1.7	27.8 ± 1.7	28.2 ± 1.7

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE A 10**

**FOOD CONSUMPTION CHANGES AND  
SURVIVAL ANIMAL NUMBERS : MALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

MEAN FOOD CONSUMPTION (FC) AND SURVIVAL

Week-Day on Study	Control		100 ppm		300 ppm		1000 ppm				
	Av. FC.	No. of Surviv. <25>	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.
1-7	3.9 (25)	25/25	3.8 (25)	97	25/25	3.8 (25)	97	25/25	3.6 (25)	92	25/25
2-7	3.6 (25)	25/25	3.7 (25)	103	25/25	3.8 (25)	106	25/25	3.8 (25)	106	25/25
3-7	3.7 (25)	25/25	3.9 (25)	105	25/25	4.0 (25)	108	25/25	4.0 (25)	108	25/25
4-7	3.8 (25)	25/25	3.9 (25)	103	25/25	4.1 (25)	108	25/25	4.0 (25)	105	25/25
5-7	3.7 (25)	25/25	3.9 (25)	105	25/25	4.1 (25)	111	25/25	4.0 (25)	108	25/25
6-7	3.8 (25)	25/25	4.0 (25)	105	25/25	4.1 (25)	108	25/25	4.1 (25)	108	25/25
7-7	3.7 (25)	25/25	3.9 (25)	105	25/25	4.1 (25)	111	25/25	4.0 (25)	108	25/25
8-7	3.8 (25)	25/25	3.9 (25)	103	25/25	4.1 (25)	108	25/25	4.0 (25)	105	25/25
9-7	3.8 (25)	25/25	4.0 (25)	105	25/25	4.1 (25)	108	25/25	4.0 (25)	105	25/25
10-7	3.8 (25)	25/25	3.9 (25)	103	25/25	4.0 (25)	105	25/25	4.0 (25)	105	25/25
11-7	3.8 (25)	25/25	4.0 (25)	105	25/25	4.1 (25)	108	25/25	4.0 (25)	105	25/25
12-7	3.7 (25)	25/25	3.9 (25)	105	25/25	4.0 (25)	108	25/25	4.0 (25)	108	25/25
13-7	3.8 (25)	25/25	4.0 (24)	105	24/25	4.0 (25)	105	25/25	4.0 (25)	105	25/25
14-7	3.8 (25)	25/25	3.9 (24)	103	24/25	4.1 (25)	108	25/25	4.1 (25)	108	25/25
15-7	3.8 (25)	25/25	4.0 (24)	105	24/25	4.1 (25)	108	25/25	4.0 (25)	105	25/25
16-7	3.7 (25)	25/25	3.9 (24)	105	24/25	4.0 (25)	108	25/25	3.9 (25)	105	25/25
17-7	3.8 (25)	25/25	4.0 (24)	105	24/25	4.1 (25)	108	25/25	4.0 (23)	105	23/25
18-7	3.8 (25)	25/25	4.0 (24)	105	24/25	4.1 (24)	108	24/25	4.0 (23)	105	23/25
19-7	3.8 (25)	25/25	4.0 (24)	105	24/25	4.2 (24)	111	24/25	4.1 (23)	108	23/25
20-7	3.9 (25)	25/25	4.2 (24)	108	24/25	4.4 (24)	113	24/25	4.2 (23)	108	23/25
21-7	4.0 (25)	25/25	4.1 (24)	103	24/25	4.4 (24)	110	24/25	4.1 (19)	103	19/25
22-7	4.0 (25)	25/25	4.1 (24)	103	24/25	4.3 (23)	108	23/25	4.1 (18)	103	18/25
23-7	4.0 (25)	25/25	4.1 (24)	103	24/25	4.3 (23)	108	23/25	4.3 (14)	108	14/25
24-7	4.0 (25)	25/25	4.2 (24)	105	24/25	4.3 (22)	108	22/25	4.4 (11)	110	11/25
25-7	4.1 (25)	25/25	4.3 (24)	105	24/25	4.4 (22)	107	22/25	4.4 (11)	107	11/25
26-7	4.2 (25)	25/25	4.3 (24)	102	24/25	4.4 (22)	105	22/25	4.2 ( 8)	100	8/25

< >:No. of effective animals, ( ) :No. of measured animals Av. FC. : g



**TABLE A 11**

**FOOD CONSUMPTION CHANGES AND  
SURVIVAL ANIMAL NUMBERS : FEMALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

MEAN FOOD CONSUMPTION (FC) AND SURVIVAL

Week-Day on Study	Control		100 ppm		300 ppm		1000 ppm				
	Av. FC.	No. of Surviv. <25>	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.
1-7	3.5 (25)	25/25	3.6 (25)	103	25/25	3.4 (25)	97	25/25	3.1 (24)	89	24/25
2-7	3.4 (25)	25/25	3.3 (25)	97	25/25	3.4 (25)	100	25/25	3.6 (24)	106	24/25
3-7	3.6 (25)	25/25	3.5 (25)	97	25/25	3.7 (25)	103	25/25	3.9 (24)	108	24/25
4-7	3.7 (25)	25/25	3.6 (25)	97	25/25	3.9 (25)	105	25/25	4.0 (24)	108	24/25
5-7	3.7 (25)	25/25	3.7 (25)	100	25/25	3.9 (25)	105	25/25	4.0 (24)	108	24/25
6-7	3.8 (25)	25/25	3.9 (24)	103	24/25	4.0 (25)	105	25/25	4.1 (24)	108	24/25
7-7	3.8 (25)	25/25	3.8 (24)	100	24/25	4.1 (25)	108	25/25	4.1 (24)	108	24/25
8-7	3.7 (25)	25/25	3.9 (24)	105	24/25	4.0 (25)	108	25/25	4.1 (24)	111	24/25
9-7	3.7 (25)	25/25	3.8 (24)	103	24/25	3.9 (25)	105	25/25	4.0 (24)	108	24/25
10-7	3.6 (25)	25/25	3.8 (24)	106	24/25	3.9 (25)	108	25/25	4.1 (24)	114	24/25
11-7	3.7 (25)	25/25	3.7 (24)	100	24/25	3.8 (25)	103	25/25	4.1 (24)	111	24/25
12-7	3.6 (25)	25/25	3.7 (24)	103	24/25	3.9 (25)	108	25/25	4.1 (24)	114	24/25
13-7	3.5 (25)	25/25	3.7 (24)	106	24/25	3.8 (25)	109	25/25	4.0 (23)	114	23/25
14-7	3.6 (25)	25/25	3.7 (24)	103	24/25	3.9 (25)	108	25/25	4.2 (23)	117	23/25
15-7	3.6 (25)	25/25	3.8 (24)	106	24/25	3.9 (25)	108	25/25	4.2 (23)	117	23/25
16-7	3.6 (25)	25/25	3.7 (24)	103	24/25	3.9 (25)	108	25/25	4.1 (23)	114	23/25
17-7	3.7 (25)	25/25	3.8 (24)	103	24/25	4.0 (25)	108	25/25	4.3 (23)	116	23/25
18-7	3.6 (25)	25/25	3.8 (24)	106	24/25	4.0 (25)	111	25/25	4.4 (22)	122	22/25
19-7	3.8 (25)	25/25	3.9 (24)	103	24/25	4.1 (25)	108	25/25	4.5 (22)	118	22/25
20-7	4.0 (25)	25/25	3.9 (24)	98	24/25	4.1 (25)	103	25/25	4.6 (22)	115	22/25
21-7	3.8 (24)	24/25	4.0 (24)	105	24/25	4.1 (25)	108	25/25	4.7 (22)	124	22/25
22-7	3.8 (24)	24/25	3.9 (24)	103	24/25	4.1 (25)	108	25/25	4.6 (21)	121	21/25
23-7	3.8 (24)	24/25	3.9 (24)	103	24/25	4.0 (25)	105	25/25	4.4 (19)	116	19/25
24-7	3.6 (24)	24/25	3.8 (24)	106	24/25	4.1 (25)	114	25/25	4.5 (17)	125	17/25
25-7	3.7 (23)	23/25	3.9 (24)	105	24/25	4.1 (25)	111	25/25	4.6 (15)	124	15/25
26-7	3.9 (23)	23/25	4.0 (24)	103	24/25	4.2 (25)	108	25/25	4.5 (10)	115	10/25

< >:No. of effective animals, ( ) :No. of measured animals Av. FC. : g

**TABLE A 12**

**FOOD CONSUMPTION CHANGES : MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	1-7 (7)	2-7 (7)	3-7 (7)	4-7 (7)	5-7 (7)	6-7 (7)	7-7 (7)
Control	3.9± 0.3	3.6± 0.3	3.7± 0.3	3.8± 0.3	3.7± 0.3	3.8± 0.3	3.7± 0.3
100 ppm	3.8± 0.2	3.7± 0.3	3.9± 0.3	3.9± 0.2	3.9± 0.3*	4.0± 0.3*	3.9± 0.2**
300 ppm	3.8± 0.3	3.8± 0.3**	4.0± 0.2**	4.1± 0.2**	4.1± 0.2**	4.1± 0.2**	4.1± 0.2**
1000 ppm	3.6± 0.3**	3.8± 0.2**	4.0± 0.2**	4.0± 0.2**	4.0± 0.2*	4.1± 0.3**	4.0± 0.2**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	3.8± 0.3	3.8± 0.3	3.8± 0.2	3.8± 0.3	3.7± 0.3	3.8± 0.4	3.8± 0.3
100 ppm	3.9± 0.3	4.0± 0.2**	3.9± 0.4	4.0± 0.4	3.9± 0.4*	4.0± 0.3*	3.9± 0.3
300 ppm	4.1± 0.2**	4.1± 0.3**	4.0± 0.2**	4.1± 0.2**	4.0± 0.2**	4.0± 0.3**	4.1± 0.3**
1000 ppm	4.0± 0.3*	4.0± 0.2*	4.0± 0.2**	4.0± 0.2	4.0± 0.2**	4.0± 0.2	4.1± 0.2**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	15-7 (7)	16-7 (7)	17-7 (7)	18-7 (7)	19-7 (7)	20-7 (7)	21-7 (7)
Control	3.8 ± 0.3	3.7 ± 0.3	3.8 ± 0.3	3.8 ± 0.4	3.8 ± 0.3	3.9 ± 0.4	4.0 ± 0.4
100 ppm	4.0 ± 0.2	3.9 ± 0.3	4.0 ± 0.5	4.0 ± 0.4	4.0 ± 0.3	4.2 ± 0.5	4.1 ± 0.5
300 ppm	4.1 ± 0.3**	4.0 ± 0.3**	4.1 ± 0.6**	4.1 ± 0.4	4.2 ± 0.4**	4.4 ± 0.5**	4.4 ± 0.4**
1000 ppm	4.0 ± 0.2*	3.9 ± 0.2	4.0 ± 0.3*	4.0 ± 0.2	4.1 ± 0.2*	4.2 ± 0.4	4.1 ± 0.7

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)				
	22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	4.0± 0.4	4.0± 0.4	4.0± 0.4	4.1± 0.4	4.2± 0.5
100 ppm	4.1± 0.5	4.1± 0.5	4.2± 0.6	4.3± 0.6	4.3± 0.6
300 ppm	4.3± 0.3**	4.3± 0.3	4.3± 0.6**	4.4± 0.4	4.4± 0.3
1000 ppm	4.1± 0.8	4.3± 0.4	4.4± 0.3**	4.4± 0.4	4.2± 0.6

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE A 13**

**FOOD CONSUMPTION CHANGES : FEMALE**

(Control, 100, 300 and 1,000 ppm groups)



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	3.5± 0.3	3.4± 0.3	3.6± 0.3	3.7± 0.3	3.7± 0.3	3.8± 0.3	3.8± 0.3
100 ppm	3.6± 0.3	3.3± 0.3	3.5± 0.3	3.6± 0.4	3.7± 0.4	3.9± 0.3	3.8± 0.3
300 ppm	3.4± 0.3	3.4± 0.3	3.7± 0.3	3.9± 0.3*	3.9± 0.3*	4.0± 0.3*	4.1± 0.2*
1000 ppm	3.1± 0.6*	3.6± 0.3	3.9± 0.2**	4.0± 0.2**	4.0± 0.2**	4.1± 0.2**	4.1± 0.2*

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	3.7± 0.3	3.7± 0.2	3.6± 0.4	3.7± 0.4	3.6± 0.4	3.5± 0.5	3.6± 0.5
100 ppm	3.9± 0.2*	3.8± 0.2	3.8± 0.2	3.7± 0.2	3.7± 0.2	3.7± 0.3**	3.7± 0.2
300 ppm	4.0± 0.3**	3.9± 0.2**	3.9± 0.3**	3.8± 0.2*	3.9± 0.3**	3.8± 0.3**	3.9± 0.3**
1000 ppm	4.1± 0.2**	4.0± 0.2**	4.1± 0.3**	4.1± 0.2**	4.1± 0.2**	4.0± 0.3**	4.2± 0.2**

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	3.6± 0.5	3.6± 0.5	3.7± 0.5	3.6± 0.5	3.8± 0.5	4.0± 0.5	3.8± 0.2
100 ppm	3.8± 0.3**	3.7± 0.3*	3.8± 0.3	3.8± 0.3**	3.9± 0.2	3.9± 0.3	4.0± 0.2*
300 ppm	3.9± 0.3**	3.9± 0.3**	4.0± 0.3**	4.0± 0.3**	4.1± 0.3**	4.1± 0.3*	4.1± 0.3**
1000 ppm	4.2± 0.2**	4.1± 0.3**	4.3± 0.4**	4.4± 0.3**	4.5± 0.3**	4.6± 0.5**	4.7± 0.6**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)				
	22-7 (7)	23-7 (7)	24-7 (7)	25-7 (7)	26-7 (7)
Control	3.8 ± 0.2	3.8 ± 0.2	3.6 ± 0.2	3.7 ± 0.2	3.9 ± 0.3
100 ppm	3.9 ± 0.2	3.9 ± 0.3	3.8 ± 0.2	3.9 ± 0.3	4.0 ± 0.2
300 ppm	4.1 ± 0.3**	4.0 ± 0.3**	4.1 ± 0.3**	4.1 ± 0.3**	4.2 ± 0.3**
1000 ppm	4.6 ± 0.4**	4.4 ± 0.6**	4.5 ± 0.6**	4.6 ± 0.4**	4.5 ± 0.5**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE A 14**

**HEMATOLOGY : MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH Pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	25	10.10±	0.30	14.4±	0.3	44.6±	1.0	44.1±	0.7	14.3±	0.3	32.4±	0.4	1394±	185
100 ppm	24	10.14±	0.61	15.1±	0.7**	45.8±	1.9**	45.3±	1.5**	14.9±	0.3**	32.9±	0.7**	1313±	257
300 ppm	22	10.75±	0.62**	16.9±	0.9**	50.4±	2.4**	47.0±	1.1**	15.7±	0.4**	33.5±	0.4**	1167±	277**
1000 ppm	8	9.19±	0.97	15.8±	1.4**	47.9±	4.6**	52.2±	0.8**	17.3±	0.4**	33.1±	0.5**	738±	232**

Significant difference ; \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	25	3.7±	0.4
100 ppm	24	3.6±	2.5**
300 ppm	22	2.6±	0.6**
1000 ppm	8	3.0±	1.6**

---

Significant difference ; \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^3/\mu l$		NEUTRO		LYMPHO							
Control	25	3.50±	1.44	13.2±	4.9	82.2±	6.3	3.9±	2.1	0.7±	0.6	0.0±	0.0
100 ppm	24	4.62±	2.42	14.2±	11.8	80.6±	12.5	4.1±	1.6	1.1±	0.8	0.0±	0.1
300 ppm	22	5.17±	1.97**	12.5±	6.0	81.6±	7.7	4.4±	1.9	1.5±	0.9**	0.0±	0.1
1000 ppm	8	2.05±	1.07*	29.2±	12.2**	65.1±	13.0**	4.8±	1.7	0.8±	0.5	0.0±	0.0

Significant difference ; \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$       Test of Dunnett



**TABLE A 15**

**HEMATOLOGY : FEMALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH Pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	22	10.37±	0.38	15.1±	0.5	45.5±	1.4	43.9±	0.7	14.5±	0.4	33.1±	0.4	1196±	175
100 ppm	24	10.32±	0.38	15.5±	0.4**	46.5±	1.2	45.0±	1.0**	15.0±	0.4**	33.4±	0.4*	1155±	157
300 ppm	25	10.29±	0.69	16.3±	0.9**	48.4±	2.8**	47.0±	1.0**	15.9±	0.4**	33.7±	0.3**	1061±	308**
1000 ppm	9	8.61±	0.89**	14.8±	1.6	43.8±	4.5	50.9±	0.7**	17.2±	0.3**	33.8±	0.8**	548±	137**

Significant difference ; \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 5

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	22	3.6 ±	0.4
100 ppm	24	3.1 ±	0.5**
300 ppm	25	2.4 ±	0.8**
1000 ppm	9	3.3 ±	1.4

---

Significant difference ; \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^3/\mu\ell$		NEUTRO		LYMPHO							
Control	22	2.99±	1.23	14.4±	4.4	82.9±	4.6	2.2±	1.0	0.5±	0.7	0.0±	0.1
100 ppm	24	2.92±	1.37	13.9±	4.8	83.3±	4.7	2.4±	1.1	0.4±	0.7	0.0±	0.1
300 ppm	25	3.90±	2.00	12.8±	4.5	83.2±	4.3	3.3±	1.3**	0.7±	0.7	0.0±	0.0
1000 ppm	9	6.64±	4.19**	13.3±	7.5	78.3±	11.6	7.3±	8.0**	0.9±	0.6	0.2±	0.3**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE A 16**

**BIOCHEMISTRY : MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	25	5.2±	0.3	3.2±	0.2	1.5±	0.1	0.11±	0.02	189±	30	86±	11	41±	8
100 ppm	24	5.2±	0.2	3.2±	0.3	1.5±	0.2	0.11±	0.02	198±	35	84±	12	51±	17*
300 ppm	22	5.2±	0.3	3.1±	0.2	1.5±	0.1	0.14±	0.04**	226±	31**	83±	17	55±	15**
1000 ppm	8	5.0±	0.3	3.0±	0.2	1.6±	0.2	0.14±	0.04*	189±	29	83±	21	40±	9

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	25	184±	20	65±	28	17±	2	239±	69	212±	25	0.2±	0.2	93±	45
100 ppm	24	174±	29	72±	29	21±	8	238±	56	196±	23	0.1±	0.2	107±	82
300 ppm	22	176±	31	70±	28	20±	8	266±	52	201±	41	0.2±	0.2	86±	26
1000 ppm	8	161±	30	155±	83**	27±	10**	1614±	1478**	209±	25	0.2±	0.2	87±	29

Significant difference ; \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 3

Group Name	NO. of Animals	UREANITROGEN mg/dl		SODIUM mEq/l		POTASSIUM mEq/l		CHLORIDE mEq/l		CALCIUM mg/dl		INORGANIC PHOSPHRUS mg/dl	
Control	25	31.1±	3.0	151±	1	4.0±	0.3	118±	2	8.7±	0.2	5.2±	0.8
100 ppm	24	29.9±	12.8**	151±	2	4.0±	0.3	120±	4	8.8±	0.3	5.3±	1.5
300 ppm	22	25.3±	3.1**	149±	1**	4.0±	0.3	121±	5*	8.7±	0.3	4.7±	0.6
1000 ppm	8	25.7±	7.3**	151±	2	3.9±	0.4	123±	3**	9.0±	0.5	5.6±	1.4

Significant difference ; \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett



**TABLE A 17**

**BIOCHEMISTRY : FEMALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	22	5.2±	0.3	3.3±	0.2	1.7±	0.1	0.13±	0.04	197±	27	69±	13	30±	6
100 ppm	24	5.3±	0.2	3.4±	0.2	1.8±	0.1	0.12±	0.03	202±	27	70±	11	34±	10
300 ppm	25	5.3±	0.2	3.3±	0.1	1.7±	0.1	0.13±	0.03	203±	38	68±	12	37±	13
1000 ppm	9	5.2±	0.3	3.3±	0.2	1.7±	0.2	0.13±	0.02	202±	35	75±	10	53±	18**

Significant difference ; \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 5

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	22	147±	23	66±	23	17±	3	194±	57	349±	51	0.3±	0.3	83±	73
100 ppm	24	150±	23	65±	20	18±	3	199±	46	355±	195	0.3±	0.3	67±	14
300 ppm	25	147±	24	76±	32	23±	6**	261±	57**	365±	130	0.1±	0.2	126±	183
1000 ppm	9	158±	19	75±	28	31±	13**	711±	504**	391±	132	0.2±	0.1	80±	47

Significant difference ; \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

PAGE : 6

Group Name	NO. of Animals	UREANITROGEN mg/dl		SODIUM mEq/l		POTASSIUM mEq/l		CHLORIDE mEq/l		CALCIUM mg/dl		INORGANIC PHOSPHRUS mg/dl	
Control	22	24.5±	4.1	150±	2	3.7±	0.3	117±	3	8.7±	0.3	5.4±	1.3
100 ppm	24	22.9±	3.2	149±	1	3.6±	0.3	119±	3	8.7±	0.2	4.8±	1.1
300 ppm	25	22.9±	6.7	149±	1*	3.7±	0.4	121±	4**	8.7±	0.2	4.6±	1.0*
1000 ppm	9	24.0±	2.9	149±	1*	3.7±	0.3	122±	4**	9.0±	0.3	5.6±	0.7

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS 6

**TABLE A 18**

**GROSS FINDINGS : MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control		100 ppm		300 ppm		1000 ppm	
			25	(%)	25	(%)	25	(%)	25	(%)
skin/app	erosion		0	( 0)	1	( 4)	1	( 4)	0	( 0)
lung	white zone		0	( 0)	0	( 0)	0	( 0)	1	( 4)
	red zone		0	( 0)	1	( 4)	1	( 4)	4	( 16)
lymph node	enlarged		0	( 0)	0	( 0)	0	( 0)	1	( 4)
thymus	enlarged		0	( 0)	0	( 0)	1	( 4)	20	( 80)
	red zone		0	( 0)	0	( 0)	0	( 0)	1	( 4)
spleen	enlarged		0	( 0)	1	( 4)	2	( 8)	3	( 12)
	black zone		4	( 16)	4	( 16)	3	( 12)	0	( 0)
	cyst		0	( 0)	0	( 0)	0	( 0)	1	( 4)
heart	white		0	( 0)	0	( 0)	0	( 0)	1	( 4)
	hypertrophy		0	( 0)	1	( 4)	0	( 0)	0	( 0)
stomach	forestomach:nodule		0	( 0)	0	( 0)	0	( 0)	1	( 4)
	forestomach:white zone		1	( 4)	0	( 0)	0	( 0)	5	( 20)
	glandular stomach:ulcer		0	( 0)	1	( 4)	0	( 0)	0	( 0)
	glandular stomach:black zone		0	( 0)	0	( 0)	1	( 4)	0	( 0)
	glandular stomach:red zone		1	( 4)	0	( 0)	1	( 4)	0	( 0)
liver	enlarged		0	( 0)	0	( 0)	1	( 4)	0	( 0)
	nodule		0	( 0)	1	( 4)	0	( 0)	0	( 0)
	scarred		0	( 0)	1	( 4)	0	( 0)	0	( 0)
urin bladd	urine:marked retention		0	( 0)	0	( 0)	0	( 0)	1	( 4)
testis	small		0	( 0)	0	( 0)	24	( 96)	24	( 96)
periph nerv	thick		0	( 0)	0	( 0)	0	( 0)	1	( 4)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control		100 ppm		300 ppm		1000 ppm	
			25	(%)	25	(%)	25	(%)	25	(%)
eye	white		0	( 0)	0	( 0)	0	( 0)	1	( 4)
pleura	thick		0	( 0)	0	( 0)	0	( 0)	5	( 20)
mediastinum	mass		1	( 4)	0	( 0)	0	( 0)	0	( 0)
thoracic ca	pleural fluid		0	( 0)	1	( 4)	0	( 0)	14	( 56)
other	lower jaw:nodule		0	( 0)	0	( 0)	0	( 0)	1	( 4)

**TABLE A 19**

**GROSS FINDINGS : FEMALE**

(Control, 100, 300 and 1,000 ppm groups)



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control		100 ppm		300 ppm		1000 ppm	
			25	(%)	25	(%)	25	(%)	25	(%)
skin/app	ulcer		1	( 4)	0	( 0)	0	( 0)	0	( 0)
subcutis	mass		0	( 0)	0	( 0)	0	( 0)	1	( 4)
lung	white zone		0	( 0)	0	( 0)	1	( 4)	1	( 4)
	red zone		0	( 0)	0	( 0)	0	( 0)	2	( 8)
lymph node	enlarged		0	( 0)	0	( 0)	0	( 0)	1	( 4)
thymus	enlarged		1	( 4)	1	( 4)	0	( 0)	13	( 52)
	red zone		0	( 0)	0	( 0)	0	( 0)	1	( 4)
spleen	enlarged		1	( 4)	0	( 0)	0	( 0)	12	( 48)
	white zone		0	( 0)	0	( 0)	0	( 0)	1	( 4)
	black zone		1	( 4)	2	( 8)	1	( 4)	0	( 0)
heart	hypertrophy		0	( 0)	0	( 0)	0	( 0)	1	( 4)
stomach	forestomach:ulcer		0	( 0)	0	( 0)	0	( 0)	1	( 4)
	forestomach:white zone		0	( 0)	0	( 0)	0	( 0)	5	( 20)
	glandular stomach:red zone		0	( 0)	1	( 4)	1	( 4)	0	( 0)
	glandular stomach:white zone		3	( 12)	0	( 0)	1	( 4)	0	( 0)
liver	enlarged		0	( 0)	0	( 0)	0	( 0)	2	( 8)
	red zone		0	( 0)	0	( 0)	0	( 0)	2	( 8)
	nodule		1	( 4)	0	( 0)	0	( 0)	1	( 4)
	cyst		0	( 0)	0	( 0)	0	( 0)	1	( 4)
kidney	white zone		0	( 0)	1	( 4)	0	( 0)	0	( 0)
	red zone		1	( 4)	0	( 0)	0	( 0)	0	( 0)
	absence		1	( 4)	0	( 0)	0	( 0)	0	( 0)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control		100 ppm		300 ppm		1000 ppm	
			25	(%)	25	(%)	25	(%)	25	(%)
urin bladd	urine:marked retention		0	( 0)	0	( 0)	0	( 0)	1	( 4)
ovary	small		0	( 0)	0	( 0)	0	( 0)	1	( 4)
brain	red zone		0	( 0)	0	( 0)	1	( 4)	0	( 0)
spinal cord	red zone		0	( 0)	0	( 0)	0	( 0)	1	( 4)
eye	turbid		0	( 0)	0	( 0)	0	( 0)	1	( 4)
muscle	mass		0	( 0)	0	( 0)	0	( 0)	1	( 4)
pleura	thick		0	( 0)	1	( 4)	0	( 0)	0	( 0)
thoracic ca	pleural fluid		1	( 4)	1	( 4)	0	( 0)	10	( 40)
whole body	anemic		1	( 4)	0	( 0)	0	( 0)	0	( 0)

TABLE A 20

ORGAN WEIGHT, ABSOLUTE : MALE  
(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
Control	25	30.5 ± 2.7	0.011 ±	0.003	0.224 ±	0.020	0.155 ±	0.018	0.154 ±	0.017	0.428 ±	0.043
100 ppm	24	31.6 ± 3.8	0.011 ±	0.003	0.200 ±	0.023**	0.157 ±	0.015	0.158 ±	0.011	0.421 ±	0.046
300 ppm	22	31.4 ± 3.2	0.013 ±	0.005	0.071 ±	0.019**	0.156 ±	0.013	0.162 ±	0.013	0.415 ±	0.041
1000 ppm	8	25.2 ± 1.6**	0.009 ±	0.001	0.054 ±	0.006**	0.164 ±	0.015	0.160 ±	0.011	0.405 ±	0.049

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	25	0.073 ±	0.016	1.292 ±	0.086	0.469 ±	0.015
100 ppm	24	0.082 ±	0.037	1.298 ±	0.157	0.467 ±	0.015
300 ppm	22	0.084 ±	0.012**	1.295 ±	0.165	0.466 ±	0.018
1000 ppm	8	0.101 ±	0.026**	1.249 ±	0.145	0.437 ±	0.017**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL040)

BAIS 6

TABLE A 21

ORGAN WEIGHT, ABSOLUTE : FEMALE

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	ADRENALS		OVARIES		HEART		LUNGS		KIDNEYS	
Control	23	23.0± 1.3	0.015±	0.002	0.030±	0.006	0.132±	0.013	0.147±	0.013	0.347±	0.034
100 ppm	24	23.8± 1.7	0.015±	0.003	0.028±	0.004	0.133±	0.014	0.149±	0.013	0.343±	0.030
300 ppm	25	23.8± 1.8	0.014±	0.002	0.026±	0.007	0.138±	0.015	0.149±	0.011	0.351±	0.037
1000 ppm	9	24.2± 1.6	0.013±	0.002*	0.022±	0.012**	0.156±	0.014**	0.160±	0.015	0.399±	0.020**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	23	0.078 ±	0.009	1.008 ±	0.131	0.483 ±	0.021
100 ppm	24	0.080 ±	0.010	1.061 ±	0.116	0.478 ±	0.017
300 ppm	25	0.091 ±	0.014**	1.105 ±	0.135*	0.476 ±	0.013
1000 ppm	9	0.261 ±	0.301**	1.444 ±	0.113**	0.459 ±	0.011**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL040)

BAIS 6



TABLE A 22

ORGAN WEIGHT, RELATIVE : MALE

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	25	30.5 ± 2.7	0.035 ± 0.009	0.740 ± 0.095	0.510 ± 0.048	0.506 ± 0.050	1.405 ± 0.108
100 ppm	24	31.6 ± 3.8	0.034 ± 0.010	0.641 ± 0.096**	0.504 ± 0.083	0.506 ± 0.062	1.356 ± 0.246
300 ppm	22	31.4 ± 3.2	0.040 ± 0.016	0.226 ± 0.047**	0.500 ± 0.048	0.521 ± 0.068	1.330 ± 0.173
1000 ppm	8	25.2 ± 1.6**	0.036 ± 0.005	0.214 ± 0.016**	0.651 ± 0.084**	0.635 ± 0.071**	1.606 ± 0.174*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	25	0.238 ± 0.037	4.256 ± 0.385	1.546 ± 0.132
100 ppm	24	0.272 ± 0.192	4.135 ± 0.440	1.504 ± 0.202
300 ppm	22	0.269 ± 0.045**	4.125 ± 0.383	1.497 ± 0.157
1000 ppm	8	0.404 ± 0.115**	4.944 ± 0.439**	1.738 ± 0.094*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL042)

BAIS 6

**TABLE A 23**

**ORGAN WEIGHT, RELATIVE : FEMALE**

**(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	23	23.0± 1.3	0.065± 0.009	0.130± 0.023	0.577± 0.062	0.643± 0.052	1.509± 0.146
100 ppm	24	23.8± 1.7	0.065± 0.012	0.119± 0.018	0.561± 0.057	0.629± 0.055	1.446± 0.131
300 ppm	25	23.8± 1.8	0.059± 0.008	0.112± 0.033**	0.584± 0.064	0.629± 0.046	1.479± 0.154
1000 ppm	9	24.2± 1.6	0.052± 0.008**	0.093± 0.048**	0.647± 0.075*	0.662± 0.051	1.656± 0.141*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	23	0.341 ± 0.041	4.387 ± 0.499	2.106 ± 0.114
100 ppm	24	0.336 ± 0.035	4.471 ± 0.464	2.019 ± 0.129
300 ppm	25	0.382 ± 0.051**	4.644 ± 0.437	2.010 ± 0.132*
1000 ppm	9	1.054 ± 1.170**	5.977 ± 0.455**	1.905 ± 0.160**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL042)

BAIS 6

**TABLE A 24**

**HISTOPATHOLOGICAL FINDINGS :**

**NEOPLASTIC LESIONS : MALE**

**(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	100 ppm 25	300 ppm 25	1000 ppm 25
{Respiratory system}						
nasal cavit	esthesioneuroepithelioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
lung	bronchiolar-alveolar adenoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
{Hematopoietic system}						
lymph node	malignant lymphoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
thymus	histiocytic sarcoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
	malignant lymphoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 21 ( 84%)
{Digestive system}						
small intes	adenocarcinoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)
{Musculoskeletal system}						
muscle	rhabdomyosarcoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
{Body cavities}						
mediastinum	histiocytic sarcoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100



**TABLE A 25**

**HISTOPATHOLOGICAL FINDINGS :**

**NEOPLASTIC LESIONS : FEMALE**

**(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	100 ppm 25	300 ppm 25	1000 ppm 25
{Integumentary system/appandage}						
skin/app	basal cell carcinoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
subcutis	sarcoma:NOS		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
{Respiratory system}						
lung	bronchiolar-alveolar adenoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)
{Hematopoietic system}						
thymus	malignant lymphoma		<25> 1 ( 4%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 14 ( 56%)
spleen	malignant lymphoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 2 ( 8%)
{Digestive system}						
liver	hemangioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
{Nervous system}						
brain	glioblastoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

**TABLE A 26**

**NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : MALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : nasal cavity TUMOR : esthesioneuroepithelioma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	12.50
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	1/ 8 ( 12.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0406*			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	5.56
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	0/ 8 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1054			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : lymph node TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	0/ 8 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1054			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1054			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000

STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : thymus TUMOR : histiocytic sarcoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	0/ 8 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1440			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1440			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : thymus TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)	21/25 ( 84.0)
Adjusted rates(b)	0.00	0.00	0.00	87.50
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	7/ 8 ( 87.5)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P < 0.0001**
SITE : small intestine TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)	0/25 ( 0.0)
Adjusted rates(b)	0.00	0.00	4.55	0.00
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	1/22 ( 4.5)	0/ 8 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.2237			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8976			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.

STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : muscle				
TUMOR : rhabdomyosarcoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	0/ 8 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1119			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1119			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : mediastinum				
TUMOR : histiocytic sarcoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)
Adjusted rates(b)	4.00	0.00	0.00	0.00
Terminal rates(c)	1/25 ( 4.0)	0/24 ( 0.0)	0/22 ( 0.0)	0/ 8 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.3677			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000

STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : lymph node, thymus				
TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)	22/25 ( 88.0)
Adjusted rates(b)	0.00	0.00	0.00	87.50
Terminal rates(c)	0/25 ( 0.0)	0/24 ( 0.0)	0/22 ( 0.0)	7/ 8 ( 87.5)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P < 0.0001**

(HPT360)

BAIS6

- (a) : Number of tumor-bearing animals/number of animals examined at the site.  
 (b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c) : Observed tumor incidence at terminal kill.  
 (d) : Beneath the control incidence are the P-values associated with the trend test.  
     Standard method : Death analysis  
     Prevalence method : Incidental tumor test  
     Combined analysis : Death analysis + Incidental tumor test  
 (e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

**TABLE A 27**

**NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : FEMALE  
(Control, 100, 300 and 1,000 ppm groups)**



STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : FEMALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : skin/appendage TUMOR : basal cell carcinoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	0/10 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1271			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1271			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : subcutis TUMOR : sarcoma:NOS				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	0/10 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0705			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.0705			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)	0/25 ( 0.0)
Adjusted rates(b)	0.00	0.00	4.00	0.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	1/25 ( 4.0)	0/10 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.2545			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8976			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.

STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : FEMALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : thymus TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	1/25 ( 4.0)	0/25 ( 0.0)	14/25 ( 56.0)
Adjusted rates(b)	0.00	0.00	0.00	40.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	4/10 ( 40.0)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = 0.7551	P = 0.5000	P = 0.0001**
SITE : spleen TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	2/25 ( 8.0)
Adjusted rates(b)	0.00	0.00	0.00	10.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	1/10 ( 10.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1379			
Prevalence method(d)	P = 0.0510			
Combined analysis(d)	P = 0.0047**?			
Cochran-Armitage test(e)	P = 0.0174*			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.2449
SITE : liver TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	5.88
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	0/10 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0954			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0944			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000

STUDY No. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : FEMALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	100 ppm	300 ppm	1000 ppm
SITE : brain TUMOR : glioblastoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	0/25 ( 0.0)	1/25 ( 4.0)	0/25 ( 0.0)
Adjusted rates(b)	0.00	0.00	4.00	0.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	1/25 ( 4.0)	0/10 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.2545			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8976			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.
SITE : thymus, spleen TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	1/25 ( 4.0)	0/25 ( 0.0)	16/25 ( 64.0)
Adjusted rates(b)	0.00	0.00	0.00	50.00
Terminal rates(c)	0/23 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	5/10 ( 50.0)
Statistical analysis				
Peto test				
Standard method(d)	P < 0.0001**			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = 0.7551	P = 0.5000	P < 0.0001**

(HPT360)

BAIS6

(a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N. C. : Statistical value cannot be calculated and was not significant.

TABLE A 28

NUMBER OF ANIMALS WITH TUMORS AND  
NUMBER OF TUMORS - TIME RELATED: MALE  
(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	100 ppm	300 ppm	1000 ppm
1 - 13	NO. OF EXAMINED ANIMALS		0	1	0	0
	NO. OF ANIMALS WITH TUMORS		0	0	0	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	0	0	0
	NO. OF TOTAL TUMORS		0	0	0	0
14 - 26	NO. OF EXAMINED ANIMALS		0	0	3	17
	NO. OF ANIMALS WITH TUMORS		0	0	1	17
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	1	16
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	1
	NO. OF BENIGN TUMORS		0	0	0	1
	NO. OF MALIGNANT TUMORS		0	0	1	17
	NO. OF TOTAL TUMORS		0	0	1	18
27 - 27	NO. OF EXAMINED ANIMALS		25	24	22	8
	NO. OF ANIMALS WITH TUMORS		1	0	1	8
	NO. OF ANIMALS WITH SINGLE TUMORS		1	0	1	8
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		1	0	1	8
	NO. OF TOTAL TUMORS		1	0	1	8
1 - 27	NO. OF EXAMINED ANIMALS		25	25	25	25
	NO. OF ANIMALS WITH TUMORS		1	0	2	25
	NO. OF ANIMALS WITH SINGLE TUMORS		1	0	2	24
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	1
	NO. OF BENIGN TUMORS		0	0	0	1
	NO. OF MALIGNANT TUMORS		1	0	2	25
	NO. OF TOTAL TUMORS		1	0	2	26

**TABLE A 29**

**NUMBER OF ANIMALS WITH TUMORS AND  
NUMBER OF TUMORS - TIME RELATED: FEMALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	100 ppm	300 ppm	1000 ppm
1 - 13	NO. OF EXAMINED ANIMALS		0	1	0	2
	NO. OF ANIMALS WITH TUMORS		0	1	0	1
	NO. OF ANIMALS WITH SINGLE TUMORS		0	1	0	1
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	1	0	1
	NO. OF TOTAL TUMORS		0	1	0	1
14 - 26	NO. OF EXAMINED ANIMALS		2	0	0	13
	NO. OF ANIMALS WITH TUMORS		1	0	0	12
	NO. OF ANIMALS WITH SINGLE TUMORS		1	0	0	11
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	1
	NO. OF BENIGN TUMORS		0	0	0	1
	NO. OF MALIGNANT TUMORS		1	0	0	12
	NO. OF TOTAL TUMORS		1	0	0	13
27 - 27	NO. OF EXAMINED ANIMALS		23	24	25	10
	NO. OF ANIMALS WITH TUMORS		0	0	2	5
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	2	5
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	1	0
	NO. OF MALIGNANT TUMORS		0	0	1	5
	NO. OF TOTAL TUMORS		0	0	2	5
1 - 27	NO. OF EXAMINED ANIMALS		25	25	25	25
	NO. OF ANIMALS WITH TUMORS		1	1	2	18
	NO. OF ANIMALS WITH SINGLE TUMORS		1	1	2	17
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	1
	NO. OF BENIGN TUMORS		0	0	1	1
	NO. OF MALIGNANT TUMORS		1	1	1	18
	NO. OF TOTAL TUMORS		1	1	2	19

**TABLE A 30**

**HISTOPATHOLOGICAL FINDINGS :**

**METASTASIS OF TUMOR: MALE**

**(Control, 100, 300 and 1,000 ppm groups)**



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	100 ppm 25	300 ppm 25	1000 ppm 25
[Respiratory system]						
lung	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 16
	metastasis:mediastinum tumor		1	0	0	0
	metastasis:thymus tumor		0	0	0	1
[Hematopoietic system]						
bone marrow	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 6
lymph node	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 1
thymus	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
spleen	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 5
[Circulatory system]						
heart	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 17
	metastasis:mediastinum tumor		1	0	0	0
	metastasis:thymus tumor		0	0	0	1
[Digestive system]						
liver	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 7

< a > a : Number of animals examined at the site  
b : Number of animals with lesion

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	100 ppm 25	300 ppm 25	1000 ppm 25
{Urinary system}						
kidney	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 9
{Endocrine system}						
pituitary	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 3
{Nervous system}						
spinal cord	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
periph nerv	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
{Body cavities}						
pleura	leukemic cell infiltration		<25> 0	<25> 0	<25> 1	<25> 16
	metastasis:mediastinum tumor		1	0	0	0
	metastasis:thymus tumor		0	0	0	1

< a > a : Number of animals examined at the site  
 b : Number of animals with lesion

**TABLE A 31**

**HISTOPATHOLOGICAL FINDINGS :**

**METASTASIS OF TUMOR: FEMALE**

**(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	100 ppm 25	300 ppm 25	1000 ppm 25
[Integumentary system/appandage]						
skin/app	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
[Respiratory system]						
lung	leukemic cell infiltration		<25> 1	<25> 1	<25> 0	<25> 13
[Hematopoietic system]						
bone marrow	leukemic cell infiltration		<25> 1	<25> 1	<25> 0	<25> 9
lymph node	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 2
thymus	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 2
spleen	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 9
[Circulatory system]						
heart	leukemic cell infiltration		<25> 1	<25> 1	<25> 0	<25> 10
[Digestive system]						
liver	leukemic cell infiltration		<25> 0	<25> 1	<25> 0	<25> 11

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	100 ppm 25	300 ppm 25	1000 ppm 25
{Urinary system}						
kidney	leukemic cell infiltration		<25> 0	<25> 1	<25> 0	<25> 4
urin bladd	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
{Endocrine system}						
pituitary	leukemic cell infiltration		<25> 0	<25> 1	<25> 0	<25> 3
thyroid	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
adrenal	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
{Reproductive system}						
ovary	leukemic cell infiltration		<25> 1	<25> 1	<25> 0	<25> 1
uterus	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
vagina	leukemic cell infiltration		<25> 0	<25> 1	<25> 0	<25> 1
{Body cavities}						
pleura	leukemic cell infiltration		<25> 0	<25> 1	<25> 0	<25> 6

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

**TABLE A 32**

**HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC  
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER  
: B6.129S2-Trp53 tm1Tyj/J MALE MICE**

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN  
BIOASSAY RESEARCH CENTER : B6.129S2-Trp53 *tm1Tyj/J* MALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. – Max. (%)
Lymph node Malignant lymphoma (A)	100	1	1.0	0 – 4
Thymus Malignant lymphoma (B)	100	0	0.0	0 – 0
All organ Malignant lymphoma (A+B)	100	1	1.0	0 – 4

4 carcinogenicity studies examined in Japan Bioassay Research Center were used.  
Study No. : 0904, 0906, 0922, 0923

**TABLE A 33**

**HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC  
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER  
: B6.129S2-Trp53 tm1Tyj/J FEMALE MICE**



HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN  
BIOASSAY RESEARCH CENTER : B6.129S2-Trp53 *tm1Tyj/J* FEMALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. – Max. (%)
Lymph node Malignant lymphoma (C)	100	1	1.0	0 – 4
Thymus Malignant lymphoma (D)	100	0	0.0	0 – 0
Spleen Malignant lymphoma (E)	100	0	0.0	0 – 0
All organ Malignant lymphoma (C+D+E)	100	1	1.0	0 – 4

4 carcinogenicity studies examined in Japan Bioassay Research Center were used.  
Study No. : 0904, 0907, 0922, 0924

**TABLE A 34**

**HISTOPATHOLOGICAL FINDINGS:**

**NON-NEOPLASTIC LESIONS: MALE**

**(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Integumentary system/appandage]																		
skin/app	erosion		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	
[Respiratory system]																		
nasal cavit	malformation		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	eosinophilic change:olfactory epithelium		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	eosinophilic change:respiratory epithelium		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
lung	hemorrhage		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	inflammatory infiltration		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm			
		25				25				25				25			
Group Name No. of Animals on Study		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
Grade		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																	
lung		<25>				<25>				<25>				<25>			
	osseous metaplasia	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
		( 0 )	( 0 )	( 0 )	( 0 )	( 4 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 4 )	( 0 )	( 0 )	( 0 )
	pneumonia:NOS	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
		( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 4 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )
	bronchiolar-alveolar cell hyperplasia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 4 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )
{Hematopoietic system}																	
bone marrow		<25>				<25>				<25>				<25>			
	deposit of hemosiderin	0	0	0	0	0	0	0	0	0	0	0	0	17	0	0	0 **
		( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 68 )	( 0 )	( 0 )	( 0 )
	atrophy:focal	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
		( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 4 )	( 4 )	( 0 )	( 0 )
	decreased hematopoiesis	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 4 )	( 0 )	( 0 )	( 0 )
	increased hemotopoiesis:granulocyte/monocyte	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0 )	( 0 )	( 0 )	( 0 )	( 4 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )	( 0 )

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)			
{Hematopoietic system}																					
thymus	atrophy		<25>				<25>				<25>				<25>						
			0	0	0	0	2	0	0	0	1	0	0	0	2	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)			
spleen	atrophy		<25>				<25>				<25>				<25>						
			0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)			
	cyst		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)			
	deposit of hemosiderin		0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0 *			
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 24)	( 0)	( 0)	( 0)			
	deposit of melanin		4	0	0	0	4	0	0	0	3	0	0	0	0	0	0	0			
			( 16)	( 0)	( 0)	( 0)	( 16)	( 0)	( 0)	( 0)	( 12)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)			
	extramedullary hematopoiesis		1	0	0	0	0	2	0	0	0	0	1	0	6	2	0	0 *			
			( 4)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 24)	( 8)	( 0)	( 0)			
{Circulatory system}																					
heart	hemorrhage		<25>				<25>				<25>				<25>						
			0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)			

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
< a > a : Number of animals examined at the site  
b : Number of animals with lesion  
( c ) c : b / a \* 100  
Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Circulatory system]																		
heart	inflammatory infiltration		<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 1 (4) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)			
[Digestive system]																		
salivary gl	acinar cell hyperplasia:submaxillary gland		<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 25 (100) 0 (0) 0 (0) 0 (0) **			
	acinar cell hyperplasia:sublingual gland		<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 25 (100) 0 (0) 0 (0) 0 (0) **			
stomach	ulcer:forestomach		<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 1 (4) 0 (0) 0 (0) 0 (0)				<25> 2 (8) 1 (4) 0 (0) 0 (0)			
	hyperplasia:forestomach		<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 0 (0) 0 (0) 0 (0)				<25> 4 (16) 7 (28) 0 (0) 0 (0) **			
	erosion:glandular stomach		<25> 2 (8) 0 (0) 0 (0) 0 (0)				<25> 0 (0) 2 (8) 0 (0) 0 (0)				<25> 4 (16) 0 (0) 0 (0) 0 (0)				<25> 1 (4) 0 (0) 0 (0) 0 (0)			

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																	
small intes		<25>				<25>				<25>				<25>			
	inflammation	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	lymphocytic infiltration	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
liver		<25>				<25>				<25>				<25>			
	angiectasis	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)
	inflammatory cell nest	5	2	0	0	6	0	0	0	8	2	0	0	1	0	0	0
		( 20)	( 8)	( 0)	( 0)	( 24)	( 0)	( 0)	( 0)	( 32)	( 8)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
	extramedullary hematopoiesis	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 12)	( 0)	( 0)	( 0)
	endothelial cell hyperplasia	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
gall bladd		<25>				<25>				<25>				<25>			
	degeneration:focal	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																		
pancreas			<25>				<25>				<25>				<25>			
	vacuolic change		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
{Urinary system}																		
kidney			<25>				<25>				<25>				<25>			
	inflammatory infiltration		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	regeneration:proximal tubule		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	
	deposit of brown pigment:proximal tubule		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
urin bladd			<25>				<25>				<25>				<25>			
	dilatation		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	
{Endocrine system}																		
pituitary			<25>				<25>				<25>				<25>			
	Rathke pouch		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Endocrine system]																	
adrenal	hyperplasia:cortical cell	<25>				<25>				<25>				<25>			
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
[Reproductive system]																	
testis	degeneration:seminiferous epithelium	<25>				<25>				<25>				<25>			
		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	tubular atrophy	2	0	0	0	1	0	0	0	8	15	2	0 **	0	0	25	0 **
		( 8)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 32)	( 60)	( 8)	( 0)	( 0)	( 0)	( 100)	( 0)
epididymis	decreased:sperma	<25>				<25>				<25>				<25>			
		0	0	0	0	0	0	0	0	23	1	0	0 **	1	24	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 92)	( 4)	( 0)	( 0)	( 4)	( 96)	( 0)	( 0)
	debris of spermatic elements	0	0	0	0	0	0	0	0	25	0	0	0 **	21	0	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 100)	( 0)	( 0)	( 0)	( 84)	( 0)	( 0)	( 0)
semin ves	dilatation	<25>				<25>				<25>				<25>			
		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Reproductive system}																		
semin ves	inflammatory infiltration		<25>				<25>				<25>				<25>			
			0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
{Special sense organs/appendage}																		
eye	ulcer:cornea		<25>				<25>				<25>				<25>			
			0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
Harder gl	hyperplasia		<25>				<25>				<25>				<25>			
			0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
			( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
{Musculoskeletal system}																		
bone	osteosclerosis		<25>				<25>				<25>				<25>			
			0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

**TABLE A 35**

**HISTOPATHOLOGICAL FINDINGS:  
NON-NEOPLASTIC LESIONS: FEMALE  
(Control, 100, 300 and 1,000 ppm groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Integumentary system/appandage]																		
skin/app	ulcer		<25>				<25>				<25>				<25>			
			0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Respiratory system]																		
nasal cavit	malformation		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	
	eosinophilic change:olfactory epithelium		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	eosinophilic change:respiratory epithelium		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	inflammation:transitional epithelium		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	
lung	hemorrhage		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Respiratory system]																	
lung		<25>				<25>				<25>				<25>			
	inflammatory infiltration	2	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
		( 8)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
	inflammation:focal	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
	vacuolic change:bronchial epithelium	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 12)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	eosinophilic crystalline pneumonia	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)
[Hematopoietic system]																	
bone marrow		<25>				<25>				<25>				<25>			
	deposit of hemosiderin	1	0	0	0	2	0	0	0	4	0	0	0	2	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 16)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
thymus		<25>				<25>				<25>				<25>			
	atrophy	1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 12)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
< a > a : Number of animals examined at the site  
b : Number of animals with lesion  
( c ) c : b / a \* 100  
Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25					
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)		
{Hematopoietic system}																				
thymus	inflammation		<25>				<25>				<25>				<25>					
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)			
spleen	deposit of hemosiderin		<25>				<25>				<25>				<25>					
			1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	10 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of melanin		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	extramedullary hematopoiesis		0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 24)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
{Circulatory system}																				
heart	thrombus		<25>				<25>				<25>				<25>					
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	endothelial cell hyperplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm				
		25				25				25				25				
Group Name No. of Animals on Study Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	
{Digestive system}																		
salivary gl		<25>				<25>				<25>				<25>				
	acinar cell hyperplasia:submaxillary gland	0	0	0	0	0	0	0	0	0	0	0	0	25	0	0	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	(100)	( 0)	( 0)	( 0)	( 0)
	acinar cell hyperplasia:sublingual gland	0	0	0	0	0	0	0	0	0	0	0	0	25	0	0	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	(100)	( 0)	( 0)	( 0)	( 0)
stomach		<25>				<25>				<25>				<25>				
	erosion:forestomach	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	ulcer:forestomach	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)
	hyperplasia:forestomach	1	0	0	0	0	0	0	0	2	0	0	0	12	5	3	0	0 **
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 48)	( 20)	( 12)	( 0)	( 0)
	erosion:glandular stomach	0	2	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0
		( 0)	( 8)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)
liver		<25>				<25>				<25>				<25>				
	herniation	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm			
		25				25				25				25			
Group Name No. of Animals on Study Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																	
liver																	
		<25>				<25>				<25>				<25>			
angiectasis		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
hemorrhage		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
inflammatory cell nest		10	1	0	0	6	0	0	0	10	1	0	0	5	0	0	0
		( 40)	( 4)	( 0)	( 0)	( 24)	( 0)	( 0)	( 0)	( 40)	( 4)	( 0)	( 0)	( 20)	( 0)	( 0)	( 0)
extramedullary hematopoiesis		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
{Urinary system}																	
kidney																	
		<25>				<25>				<25>				<25>			
aplasia		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
hyaline cast		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
urin bladd																	
		<25>				<25>				<25>				<25>			
lymphocytic infiltration		1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
< a > a : Number of animals examined at the site  
b : Number of animals with lesion  
( c ) c : b / a \* 100  
Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Endocrine system]																		
pituitary	cystic degeneration:anterior lobe		<25>				<25>				<25>				<25>			
			2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
parathyroid	cyst		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
adrenal	mineralization:cortex		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	acesory cortical nodule		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
ovary	atrophy		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 24)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 24)	19 ( 76)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				100 ppm 25				300 ppm 25				1000 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Reproductive system}																		
ovary			<25>				<25>				<25>				<25>			
	hyperplasia		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	ovarian cyst		2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)
uterus			<25>				<25>				<25>				<25>			
	atrophy		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	21 ( 84)	0 ( 0)	0 ( 0)
	cystic endometrial hyperplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
vagina			<25>				<25>				<25>				<25>			
	mucification:epithelium		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	atrophy:epithelium		2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	19 ( 76)	0 ( 0)	0 ( 0)	
{Nervous system}																		
spinal cord			<25>				<25>				<25>				<25>			
	hemorrhage		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control				100 ppm				300 ppm				1000 ppm			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		25				25				25				25			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Special sense organs/appendage]																	
eye	keratitis	<25>				<25>				<25>				<25>			
		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
[Musculoskeletal system]																	
bone	osteosclerosis	<25>				<25>				<25>				<25>			
		0	0	0	0	4	0	0	0	2	0	0	0	12	11	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 16)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	( 48)	( 44)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

**TABLE A 36**

**CAUSE OF DEATH: MALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

Group Name	Control	100 ppm	300 ppm	1000 ppm
Number of Dead and Moribund Animal	0	1	3	17
no microscop confirm	0	0	1	0
integumentary sy les	0	0	1	0
pneumonia	0	1	0	0
tumor d:thymus	0	0	0	1
tumor d:small intes	0	0	0	0
tumor d:muscle	0	0	0	1
tumor d:mal lymphoma	0	0	1	15

(BI0120)

BAIS6

**TABLE A 37**

**CAUSE OF DEATH: FEMALE**

(Control, 100, 300 and 1,000 ppm groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

Group Name	Control	100 ppm	300 ppm	1000 ppm
Number of Dead and Moribund Animal	2	1	0	15
no microscop confirm	0	0	0	1
integumentary sy les	1	0	0	0
central nervo lesion	0	0	0	1
tumor d:skin/app	0	0	0	1
tumor d:subcutis	0	0	0	1
tumor d:mal lymphoma	1	1	0	11

(BI0120)

BAIS6

TABLE B 1

SURVIVAL ANIMAL NUMBERS : MALE

(Control and Positive control groups)



STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 1

Group Name	Animals At start	Administration (Days)													
		0-0	1-1	1-2	1-3	1-4	1-5	1-6	1-7	2-1	2-2	2-3	2-4	2-5	2-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 2

Group Name	Animals At start	Administration (Days)													
		2-7	3-1	3-2	3-3	3-4	3-5	3-6	3-7	4-1	4-2	4-3	4-4	4-5	4-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		4-7	5-1	5-2	5-3	5-4	5-5	5-6	5-7	6-1	6-2	6-3	6-4	6-5	6-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 4

Group Name	Animals At start	Administration (Days)													
		6-7	7-1	7-2	7-3	7-4	7-5	7-6	7-7	8-1	8-2	8-3	8-4	8-5	8-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 5

Group Name	Animals At start	Administration (Days)													
		8-7	9-1	9-2	9-3	9-4	9-5	9-6	9-7	10-1	10-2	10-3	10-4	10-5	10-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 6

Group Name	Animals At start	Administration (Days)													
		10-7	11-1	11-2	11-3	11-4	11-5	11-6	11-7	12-1	12-2	12-3	12-4	12-5	12-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 7

Group Name	Animals At start	Administration (Days)													
		12-7	13-1	13-2	13-3	13-4	13-5	13-6	13-7	14-1	14-2	14-3	14-4	14-5	14-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	19/20 95.0	19/20 95.0	18/20 90.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 8

Group Name	Animals At start	Administration (Days)													
		14-7	15-1	15-2	15-3	15-4	15-5	15-6	15-7	16-1	16-2	16-3	16-4	16-5	16-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	18/20 90.0	18/20 90.0	18/20 90.0	18/20 90.0	18/20 90.0	18/20 90.0	18/20 90.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6



STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 9

Group Name	Animals At start	Administration (Days)													
		16-7	17-1	17-2	17-3	17-4	17-5	17-6	17-7	18-1	18-2	18-3	18-4	18-5	18-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 10

Group Name	Animals At start	Administration (Days)													
		18-7	19-1	19-2	19-3	19-4	19-5	19-6	19-7	20-1	20-2	20-3	20-4	20-5	20-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	15/20 75.0	15/20 75.0	15/20 75.0	14/20 70.0	14/20 70.0	14/20 70.0	14/20 70.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : MALE

SURVIVAL ANIMAL NUMBERS

PAGE : 11

Group Name	Animals At start	Administration (Days)													
		20-7	21-1	21-2	21-3	21-4	21-5	21-6	21-7	22-1	22-2	22-3	22-4	22-5	22-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	14/20 70.0	13/20 65.0	13/20 65.0	13/20 65.0	13/20 65.0	11/20 55.0	11/20 55.0	11/20 55.0	11/20 55.0	11/20 55.0	11/20 55.0	11/20 55.0	11/20 55.0	11/20 55.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		22-7	23-1	23-2	23-3	23-4	23-5	23-6	23-7	24-1	24-2	24-3	24-4	24-5	24-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	11/20 55.0	11/20 55.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		24-7	25-1	25-2	25-3	25-4	25-5	25-6	25-7	26-1	26-2	26-3	26-4	26-5	26-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

SURVIVAL ANIMAL NUMBERS

---

Group Name	Animals At start	Administration (Days) 26-7
Control	25	25/25 100.0
Posi. Control	20	10/20 50.0

---

Number of survival/ Number of effective animals  
Survival rate(%)

---

(HAN360)

BAIS6

**TABLE B 2**

**SURVIVAL ANIMAL NUMBERS : FEMALE**

**(Control and Positive control groups)**

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 15

Group Name	Animals At start	Administration (Days)													
		0-0	1-1	1-2	1-3	1-4	1-5	1-6	1-7	2-1	2-2	2-3	2-4	2-5	2-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6



STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 16

Group Name	Animals At start	Administration (Days)													
		2-7	3-1	3-2	3-3	3-4	3-5	3-6	3-7	4-1	4-2	4-3	4-4	4-5	4-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		4-7	5-1	5-2	5-3	5-4	5-5	5-6	5-7	6-1	6-2	6-3	6-4	6-5	6-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Days)													
		6-7	7-1	7-2	7-3	7-4	7-5	7-6	7-7	8-1	8-2	8-3	8-4	8-5	8-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 19

Group Name	Animals At start	Administration (Days)													
		8-7	9-1	9-2	9-3	9-4	9-5	9-6	9-7	10-1	10-2	10-3	10-4	10-5	10-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	20/20 100.0	19/20 95.0	19/20 95.0	17/20 85.0	17/20 85.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 20

Group Name	Animals At start	Administration (Days)													
		10-7	11-1	11-2	11-3	11-4	11-5	11-6	11-7	12-1	12-2	12-3	12-4	12-5	12-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	17/20 85.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0	16/20 80.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 21

Group Name	Animals At start	Administration (Days)													
		12-7	13-1	13-2	13-3	13-4	13-5	13-6	13-7	14-1	14-2	14-3	14-4	14-5	14-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	15/20 75.0	15/20 75.0	15/20 75.0	15/20 75.0	15/20 75.0	15/20 75.0	15/20 75.0	15/20 75.0	15/20 75.0	14/20 70.0	14/20 70.0	14/20 70.0	13/20 65.0	13/20 65.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 22

Group Name	Animals At start	Administration (Days)														
		14-7	15-1	15-2	15-3	15-4	15-5	15-6	15-7	16-1	16-2	16-3	16-4	16-5	16-6	
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	
Posi. Control	20	12/20 60.0	12/20 60.0	11/20 55.0	11/20 55.0	11/20 55.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	10/20 50.0	9/20 45.0	9/20 45.0	8/20 40.0
		Number of survival/ Number of effective animals Survival rate(%)														

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 23

Group Name	Animals At start	Administration (Days)													
		16-7	17-1	17-2	17-3	17-4	17-5	17-6	17-7	18-1	18-2	18-3	18-4	18-5	18-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	8/20 40.0	8/20 40.0	8/20 40.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0	7/20 35.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6



STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 24

Group Name	Animals At start	Administration (Days)													
		18-7	19-1	19-2	19-3	19-4	19-5	19-6	19-7	20-1	20-2	20-3	20-4	20-5	20-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	20	7/20 35.0	5/20 25.0	5/20 25.0	5/20 25.0	5/20 25.0	5/20 25.0	4/20 20.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 25

Group Name	Animals At start	Administration (Days)													
		20-7	21-1	21-2	21-3	21-4	21-5	21-6	21-7	22-1	22-2	22-3	22-4	22-5	22-6
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
Posi. Control	20	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 26

Group Name	Animals At start	Administration (Days)													
		22-7	23-1	23-2	23-3	23-4	23-5	23-6	23-7	24-1	24-2	24-3	24-4	24-5	24-6
Control	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
Posi. Control	20	3/20 15.0	3/20 15.0	3/20 15.0	3/20 15.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 27

Group Name	Animals At start	Administration (Days)													
		24-7	25-1	25-2	25-3	25-4	25-5	25-6	25-7	26-1	26-2	26-3	26-4	26-5	26-6
Control	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
Posi. Control	20	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0	2/20 10.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 28

---

Group Name	Animals At start	Administration (Days) 26-7
Control	25	23/25 92.0
Posi. Control	20	2/20 10.0

---

Number of survival/ Number of effective animals  
Survival rate(%)

---

(HAN360)

BAIS6

**TABLE B 3**

**CLINICAL OBSERVATION : MALE**

**(Control and Positive control groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-7 1	2-7 1	3-7 1	4-7 1	5-7 1	6-7 1	7-7 1	8-7 1	9-7 1	10-7 1	11-7 1	12-7 1	13-7 1	14-7 1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	2
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	2	1
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	24	25
	Posi. Control	20	20	20	20	20	20	20	20	20	20	20	20	17	17

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	3	3	3	4	5	8	8	9	9	9	9
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	1	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	4	4	6	4	4	1	1	0	0	1	2
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	2	1
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	1
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	3	3	1	1	0	0	1	3
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	14	11	11	9	10	9	9	9	9	9	8	6



**TABLE B 4**

**CLINICAL OBSERVATION : FEMALE**

**(Control and Positive control groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	2	2	4	4
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	1	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	1	0	1	1
EROSION	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	1	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	0	0	1	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	1	2
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	24	24	24	24	24	24
	Posi. Control	20	20	19	20	20	20	20	20	19	17	16	14	13	9

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	2	2	3	3	3	3	3	3	3	3
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	1	1	1	1	2	2
	Posi. Control	9	11	11	11	14	14	14	14	15	15	15	15
TRAUMA	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	1	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	2	1	2	1	1	1	2	1	1	1	1
EROSION	Control	1	1	1	1	1	1	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	0	0	1	2	2	2	2	2
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	23	23
	Posi. Control	9	6	5	3	2	2	2	1	0	0	0	0

TABLE B 5

BODY WEIGHT CHANGES : MALE

(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	0-0	1-7	2-7	3-7	4-7	5-7	6-7
Control	25.2± 1.0	25.5± 1.1	25.9± 1.1	26.7± 1.1	27.4± 1.2	27.8± 1.3	28.3± 1.4
Posi. Control	25.2± 1.0	25.1± 1.2	25.8± 1.1	26.3± 1.3	27.5± 1.4	28.4± 1.4	28.9± 1.6

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	28.8 ± 1.5	29.3 ± 1.6	29.7 ± 1.7	30.1 ± 1.6	30.7 ± 1.9	30.8 ± 1.9	31.4 ± 2.2
Posi. Control	29.3 ± 1.7	29.8 ± 1.7	30.2 ± 1.7	30.3 ± 1.7	30.6 ± 2.0	30.7 ± 2.0	30.2 ± 2.8

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-7	15-7	16-7	17-7	18-7	19-7	20-7
Control	31.6 ± 2.3	32.0 ± 2.3	32.4 ± 2.4	32.6 ± 2.4	32.9 ± 2.5	33.1 ± 2.5	33.2 ± 2.4
Posi. Control	30.7 ± 3.0	30.5 ± 3.1	30.1 ± 3.2*	30.1 ± 3.8*	29.3 ± 4.0**	29.3 ± 4.7*	29.5 ± 4.5*

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day					
	21-7	22-7	23-7	24-7	25-7	26-7
Control	33.8 ± 2.4	34.0 ± 2.7	34.4 ± 2.5	34.6 ± 2.6	35.1 ± 2.7	35.2 ± 2.8
Posi. Control	31.6 ± 3.3*	31.2 ± 3.6*	32.0 ± 3.3*	31.6 ± 3.3**	31.1 ± 3.3**	30.3 ± 3.8**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t



**TABLE B 6**

**BODY WEIGHT CHANGES : FEMALE**

(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day							
	0-0	1-7	2-7	3-7	4-7	5-7	6-7	
Control	20.6± 1.0	21.0± 1.2	21.6± 1.1	22.1± 1.1	22.5± 1.1	23.1± 1.2	23.7± 1.2	
Posi. Control	20.7± 1.0	21.0± 1.4	21.3± 1.5	21.5± 1.7	22.1± 1.8	23.0± 1.9	23.5± 1.8	

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	24.2 ± 1.3	24.1 ± 1.0	24.3 ± 0.9	24.3 ± 0.9	24.5 ± 1.0	24.8 ± 1.3	24.8 ± 0.9
Posi. Control	23.6 ± 1.8	23.9 ± 1.7	23.8 ± 1.8	24.3 ± 1.9	24.2 ± 2.0	24.4 ± 1.7	24.4 ± 2.1

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-7	15-7	16-7	17-7	18-7	19-7	20-7
Control	25.0± 1.4	25.3± 0.9	25.3± 1.1	25.6± 1.1	25.6± 1.0	26.2± 1.3	26.3± 1.1
Posi. Control	24.5± 2.0	25.1± 2.8	25.1± 3.6	26.5± 3.4	25.4± 5.1	26.6± 1.5	25.3± 1.2

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day					
	21-7	22-7	23-7	24-7	25-7	26-7
Control	26.4 ± 1.3	26.5 ± 1.6	26.7 ± 1.2	26.5 ± 1.6	26.7 ± 1.4	27.1 ± 1.4
Posi. Control	23.8 ± 1.5**	24.1 ± 0.6*	22.5 ± 0.6	22.2 ± 1.8	21.6 ± 1.2	22.5 ± 1.9

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

TABLE B 7

FOOD CONSUMPTION CHANGES : MALE

(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	3.9± 0.3	3.6± 0.3	3.7± 0.3	3.8± 0.3	3.7± 0.3	3.8± 0.3	3.7± 0.3
Posi. Control	3.6± 0.4*	3.7± 0.3	3.7± 0.2	3.8± 0.2	3.8± 0.2	3.8± 0.3	3.7± 0.2

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	3.8± 0.3	3.8± 0.3	3.8± 0.2	3.8± 0.3	3.7± 0.3	3.8± 0.4	3.8± 0.3
Posi. Control	3.7± 0.2	3.6± 0.2*	3.7± 0.2	3.6± 0.3**	3.6± 0.3	3.3± 0.6**	3.6± 0.6

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of t



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	3.8± 0.3	3.7± 0.3	3.8± 0.3	3.8± 0.4	3.8± 0.3	3.9± 0.4	4.0± 0.4
Posi. Control	3.5± 0.5*	3.5± 0.4*	3.6± 0.6	3.5± 0.7	3.7± 0.8	3.9± 0.9	4.3± 0.7

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)				
	22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	4.0± 0.4	4.0± 0.4	4.0± 0.4	4.1± 0.4	4.2± 0.5
Posi. Control	4.4± 0.7	4.8± 0.9*	4.7± 0.9*	5.0± 1.2*	4.8± 0.8*

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of t

**TABLE B 8**

**FOOD CONSUMPTION CHANGES : FEMALE**

(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	3.5± 0.3	3.4± 0.3	3.6± 0.3	3.7± 0.3	3.7± 0.3	3.8± 0.3	3.8± 0.3
Posi. Control	3.2± 0.3**	3.6± 0.3*	3.6± 0.3	3.5± 0.4	3.7± 0.4	3.7± 0.4	3.7± 0.3

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	3.7± 0.3	3.7± 0.2	3.6± 0.4	3.7± 0.4	3.6± 0.4	3.5± 0.5	3.6± 0.5
Posi. Control	3.7± 0.3	3.3± 0.5**	3.6± 0.5	3.4± 0.4	3.5± 0.7	3.4± 0.9	3.5± 1.1

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	3.6± 0.5	3.6± 0.5	3.7± 0.5	3.6± 0.5	3.8± 0.5	4.0± 0.5	3.8± 0.2
Posi. Control	3.6± 1.7	3.8± 1.8	4.0± 1.7	3.3± 0.9	5.1± 2.3	4.4± 1.9	4.2± 1.9

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)				
	22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	3.8± 0.2	3.8± 0.2	3.6± 0.2	3.7± 0.2	3.9± 0.3
Posi. Control	5.2± 2.7	4.8± 2.8	5.4± 3.5	5.3± 3.3	4.1± 1.6

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

TABLE B 9

HEMATOLOGY : MALE

(Control and Positive control groups)



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH Pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	25	10.10±	0.30	14.4±	0.3	44.6±	1.0	44.1±	0.7	14.3±	0.3	32.4±	0.4	1394±	185
Posi. Control	10	3.69±	1.77**	4.8±	2.7**	20.6±	7.7**	58.7±	8.0**	12.8±	1.6*	22.0±	3.7**	1474±	369

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of t

(HCL070)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

PAGE : 2

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	25	3.7±	0.4
Posi. Control	10	57.7±	19.4**

---

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of t

(HCL070)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^3/\mu l$		NEUTRO		LYMPHO							
Control	25	3.50±	1.44	13.2±	4.9	82.2±	6.3	3.9±	2.1	0.7±	0.6	0.0±	0.0
Posi. Control	10	7.51±	3.54**	50.4±	29.2**	42.6±	30.3**	6.6±	4.7	0.4±	0.3*	0.1±	0.1*

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$       Test of t

TABLE B 10

HEMATOLOGY : FEMALE

(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 4

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH Pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	22	10.37±	0.38	15.1±	0.5	45.5±	1.4	43.9±	0.7	14.5±	0.4	33.1±	0.4	1196±	175
Posi. Control	2	4.29±	1.81	4.6±	1.6	23.4±	6.2	56.5±	9.3	10.8±	0.8	19.2±	1.8	1741±	1032

(HCL070)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 5

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	22	3.6 ±	0.4
Posi. Control	2	74.6 ±	12.9

---

(HCL070)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^3/\mu l$		NEUTRO		LYMPHO							
Control	22	2.99±	1.23	14.4±	4.4	82.9±	4.6	2.2±	1.0	0.5±	0.7	0.0±	0.1
Posi. Control	2	5.66±	5.15	61.4±	0.1	16.3±	16.7	21.3±	17.5	1.0±	0.6	0.1±	0.1

**TABLE B 11**

**BIOCHEMISTRY : MALE**

(Control and Positive control groups)



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	25	5.2±	0.3	3.2±	0.2	1.5±	0.1	0.11±	0.02	189±	30	86±	11	41±	8
Posi. Control	10	3.6±	0.9**	1.9±	0.5**	1.2±	0.2**	0.10±	0.05	135±	87	99±	10**	63±	41

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	25	184±	20	65±	28	17±	2	239±	69	212±	25	0.2±	0.2	93±	45
Posi. Control	10	179±	48	89±	65	47±	48	299±	167	142±	86*	0.3±	0.4	350±	557

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

PAGE : 3

Group Name	NO. of Animals	UREANITROGEN mg/dl		SODIUM mEq/l		POTASSIUM mEq/l		CHLORIDE mEq/l		CALCIUM mg/dl		INORGANIC PHOSPHRUS mg/dl	
Control	25	31.1±	3.0	151±	1	4.0±	0.3	118±	2	8.7±	0.2	5.2±	0.8
Posi. Control	10	60.2±	22.6**	154±	4	4.9±	1.1*	123±	6*	8.9±	0.3	8.1±	2.2**

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 6

**TABLE B 12**

**BIOCHEMISTRY : FEMALE**

(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	22	5.2±	0.3	3.3±	0.2	1.7±	0.1	0.13±	0.04	197±	27	69±	13	30±	6
Posi. Control	2	4.5±	0.3	2.7±	0.2	1.5±	0.1	0.13±	0.03	154±	13	147±	8	69±	69

(HCL074)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 5

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	22	147±	23	66±	23	17±	3	194±	57	349±	51	0.3±	0.3	83±	73
Posi. Control	2	212±	1	94±	47	30±	1	361±	158	208±	94	1.3±	1.3	313±	247

(HCL074)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE      REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	UREANITROGEN mg/dl		SODIUM mEq/l		POTASSIUM mEq/l		CHLORIDE mEq/l		CALCIUM mg/dl		INORGANIC PHOSPHRUS mg/dl	
Control	22	24.5±	4.1	150±	2	3.7±	0.3	117±	3	8.7±	0.3	5.4±	1.3
Posi. Control	2	48.1±	12.2	154±	2	4.3±	0.5	118±	4	9.4±	0.7	8.0±	1.3

**TABLE B 13**

**GROSS FINDINGS : MALE**

(Control and Positive control groups)



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control		Posi. Control	
			25	(%)	20	(%)
skin/app	erosion		0	( 0)	1	( 5)
	scab		0	( 0)	1	( 5)
lung	red zone		0	( 0)	4	( 20)
lymph node	enlarged		0	( 0)	2	( 10)
thymus	enlarged		0	( 0)	9	( 45)
	atrophic		0	( 0)	1	( 5)
spleen	enlarged		0	( 0)	13	( 65)
	white zone		0	( 0)	3	( 15)
	black zone		4	( 16)	3	( 15)
	nodule		0	( 0)	1	( 5)
heart	hypertrophy		0	( 0)	1	( 5)
stomach	forestomach:nodule		0	( 0)	1	( 5)
	forestomach:white zone		1	( 4)	2	( 10)
	glandular stomach:red zone		1	( 4)	0	( 0)
small intes	white zone		0	( 0)	1	( 5)
	nodule		0	( 0)	1	( 5)
	stenosed		0	( 0)	1	( 5)
	invagination		0	( 0)	1	( 5)
liver	white zone		0	( 0)	2	( 10)
kidney	white zone		0	( 0)	2	( 10)
	hydronephrosis		0	( 0)	1	( 5)
testis	small		0	( 0)	2	( 10)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

---

Organ	Findings	Group Name NO. of Animals	Control 25 (%)	Posi. Control 20 (%)
semin ves	small		0 ( 0)	1 ( 5)
pleura	thick		0 ( 0)	3 ( 15)
mediastinum	mass		1 ( 4)	0 ( 0)
thoracic ca	pleural fluid		0 ( 0)	6 ( 30)
whole body	anemic		0 ( 0)	8 ( 40)

---

**TABLE B 14**

**GROSS FINDINGS : FEMALE**

(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control	Posi. Control
			25 (%)	20 (%)
skin/app	ulcer		1 ( 4)	0 ( 0)
lung	red		0 ( 0)	1 ( 5)
	red zone		0 ( 0)	4 ( 20)
lymph node	enlarged		0 ( 0)	3 ( 15)
thymus	enlarged		1 ( 4)	17 ( 85)
spleen	enlarged		1 ( 4)	14 ( 70)
	black zone		1 ( 4)	3 ( 15)
stomach	forestomach:ulcer		0 ( 0)	1 ( 5)
	forestomach:white zone		0 ( 0)	1 ( 5)
	glandular stomach:white zone		3 ( 12)	0 ( 0)
liver	enlarged		0 ( 0)	1 ( 5)
	white zone		0 ( 0)	1 ( 5)
	nodule		1 ( 4)	0 ( 0)
kidney	white		0 ( 0)	1 ( 5)
	red zone		1 ( 4)	0 ( 0)
	absence		1 ( 4)	0 ( 0)
pituitary	white zone		0 ( 0)	1 ( 5)
peritoneum	nodule		0 ( 0)	1 ( 5)
abdominal c	ascites		0 ( 0)	1 ( 5)
thoracic ca	pleural fluid		1 ( 4)	11 ( 55)
whole body	anemic		1 ( 4)	7 ( 35)

**TABLE B 15**

**ORGAN WEIGHT, ABSOLUTE : MALE**

**(Control and Positive control groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
Control	25	30.5 ± 2.7	0.011 ±	0.003	0.224 ±	0.020	0.155 ±	0.018	0.154 ±	0.017	0.428 ±	0.043
Posi. Control	10	26.9 ± 2.9**	0.008 ±	0.001**	0.189 ±	0.036**	0.193 ±	0.036**	0.157 ±	0.013	0.389 ±	0.068*

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of t

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	25	0.073±	0.016	1.292±	0.086	0.469±	0.015
Posi. Control	10	0.563±	0.295**	1.576±	0.324*	0.445±	0.014**
Significant difference :		* : P ≤ 0.05	** : P ≤ 0.01	Test of t			

(HCL040)

BAIS 6

TABLE B 16

ORGAN WEIGHT, ABSOLUTE : FEMALE

(Control and Positive control groups)



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 3

Group Name	NO. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	23	23.0± 1.3	0.015± 0.002	0.030± 0.006	0.132± 0.013	0.147± 0.013	0.347± 0.034
Posi. Control	2	18.1± 1.3	0.009± 0.001	0.013± 0.002	0.174± 0.081	0.139± 0.016	0.303± 0.014

(HCL040)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 4

---

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	23	0.078±	0.009	1.008±	0.131	0.483±	0.021
Posi. Control	2	0.548±	0.289	1.196±	0.319	0.438±	0.005

---

(HCL040)

BAIS 6

TABLE B 17

ORGAN WEIGHT, RELATIVE : MALE

(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	25	30.5 ± 2.7	0.035 ± 0.009	0.740 ± 0.095	0.510 ± 0.048	0.506 ± 0.050	1.405 ± 0.108
Posi. Control	10	26.9 ± 2.9**	0.032 ± 0.004	0.699 ± 0.080	0.732 ± 0.178**	0.589 ± 0.063**	1.446 ± 0.190

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	25	0.238 ± 0.037	4.256 ± 0.385	1.546 ± 0.132
Posi. Control	10	2.182 ± 1.289**	5.908 ± 1.221**	1.671 ± 0.137*

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

(HCL042)

BAIS 6

TABLE B 18

ORGAN WEIGHT, RELATIVE : FEMALE

(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	23	23.0± 1.3	0.065± 0.009	0.130± 0.023	0.577± 0.062	0.643± 0.052	1.509± 0.146
Posi. Control	2	18.1± 1.3	0.047± 0.000	0.070± 0.017	0.950± 0.376	0.769± 0.028	1.680± 0.047

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 4

---

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	23	0.341 ± 0.041	4.387 ± 0.499	2.106 ± 0.114
Posi. Control	2	2.982 ± 1.380	6.576 ± 1.277	2.432 ± 0.209

---

(HCL042)

BAIS 6



**TABLE B 19**

**HISTOPATHOLOGICAL FINDINGS :**

**NEOPLASTIC LESIONS : MALE**

**(Control and Positive control groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	Posi. Control 20
{Hematopoietic system}				
lymph node	malignant lymphoma		<25> 0 ( 0%)	<20> 1 ( 5%)
thymus	malignant lymphoma		<25> 0 ( 0%)	<20> 9 ( 45%)
{Digestive system}				
stomach	squamous cell papilloma		<25> 0 ( 0%)	<20> 1 ( 5%)
	adenocarcinoma		0 ( 0%)	1 ( 5%)
small intes	adenoma		<25> 0 ( 0%)	<20> 1 ( 5%)
	adenocarcinoma		0 ( 0%)	15 ( 75%)
{Body cavities}				
mediastinum	histiocytic sarcoma		<25> 1 ( 4%)	<20> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

**TABLE B 20**

**HISTOPATHOLOGICAL FINDINGS :**

**NEOPLASTIC LESIONS : FEMALE**

**(Control and Positive control groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	Posi. Control 20
{Respiratory system}				
lung	bronchiolar-alveolar adenoma		<25> 0 ( 0%)	<20> 1 ( 5%)
{Hematopoietic system}				
thymus	malignant lymphoma		<25> 1 ( 4%)	<20> 18 ( 90%)
{Digestive system}				
small intes	adenocarcinoma		<25> 0 ( 0%)	<20> 7 ( 35%)
pancreas	ductal adenocarcinoma		<25> 0 ( 0%)	<20> 1 ( 5%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

**TABLE B 21**

**NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : MALE  
(Control and Positive control groups)**

NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : MALE

PAGE: 1

Group Name	Control	Posi. Control
	SITE : small intestine TUMOR : adenoma	
Tumor rate (a)	0/25 ( 0.0 )	1/20 ( 5.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4444
	SITE : small intestine TUMOR : adenocarcinoma	
Tumor rate (a)	0/25 ( 0.0 )	15/20 ( 75.0 )
Statistical analysis		
Fisher Exact test (b)		P =0.0001**
	SITE : small intestine TUMOR : adenoma, adenocarcinoma	
Tumor rate (a)	0/25 ( 0.0 )	16/20 ( 80.0 )
Statistical analysis		
Fisher Exact test (b)		P =0.0001**
	SITE : lymph node TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	1/20 ( 5.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4444
	SITE : thymus TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	9/20 ( 45.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0002**
	SITE : lymph node + thymus TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	10/20 ( 50.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0001**

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Fisher exact test compare directly the overall incidence rates.

Significant difference: \* : P ≤ 0.05 \*\* : P ≤ 0.01

NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : MALE

PAGE: 2

Group Name	Control	Posi. Control
	SITE : stomach	
	TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	1/20 ( 5.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4444
	SITE : stomach	
	TUMOR : adenocarcinoma	
Tumor rate (a)	0/25 ( 0.0 )	1/20 ( 5.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4444
	SITE : mediastium	
	TUMOR : histiocytic sarcoma	
Tumor rate (a)	1/25 ( 4.0 )	0/20 ( 0.0 )
Statistical analysis		
Fisher Exact test (b)		P =0.5556

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Fisher exact test compare directly the overall incidence rates.

Significant difference: \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

**TABLE B 22**

**NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : FEMALE  
(Control and Positive control groups)**



NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 SEX : FEMALE

PAGE: 1

Group Name	Control	Posi. Control
	SITE : small intestine TUMOR : adenocarcinoma	
Tumor rate (a)	0/25 ( 0.0 )	7/20 ( 35.0 )
Statistical analysis		
Fisher Exact test (b)		P =0.0017**
	SITE : thymus TUMOR : malignant lymphoma	
Tumor rate (a)	1/25 ( 4.0 )	18/20 ( 90.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0001**
	SITE : lung TUMOR : bronchiolar-alveolar adenoma	
Tumor rate (a)	0/25 ( 0.0 )	1/20 ( 5.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4444
	SITE : pancreas TUMOR : ductal adenocarcinoma	
Tumor rate (a)	0/25 ( 0.0 )	1/20 ( 5.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4444

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Fisher exact test compare directly the overall incidence rates.

Significant difference: \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

TABLE B 23

NUMBER OF ANIMALS WITH TUMORS AND  
NUMBER OF TUMORS - TIME RELATED: MALE  
(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	Posi. Control
1 - 13	NO. OF EXAMINED ANIMALS		0	0
	NO. OF ANIMALS WITH TUMORS		0	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0
	NO. OF BENIGN TUMORS		0	0
	NO. OF MALIGNANT TUMORS		0	0
	NO. OF TOTAL TUMORS		0	0
14 - 26	NO. OF EXAMINED ANIMALS		0	10
	NO. OF ANIMALS WITH TUMORS		0	10
	NO. OF ANIMALS WITH SINGLE TUMORS		0	6
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	4
	NO. OF BENIGN TUMORS		0	1
	NO. OF MALIGNANT TUMORS		0	14
	NO. OF TOTAL TUMORS		0	15
27 - 27	NO. OF EXAMINED ANIMALS		25	10
	NO. OF ANIMALS WITH TUMORS		1	10
	NO. OF ANIMALS WITH SINGLE TUMORS		1	7
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	3
	NO. OF BENIGN TUMORS		0	1
	NO. OF MALIGNANT TUMORS		1	12
	NO. OF TOTAL TUMORS		1	13
1 - 27	NO. OF EXAMINED ANIMALS		25	20
	NO. OF ANIMALS WITH TUMORS		1	20
	NO. OF ANIMALS WITH SINGLE TUMORS		1	13
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	7
	NO. OF BENIGN TUMORS		0	2
	NO. OF MALIGNANT TUMORS		1	26
	NO. OF TOTAL TUMORS		1	28

TABLE B 24

NUMBER OF ANIMALS WITH TUMORS AND  
NUMBER OF TUMORS - TIME RELATED: FEMALE  
(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	Posi. Control
1 - 13	NO. OF EXAMINED ANIMALS		0	5
	NO. OF ANIMALS WITH TUMORS		0	4
	NO. OF ANIMALS WITH SINGLE TUMORS		0	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	2
	NO. OF BENIGN TUMORS		0	0
	NO. OF MALIGNANT TUMORS		0	6
	NO. OF TOTAL TUMORS		0	6
14 - 26	NO. OF EXAMINED ANIMALS		2	13
	NO. OF ANIMALS WITH TUMORS		1	13
	NO. OF ANIMALS WITH SINGLE TUMORS		1	7
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	6
	NO. OF BENIGN TUMORS		0	1
	NO. OF MALIGNANT TUMORS		1	18
	NO. OF TOTAL TUMORS		1	19
27 - 27	NO. OF EXAMINED ANIMALS		23	2
	NO. OF ANIMALS WITH TUMORS		0	1
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1
	NO. OF BENIGN TUMORS		0	0
	NO. OF MALIGNANT TUMORS		0	2
	NO. OF TOTAL TUMORS		0	2
1 - 27	NO. OF EXAMINED ANIMALS		25	20
	NO. OF ANIMALS WITH TUMORS		1	18
	NO. OF ANIMALS WITH SINGLE TUMORS		1	9
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	9
	NO. OF BENIGN TUMORS		0	1
	NO. OF MALIGNANT TUMORS		1	26
	NO. OF TOTAL TUMORS		1	27

**TABLE B 25**

**HISTOPATHOLOGICAL FINDINGS:  
NON-NEOPLASTIC LESIONS: MALE  
(Control and Positive control groups)**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				Posi. Control 20			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Integumentary system/appandage]										
skin/app	ulcer		<25>				<20>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 10)	0 ( 0)	0 ( 0)
[Respiratory system]										
nasal cavit	eosinophilic change:olfactory epithelium		<25>				<20>			
			1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
lung	inflammatory infiltration		<25>				<20>			
			1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
	osseous metaplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
	bronchiolar-alveolar cell hyperplasia		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
	atelectasis		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	1 ( 5)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name Control				Posi. Control				
		No. of Animals on Study Grade				20				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
{Hematopoietic system}										
lymph node	thrombus	<25>				<20>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	
thymus	atrophy	<25>				<20>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 25)	0 ( 0)	0 ( 0)	0 * ( 0)	
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	
spleen	thrombus	<25>				<20>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 15)	1 ( 5)	0 ( 0)	0 ( 0)	
	deposit of hemosiderin	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	
		deposit of melanin	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
			extramedullary hematopoiesis	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 10)	6 ( 30)	8 ( 40)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				Posi. Control 20				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Circulatory system}														
heart			<25>				<20>							
	dilatation		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
	thrombus		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)				
	inflammatory infiltration		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
{Digestive system}														
stomach			<25>				<20>							
	erosion:forestomach		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
	ulcer:forestomach		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
	hyperplasia:forestomach		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 25)	4 ( 20)	0 ( 0)	0 ( 0)	**			
	erosion:glandular stomach		2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				Posi. Control 20				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}														
stomach			<25>				<20>							
	ulcer:glandular stomach		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	1 ( 5)	0 ( 0)				
liver			<25>				<20>							
	necrosis:focal		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)				
	inflammatory infiltration		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 15)	0 ( 0)	0 ( 0)	0 ( 0)				
	inflammatory cell nest		5 ( 20)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	*
	extramedullary hematopoiesis		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
	biliary cyst		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
gall bladd			<25>				<20>							
	degeneration:focal		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				Posi. Control 20				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Urinary system}														
kidney	hydronephrosis		<25>				<20>							
			0	0	0	0	0	1	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)			
urin bladd	lymphocytic infiltration		<25>				<20>							
			0	0	0	0	1	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)				
{Endocrine system}														
pituitary	cystic degeneration:anterior lobe		<25>				<20>							
			0	0	0	0	1	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)				
{Reproductive system}														
testis	mineralization		<25>				<20>							
			0	0	0	0	1	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)				
	degeneration:seminiferous epithelium		0	0	0	0	2	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 10)	( 0)	( 0)	( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				Posi. Control 20				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Reproductive system}														
testis			<25>				<20>							
	multinucleated giant cell formation		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
	tubular atrophy		2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)				
epididymis			<25>				<20>							
	decreased:sperma		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)				
	debris of spermatic elements		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	8 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	**		
semin ves			<25>				<20>							
	dilatation		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				
	atrophy		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				
{Special sense organs/appendage}														
Harder gl			<25>				<20>							
	hyperplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

TABLE B 26

HISTOPATHOLOGICAL FINDINGS:  
NON-NEOPLASTIC LESIONS: FEMALE  
(Control and Positive control groups)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name Control				Posi. Control			
		No. of Animals on Study Grade				20			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Integumentary system/appandage]									
skin/app	ulcer	<25>				<20>			
		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
subcutis	epidermal cyst	<25>				<20>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
[Respiratory system]									
nasal cavit	eosinophilic change:olfactory epithelium	<25>				<20>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)
	eosinophilic change:respiratory epithelium	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
lung	hemorrhage	<25>				<20>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	1 ( 5)	0 ( 0)
	inflammatory infiltration	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name Control				Posi. Control			
		No. of Animals on Study Grade				No. of Animals on Study Grade			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Hematopoietic system}									
bone marrow	deposit of hemosiderin	<25>				<20>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	decreased hematopoiesis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)
thymus	atrophy	<25>				<20>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
spleen	thrombus	<25>				<20>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of hemosiderin	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of melanin	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)
	extramedullary hematopoiesis	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	3 ( 15)	10 ( 50)	1 ( 5)	0 ( 0) **

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				Posi. Control 20				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Circulatory system]														
heart	necrosis:focal		<25>				<20>							
			0	0	0	0	1	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)				
[Digestive system]														
stomach	erosion:forestomach		<25>				<20>							
			1	0	0	0	0	0	0	0				
			( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)				
	hyperplasia:forestomach		1	0	0	0	10	1	0	0	**			
			( 4)	( 0)	( 0)	( 0)	( 50)	( 5)	( 0)	( 0)				
	erosion:glandular stomach		0	2	0	0	0	0	0	0				
			( 0)	( 8)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)				
liver	herniation		<25>				<20>							
			1	0	0	0	0	0	0	0				
			( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)				
	inflammatory cell nest		10	1	0	0	0	0	0	0	**			
			( 40)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				Posi. Control 20				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Urinary system}														
kidney	aplasia		<25>				<20>							
			1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
urin bladd	mineralization		<25>				<20>							
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
			1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
adrenal	hyperplasia:cortical cell		<25>				<20>							
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
			2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
pituitary	ectasia of sinus		<25>				<20>							
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
pituitary	cystic degeneration:anterior lobe		<25>				<20>							
			2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 5)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control				Posi. Control				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Endocrine system]														
adrenal	focal fatty change:cortex		<25>				<20>							
			0	0	0	0	1	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)				
[Reproductive system]														
ovary	atrophy		<25>				<20>							
			0	0	0	0	2	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 10)	( 0)	( 0)	( 0)				
	lymphocytic infiltration		0	0	0	0	1	0	0	0				
			( 0)	( 0)	( 0)	( 0)	( 5)	( 0)	( 0)	( 0)				
	hyperplasia		1	0	0	0	0	0	0	0				
			( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)				
	ovarian cyst		2	0	0	0	0	0	0	0				
			( 8)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)				
uterus	atrophy		<25>				<20>							
			1	0	0	0	8	0	0	0	0	**		
			( 4)	( 0)	( 0)	( 0)	( 40)	( 0)	( 0)	( 0)	( 0)			

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name Control				Posi. Control			
		No. of Animals on Study 25				20			
		1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)

{Reproductive system}

vagina		<25>				<20>			
	atrophy:epithelium	2	0	0	0	7	0	0	0
		( 8)	( 0)	( 0)	( 0)	( 35)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

**TABLE B 27**

**CAUSE OF DEATH: MALE**

(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

Group Name	Control	Posi. Control
Number of Dead and Moribund Animal	0	10
no microscop confirm	0	0
integumentary sy les	0	0
pneumonia	0	0
tumor d:thymus	0	0
tumor d:small intes	0	2
tumor d:muscle	0	0
tumor d:mal lymphoma	0	8

(BI0120)

BAIS6

TABLE B 28

CAUSE OF DEATH: FEMALE

(Control and Positive control groups)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

Group Name	Control	Posi. Control
Number of Dead and Moribund Animal	2	18
no microscop confirm	0	1
integumentary sy les	1	0
central nervo lesion	0	0
tumor d:skin/app	0	0
tumor d:subcutis	0	0
tumor d:mal lymphoma	1	17

(B10120)

ジブロモメタンの p53 ヘテロ欠損マウスを  
用いた吸入による中期発がん性試験報告書


試験番号 : 0944

# FIGURES



## FIGURES

- FIGURE 1 DIBROMOMETHANE VAPOR GENERATION AND INHALATION EXPOSURE SYSTEM
- FIGURE 2 SURVIVAL RATE OF MALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)
- FIGURE 3 SURVIVAL RATE OF FEMALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)
- FIGURE 4 BODY WEIGHT CHANGES OF MALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)
- FIGURE 5 BODY WEIGHT CHANGES OF FEMALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)
- FIGURE 6 FOOD CONSUMPTION CHANGES OF MALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)
- FIGURE 7 FOOD CONSUMPTION CHANGES OF FEMALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)



**FIGURE 1 DIBROMOMETHANE VAPOR GENERATION AND INHALATION EXPOSURE SYSTEM**




FIGURE 2 SURVIVAL RATE OF MALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)




FIGURE 3 SURVIVAL RATE OF FEMALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)




FIGURE 4 BODY WEIGHT CHANGES OF MALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)




FIGURE 5 BODY WEIGHT CHANGES OF FEMALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)




FIGURE 6 FOOD CONSUMPTION CHANGES OF MALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)





FIGURE 7 FOOD CONSUMPTION CHANGES OF FEMALE p53 KO MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF DIBROMOMETHANE (INHALATION STUDY)


ジブロモメタンの p53 ヘテロ欠損マウスを  
用いた吸入による中期発がん性試験報告書

試験番号 : 0944


# PHOTOGRAPHS




Photograph 1  
Thymus: Malignant lymphoma  
Male, 1,000 ppm, Animal No. 0944-1320 (H&E)



Photograph 2  
High magnification of Photograph 1



Photograph 3  
Lung: metastasis of Malignant lymphoma  
(leukemic cell infiltration)  
Male, 1,000 ppm, Animal No. 0944-1320 (H&E)



Photograph 4  
Pleura and bone marrow: metastasis of  
Malignant lymphoma (leukemic cell infiltration)  
Male, 1,000 ppm, Animal No. 0944-1320 (H&E)

ジブロモメタンの p53 ヘテロ欠損マウスを  
用いた吸入による中期発がん性試験報告書

試験番号：0944

# APPENDICES



## APPENDICES

- APPENDIX 1-1 IDENTITY OF DIBROMOMETHANE
- APPENDIX 1-2 STABILITY OF DIBROMOMETHANE
- APPENDIX 2-1 IDENTITY OF *N*-NITROSO-*N*-METHYLUREA
- APPENDIX 2-2 CONCENTRATION OF *N*-NITROSO-*N*-METHYLUREA
- APPENDIX 2-3 HOMOGENEITY OF *N*-NITROSO-*N*-METHYLUREA
- APPENDIX 3 ENVIRONMENTAL CONDITIONS OF INHALATION CHAMBER
- APPENDIX 4 METHODS, UNITS AND DECIMAL PLACE FOR HEMATOLOGY AND BIOCHEMISTRY

< INDIVIDUAL DATA (APPENDIX 5-1~14-2) : ATTACHED CD >

- APPENDIX 5-1 CLINICAL OBSERVATION (INDIVIDUAL) : MALE
- APPENDIX 5-2 CLINICAL OBSERVATION (INDIVIDUAL) : FEMALE
- APPENDIX 6-1 BODY WEIGHT CHANGES (INDIVIDUAL) : MALE
- APPENDIX 6-2 BODY WEIGHT CHANGES (INDIVIDUAL) : FEMALE
- APPENDIX 7-1 FOOD CONSUMPTION CHANGES (INDIVIDUAL) : MALE
- APPENDIX 7-2 FOOD CONSUMPTION CHANGES (INDIVIDUAL) : FEMALE
- APPENDIX 8-1 HEMATOLOGY (INDIVIDUAL) : MALE
- APPENDIX 8-2 HEMATOLOGY (INDIVIDUAL) : FEMALE
- APPENDIX 9-1 BIOCHEMISTRY (INDIVIDUAL) : MALE
- APPENDIX 9-2 BIOCHEMISTRY (INDIVIDUAL) : FEMALE
- APPENDIX 10-1 GROSS FINDINGS (INDIVIDUAL) : MALE
- APPENDIX 10-2 GROSS FINDINGS (INDIVIDUAL) : FEMALE

## APPENDICES (CONTINUED)

APPENDIX 11-1 ORGAN WEIGHT, ABSOLUTE (INDIVIDUAL) : MALE

APPENDIX 11-2 ORGAN WEIGHT, ABSOLUTE (INDIVIDUAL) : FEMALE

APPENDIX 12-1 ORGAN WEIGHT, RELATIVE (INDIVIDUAL) : MALE

APPENDIX 12-2 ORGAN WEIGHT, RELATIVE (INDIVIDUAL) : FEMALE

APPENDIX 13-1 HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL) : MALE

APPENDIX 13-2 HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL) : FEMALE

APPENDIX 14-1 CAUSE OF DEATH (INDIVIDUAL) : MALE

APPENDIX 14-2 CAUSE OF DEATH (INDIVIDUAL) : FEMALE

APPENDIX 1-1

IDENTITY OF DIBROMOMETHANE


## IDENTITY OF DIBROMOMETHANE

Test Substance : Dibromomethane (FUJIFILM Wako Pure Chemical Corporation)


Lot No. : SKG4416

## 1. Infrared Spectrometry

Instrument : Shimadzu IRAffinity-1  
 Cell : KBr Liquid Cell  
 Resolution : 4  $\text{cm}^{-1}$



Infrared Spectrum of Test Substance



Infrared Spectrum of Literature Data\*

Result: The infrared spectrum was consistent with literature spectrum.

\* Performed by National Institute of Advanced Industrial Science and Technology. Spectra Database for Organic Compounds, SDDBS.  
[http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre\\_index.cgi](http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre_index.cgi) [accessed 2020/4/27]

2. Conclusion: The test substance was identified as dibromomethane by infrared spectrum.

## APPENDIX 1-2

### STABILITY OF DIBROMOMETHANE

# STABILITY OF DIBROMOMETHANE

Test Substance : Dibromomethane (FUJIFILM Wako Pure Chemical Corporation)


Lot No. : SKG4416

## 1. Infrared Spectrometry


Instrument : Shimadzu IRAffinity-1

Cell : KBr Liquid Cell

Resolution : 4  $\text{cm}^{-1}$



Infrared Spectrum of Test Substance (before use)



Infrared Spectrum of Test Substance (after use)

Result: The infrared spectra were not changed before used on 2020.11.27 and after used on 2021.6.7.

2. Conclusion: The test substance was stable for the period that the test substance had been used for the study.

APPENDIX 2-1

IDENTITY OF *N*-NITROSO-*N*-METHYLUREA


IDENTITY OF *N*-NITROSO-*N*-METHYLUREA

Test Substance : *N*-Nitroso-*N*-Methylurea (Sigma-Aldrich Co. LLC.)


Lot No. : MKBQ7120V

## 1. Infrared Spectrometry

Instrument : Shimadzu IRAffinity-1  
Cell : KBr  
Resolution : 4 cm<sup>-1</sup>



Infrared Spectrum of Test Substance



Infrared Spectrum of Literature Data\*

Result: The infrared spectrum was consistent with literature spectrum.

\* Performed by National Institute of Standards and Technology (NIST).  
NIST Chemistry WebBook, SRD 69  
<https://webbook.nist.gov/cgi/cbook.cgi?Name=684-93-5&Units=SI&cIR=on#IR-Spec>  
[accessed 2020/10/22]

2. Conclusion: The test substance was identified as *N*-nitroso-*N*-methylurea by infrared spectrum.



APPENDIX 2-2

CONCENTRATION OF *N*-NITROSO-*N*-METHYLUREA

CONCENTRATION OF *N*-NITROSO-*N*-METHYLUREA

Analytical Method : The samples were analyzed by high performance liquid chromatography.

Instrument : Shimadzu LC-10 High Performance Liquid Chromatograph

Column : L-Column ODS 5  $\mu\text{m}$  (4.6 mm  $\phi$   $\times$  15 cm)

Column Temperature: 40  $^{\circ}\text{C}$

Mobile Phase : Ultrapure Water : Methanol = 95 : 5

Flow Rate : 1.0 mL/min

Detector : UV (210 nm)

Injection Volume : 10  $\mu\text{L}$

Study No.	Date Analyzed	Target Concentration
		7.5 <sup>a</sup>
0944	2020.12.01	7.98 <sup>b</sup> (106) <sup>c</sup>

<sup>a</sup> mg/mL

<sup>b</sup> mg/mL (Mean measured concentration)

<sup>c</sup> % (Mean measured concentration/target concentration  $\times$  100)

APPENDIX 2-3

HOMOGENEITY OF *N*-NITROSO-*N*-METHYLUREA

HOMOGENEITY OF *N*-NITROSO-*N*-METHYLUREA

Analytical Method : The samples were analyzed by high performance liquid chromatography.

Instrument : Shimadzu LC-10 High Performance Liquid Chromatograph

Column : L-Column ODS 5  $\mu\text{m}$  (4.6 mm  $\phi$   $\times$  15 cm)

Column Temperature: 40  $^{\circ}\text{C}$

Mobile Phase : Ultrapure Water : Methanol = 95 : 5

Flow Rate : 1.0 mL/min

Detector : UV (210 nm)

Injection Volume : 10  $\mu\text{L}$

Study No.	Target Concentration	
	Date Analyzed	7.5 <sup>a</sup>
0944	2020.12.01	0.125 <sup>b</sup>

<sup>a</sup> mg/mL

<sup>b</sup> Coefficient of Variation (%), (n=3)

## APPENDIX 3

### ENVIRONMENTAL CONDITIONS OF INHALATION CHAMBER

## ENVIRONMENTAL CONDITIONS OF INHALATION CHAMBER

Group Name	Temperature (°C) Mean ± S.D.	Humidity (%) Mean ± S.D.	Ventilation Rate (L/min) Mean ± S.D.	Air Change (time/h) Mean
Control	23.0 ± 0.0	56.8 ± 0.4	222.2 ± 0.6	6.0
100 ppm	23.1 ± 0.0	52.2 ± 0.5	221.9 ± 0.5	6.0
300 ppm	23.0 ± 0.0	48.0 ± 0.7	221.7 ± 0.5	6.0
1000 ppm	23.1 ± 0.1	43.3 ± 0.7	222.6 ± 0.7	6.0

## APPENDIX 4

### METHODS, UNITS AND DECIMAL PLACE FOR HEMATOLOGY AND BIOCHEMISTRY

## METHODS, UNITS AND DECIMAL PLACE FOR HEMATOLOGY AND BIOCHEMISTRY

Item	Method	Unit	Decimal place
<b>Hematology</b>			
Red blood cell (RBC)	Hydrodynamically focussed DC detection method <sup>1)</sup>	$\times 10^6/\mu\text{L}$	2
Hemoglobin(Hgb)	SLS-Hemoglobin method <sup>1)</sup>	g/dL	1
Hematocrit(Hct)	Hydrodynamically focussed DC detection method <sup>1)</sup>	%	1
Mean corpuscular volume(MCV)	Calculated as $\text{Hct}/\text{RBC} \times 10$ <sup>1)</sup>	fL	1
Mean corpuscular hemoglobin(MCH)	Calculated as $\text{Hgb}/\text{RBC} \times 10$ <sup>1)</sup>	pg	1
Mean corpuscular hemoglobin concentration (MCHC)	Calculated as $\text{Hgb}/\text{Hct} \times 100$ <sup>1)</sup>	g/dL	1
Platelet	Hydrodynamically focussed DC detection method <sup>1)</sup>	$\times 10^3/\mu\text{L}$	0
Reticulocyte	Flow cytometry method using semiconductor laser <sup>1)</sup>	%	1
White blood cell(WBC)	Flow cytometry method using semiconductor laser <sup>1)</sup>	$\times 10^3/\mu\text{L}$	2
Differential WBC	Flow cytometry method using semiconductor laser <sup>1)</sup>	%	1
<b>Biochemistry</b>			
Total protein(TP)	Biuret method <sup>2)</sup>	g/dL	1
Albumin (Alb)	BCG method <sup>2)</sup>	g/dL	1
A/G ratio	Calculated as $\text{Alb}/(\text{TP}-\text{Alb})$ <sup>2)</sup>	—	1
T-bilirubin	BOD method <sup>2)</sup>	mg/dL	2
Glucose	GlcK·G-6-PDH method <sup>2)</sup>	mg/dL	0
T-cholesterol	CE·COD·POD method <sup>2)</sup>	mg/dL	0
Triglyceride	MGLP·GK·GPO·POD method <sup>2)</sup>	mg/dL	0
Phospholipid	PLD·ChOD·POD method <sup>2)</sup>	mg/dL	0
Aspartate aminotransferase (AST)	JSCC method <sup>2)</sup>	U/L	0
Alanine aminotransferase (ALT)	JSCC method <sup>2)</sup>	U/L	0
Lactate dehydrogenase (LDH)	JSCC method <sup>2)</sup>	U/L	0
Alkaline phosphatase (ALP)	JSCC method <sup>2)</sup>	U/L	0
$\gamma$ -Glutamyl transpeptidase ( $\gamma$ -GTP)	JSCC method <sup>2)</sup>	U/L	1
Creatine kinase (CK)	JSCC method <sup>2)</sup>	U/L	0
Urea nitrogen	Urease·GLDH method <sup>2)</sup>	mg/dL	1
Sodium	Ion selective electrode method <sup>2)</sup>	mEq/L	0
Potassium	Ion selective electrode method <sup>2)</sup>	mEq/L	1
Chloride	Ion selective electrode method <sup>2)</sup>	mEq/L	0
Calcium	OCPC method <sup>2)</sup>	mg/dL	1
Inorganic phosphorus	PNP·XOD·POD method <sup>2)</sup>	mg/dL	1

1) Automated Hematology Analyzer (XN-2000V : Sysmex Corporation)

2) Automatic analyzer (Hitachi 7180 : Hitachi High-Tech Corporation)



APPENDIX 5-1

CLINICAL OBSERVATION (INDIVIDUAL) : MALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 1

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1012	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1020	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name Control

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1012	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NORMAL	NON REMARKABLE
1013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1020	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 3

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1012	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1020	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 4

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1012	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1020	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 5

Animal ID-NO.	Administration	Week-day	2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 6

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 7

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

Group Name 100 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1103	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1108	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1114	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1103	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1108	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1114	NON REMARKABLE	NON REMARKABLE	IRREGULAR BREATHING	IRREGULAR BREATHING	IRREGULAR BREATHING	MORIBUND ( 13-7)	ALREADY DEAD
1115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1103	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1108	NON REMARKABLE	NON REMARKABLE	EROSION v	EROSION v	EROSION v EROSION n	EROSION c EROSION v EROSION n	EROSION c EROSION n EROSION v
1109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1114	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1103	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1108	EROSION v EROSION n EROSION c	EROSION v EROSION n EROSION c	EROSION v EROSION n EROSION c	EROSION v EROSION n EROSION c	EROSION v EROSION n
1109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1114	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1120	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1121	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1122	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1123	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1124	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1125	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

PAGE : 14

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1120	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1120	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

PAGE : 16

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1120	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1201	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1218	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1201	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1218	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	EROSION k	EROSION k
1219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 300 ppm

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1201	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 18-2)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1218	EROSION k	EROSION k	EROSION k	EROSION k EROSION j	EROSION j EROSION k	EROSION k EROSION j EROSION c	EROSION k EROSION j
1219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 300 ppm

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1201	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1218	MORIBUND ( 22-1)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1220	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1221	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1222	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1223	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1224	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1225	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

PAGE : 22

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1220	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1221	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1222	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1223	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1224	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1225	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1220	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1221	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1222	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1223	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1224	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1225	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

PAGE : 24

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1220	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1221	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1222	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	MORIBUND ( 24-7)	ALREADY DEAD
1223	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1224	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1225	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1303	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1304	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1309	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1310	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1312	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1318	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1319	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1303	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1304	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1309	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1310	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1312	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1318	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1319	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1303	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1304	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 21-2)
1305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING
1306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 21-1)
1308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1309	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 17-7)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1310	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING
1312	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 21-3)
1314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1318	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 17-7)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1319	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1301	MORIBUND ( 22-7)		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1302	NON REMARKABLE		MORIBUND ( 23-2)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1303	NON REMARKABLE		DEEP BREATHING	MORIBUND ( 23-7)	ALREADY DEAD	ALREADY DEAD
1304	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1305	EXTERNAL MASS M. HEAD 3c DEEP BREATHING		DEAD ( 23-1)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1306	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING
1307	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1308	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1309	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1310	NON REMARKABLE		NON REMARKABLE	MORIBUND ( 24-1)	ALREADY DEAD	ALREADY DEAD
1311	MORIBUND ( 21-7)		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1312	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING
1313	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1314	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 26-5)
1315	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	MORIBUND ( 24-7)	ALREADY DEAD
1316	DEEP BREATHING		DEAD ( 23-3)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1317	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 26-3)
1318	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1319	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1320	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1321	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1322	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1323	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1324	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1325	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

PAGE : 30

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1320	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1321	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1322	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1323	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1324	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1325	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1320	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1321	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1322	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1323	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1324	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1325	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

Group Name 1000 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

PAGE : 32

Animal ID-NO.	Administration	Week-day				
	22- 7- 1		23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1320	NON REMARKABLE		NON REMARKABLE	DEEP BREATHING	MORIBUND ( 24-7)	ALREADY DEAD
1321	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1322	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1323	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1324	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1325	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1401	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1402	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1403	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1404	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1405	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1406	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1408	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1409	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1410	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1411	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1412	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1413	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1414	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1415	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1401	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1402	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1403	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	IRREGULAR BREATHING	MORIBUND ( 14-6)
1404	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1405	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	IRREGULAR BREATHING	MORIBUND ( 14-4)
1406	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1408	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1409	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1410	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1411	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1412	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1413	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1414	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1415	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1401	EROSION c	EROSION c	EROSION c	EROSION c	EROSION c	EROSION c	EROSION c
1402	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA	PILOERECTON ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING	MORIBUND ( 21-5)
1403	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1404	NON REMARKABLE	ANEMIA	ANEMIA	ANEMIA	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING	MORIBUND ( 21-1)
1405	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1406	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1408	DEAD ( 15-7)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1409	NON REMARKABLE	MORIBUND ( 16-7)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1410	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1411	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1412	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1413	NON REMARKABLE	ANEMIA	ANEMIA	ANEMIA	MORIBUND ( 19-7)	ALREADY DEAD	ALREADY DEAD
1414	ANEMIA	ANEMIA	ANEMIA	ANEMIA	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING
1415	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1401	EROSION c	EROSION c	EROSION c	EROSION c	EROSION c
1402	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1403	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1404	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1405	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1406	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA EROSION g DEEP BREATHING	ANEMIA CRUSTA g3 DEEP BREATHING
1408	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1409	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1410	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1411	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1412	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA DEEP BREATHING
1413	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1414	ANEMIA DEEP BREATHING	MORIBUND ( 23-2)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1415	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

PAGE : 37

Animal ID-NO.	Administration	Week-day	2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
1417	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1418	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1419	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1420	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

PAGE : 38

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
1417	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA	ANEMIA IRREGULAR BREATHING
1418	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1419	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1420	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration	Week-day	15- 7- 1	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
1417	ANEMIA IRREGULAR BREATHING			ANEMIA IRREGULAR BREATHING	ANEMIA IRREGULAR BREATHING	ANEMIA IRREGULAR BREATHING	ANEMIA IRREGULAR BREATHING	ANEMIA IRREGULAR BREATHING	MORIBUND ( 21-5)
1418	NON REMARKABLE			NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1419	NON REMARKABLE			NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 20-3)	ALREADY DEAD
1420	NON REMARKABLE			NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : MALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

PAGE : 40

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
1417	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1418	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
1419	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
1420	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

**APPENDIX 5-2**

**CLINICAL OBSERVATION (INDIVIDUAL) : FEMALE**

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 41

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2012	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2012	NON REMARKABLE	EROSION j EROSION k EROSION t	EROSION t EROSION k EROSION j	EROSION t EROSION k	EROSION k EROSION z	EROSION k EROSION z	EROSION c EROSION z EROSION k
2013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name Control

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2012	EROSION z EROSION c	EROSION z EROSION c	EROSION c EROSION n	EROSION c EROSION n	EROSION c EROSION n	EROSION c EROSION n	MORIBUND ( 21-3)
2013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Animal ID-NO.	Administration	Week-day	Control			
	22- 7- 1	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1	
2001	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2002	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2003	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2004	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2005	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2006	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2007	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2008	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 25-6)	ALREADY DEAD	
2009	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2010	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2011	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2012	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	
2013	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2014	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2015	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2016	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2017	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2018	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	
2019	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2020	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2021	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2022	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2023	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2024	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2025	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 46

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2020	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Control

PAGE : 47

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2020	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration	Week-day	Control			
	22- 7- 1		23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2020	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2021	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2022	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2023	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2024	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2025	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2103	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 6-4)	ALREADY DEAD
2104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2108	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2114	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2120	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

PAGE : 50

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2103	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2108	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2114	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2120	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2103	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2108	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2114	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2120	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

Group Name 100 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

PAGE : 52

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2101	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2102	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2103	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2104	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2105	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2106	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2107	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2108	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2109	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2110	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2111	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2112	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2113	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2114	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2115	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2116	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2117	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2118	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2119	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2120	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration	Week-day	2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 100 ppm

PAGE : 56

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2121	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2122	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2123	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2124	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2125	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2201	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2218	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2220	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2201	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2218	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2220	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2201	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2202	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2203	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2204	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2205	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2206	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2207	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2208	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2209	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2210	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2211	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2212	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2213	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2214	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2215	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2216	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2217	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2218	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2219	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2220	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

Group Name 300 ppm

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

PAGE : 60

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2201	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2202	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2203	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2204	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2205	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2206	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2207	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2208	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2209	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2210	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2211	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2212	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2213	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2214	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2215	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2216	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2217	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2218	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2219	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2220	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2221	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2222	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2223	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2224	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2225	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

PAGE : 62

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2221	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2222	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2223	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2224	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2225	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

PAGE : 63

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2221	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2222	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2223	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2224	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2225	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 300 ppm

PAGE : 64

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2221	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2222	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2223	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2224	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2225	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BATS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2303	MORIBUND ( 1-7)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2304	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	CORNEAL OPACITY e	CORNEAL OPACITY e
2305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2309	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2310	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2312	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2318	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2319	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2303	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2304	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e
2305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2309	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2310	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2312	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2318	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2319	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2303	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2304	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e
2305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2309	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2310	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 18-7)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2312	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2318	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	LOOSE STOOL	NON REMARKABLE
2319	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	LOOSE STOOL	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2301	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	PARALYTIC GAIT z	MORIBUND ( 26-5)
2302	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 26-5)
2303	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2304	CORNEAL OPACITY e	CORNEAL OPACITY e	CORNEAL OPACITY e	MORIBUND ( 25-1)	ALREADY DEAD
2305	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2306	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 25-4)	ALREADY DEAD
2307	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2308	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	PARALYTIC GAIT z
2309	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2310	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2311	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA DEEP BREATHING
2312	NON REMARKABLE	MORIBUND ( 23-6)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2313	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2314	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2315	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2316	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2317	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING	MORIBUND ( 26-1)
2318	EXTERNAL MASS M. MANDIBULAR 3b	MORIBUND ( 23-4)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2319	NON REMARKABLE	NON REMARKABLE	EXTERNAL MASS M. FORELIMB 4c	EXTERNAL MASS M. FORELIMB 5c	MORIBUND ( 26-3)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2320	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2321	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2322	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2323	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2324	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2325	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

PAGE : 70

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2320	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEAD ( 13-7)	ALREADY DEAD
2321	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2322	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2323	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2324	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2325	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name 1000 ppm

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2320	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2321	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2322	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2323	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2324	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	EXTERNAL MASS M. NECK 4c	EXTERNAL MASS M. NECK 4c	EXTERNAL MASS M. NECK 4c LOOSE STOOL	EXTERNAL MASS M. NECK 5c
2325	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name 1000 ppm

PAGE : 72

Animal ID-NO.	Administration	Week-day	23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2320	ALREADY DEAD		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2321	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2322	NON REMARKABLE		DEEP BREATHING	MORIBUND ( 24-2)	ALREADY DEAD	ALREADY DEAD
2323	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 26-2)
2324	MORIBUND ( 22-1)		ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2325	NON REMARKABLE		DEEP BREATHING	MORIBUND ( 24-2)	ALREADY DEAD	ALREADY DEAD

(HAN230)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1 26  
 SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
 ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 1- 7- 1	Week-day 2- 7- 1	3- 7- 1	4- 7- 1	5- 7- 1	6- 7- 1	7- 7- 1
2401	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2402	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2403	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2404	NON REMARKABLE	NON REMARKABLE	TRAUMA v HEMORRHAGE v	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2405	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2406	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2408	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2409	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2410	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2411	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2412	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2413	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2414	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2415	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2417	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2418	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2419	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 8- 7- 1	Week-day 9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2401	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2402	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	IRREGULAR BREATHING	DEEP BREATHING	MORIBUND ( 14-4)
2403	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA	ANEMIA
2404	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2405	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA	MORIBUND ( 12-1)	ALREADY DEAD	ALREADY DEAD
2406	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 10-2)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2408	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2409	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 14-1)
2410	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING
2411	NON REMARKABLE	IRREGULAR BREATHING	DEAD ( 10-4)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2412	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2413	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2414	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 12-7)	ALREADY DEAD	ALREADY DEAD
2415	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 14-7)
2416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2417	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 10-4)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2418	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2419	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 15- 7- 1	Week-day 16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2401	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	FROG BELLY	DEAD ( 19-1)	ALREADY DEAD	ALREADY DEAD
2402	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2403	MORIBUND ( 15-5)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2404	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2405	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2406	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2407	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	MORIBUND ( 19-6)	ALREADY DEAD	ALREADY DEAD
2408	NON REMARKABLE	NON REMARKABLE	DEEP BREATHING	DEEP BREATHING	MORIBUND ( 19-1)	ALREADY DEAD	ALREADY DEAD
2409	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2410	DEEP BREATHING	MORIBUND ( 16-6)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2411	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2412	NON REMARKABLE	MORIBUND ( 16-4)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2413	NON REMARKABLE	ANEMIA	ANEMIA	ANEMIA	MORIBUND ( 19-7)	ALREADY DEAD	ALREADY DEAD
2414	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2415	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2416	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE
2417	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2418	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	ANEMIA	ANEMIA	ANEMIA	ANEMIA DEEP BREATHING
2419	MORIBUND ( 15-2)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

Animal ID-NO.	Administration 22- 7- 1	Week-day 23- 7- 1	24- 7- 1	25- 7- 1	26- 7- 1
2401	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2402	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2403	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2404	ANEMIA DEEP BREATHING	MORIBUND ( 23-4)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2405	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2406	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2407	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2408	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2409	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2410	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2411	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2412	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2413	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2414	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2415	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2416	NON REMARKABLE	DEEP BREATHING	DEEP BREATHING	DEEP BREATHING	DEEP BREATHING
2417	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD
2418	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING	ANEMIA DEEP BREATHING
2419	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

PAGE : 77

Animal ID-NO.	Administration	Week-day						
2420	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

PAGE : 78

Animal ID-NO.	Administration	Week-day	9- 7- 1	10- 7- 1	11- 7- 1	12- 7- 1	13- 7- 1	14- 7- 1
2420	NON REMARKABLE		NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE	NON REMARKABLE

(HAN230)

BAIS 6



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name Posi. Control

PAGE : 79

Animal ID-NO.	Administration	Week-day	16- 7- 1	17- 7- 1	18- 7- 1	19- 7- 1	20- 7- 1	21- 7- 1
2420	NON REMARKABLE	ANEMIA DEEP BREATHING	DEAD ( 17-3)	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD

(HAN230)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1 26  
SEX : FEMALE

CLINICAL OBSERVATION (TIME-RELATED)  
ALL ANIMALS

Group Name    Posi. Control

PAGE : 80

---

Animal ID-NO.	Administration	Week-day				
2420	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD	ALREADY DEAD

---

(HAN230)

BAIS 6

APPENDIX 6-1

BODY WEIGHT CHANGES (INDIVIDUAL) : MALE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
Control	1001	24.6	24.7	25.2	26.3	27.1	26.9	26.9
	1002	24.9	25.6	25.1	25.1	25.7	26.3	26.6
	1003	24.8	24.0	25.3	26.5	27.0	28.1	28.5
	1004	23.8	26.3	26.0	25.8	28.0	28.9	29.8
	1005	25.9	25.8	25.8	26.1	27.4	28.3	29.4
	1006	24.9	24.9	24.6	26.2	26.6	27.0	27.6
	1007	26.1	26.9	27.0	28.0	29.8	29.8	30.6
	1008	23.1	23.1	23.9	24.6	24.9	25.3	25.9
	1009	26.4	27.1	27.2	27.8	28.5	28.3	29.5
	1010	25.6	25.6	26.1	27.6	27.1	27.9	28.7
	1011	24.4	25.7	25.2	26.3	27.2	26.8	27.5
	1012	25.1	25.5	26.1	27.9	28.6	28.1	29.4
	1013	25.3	25.1	25.7	26.6	27.6	28.6	28.7
	1014	24.2	23.9	25.4	26.3	26.8	26.9	27.4
	1015	26.6	26.2	27.6	27.6	28.1	28.9	29.0
	1016	25.3	25.7	26.9	27.0	27.5	27.3	28.2
	1017	26.5	25.6	27.0	28.9	30.1	31.0	30.7
	1018	26.2	26.1	26.1	26.5	26.4	26.5	27.6
	1019	26.0	26.8	27.5	27.3	27.7	28.5	29.2
	1020	25.7	25.1	24.5	26.4	25.6	26.5	26.2
	1021	24.0	25.2	25.2	26.6	27.6	28.8	28.9
	1022	24.3	25.0	25.3	25.3	26.8	26.9	27.2
	1023	23.7	24.4	24.4	25.3	26.2	26.5	26.7
	1024	27.1	28.1	28.6	28.9	29.2	29.4	30.6
	1025	25.7	25.2	25.8	26.3	27.4	27.9	27.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	1001	28.0	27.1	28.1	28.9	29.5	30.0	30.0
	1002	27.2	27.1	27.8	29.1	29.2	28.5	29.8
	1003	29.1	29.6	30.5	30.4	30.9	30.5	31.1
	1004	30.0	31.4	31.5	32.6	34.3	34.2	33.9
	1005	29.3	30.2	31.3	30.8	31.3	31.5	32.1
	1006	28.0	28.4	28.1	29.2	29.8	30.0	30.1
	1007	32.5	32.4	33.0	33.1	33.4	34.3	36.1
	1008	25.3	26.1	26.4	27.0	27.2	27.9	28.5
	1009	29.3	30.0	30.4	30.9	30.6	31.1	31.6
	1010	28.7	29.5	30.3	30.4	30.6	31.0	30.8
	1011	29.1	29.2	28.1	29.1	29.8	31.3	29.9
	1012	29.2	30.1	29.3	30.7	31.1	31.1	31.3
	1013	28.9	29.2	30.2	29.9	30.9	31.2	31.9
	1014	27.9	28.7	29.1	29.7	30.1	30.0	29.9
	1015	29.5	30.5	30.4	30.4	32.0	31.9	32.8
	1016	28.4	29.5	29.6	30.8	29.9	30.7	31.5
	1017	31.2	31.8	32.6	33.2	34.9	34.5	37.0
	1018	28.6	28.6	28.7	28.9	29.5	28.7	29.7
	1019	29.0	29.1	29.9	31.1	31.3	30.5	32.4
	1020	27.5	28.4	28.4	27.7	29.0	30.1	28.9
	1021	29.7	30.2	31.2	31.1	32.4	32.1	33.2
	1022	26.6	27.0	27.4	27.9	27.7	27.5	28.3
	1023	27.1	27.7	27.6	28.0	28.2	28.0	28.7
	1024	30.4	31.6	31.9	31.9	32.1	32.2	33.0
	1025	29.0	29.3	29.7	30.7	30.8	32.1	32.2

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
Control	1001	31.1	31.4	32.5	32.3	33.0	32.8	33.0
	1002	29.4	29.8	30.1	31.5	32.1	32.2	32.4
	1003	31.3	31.5	32.4	32.4	33.0	32.4	33.3
	1004	34.6	35.7	36.6	35.4	35.8	35.7	36.9
	1005	32.3	32.1	33.0	32.6	33.9	33.6	32.6
	1006	30.2	30.0	30.9	30.8	30.7	31.3	32.0
	1007	36.4	36.7	37.9	38.1	38.7	38.7	39.1
	1008	28.1	28.4	28.6	28.8	29.2	29.4	29.3
	1009	31.6	32.3	32.6	32.6	32.5	31.5	33.3
	1010	31.7	32.0	31.5	32.2	31.1	31.5	32.7
	1011	30.1	32.0	30.7	30.2	31.4	32.6	31.5
	1012	32.2	34.2	34.5	34.3	33.8	33.8	34.2
	1013	32.2	32.0	32.2	33.4	33.8	34.2	34.0
	1014	30.8	31.8	32.1	31.8	32.1	32.8	32.7
	1015	33.7	34.2	34.3	35.2	35.7	35.8	35.1
	1016	31.2	31.2	32.6	33.5	34.2	32.9	33.1
	1017	37.5	37.2	37.7	38.1	37.6	38.6	37.6
	1018	30.1	30.7	30.2	31.1	30.5	31.1	31.5
	1019	31.8	32.5	32.8	33.4	33.5	33.9	34.6
	1020	28.9	29.9	30.1	30.5	29.9	30.5	31.0
	1021	32.9	34.2	34.1	33.9	35.0	35.4	35.4
	1022	28.5	28.7	29.5	29.6	28.9	30.1	30.0
	1023	29.1	28.8	29.3	29.1	29.3	29.0	29.2
	1024	32.3	32.3	33.2	33.5	34.1	34.0	33.4
	1025	31.4	31.6	31.4	31.7	32.5	32.9	32.6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
Control	1001	34.1	33.2	34.1	34.3	35.8	34.4
	1002	33.3	32.2	32.8	33.7	35.1	34.6
	1003	33.7	33.7	34.9	35.6	34.6	35.1
	1004	36.6	37.8	37.9	38.7	39.6	39.4
	1005	33.7	34.0	34.2	35.5	35.2	35.4
	1006	31.6	32.4	32.9	33.0	32.4	33.2
	1007	39.8	39.7	39.2	39.6	40.6	41.4
	1008	29.8	29.9	30.8	30.7	30.7	31.8
	1009	33.2	33.7	33.6	33.7	34.6	34.5
	1010	32.0	32.8	33.0	33.4	33.8	33.5
	1011	33.5	31.1	33.4	32.8	32.7	33.8
	1012	34.6	36.6	36.5	36.3	36.7	37.4
	1013	35.1	35.1	36.4	37.1	37.9	38.3
	1014	34.1	33.6	34.7	35.1	35.2	35.1
	1015	35.9	37.0	37.1	38.0	38.5	38.3
	1016	34.9	34.3	35.0	33.0	33.6	32.7
	1017	39.0	39.6	40.6	39.9	40.4	41.8
	1018	31.3	31.7	31.8	32.0	33.5	33.9
	1019	34.9	35.3	35.0	35.6	36.6	36.0
	1020	31.9	31.2	31.7	32.6	33.1	32.0
	1021	35.6	35.8	35.4	35.2	36.1	35.9
	1022	30.7	32.1	31.4	31.5	31.4	32.6
	1023	30.0	29.8	30.6	30.3	31.6	31.2
	1024	33.9	33.7	34.3	34.4	34.7	34.8
	1025	32.7	33.1	33.1	33.5	33.7	34.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
100 ppm	1101	24.9	25.9	25.6	26.3	26.8	26.5	28.2
	1102	24.7	26.0	25.9	26.5	26.8	28.0	28.6
	1103	26.3	27.0	27.4	28.0	29.3	29.9	31.2
	1104	25.5	26.1	26.2	26.2	27.5	27.8	28.3
	1105	26.2	27.2	27.5	28.2	28.7	30.6	30.7
	1106	24.0	24.6	26.0	25.4	27.1	29.2	27.7
	1107	25.9	26.7	27.5	27.9	28.1	29.4	29.5
	1108	25.7	26.7	27.4	26.9	27.3	28.2	28.6
	1109	25.4	27.1	27.5	27.2	28.4	29.5	29.9
	1110	24.4	24.5	25.0	26.2	26.6	26.8	27.0
	1111	24.1	25.0	26.0	27.1	28.2	28.8	29.3
	1112	24.3	24.1	24.9	26.1	27.3	27.3	27.2
	1113	23.6	26.4	27.4	27.9	28.8	29.7	30.1
	1114	24.8	25.1	26.1	26.5	27.2	27.6	28.5
	1115	25.8	24.9	25.4	26.3	26.9	28.2	30.3
	1116	26.4	26.6	27.3	27.8	28.5	29.3	30.1
	1117	27.0	26.8	26.9	27.4	28.6	29.2	29.6
	1118	25.9	26.2	27.0	27.7	28.5	29.5	30.2
	1119	24.1	26.0	27.5	27.8	27.5	29.5	29.4
	1120	24.9	26.1	26.6	27.2	27.8	28.5	28.5
	1121	23.1	23.2	22.8	24.2	24.9	24.9	25.0
	1122	25.2	25.5	26.2	26.7	27.6	27.8	28.1
	1123	25.0	25.5	25.0	25.7	26.4	26.8	28.0
	1124	26.6	28.1	27.1	28.7	28.9	27.7	31.1
	1125	26.5	26.8	27.9	28.8	30.0	30.1	30.0



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
100 ppm	1101	29.0	28.8	29.9	30.4	30.7	32.3	32.5
	1102	28.4	28.4	28.8	29.8	30.2	30.8	30.3
	1103	32.2	32.5	32.6	32.8	34.5	34.4	34.9
	1104	28.5	28.7	29.2	29.5	29.9	30.1	30.8
	1105	31.9	32.2	33.6	34.0	34.8	35.8	37.1
	1106	28.8	28.8	29.5	30.2	30.8	30.6	32.4
	1107	29.5	30.3	31.3	33.0	34.2	34.8	34.6
	1108	28.8	29.5	29.7	29.8	30.2	30.9	31.3
	1109	29.5	30.0	30.9	31.2	32.2	32.8	32.6
	1110	27.0	27.3	27.5	29.1	29.5	29.5	29.9
	1111	29.8	30.6	32.1	32.9	33.7	32.8	34.3
	1112	28.2	28.4	29.6	30.3	31.3	30.9	31.8
	1113	28.0	30.3	30.0	30.6	31.4	30.4	30.5
	1114	29.1	29.0	29.2	25.6	25.0	22.4	
	1115	29.4	31.2	30.2	31.5	32.2	32.2	31.3
	1116	29.9	30.9	31.6	31.9	33.4	32.7	34.8
	1117	30.2	31.4	32.2	32.4	33.1	33.2	34.8
	1118	30.5	31.2	31.6	32.4	33.2	33.1	33.7
	1119	29.2	30.5	30.7	31.9	31.3	31.6	31.2
	1120	29.4	31.2	31.4	31.9	33.1	33.6	34.6
	1121	24.8	25.6	26.0	26.0	26.4	26.3	26.3
	1122	30.2	29.9	29.8	30.2	32.3	32.0	31.4
	1123	27.9	28.2	28.2	28.3	29.0	29.1	29.7
	1124	29.6	29.2	30.4	30.2	31.2	30.8	31.0
	1125	29.4	29.5	30.3	30.1	30.4	30.6	31.7

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
100 ppm	1101	33.7	34.0	34.2	34.6	34.5	35.7	35.4
	1102	30.9	30.8	30.9	31.5	31.9	31.0	31.4
	1103	35.4	36.5	36.5	37.0	37.1	36.8	37.9
	1104	30.4	30.8	31.4	31.1	31.5	31.9	32.0
	1105	36.5	37.2	37.5	38.1	37.5	37.9	38.1
	1106	33.0	33.4	33.0	32.5	33.4	32.3	32.2
	1107	35.2	35.7	36.1	36.1	36.6	37.1	37.5
	1108	31.0	30.2	29.5	28.9	29.4	28.4	28.3
	1109	32.4	34.0	33.8	33.8	34.0	34.7	36.6
	1110	30.1	31.3	31.1	31.7	30.3	30.3	31.2
	1111	35.0	35.1	35.9	36.3	37.7	37.5	37.8
	1112	32.6	32.6	32.9	32.7	34.1	33.3	35.0
	1113	31.8	31.6	31.3	31.1	31.2	32.4	32.5
	1114							
	1115	31.3	32.7	32.8	32.9	32.9	33.2	32.6
	1116	34.5	35.0	34.7	35.0	35.1	35.9	35.5
	1117	35.0	36.6	35.1	35.6	36.6	37.0	37.5
	1118	34.3	34.8	35.1	34.8	35.8	36.3	37.2
	1119	31.6	32.3	33.3	33.7	33.2	33.0	32.9
	1120	35.3	35.6	35.5	36.9	37.9	37.7	38.6
	1121	26.9	27.4	26.7	26.9	27.0	27.0	29.1
	1122	32.5	32.8	33.5	34.4	35.3	36.2	37.1
	1123	29.2	30.4	30.8	31.3	31.7	32.4	32.9
	1124	31.1	30.3	30.8	31.2	31.9	31.9	32.1
	1125	31.2	31.8	31.6	32.8	33.4	32.8	33.4

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
100 ppm	1101	35.5	32.9	34.1	36.5	36.3	35.9
	1102	30.8	30.5	32.0	31.3	31.6	31.7
	1103	38.6	39.3	38.9	39.2	39.7	41.3
	1104	32.2	31.8	32.9	32.8	32.7	32.7
	1105	38.8	38.3	39.7	39.8	40.6	40.4
	1106	33.1	33.3	33.7	34.0	33.9	35.0
	1107	37.5	38.3	38.6	39.5	40.3	40.3
	1108	28.5	28.1	27.5	26.8	26.7	27.7
	1109	36.9	36.4	36.6	37.9	37.8	38.5
	1110	30.8	30.6	31.5	31.6	31.9	32.2
	1111	38.2	39.2	39.7	40.2	39.8	40.2
	1112	33.2	34.0	34.9	36.0	36.0	36.2
	1113	32.4	32.4	33.1	34.0	33.7	34.2
	1114						
	1115	32.1	33.1	33.1	34.7	33.7	33.6
	1116	36.1	36.2	36.2	36.1	37.4	36.4
	1117	37.6	39.5	39.6	39.6	39.7	40.1
	1118	36.8	37.1	37.0	38.2	38.3	38.7
	1119	33.1	33.9	33.7	34.5	35.1	35.5
	1120	38.5	39.4	40.0	40.1	40.4	40.2
	1121	28.4	29.4	29.5	28.4	28.7	29.3
	1122	35.7	37.4	37.5	38.3	37.7	37.6
	1123	32.7	34.2	34.3	34.2	35.6	35.8
	1124	31.0	32.6	32.0	31.9	33.8	32.9
	1125	33.6	34.9	35.0	35.5	35.7	36.6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
300 ppm	1201	24.6	25.0	25.0	26.4	26.7	27.4	27.5
	1202	25.5	25.5	26.7	27.0	27.7	28.4	28.7
	1203	26.4	26.8	26.9	27.5	28.7	30.4	30.6
	1204	24.9	25.5	25.9	26.3	27.2	28.0	28.7
	1205	23.6	23.5	24.8	25.6	25.9	26.2	27.6
	1206	26.7	26.4	27.8	29.7	29.6	30.7	31.2
	1207	25.2	24.8	26.0	26.2	27.3	27.6	28.8
	1208	24.9	25.3	25.8	27.7	27.6	28.1	28.7
	1209	25.7	25.7	27.6	28.5	28.8	30.5	30.2
	1210	25.1	25.6	26.6	28.3	28.9	29.3	30.4
	1211	25.8	27.7	27.9	29.2	29.7	30.2	30.8
	1212	26.0	27.8	27.8	28.3	28.5	29.5	29.9
	1213	23.9	24.7	25.3	25.7	26.1	26.5	27.0
	1214	23.3	24.2	24.7	25.4	26.4	26.7	27.0
	1215	24.4	24.8	25.2	25.8	27.1	28.3	29.1
	1216	25.3	26.0	26.4	27.0	27.4	28.9	29.5
	1217	24.8	25.7	27.4	27.7	28.0	29.7	29.1
	1218	25.9	27.7	28.1	28.1	28.0	28.5	28.9
	1219	26.9	28.0	30.2	30.2	30.8	31.4	32.8
	1220	24.3	25.6	26.4	26.9	28.3	28.2	29.0
	1221	24.1	24.9	25.4	25.7	27.1	27.4	27.3
	1222	26.1	26.8	27.9	28.8	30.5	29.9	30.6
	1223	26.2	26.6	26.6	27.1	27.9	27.8	28.2
	1224	26.6	26.6	27.4	28.3	29.3	30.5	31.2
	1225	24.2	24.6	26.3	26.7	26.5	27.5	27.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
300 ppm	1201	28.1	28.0	28.8	29.4	29.4	29.7	30.1
	1202	30.0	30.3	29.9	30.0	30.4	30.6	31.4
	1203	30.6	31.3	32.4	32.7	32.2	33.5	34.1
	1204	28.7	29.6	30.0	30.2	30.7	31.4	31.9
	1205	28.2	28.8	28.9	29.2	29.4	30.5	30.8
	1206	31.5	32.9	32.9	33.1	34.2	34.6	34.2
	1207	29.2	30.6	28.9	30.3	30.3	31.6	32.2
	1208	28.6	29.4	28.4	29.5	30.0	30.3	29.9
	1209	31.1	31.5	32.3	32.1	33.6	34.0	33.5
	1210	31.3	32.0	33.3	33.2	33.0	33.1	33.6
	1211	31.1	31.8	32.8	32.8	33.9	33.7	34.0
	1212	30.4	30.9	31.5	30.9	32.4	32.7	33.1
	1213	28.4	27.9	29.3	29.0	29.5	30.6	30.6
	1214	27.2	27.9	28.5	28.4	29.0	30.5	30.6
	1215	29.3	29.0	29.8	29.8	30.3	30.8	31.6
	1216	30.6	30.1	29.9	30.3	30.8	30.8	31.7
	1217	29.8	29.6	29.6	29.2	28.8	31.4	31.8
	1218	27.9	29.3	29.3	30.4	29.1	29.2	28.8
	1219	32.9	33.6	33.4	34.9	34.6	35.1	35.6
	1220	29.7	30.0	31.0	30.8	32.2	31.9	32.8
	1221	28.0	28.6	28.8	28.9	29.3	31.3	31.1
	1222	31.5	30.0	30.8	30.8	32.6	32.8	34.9
	1223	28.7	29.3	29.8	30.1	30.5	31.1	30.6
	1224	31.7	32.3	33.7	33.1	34.2	33.3	34.9
	1225	27.3	27.6	27.8	28.5	28.2	28.5	28.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
300 ppm	1201	31.7	31.2	31.6	23.2			
	1202	31.9	31.6	31.5	31.8	32.2	32.3	31.0
	1203	35.6	35.4	35.5	36.0	37.1	36.7	37.7
	1204	32.6	33.3	33.0	32.7	33.7	33.4	34.5
	1205	31.7	31.2	31.9	31.8	32.9	32.6	33.9
	1206	34.8	34.6	35.5	35.4	36.5	36.8	37.4
	1207	32.3	31.5	32.1	32.3	32.1	32.4	32.4
	1208	30.2	31.0	31.3	31.8	32.2	32.3	32.9
	1209	33.8	34.8	34.9	35.5	36.2	36.3	35.9
	1210	34.2	34.6	33.7	34.6	34.5	34.8	34.7
	1211	33.3	33.8	34.3	34.5	34.9	36.1	36.3
	1212	33.2	34.0	34.4	34.4	33.7	35.6	34.9
	1213	30.9	30.8	30.5	30.8	30.9	30.9	31.8
	1214	30.3	31.0	32.0	32.2	32.5	33.0	33.4
	1215	31.6	31.3	32.0	32.7	32.7	32.6	33.0
	1216	31.6	32.3	32.7	33.4	33.6	33.7	34.2
	1217	31.3	31.8	32.4	32.4	31.7	33.2	32.7
	1218	29.2	28.5	28.2	28.8	28.7	28.7	28.5
	1219	37.5	37.5	37.9	37.8	39.3	38.6	39.8
	1220	33.2	33.9	33.7	33.5	34.0	34.5	34.1
	1221	30.7	31.7	31.9	32.3	31.7	32.3	32.7
	1222	35.1	34.5	34.6	35.3	36.4	34.4	36.8
	1223	31.9	31.9	31.5	32.2	31.9	31.9	33.8
	1224	35.6	36.2	36.2	36.2	37.1	36.8	37.0
	1225	28.7	29.4	29.1	28.7	29.1	29.3	29.7

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
300 ppm	1201						
	1202	32.3	33.2	33.6	33.2	34.0	33.5
	1203	37.4	38.7	38.8	39.4	39.4	39.8
	1204	35.2	34.7	34.2	34.6	34.0	34.8
	1205	33.9	33.9	34.2	35.2	34.1	33.9
	1206	38.0	37.8	38.2	39.1	39.1	40.1
	1207	33.5	33.8	33.7	33.9	34.2	34.9
	1208	32.2	31.1	31.3	31.4	32.1	32.1
	1209	36.7	37.0	37.4	37.7	38.2	39.2
	1210	34.2	35.1	34.4	34.7	35.5	35.3
	1211	36.4	37.7	36.3	36.0	37.4	37.4
	1212	35.8	34.9	34.4	33.6	33.7	33.2
	1213	32.2	31.8	32.2	32.7	33.1	33.0
	1214	33.8	34.0	34.7	35.7	35.5	35.7
	1215	33.9	33.1	33.7	34.8	34.7	34.9
	1216	34.5	35.5	35.6	35.6	35.7	36.9
	1217	33.3	33.5	33.6	34.4	33.9	35.7
	1218	27.6					
	1219	40.3	40.6	41.7	41.3	41.0	42.1
	1220	35.2	35.8	36.4	37.2	37.5	37.1
	1221	34.1	33.4	34.2	33.8	33.9	34.0
	1222	37.3	38.3	37.7			
	1223	33.6	33.1	34.5	34.1	34.1	33.4
	1224	37.9	38.3	38.7	39.2	39.7	40.3
	1225	30.2	30.0	30.0	25.1	26.8	28.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
1000 ppm	1301	23.6	24.8	25.1	25.3	24.9	25.7	25.6
	1302	24.7	25.3	26.3	27.3	27.9	28.9	29.2
	1303	24.0	24.3	25.9	25.5	25.8	26.7	26.6
	1304	26.2	26.1	27.6	28.1	27.9	28.4	28.6
	1305	25.3	26.4	26.1	26.7	26.8	28.3	27.4
	1306	24.9	25.7	27.5	28.5	27.9	27.9	28.0
	1307	24.0	24.3	24.2	25.2	25.7	26.0	26.4
	1308	25.6	26.7	27.7	27.7	28.3	29.1	28.7
	1309	26.8	28.0	29.2	29.8	29.6	30.3	30.5
	1310	26.8	27.5	28.5	28.7	28.9	29.0	28.9
	1311	25.0	25.3	25.7	25.5	25.9	26.3	26.5
	1312	24.2	26.0	26.4	28.0	28.0	28.0	28.7
	1313	24.5	24.8	26.3	25.3	26.2	26.6	26.8
	1314	25.3	25.8	26.4	26.0	25.9	26.3	26.3
	1315	26.0	26.1	27.7	28.9	28.9	29.1	29.7
	1316	26.6	27.0	28.2	28.0	28.8	29.2	30.0
	1317	23.4	23.8	25.1	25.3	25.4	25.5	25.4
	1318	25.8	24.6	24.9	24.5	26.4	25.9	26.6
	1319	25.8	25.4	25.2	26.4	25.9	26.9	26.6
	1320	26.2	26.0	27.0	26.9	27.1	27.6	27.6
	1321	25.6	26.5	26.3	26.2	26.2	26.9	27.7
	1322	24.2	24.5	25.5	26.1	25.9	27.0	27.0
	1323	24.6	24.5	24.8	25.5	25.8	25.6	28.7
	1324	26.4	27.7	28.8	28.8	29.6	29.8	30.7
	1325	25.0	25.3	26.6	26.0	26.6	26.9	27.3



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
1000 ppm	1301	26.8	26.2	26.2	26.5	26.8	26.9	26.9
	1302	28.7	28.8	29.2	29.8	29.8	30.1	30.1
	1303	27.1	28.0	28.1	28.4	28.9	28.7	28.8
	1304	28.5	28.7	28.9	30.0	29.9	29.4	29.5
	1305	28.2	28.4	28.5	28.8	28.6	29.3	29.3
	1306	28.5	28.8	28.6	29.6	29.8	30.8	30.1
	1307	26.7	26.4	27.0	27.5	27.7	27.6	27.5
	1308	29.3	28.9	29.7	29.3	29.5	29.0	29.6
	1309	30.4	30.7	31.3	31.6	31.9	31.8	32.5
	1310	29.6	30.4	29.9	30.8	31.2	31.3	31.3
	1311	26.9	26.8	27.3	27.2	27.5	28.0	27.5
	1312	29.3	29.4	29.5	29.6	30.2	30.1	30.7
	1313	27.0	27.0	27.4	27.3	27.3	27.4	27.8
	1314	27.0	27.4	27.7	27.6	28.1	28.3	28.3
	1315	29.6	29.8	30.5	30.6	31.6	31.2	31.5
	1316	29.9	29.5	29.4	30.2	29.7	30.0	30.0
	1317	26.2	25.8	26.5	26.1	27.3	27.2	27.1
	1318	26.9	26.1	27.1	27.3	28.7	27.9	28.0
	1319	26.8	27.2	26.6	26.9	27.3	27.4	27.0
	1320	28.2	28.1	28.8	28.4	29.5	29.7	29.3
	1321	27.1	27.0	27.6	28.1	28.4	28.4	26.7
	1322	26.8	27.7	27.4	27.2	27.7	28.1	28.5
	1323	25.9	26.7	27.4	27.5	28.5	27.7	28.3
	1324	30.3	31.0	31.1	32.4	31.9	32.1	31.7
	1325	27.8	27.8	28.4	28.3	29.1	28.7	29.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
1000 ppm	1301	27.6	27.4	27.0	27.6	27.4	26.8	25.6
	1302	30.2	30.4	31.0	31.1	30.6	31.2	30.9
	1303	28.8	28.8	28.6	28.9	29.3	29.3	29.3
	1304	29.5	29.8	30.0	30.1	30.4	30.1	29.5
	1305	29.4	29.8	29.8	29.7	30.0	29.8	29.5
	1306	30.6	30.0	30.4	29.7	30.6	30.6	29.9
	1307	27.8	27.5	27.5	27.8	28.3	27.8	26.1
	1308	29.9	29.4	29.7	29.9	29.4	29.6	30.4
	1309	31.5	31.1	29.3				
	1310	31.5	31.2	30.7	31.2	30.5	31.3	32.3
	1311	28.1	28.4	28.7	28.2	28.7	29.4	28.9
	1312	30.2	31.5	31.6	31.1	30.4	28.8	29.0
	1313	28.0	29.1	28.4	27.8	28.1	28.8	29.4
	1314	28.3	28.4	28.5	29.0	28.9	28.7	29.0
	1315	31.6	31.4	31.2	31.4	32.3	32.1	32.0
	1316	29.8	30.5	30.1	30.4	30.4	30.1	30.6
	1317	27.4	27.3	27.1	27.9	28.2	27.3	27.8
	1318	28.2	29.4	29.4				
	1319	27.1	27.2	27.7	27.2	27.7	27.4	27.7
	1320	30.1	29.5	29.8	30.5	30.1	30.2	30.4
	1321	28.1	28.9	28.2	28.5	28.2	28.5	28.2
	1322	29.1	28.5	28.0	28.6	29.4	28.7	29.0
	1323	28.8	29.4	28.3	29.7	28.6	29.0	28.9
	1324	31.7	31.4	32.5	32.0	32.3	32.4	32.2
	1325	28.3	29.6	30.2	29.7	30.1	29.4	30.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
1000 ppm	1301	22.0					
	1302	31.7	30.0				
	1303	29.7	30.2				
	1304						
	1305	25.4	19.9				
	1306	30.2	30.5	30.4	30.9	31.0	
	1307						
	1308	29.8	30.2	30.9	30.5	31.0	30.6
	1309						
	1310	32.2	31.7	31.1			
	1311						
	1312	28.9	28.5	29.2	29.5	29.1	27.4
	1313						
	1314	29.2	29.3	30.5	30.2	29.9	
	1315	33.3	32.2	33.0			
	1316	30.8	26.2				
	1317	26.7	27.7	28.4	28.3	27.2	
	1318						
	1319	28.3	27.5	28.1	28.1	28.0	25.7
	1320	30.8	29.9	31.5			
	1321	26.6	28.8	28.3	29.0	29.1	29.3
	1322	28.8	29.2	29.4	29.3	29.1	29.4
	1323	29.3	28.4	29.1	29.6	29.3	29.6
	1324	32.6	32.7	32.5	33.3	32.4	33.0
	1325	30.6	29.8	30.1	30.5	30.1	30.9

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
Posi. Control	1401	27.0	27.2	27.7	28.8	30.0	30.7	30.7
	1402	26.1	26.8	26.3	26.9	28.2	29.4	30.0
	1403	24.7	24.1	24.7	25.3	26.6	27.2	28.1
	1404	23.7	23.8	24.6	23.7	25.2	25.4	26.0
	1405	26.5	25.7	26.2	26.8	28.1	29.4	30.0
	1406	25.9	25.8	26.6	26.9	27.5	29.0	29.3
	1407	25.0	24.3	24.7	25.7	26.6	27.6	27.7
	1408	24.0	23.4	24.6	25.1	26.0	27.3	27.4
	1409	26.6	26.8	27.6	27.9	28.7	29.6	30.6
	1410	25.4	25.3	25.6	25.7	27.0	27.2	27.8
	1411	24.8	25.0	25.1	25.3	25.8	27.2	27.4
	1412	25.3	24.1	25.4	26.5	28.3	28.7	28.9
	1413	24.6	26.0	28.0	28.3	29.1	29.9	31.6
	1414	24.3	24.5	24.9	26.7	27.3	28.2	30.0
	1415	25.7	25.0	25.3	26.2	27.9	29.1	28.4
	1416	24.1	24.3	25.2	25.5	26.6	26.9	27.1
	1417	25.1	24.1	25.1	25.3	26.6	27.0	28.3
	1418	23.5	23.7	24.4	24.9	26.2	27.5	27.8
	1419	26.4	25.7	26.5	27.4	29.3	29.5	30.9
	1420	25.8	26.5	26.8	27.6	29.7	30.4	30.7

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
Posi. Control	1401	31.3	32.4	32.9	32.7	32.3	31.9	31.4
	1402	30.5	30.8	30.9	30.8	30.4	29.6	29.3
	1403	27.5	27.6	27.9	28.5	29.2	29.0	24.6
	1404	26.5	27.1	28.1	27.7	27.3	27.8	28.5
	1405	30.4	31.3	31.9	31.6	33.0	33.3	27.2
	1406	29.4	29.4	31.1	29.9	31.5	31.4	32.2
	1407	28.0	28.7	28.3	28.7	29.8	30.3	30.0
	1408	27.6	28.2	29.2	29.2	29.8	30.4	31.3
	1409	32.0	32.1	32.7	32.6	34.6	33.6	35.2
	1410	28.5	28.9	28.8	29.3	29.4	29.5	29.3
	1411	27.4	27.8	28.1	28.1	29.3	29.7	30.6
	1412	29.9	30.1	30.9	31.1	30.6	31.0	30.9
	1413	31.6	31.7	32.8	32.4	32.2	33.2	33.8
	1414	29.8	30.5	29.8	30.1	28.8	29.2	28.6
	1415	29.0	28.9	29.4	29.6	30.3	30.0	29.5
	1416	27.9	28.8	29.2	28.8	29.1	29.9	30.0
	1417	28.6	29.0	28.8	28.7	28.5	27.1	25.0
	1418	28.0	28.3	29.0	29.7	29.8	29.8	29.9
	1419	31.2	31.3	31.8	33.1	34.4	34.8	35.1
	1420	31.4	32.4	32.0	32.6	32.4	33.2	32.4

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
Posi. Control	1401	32.3	32.2	32.5	32.4	33.0	33.0	32.5
	1402	30.2	28.9	29.8	29.8	27.1	22.5	28.1
	1403							
	1404	27.9	27.7	26.6	26.3	25.6	22.5	21.2
	1405							
	1406	32.4	33.1	31.9	33.4	33.6	35.4	35.4
	1407	29.8	29.7	30.0	30.7	30.1	30.4	31.0
	1408	29.5						
	1409	35.9	32.6					
	1410	30.0	29.5	30.7	30.6	30.5	31.3	31.4
	1411	30.8	30.2	30.4	30.8	31.5	31.4	31.7
	1412	30.2	32.2	30.6	31.3	30.9	32.2	31.8
	1413	33.7	33.4	30.6	29.3	28.0		
	1414	27.1	25.7	24.7	24.0	23.9	23.5	23.7
	1415	30.1	30.1	30.3	29.6	29.4	29.6	30.0
	1416	29.9	29.2	29.0	27.9	23.2	27.0	27.4
	1417	24.1	23.6	23.6	22.0	22.3	21.8	22.1
1418	29.5	30.1	29.7	31.0	30.8	31.4	31.5	
1419	35.9	36.1	36.3	36.6	32.2	32.0		
1420	33.9	34.4	34.6	36.2	36.2	35.8	35.3	

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
Posi. Control	1401	33.4	32.4	32.9	32.6	31.5	30.5
	1402						
	1403						
	1404						
	1405						
	1406	35.5	36.2	37.0	36.6	36.0	34.2
	1407	29.8	29.0	28.3	28.4	26.4	26.4
	1408						
	1409						
	1410	32.4	32.3	31.8	31.4	29.3	30.2
	1411	32.5	32.6	33.1	33.0	33.8	34.0
	1412	32.6	31.8	32.2	31.9	29.6	25.9
	1413						
	1414	24.1	22.9				
	1415	30.5	29.4	28.4	27.3	28.0	26.2
1416	28.6	29.2	27.3	27.1	28.9	26.6	
1417							
1418	32.2	31.9	31.7	32.0	32.1	32.8	
1419							
1420	35.6	35.7	36.9	36.1	35.7	35.9	

**APPENDIX 6-2**

**BODY WEIGHT CHANGES (INDIVIDUAL) : FEMALE**



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
UNIT : g  
REPORT TYPE : A1 26  
SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
Control	2001	20.7	20.9	23.4	23.5	24.7	25.6	25.4
	2002	20.6	21.0	20.7	21.8	21.9	23.9	23.0
	2003	20.2	19.4	20.3	21.0	22.0	21.7	22.8
	2004	21.0	22.2	23.3	22.9	23.5	24.2	25.2
	2005	20.5	21.0	20.5	22.8	22.3	21.8	23.4
	2006	21.3	21.6	21.7	24.2	23.5	23.5	24.3
	2007	20.5	21.1	21.7	22.2	23.2	24.8	23.3
	2008	22.1	22.1	21.2	22.3	22.5	23.1	24.2
	2009	18.8	18.2	19.6	20.2	20.1	21.4	22.9
	2010	19.8	20.7	21.9	21.9	22.9	22.5	24.1
	2011	20.9	22.1	22.6	21.2	22.7	24.3	22.8
	2012	21.8	22.5	23.5	24.5	24.9	24.2	26.8
	2013	21.5	21.4	21.8	21.5	22.4	23.3	23.1
	2014	19.0	20.3	19.9	21.1	21.7	22.3	23.4
	2015	22.5	23.0	23.2	23.5	22.9	23.0	24.7
	2016	22.0	21.5	22.0	23.0	22.4	22.8	24.4
	2017	21.7	21.2	21.4	21.4	21.7	21.7	22.2
	2018	20.1	19.3	20.6	21.7	21.2	23.0	24.0
	2019	20.7	20.1	20.6	21.4	22.0	22.0	23.0
	2020	21.4	22.2	21.8	22.1	22.3	23.5	23.3
	2021	19.6	20.3	21.0	20.8	21.9	22.2	21.4
	2022	21.2	22.7	23.2	23.0	24.8	25.4	25.2
	2023	19.2	19.7	21.3	22.2	22.3	23.3	22.8
	2024	19.5	20.3	21.4	22.2	22.2	22.2	23.4
	2025	19.3	19.8	20.2	20.3	21.1	22.5	22.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	2001	26.6	25.3	25.7	26.5	26.1	26.9	26.1
	2002	24.1	23.8	23.4	23.5	25.0	24.5	25.0
	2003	24.3	23.1	23.8	24.7	25.0	22.4	23.3
	2004	24.9	24.7	25.0	25.6	25.0	26.5	26.2
	2005	23.8	24.6	23.8	23.4	24.2	26.4	24.7
	2006	24.1	24.7	25.0	24.4	25.3	25.0	24.9
	2007	24.2	25.1	24.7	24.5	25.6	25.3	26.4
	2008	24.9	24.7	25.0	23.5	25.1	26.1	25.6
	2009	22.6	22.8	23.3	24.7	23.5	23.6	23.6
	2010	24.6	23.7	24.6	24.0	24.9	25.9	24.7
	2011	24.3	24.5	25.0	25.1	24.3	26.1	24.7
	2012	27.6	25.7	24.7	24.3	23.7	24.4	25.4
	2013	24.2	23.1	24.3	24.9	25.1	24.3	23.7
	2014	24.4	23.7	24.3	24.0	24.3	23.6	25.5
	2015	25.7	25.4	25.9	24.8	26.0	26.7	25.9
	2016	24.1	23.8	24.0	23.4	23.9	24.3	24.4
	2017	22.8	24.0	24.4	23.4	22.7	23.8	23.3
	2018	23.2	22.5	24.0	24.0	23.6	23.9	24.8
	2019	22.3	23.8	23.7	23.7	24.6	23.4	24.7
	2020	23.2	24.0	25.0	26.1	25.8	24.9	25.5
	2021	21.7	22.2	22.4	23.4	22.5	22.9	23.9
	2022	25.7	26.4	25.7	25.0	25.2	26.6	25.0
	2023	24.6	23.3	23.8	24.2	23.4	24.7	24.3
	2024	24.1	24.5	22.7	22.7	23.5	24.5	23.9
	2025	22.6	23.6	23.2	23.2	23.4	22.7	23.7

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
Control	2001	27.6	28.1	27.0	27.3	27.2	28.6	28.4
	2002	25.1	25.1	24.7	25.9	26.4	25.6	26.4
	2003	25.0	24.5	23.4	25.6	24.2	25.1	25.9
	2004	27.3	26.2	25.6	26.8	26.2	26.3	26.6
	2005	23.9	25.7	25.2	25.0	25.7	26.1	27.2
	2006	27.1	26.4	25.1	26.2	25.9	27.9	26.3
	2007	26.0	25.8	26.2	28.1	27.0	28.6	28.1
	2008	25.4	25.3	25.7	25.3	24.4	26.3	26.5
	2009	23.2	24.4	23.8	25.5	24.3	25.0	24.0
	2010	25.0	25.1	25.0	25.8	25.6	26.2	25.3
	2011	25.2	24.9	25.5	26.9	26.1	27.3	26.2
	2012	24.9	25.4	25.9	25.8	26.1	26.7	26.5
	2013	24.8	25.4	25.4	25.5	24.3	26.1	25.4
	2014	23.9	25.4	26.0	24.5	25.8	24.8	26.6
	2015	27.0	25.5	25.5	25.9	25.4	26.6	26.9
	2016	25.7	25.7	26.1	26.1	26.2	25.8	26.9
	2017	23.4	23.8	23.9	24.1	25.8	24.9	25.1
	2018	24.0	25.5	25.4	25.6	25.6	25.8	25.8
	2019	24.8	25.1	25.2	24.9	25.1	26.4	26.6
	2020	24.6	25.4	25.1	25.4	27.0	27.2	26.4
	2021	23.1	24.3	23.8	23.5	24.2	23.0	24.9
	2022	27.1	25.8	28.8	27.2	27.7	27.7	28.5
	2023	24.7	25.0	25.1	25.0	25.3	26.1	25.9
	2024	22.7	24.1	25.0	24.8	24.0	25.7	26.2
	2025	23.3	23.7	24.5	24.2	25.0	24.3	23.9

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
Control	2001	27.9	28.9	28.9	29.1	29.8	29.3
	2002	26.9	26.4	27.1	27.6	27.9	27.4
	2003	25.1	24.9	26.2	24.1	24.4	26.6
	2004	27.3	25.7	26.9	26.7	26.3	27.3
	2005	27.9	27.1	26.6	25.8	26.0	26.5
	2006	26.0	26.8	26.7	25.6	27.3	28.0
	2007	28.4	30.2	29.2	30.2	29.8	30.9
	2008	25.8	26.3	26.9	26.8		
	2009	25.0	24.2	25.1	24.9	25.6	25.7
	2010	26.9	26.1	27.0	27.0	25.8	27.3
	2011	27.4	28.3	27.6	27.7	27.5	27.9
	2012						
	2013	26.3	26.9	25.8	26.4	25.6	25.9
	2014	25.8	26.9	26.2	25.4	26.5	27.0
	2015	27.7	27.8	27.5	28.0	27.8	27.1
	2016	26.4	27.7	27.0	26.9	26.5	27.6
	2017	25.2	24.0	25.8	24.2	24.7	25.3
	2018	25.7	26.1	26.4	26.3	26.7	27.0
	2019	25.3	26.7	26.6	26.5	27.6	26.2
	2020	26.7	27.4	27.7	26.9	28.2	27.9
	2021	24.1	24.6	24.7	24.6	25.3	25.1
	2022	28.6	28.6	29.1	28.8	27.8	29.3
	2023	27.3	24.6	25.2	26.0	26.2	26.6
	2024	24.9	25.1	26.3	25.3	26.6	25.7
	2025	24.7	25.0	25.1	24.1	25.1	24.9

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
100 ppm	2101	20.6	20.9	21.5	22.2	22.4	23.3	23.2
	2102	21.1	22.0	22.2	21.3	22.8	24.5	23.8
	2103	19.2	20.4	20.7	21.6	20.8	19.7	
	2104	21.8	22.1	23.1	23.7	23.9	25.1	24.6
	2105	21.4	22.8	22.7	22.7	22.2	23.5	24.3
	2106	20.3	22.8	23.1	23.4	24.8	25.6	27.6
	2107	21.6	22.6	23.7	23.9	24.0	24.2	24.5
	2108	20.5	21.1	20.5	22.1	22.1	24.3	24.2
	2109	18.6	19.4	19.8	19.8	20.5	22.0	23.1
	2110	20.4	21.9	23.4	22.4	22.5	22.9	24.4
	2111	21.5	23.6	23.4	24.4	23.4	24.7	24.3
	2112	20.0	20.4	21.5	21.9	21.4	23.6	22.7
	2113	21.2	22.0	23.4	22.4	22.2	23.1	23.6
	2114	19.6	21.4	21.5	23.0	22.8	23.8	24.3
	2115	21.2	21.6	21.9	21.9	21.3	22.5	22.7
	2116	20.8	22.3	22.1	22.0	23.1	24.9	25.0
	2117	19.1	20.9	20.4	21.6	21.9	21.9	22.6
	2118	19.3	20.3	20.4	20.6	21.7	22.8	23.7
	2119	22.7	23.8	23.7	24.7	25.9	26.2	27.3
	2120	20.8	22.2	22.0	22.6	23.4	23.3	24.2
	2121	21.9	22.8	21.8	23.8	23.6	24.0	26.1
	2122	22.1	21.9	23.3	21.6	22.1	22.9	24.4
	2123	20.7	21.8	21.2	23.0	23.7	24.0	25.7
	2124	19.4	20.3	21.5	22.2	21.8	23.1	22.3
	2125	20.5	21.1	21.7	21.5	22.5	23.6	24.4

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
100 ppm	2101	24.1	24.5	24.7	24.9	24.9	25.5	26.2
	2102	25.9	24.0	25.3	25.1	25.3	25.4	25.0
	2103							
	2104	25.9	25.3	25.4	26.1	26.0	26.8	26.8
	2105	24.5	25.0	23.7	24.8	24.8	25.2	25.2
	2106	26.4	26.8	26.9	26.4	26.7	26.8	26.6
	2107	26.1	23.5	26.6	26.6	26.7	27.1	27.0
	2108	22.8	23.7	23.7	24.2	25.1	24.9	25.6
	2109	22.2	22.9	23.4	23.0	22.3	24.1	23.4
	2110	24.1	24.1	23.9	25.5	24.3	24.6	24.2
	2111	23.2	24.4	24.2	25.5	25.8	24.3	27.2
	2112	23.2	22.8	24.4	23.0	23.2	22.8	23.4
	2113	24.5	24.5	25.4	24.4	24.9	24.5	24.7
	2114	24.2	25.1	25.3	25.1	25.0	26.5	24.7
	2115	22.8	23.8	23.5	23.6	23.5	23.7	24.5
	2116	25.8	24.8	24.9	24.8	25.0	25.5	25.5
	2117	23.6	22.3	23.6	23.1	24.3	23.5	24.8
	2118	24.0	23.1	23.9	24.4	24.1	24.4	24.9
	2119	26.1	29.1	28.3	29.0	28.5	27.8	29.8
	2120	24.0	24.3	24.6	24.3	24.6	25.0	24.3
	2121	26.1	26.0	25.4	26.4	25.4	27.0	26.6
	2122	24.9	24.8	24.7	25.8	24.7	25.1	26.0
	2123	24.4	25.2	24.9	25.3	25.1	25.9	25.8
	2124	21.5	23.4	23.8	23.8	24.2	23.2	22.9
	2125	24.4	23.6	24.5	24.3	24.9	25.2	24.6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day							
		14-7	15-7	16-7	17-7	18-7	19-7	20-7	
100 ppm	2101	26.8	26.5	27.1	27.9	27.1	28.5	27.6	
	2102	26.2	26.7	26.4	25.7	26.5	27.2	26.5	
	2103								
	2104	27.9	27.5	27.6	28.0	28.6	29.5	30.4	
	2105	24.8	25.9	26.1	27.1	26.7	26.8	27.6	
	2106	27.3	27.4	28.0	28.6	27.7	28.2	28.4	
	2107	27.2	27.9	26.4	27.7	28.4	28.9	28.2	
	2108	24.8	26.1	25.8	25.3	26.2	26.6	25.8	
	2109	24.6	24.2	25.8	24.7	24.2	25.6	24.1	
	2110	25.1	25.3	26.0	25.3	25.8	26.1	26.5	
	2111	26.0	24.5	25.8	25.9	25.9	26.7	26.2	
	2112	23.6	24.0	24.9	25.6	26.3	25.8	23.9	
	2113	25.4	25.3	26.1	25.9	27.4	26.5	26.9	
	2114	25.3	25.8	26.3	25.7	24.7	25.5	26.6	
	2115	24.1	24.7	24.6	24.7	25.5	25.8	25.4	
	2116	26.1	25.3	25.9	25.7	26.0	26.8	25.9	
	2117	24.8	24.9	24.0	24.6	24.1	24.9	25.7	
	2118	24.7	25.1	25.3	26.2	26.2	26.4	25.4	
	2119	30.4	27.9	29.0	30.2	29.4	28.9	30.3	
	2120	24.4	25.7	25.7	25.7	25.5	25.8	26.3	
	2121	26.8	27.0	26.3	26.8	28.3	27.3	28.0	
	2122	25.1	26.6	26.3	26.3	26.6	26.3	26.6	
	2123	26.4	27.8	27.4	27.5	27.3	26.9	27.8	
	2124	24.0	23.4	24.1	24.1	24.1	24.5	25.4	
	2125	25.1	24.7	25.5	25.6	26.4	27.6	26.0	

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
100 ppm	2101	28.8	28.4	29.5	28.8	28.8	29.7
	2102	27.2	26.9	26.9	27.0	27.5	26.7
	2103						
	2104	30.7	30.9	30.8	32.2	31.7	33.2
	2105	27.9	27.8	27.4	27.4	26.7	28.2
	2106	28.9	28.9	29.1	29.1	29.3	29.4
	2107	29.3	28.9	29.4	30.1	29.3	30.1
	2108	26.2	25.6	26.6	26.1	26.1	26.9
	2109	24.6	24.9	25.0	24.3	24.9	25.4
	2110	25.8	26.4	26.3	26.7	27.0	28.1
	2111	28.3	28.3	27.2	27.9	29.3	27.6
	2112	25.5	25.4	25.9	25.7	24.9	26.2
	2113	28.2	26.9	27.1	27.8	27.2	27.4
	2114	26.4	26.4	26.3	26.9	26.4	26.8
	2115	25.7	25.5	26.4	24.8	26.7	26.2
	2116	28.0	26.5	26.4	26.4	27.2	27.9
	2117	26.2	25.8	25.3	25.2	26.4	24.9
	2118	25.8	27.7	25.7	26.2	25.9	27.3
	2119	30.1	29.4	30.8	30.5	30.2	31.5
	2120	25.9	26.3	26.2	26.7	27.3	27.0
	2121	28.9	28.4	28.2	27.9	27.0	26.7
	2122	26.4	25.6	26.7	26.8	27.9	27.9
	2123	27.3	28.0	27.5	27.9	28.8	28.4
	2124	24.9	26.0	24.2	25.2	25.3	24.8
	2125	26.8	26.2	27.5	26.7	27.0	27.4



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
300 ppm	2201	20.5	21.6	21.9	22.5	22.8	22.9	24.3
	2202	19.9	19.5	23.0	21.7	22.1	21.9	23.3
	2203	21.4	21.9	21.3	22.5	22.6	23.2	24.3
	2204	21.0	21.5	22.1	22.4	21.3	22.1	23.0
	2205	18.8	20.0	20.2	21.2	21.0	23.1	23.1
	2206	21.8	21.6	21.5	24.1	24.5	24.8	23.2
	2207	20.9	21.2	21.6	22.7	21.5	22.8	24.4
	2208	19.4	20.8	20.9	21.5	21.7	21.8	23.0
	2209	22.1	22.4	22.8	23.0	23.6	23.8	25.0
	2210	21.7	22.5	22.3	21.4	22.6	22.9	22.7
	2211	19.6	20.8	20.5	21.1	22.4	22.5	22.9
	2212	20.7	21.1	21.3	21.1	22.3	24.3	24.1
	2213	20.7	21.2	20.3	22.2	22.7	23.3	23.8
	2214	20.4	21.0	22.7	22.2	24.0	23.5	24.2
	2215	20.6	20.5	21.8	21.9	22.0	24.1	24.7
	2216	20.1	20.9	21.6	23.0	23.7	24.5	25.8
	2217	22.5	21.9	21.7	22.4	22.6	22.6	24.3
	2218	19.1	20.7	22.1	22.2	22.9	23.3	24.0
	2219	21.3	23.0	24.0	23.9	25.2	25.9	27.2
	2220	19.0	20.3	21.5	20.8	22.0	21.8	21.9
	2221	21.5	22.1	22.6	23.3	23.9	24.0	23.9
	2222	20.3	22.1	22.3	22.2	23.9	24.8	24.5
	2223	22.0	23.6	24.6	24.4	24.5	25.6	25.9
	2224	19.4	21.4	21.7	21.4	22.5	24.1	24.5
	2225	21.2	20.8	20.9	20.2	21.5	21.6	21.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
300 ppm	2201	23.7	23.5	23.6	24.1	24.3	25.4	24.7
	2202	23.6	24.2	24.1	25.1	23.7	24.5	24.8
	2203	24.0	24.7	24.3	25.7	26.6	25.4	24.6
	2204	23.0	24.1	24.0	23.1	23.8	24.8	24.2
	2205	23.2	23.4	23.5	23.8	23.3	22.9	23.2
	2206	25.9	25.7	25.9	25.4	25.3	26.3	25.9
	2207	25.1	24.9	24.8	25.0	25.0	24.4	25.2
	2208	23.3	23.2	22.8	24.4	23.9	24.8	23.7
	2209	25.5	25.0	25.8	25.6	26.2	26.0	26.1
	2210	23.8	24.1	24.4	25.4	24.3	26.1	26.2
	2211	23.4	23.1	23.1	24.1	24.0	23.1	23.6
	2212	23.9	24.2	23.8	24.5	24.3	24.5	24.6
	2213	23.5	23.9	24.4	23.8	24.8	25.2	24.5
	2214	24.1	23.4	24.7	24.9	25.2	24.6	25.7
	2215	24.6	24.7	24.6	24.8	25.8	25.7	25.1
	2216	25.4	25.8	25.2	26.0	24.1	24.2	24.6
	2217	23.2	24.1	23.9	25.3	25.1	25.1	24.6
	2218	23.9	23.8	24.9	25.0	24.8	25.1	24.6
	2219	27.3	25.8	27.2	26.6	27.1	28.5	27.6
	2220	22.9	23.1	22.9	23.8	23.1	23.5	24.2
	2221	24.3	24.2	25.2	24.7	25.5	25.2	25.7
	2222	24.5	24.9	24.8	24.7	24.6	26.1	25.6
	2223	26.3	27.9	25.8	26.5	26.9	28.2	28.2
	2224	24.3	25.5	25.5	24.5	24.6	25.6	24.9
	2225	22.0	22.7	22.0	22.4	22.4	22.5	23.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
300 ppm	2201	26.0	26.0	25.7	25.7	26.1	26.0	26.1
	2202	25.6	24.6	24.7	24.2	25.8	26.1	26.4
	2203	25.3	25.9	26.1	25.5	27.8	27.4	27.8
	2204	25.3	25.8	25.4	25.0	25.6	26.2	24.9
	2205	23.3	24.2	24.3	24.4	24.9	24.9	24.8
	2206	27.0	27.0	27.2	27.1	27.5	27.8	28.1
	2207	24.9	25.5	26.1	27.3	26.6	26.6	27.5
	2208	24.3	24.0	24.2	24.2	24.7	25.7	25.5
	2209	27.0	26.4	27.1	27.6	27.3	27.5	27.5
	2210	24.9	25.3	24.8	25.1	26.2	27.1	28.6
	2211	23.6	24.5	24.0	24.7	25.5	25.4	25.1
	2212	25.0	25.6	25.8	26.1	26.5	26.3	25.7
	2213	24.8	24.8	25.6	25.0	26.7	26.8	26.7
	2214	25.7	25.5	25.9	25.5	26.1	26.3	26.9
	2215	26.0	27.2	26.5	26.6	26.0	26.7	27.3
	2216	26.4	25.7	26.6	26.6	26.3	27.6	27.3
	2217	24.9	24.9	25.5	25.2	27.1	26.0	25.9
	2218	24.6	25.2	25.3	25.0	26.1	27.2	27.1
	2219	27.6	27.6	28.4	29.5	28.3	29.0	29.2
	2220	24.2	25.0	24.5	25.4	25.9	26.6	27.0
	2221	25.7	26.2	25.6	26.7	26.3	26.9	27.8
	2222	26.9	26.7	26.0	25.8	26.4	26.9	26.8
	2223	28.4	28.6	28.6	29.5	31.3	30.1	32.0
	2224	25.0	26.2	25.0	26.2	26.0	26.1	25.5
	2225	22.2	23.1	23.2	23.1	23.1	23.9	24.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
300 ppm	2201	27.5	26.6	27.5	27.2	28.0	27.9
	2202	26.9	27.1	26.1	26.6	25.6	27.2
	2203	27.6	27.1	28.0	27.8	27.4	27.9
	2204	25.6	25.3	25.8	26.0	26.2	26.3
	2205	24.9	26.6	26.3	26.3	26.7	27.2
	2206	27.3	26.1	26.1	27.2	26.9	25.4
	2207	26.7	26.3	26.5	27.4	26.9	27.5
	2208	25.5	25.7	25.0	25.6	25.1	25.7
	2209	28.7	28.8	29.1	29.2	29.0	30.1
	2210	26.6	28.0	28.2	29.3	28.7	29.1
	2211	25.6	26.4	24.9	26.1	26.2	26.1
	2212	26.6	26.8	26.5	26.5	26.0	26.7
	2213	26.8	27.2	27.5	28.6	26.6	27.2
	2214	26.8	26.8	27.4	27.2	27.2	27.9
	2215	26.8	26.9	26.9	27.8	27.6	28.1
	2216	27.5	27.5	27.5	27.7	29.0	29.3
	2217	25.7	25.7	26.3	26.2	26.4	26.6
	2218	26.0	26.3	26.6	26.6	26.7	26.7
	2219	29.1	29.3	30.2	30.2	27.8	29.2
	2220	26.5	26.3	26.4	27.1	27.1	27.3
	2221	27.2	27.5	27.3	28.1	27.1	30.4
	2222	27.9	27.3	26.7	27.9	27.4	28.3
	2223	30.6	31.8	31.7	32.3	32.7	32.7
	2224	25.7	25.8	25.8	26.3	26.4	26.9
	2225	24.7	24.4	23.5	24.5	23.7	24.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
1000 ppm	2301	20.7	22.1	22.3	23.3	22.7	22.8	24.7
	2302	19.6	20.3	21.7	22.8	23.4	23.5	24.1
	2303	22.4						
	2304	20.5	20.3	21.0	22.7	23.1	23.0	23.6
	2305	21.4	18.3	21.1	21.2	22.1	22.7	23.6
	2306	21.7	22.2	22.0	22.4	23.6	24.0	24.6
	2307	21.2	22.2	21.7	22.7	22.3	22.9	22.7
	2308	20.0	20.6	22.3	22.0	22.9	23.1	24.0
	2309	20.4	20.6	21.0	21.7	21.9	22.6	22.7
	2310	20.8	18.2	20.2	20.4	21.3	22.6	22.7
	2311	19.9	20.3	20.9	21.5	22.0	23.0	24.1
	2312	19.5	20.4	20.7	22.2	22.6	24.1	23.7
	2313	22.4	22.6	22.4	22.9	23.5	24.1	24.8
	2314	21.4	22.0	21.9	22.9	23.5	24.0	24.2
	2315	21.5	21.8	22.4	22.8	23.6	24.0	24.1
	2316	20.8	22.6	22.3	23.3	23.2	22.9	23.8
	2317	19.0	20.4	21.0	21.0	21.8	21.9	22.3
	2318	21.7	21.6	21.7	22.6	23.4	23.5	23.8
	2319	20.6	21.3	20.7	22.0	22.6	23.3	23.3
	2320	18.7	19.1	20.5	21.3	22.5	22.9	23.6
	2321	19.3	20.7	20.1	21.4	22.5	22.4	22.9
	2322	21.0	22.1	23.2	23.8	24.5	24.8	24.9
	2323	20.3	20.4	20.2	21.5	22.1	22.8	22.6
	2324	19.2	20.2	20.7	21.9	22.0	22.6	22.6
	2325	21.9	17.4	22.0	21.5	22.1	22.9	23.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
1000 ppm	2301	24.2	24.9	24.9	26.6	25.3	25.9	26.0
	2302	24.4	24.3	23.6	25.0	25.2	24.5	25.5
	2303							
	2304	22.7	24.1	24.1	24.0	24.2	24.1	24.0
	2305	23.5	24.4	25.3	24.2	24.9	25.5	25.2
	2306	24.5	24.6	25.3	26.3	26.2	26.0	25.8
	2307	24.1	23.5	24.2	25.3	24.9	25.4	24.7
	2308	24.1	23.6	24.6	24.3	24.9	25.6	26.0
	2309	23.1	22.6	23.3	23.7	23.8	24.0	23.7
	2310	23.3	23.1	23.5	23.5	23.4	24.1	23.5
	2311	24.8	23.9	23.8	25.1	25.0	24.0	25.2
	2312	23.9	24.5	24.3	24.4	25.6	25.4	25.6
	2313	25.0	25.5	25.9	26.1	25.7	26.6	27.4
	2314	24.5	24.5	24.4	25.3	24.5	25.8	25.2
	2315	23.5	23.8	24.2	24.5	25.1	25.2	25.3
	2316	24.5	24.9	25.2	25.5	25.4	25.2	25.3
	2317	22.7	23.6	22.0	23.5	24.0	23.4	23.5
	2318	23.7	25.0	24.0	24.8	25.3	25.2	24.7
	2319	23.8	24.3	24.6	24.7	24.6	24.7	25.7
	2320	23.7	24.2	24.6	24.5	24.7	25.2	
	2321	23.1	24.1	23.2	24.6	23.8	25.4	25.2
	2322	25.6	25.6	26.0	25.4	26.2	27.4	25.9
	2323	22.9	23.2	23.1	23.6	23.8	24.4	24.2
	2324	22.5	23.2	23.2	24.0	24.9	24.4	24.9
	2325	24.0	23.8	24.2	24.9	24.8	24.7	25.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day							
		14-7	15-7	16-7	17-7	18-7	19-7	20-7	
1000 ppm	2301	26.0	26.3	26.5	26.6	27.5	27.9	28.1	
	2302	24.4	25.5	27.3	27.6	27.1	27.4	27.7	
	2303								
	2304	25.2	25.3	24.9	26.1	26.4	26.3	26.0	
	2305	26.5	27.4	27.3	26.8	26.6	27.4	27.3	
	2306	26.2	26.5	26.5	26.8	26.9	27.4	26.3	
	2307	25.4	24.8	25.6	26.5	27.2	26.7	28.9	
	2308	25.7	25.6	25.1	26.0	26.6	27.0	26.7	
	2309	23.9	24.9	25.5	25.4	25.4	27.1	26.9	
	2310	24.1	25.4	25.1	24.9				
	2311	26.7	26.2	26.1	26.2	26.9	26.4	27.5	
	2312	25.5	25.4	25.9	26.0	25.5	25.8	26.1	
	2313	26.9	27.8	28.3	28.8	29.1	28.3	29.8	
	2314	27.0	26.6	26.6	27.6	28.6	28.9	28.7	
	2315	25.8	25.5	26.4	25.9	26.7	26.9	26.8	
	2316	25.1	26.5	25.7	26.3	26.7	26.5	27.0	
	2317	23.9	24.5	23.9	24.2	24.2	25.2	24.8	
	2318	26.5	25.5	25.4	25.3	25.8	27.1	26.0	
	2319	24.5	25.4	25.5	26.4	26.5	26.8	25.2	
	2320								
	2321	25.2	26.0	25.5	25.1	25.7	26.1	25.9	
	2322	26.7	26.8	27.1	27.0	27.1	28.0	29.2	
	2323	24.6	24.6	24.3	24.5	25.4	25.5	26.6	
	2324	24.5	24.6	25.4	25.8	26.3	27.4	30.2	
	2325	25.9	25.7	25.9	26.6	26.7	26.6	26.8	

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
1000 ppm	2301	27.9	28.3	28.0	28.7	24.4	
	2302	27.6	27.9	27.3	28.0	27.1	
	2303						
	2304	26.8	27.0	25.7	23.9		
	2305	27.1	27.3	26.8	27.3	27.6	27.8
	2306	26.5	27.5	27.6	24.5		
	2307	28.6	27.1	27.4	26.8	28.6	29.2
	2308	26.5	26.5	26.7	27.8	27.9	24.3
	2309	27.1	27.4	28.2	28.1	28.2	28.3
	2310						
	2311	28.5	28.8	27.4	28.3	29.4	27.6
	2312	26.2	27.3				
	2313	30.8	30.7	30.6	30.9	30.7	30.7
	2314	29.2	28.8	28.2	28.7	29.0	29.6
	2315	27.4	27.4	27.3	27.8	27.6	27.9
	2316	27.2	29.2	29.4	29.3	29.3	28.7
	2317	24.7	24.7	26.5	25.7	24.7	
	2318	25.7	23.4				
	2319	26.5	27.1	27.4	27.7	28.3	
	2320						
	2321	27.0	28.4	29.0	28.6	28.3	28.3
	2322	28.5	28.8	24.6			
	2323	26.6	26.8	28.5	27.9	25.8	
	2324	34.1					
	2325	29.3	29.2	25.3			



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		0-0	1-7	2-7	3-7	4-7	5-7	6-7
Posi. Control	2401	21.2	21.5	21.8	22.7	24.5	25.0	25.1
	2402	20.4	21.0	22.4	23.1	22.8	23.6	24.7
	2403	22.6	23.9	24.0	24.2	25.2	26.1	26.4
	2404	21.2	21.9	22.5	22.5	22.1	25.8	25.9
	2405	19.9	19.5	19.4	18.6	20.0	20.6	20.5
	2406	20.5	21.4	21.5	21.7	20.9	22.7	23.9
	2407	21.4	21.7	22.5	22.3	23.0	23.8	23.8
	2408	19.0	20.0	20.3	21.0	21.8	23.5	23.5
	2409	20.7	20.5	20.6	21.0	20.5	21.8	21.7
	2410	20.8	21.0	22.0	22.4	22.9	23.0	23.6
	2411	20.2	19.4	19.6	20.2	20.1	20.8	22.7
	2412	19.7	20.0	20.5	20.8	20.8	22.5	23.1
	2413	21.7	22.9	22.1	22.7	22.6	23.8	24.1
	2414	22.1	20.9	21.0	21.0	23.0	22.9	23.9
	2415	19.2	18.8	18.7	18.0	18.4	18.5	19.1
	2416	20.7	22.1	23.3	23.0	23.2	23.0	23.9
	2417	21.8	22.0	21.9	22.6	24.3	24.5	24.9
	2418	21.4	22.5	23.1	23.0	24.1	24.7	24.8
	2419	19.1	18.9	18.9	19.1	20.5	21.8	22.4
	2420	19.4	19.2	19.5	19.7	20.8	21.0	21.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		7-7	8-7	9-7	10-7	11-7	12-7	13-7
Posi. Control	2401	25.2	25.9	25.2	27.6	25.8	26.9	28.4
	2402	23.0	23.7	24.4	24.2	25.7	21.4	21.0
	2403	26.2	25.8	26.2	25.9	26.6	24.7	23.4
	2404	25.3	24.6	26.4	27.0	26.6	26.0	25.7
	2405	20.9	21.7	22.1	22.2	19.2		
	2406	23.9	23.7	22.5				
	2407	24.3	25.4	24.3	24.6	24.4	26.0	25.4
	2408	22.6	23.1	23.4	24.0	24.3	24.1	24.1
	2409	21.7	23.0	23.8	23.8	24.1	23.9	22.6
	2410	24.6	24.2	25.8	24.1	25.0	25.0	26.6
	2411	24.6	23.7	20.2				
	2412	23.8	24.0	22.7	23.1	24.1	23.7	23.6
	2413	24.9	25.7	26.1	26.2	25.4	26.5	26.2
	2414	24.0	24.2	24.2	24.2	22.8		
	2415	19.0	19.1	20.1	19.3	21.1	21.8	21.6
	2416	24.7	25.3	24.7	23.7	24.8	24.6	24.2
	2417	24.6	26.0	25.0				
	2418	24.9	24.5	24.0	26.0	26.0	25.9	26.9
	2419	22.2	22.9	22.8	23.4	22.7	23.4	24.0
	2420	21.6	21.7	22.2	23.4	22.8	22.3	22.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day						
		14-7	15-7	16-7	17-7	18-7	19-7	20-7
Posi. Control	2401	28.0	30.5	31.7	33.7	35.7		
	2402							
	2403	22.0						
	2404	26.2	26.7	24.8	26.5	26.3	27.1	25.6
	2405							
	2406							
	2407	25.1	24.5	25.0	25.0	24.2		
	2408	24.7	24.9	24.0	23.3	20.1		
	2409							
	2410	23.9	21.0					
	2411							
	2412	24.4	24.7					
	2413	25.3	26.7	24.1	25.5	25.4		
	2414							
	2415							
2416	24.4	24.8	25.4	24.9	25.4	27.7	26.3	
2417								
2418	26.2	26.3	27.0	26.7	20.7	24.9	23.9	
2419	20.6							
2420	22.6	21.1	18.7					

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day					
		21-7	22-7	23-7	24-7	25-7	26-7
Posi. Control	2401						
	2402						
	2403						
	2404	25.4	23.4				
	2405						
	2406						
	2407						
	2408						
	2409						
	2410						
	2411						
	2412						
	2413						
	2414						
	2415						
2416	23.7	24.3	22.0	20.9	20.7	21.1	
2417							
2418	22.4	24.6	22.9	23.4	22.4	23.8	
2419							
2420							

APPENDIX 7-1

FOOD CONSUMPTION CHANGES (INDIVIDUAL) : MALE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	1001	3.6	3.6	3.7	3.7	3.6	3.5	3.6
	1002	4.3	3.8	3.5	3.9	3.8	3.9	3.9
	1003	4.0	3.5	4.0	3.7	4.0	4.2	4.0
	1004	3.8	3.7	3.5	3.7	3.9	3.9	3.9
	1005	3.7	3.2	3.4	3.8	3.6	3.9	3.8
	1006	3.8	3.3	3.7	3.6	3.5	3.6	3.6
	1007	4.1	3.9	3.8	4.0	3.9	3.9	4.2
	1008	3.5	3.2	3.4	3.5	3.5	3.5	3.3
	1009	3.6	3.7	3.7	3.8	3.7	3.8	3.6
	1010	3.9	3.8	3.9	3.7	3.6	3.8	3.6
	1011	3.6	3.0	3.5	3.4	3.4	3.5	3.6
	1012	3.7	3.5	3.8	3.8	3.6	3.5	3.4
	1013	4.1	4.0	4.2	4.3	4.2	4.0	3.9
	1014	3.5	3.5	3.6	3.7	3.7	3.7	3.7
	1015	3.9	3.9	3.9	3.8	3.8	3.7	3.8
	1016	3.6	3.7	3.6	3.7	3.8	3.7	3.7
	1017	4.3	3.2	3.9	4.2	4.4	4.2	4.3
	1018	3.8	3.7	3.6	3.2	3.1	3.4	3.3
	1019	4.0	3.4	3.6	3.5	3.6	3.8	3.7
	1020	3.5	3.0	3.5	3.3	3.4	3.2	3.6
	1021	3.7	3.3	3.6	3.9	4.0	4.0	4.0
	1022	4.0	3.6	3.5	3.8	3.7	3.7	3.5
	1023	4.1	3.6	3.7	3.9	3.7	3.6	3.7
	1024	4.6	4.5	4.5	4.7	4.5	4.7	4.2
	1025	3.8	3.5	3.7	3.8	3.7	3.7	3.7

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	1001	3.6	3.6	3.5	3.6	3.6	3.6	3.6
	1002	4.2	3.7	3.9	4.0	3.8	4.0	4.2
	1003	4.0	4.0	4.0	3.9	3.9	4.0	4.0
	1004	4.0	3.8	4.0	4.1	4.0	4.1	4.1
	1005	4.1	4.0	3.6	3.9	3.8	3.6	3.9
	1006	3.9	3.6	3.8	3.7	3.6	3.6	3.8
	1007	3.9	4.0	4.0	3.9	3.9	4.1	4.2
	1008	3.5	3.5	3.5	3.5	3.5	3.5	3.5
	1009	3.8	3.7	3.7	3.8	3.4	3.7	3.6
	1010	3.6	3.7	3.7	3.5	3.4	3.4	3.6
	1011	3.5	3.6	3.6	3.5	3.6	3.4	3.3
	1012	3.8	3.5	3.7	3.6	3.6	3.5	3.7
	1013	3.9	4.1	4.0	4.2	4.1	4.1	4.1
	1014	3.7	3.7	3.9	3.8	3.7	3.6	3.7
	1015	3.8	3.8	3.8	3.9	3.9	4.0	4.2
	1016	3.8	3.9	3.9	3.6	3.6	3.8	3.6
	1017	4.3	4.1	4.3	4.5	4.3	4.9	4.8
	1018	3.4	3.3	3.4	3.4	3.2	3.3	3.4
	1019	3.7	3.8	3.8	3.8	3.6	3.8	3.6
	1020	3.5	3.5	3.4	3.6	3.6	3.2	3.4
	1021	4.1	4.2	4.1	4.4	4.0	4.3	4.0
	1022	3.6	3.6	3.6	3.6	3.5	3.5	3.6
	1023	3.7	3.5	3.7	3.7	3.5	3.6	3.7
	1024	4.5	4.3	4.2	4.2	4.0	4.1	4.1
	1025	3.8	3.7	3.8	3.8	3.9	3.8	3.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	1001	3.7	3.7	3.5	3.6	3.6	3.8	3.8
	1002	4.2	3.9	4.1	4.3	4.1	4.7	4.6
	1003	3.9	4.1	4.0	4.1	3.8	4.2	4.0
	1004	4.0	4.0	3.8	3.8	3.9	4.3	4.1
	1005	3.8	3.8	3.8	4.0	3.8	3.7	4.2
	1006	3.6	3.6	3.6	3.5	3.7	3.8	4.1
	1007	3.9	3.9	3.8	4.0	4.2	4.0	4.1
	1008	3.5	3.4	3.4	3.4	3.6	3.6	3.6
	1009	3.6	3.6	3.6	3.5	3.5	3.9	3.7
	1010	3.5	3.3	3.4	3.3	3.5	3.6	3.4
	1011	3.5	3.3	3.3	3.5	3.6	3.4	3.5
	1012	3.9	3.8	3.9	3.6	3.8	3.8	3.8
	1013	4.0	3.8	4.1	4.1	4.2	4.3	4.3
	1014	3.7	3.6	3.6	3.7	3.7	3.6	4.0
	1015	4.0	4.0	4.1	4.1	4.0	3.9	4.4
	1016	3.5	4.0	3.9	4.0	3.7	3.7	4.2
	1017	4.8	4.3	4.9	4.4	5.0	4.8	5.0
	1018	3.2	3.3	3.5	3.1	3.6	3.6	3.5
	1019	3.9	3.8	3.9	3.9	3.8	4.1	4.0
	1020	3.5	3.5	3.5	3.3	3.5	3.7	3.7
	1021	4.2	4.0	4.1	4.4	4.1	4.2	4.2
	1022	3.4	3.7	3.6	3.5	3.7	3.9	3.9
	1023	3.5	3.5	3.6	3.6	3.5	3.7	3.8
	1024	4.2	4.0	4.2	4.1	4.2	4.4	4.4
	1025	3.6	3.8	3.8	3.7	4.0	3.7	4.0



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	1001	3.6	3.8	3.7	4.0	3.7
	1002	4.0	4.5	4.4	4.8	4.7
	1003	4.3	4.4	4.4	4.1	4.5
	1004	4.3	4.3	4.1	4.6	4.5
	1005	4.2	4.0	4.2	4.2	4.4
	1006	3.9	3.9	3.9	4.0	4.1
	1007	4.0	4.1	4.1	4.2	4.4
	1008	3.6	3.6	3.6	3.6	3.8
	1009	3.7	3.7	3.7	3.9	4.0
	1010	3.5	3.5	3.6	3.7	3.6
	1011	3.2	3.7	3.6	3.6	3.7
	1012	3.9	4.2	3.7	4.1	4.0
	1013	4.4	4.7	4.8	4.6	4.8
	1014	3.8	3.9	3.9	3.8	4.0
	1015	4.4	4.5	4.5	4.4	4.4
	1016	3.9	3.7	3.5	3.8	3.5
	1017	5.1	5.4	4.8	5.1	5.6
	1018	3.7	3.6	3.8	3.9	3.9
	1019	4.2	3.8	3.9	4.3	4.0
	1020	3.5	3.6	3.7	3.8	3.8
	1021	4.3	3.8	4.2	4.1	4.1
	1022	3.9	3.6	3.8	3.7	4.0
	1023	3.7	3.9	3.7	3.9	4.0
	1024	4.2	4.4	4.3	4.4	4.4
	1025	3.9	3.9	3.9	4.0	4.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
100 ppm	1101	3.6	3.5	3.6	3.7	3.6	3.8	3.9
	1102	3.6	3.5	3.8	4.0	3.9	4.0	3.5
	1103	3.6	3.5	3.7	3.9	4.0	4.0	4.1
	1104	3.6	3.4	3.5	3.7	3.7	3.6	3.9
	1105	3.8	3.5	3.9	3.9	3.9	4.2	4.0
	1106	3.8	4.0	3.3	3.9	4.3	3.9	4.0
	1107	3.9	3.8	3.9	4.1	4.3	4.1	4.2
	1108	3.7	3.7	3.5	3.7	3.7	3.9	3.8
	1109	3.7	3.8	3.9	3.9	4.0	3.9	3.9
	1110	3.7	3.5	4.0	3.6	3.7	3.8	3.6
	1111	3.8	3.6	3.9	4.0	4.1	4.1	4.2
	1112	3.7	3.4	3.7	3.7	3.6	3.5	3.9
	1113	3.9	4.2	4.5	4.5	4.4	4.5	4.1
	1114	4.2	3.9	3.9	4.0	4.0	4.1	3.9
	1115	3.7	3.7	4.0	3.9	4.2	4.5	4.4
	1116	3.7	3.8	3.9	3.9	4.0	4.0	4.0
	1117	3.8	3.3	3.6	3.6	3.8	3.8	3.9
	1118	4.1	4.2	4.3	4.3	4.4	4.3	4.2
	1119	4.3	4.5	4.3	3.9	4.2	4.2	4.2
	1120	3.8	3.9	4.1	4.0	4.0	4.0	4.1
	1121	3.5	3.2	3.5	3.6	3.4	3.4	3.4
	1122	3.5	3.7	3.8	3.9	3.9	4.1	4.2
	1123	3.6	3.6	3.8	3.6	3.6	3.8	3.7
	1124	4.2	3.6	4.1	4.0	3.7	4.3	3.7
	1125	4.0	4.0	4.3	4.3	4.2	4.2	3.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
100 ppm	1101	3.7	4.1	3.9	3.8	4.0	4.0	4.1
	1102	3.8	4.0	3.9	3.6	3.9	3.7	3.6
	1103	4.0	3.9	3.9	4.1	3.9	3.9	4.2
	1104	3.8	3.7	3.9	3.7	3.7	3.8	3.7
	1105	3.9	4.3	4.1	4.2	4.1	4.3	4.1
	1106	3.9	4.0	3.9	4.1	3.9	4.2	4.1
	1107	4.1	4.2	4.5	4.4	4.5	3.9	4.2
	1108	3.9	4.0	4.0	3.9	4.0	4.0	3.9
	1109	3.6	4.0	3.9	3.9	3.9	3.9	3.6
	1110	3.6	3.7	3.5	3.7	3.5	3.3	3.6
	1111	4.1	4.4	4.2	4.7	4.2	4.3	4.1
	1112	3.7	3.9	3.8	3.8	3.7	3.7	3.8
	1113	4.4	4.2	4.3	4.2	4.2	4.1	4.4
	1114	4.0	3.9	2.9	3.0	2.5		
	1115	4.7	4.3	4.6	4.4	4.4	4.4	3.9
	1116	3.9	4.1	4.0	4.1	3.8	4.2	3.9
	1117	3.9	3.9	3.8	3.6	3.8	4.0	3.9
	1118	4.4	4.2	4.2	4.3	4.3	4.0	4.0
	1119	4.2	4.3	4.3	4.2	4.2	4.1	4.2
	1120	4.2	4.2	4.2	4.4	4.1	4.2	4.5
	1121	3.4	3.5	3.4	3.4	3.2	3.5	3.4
	1122	3.9	3.9	3.8	4.2	3.9	4.0	4.1
	1123	3.8	3.7	3.6	3.8	3.6	3.8	3.7
	1124	3.6	3.7	3.7	4.0	3.8	3.7	3.5
	1125	4.0	4.1	4.0	4.0	3.9	4.0	4.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
100 ppm	1101	4.1	4.0	4.0	3.9	4.2	4.1	4.1
	1102	3.6	3.6	3.7	3.7	3.7	3.9	3.5
	1103	4.4	4.2	4.0	4.2	4.2	4.4	4.4
	1104	3.7	3.7	3.6	3.7	3.8	3.8	3.7
	1105	4.3	4.2	4.3	4.0	3.8	4.2	4.3
	1106	4.0	4.0	3.9	3.8	3.8	4.1	4.0
	1107	4.1	4.1	4.1	3.8	4.3	4.5	4.2
	1108	4.0	4.6	5.9	5.4	4.8	5.9	6.1
	1109	3.8	3.6	3.9	3.7	4.0	4.1	4.2
	1110	3.8	3.7	3.6	3.4	3.4	3.8	3.7
	1111	4.1	4.1	4.2	4.4	4.1	4.2	4.4
	1112	3.7	3.6	3.6	3.8	3.5	4.0	3.6
	1113	4.0	4.0	4.3	4.1	4.3	4.6	4.4
	1114							
	1115	4.1	4.3	4.3	4.7	4.0	4.3	4.2
	1116	3.9	3.9	3.9	3.8	4.0	4.0	4.0
	1117	4.0	3.7	4.0	4.0	3.9	4.0	3.9
	1118	4.0	4.0	4.1	4.4	4.2	4.5	4.1
	1119	4.0	4.0	4.1	4.2	4.2	4.2	4.1
	1120	4.2	4.1	4.3	4.3	4.3	4.6	4.4
	1121	3.5	3.3	3.4	3.3	3.3	3.6	3.4
	1122	4.2	4.1	4.3	4.3	4.4	4.5	4.2
	1123	3.9	3.7	3.8	3.9	3.8	4.0	3.6
	1124	3.6	3.6	3.7	3.5	3.8	3.7	3.6
	1125	3.8	3.9	4.0	4.1	3.9	4.0	4.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
100 ppm	1101	3.4	4.1	4.2	4.3	4.0
	1102	3.7	3.8	3.8	3.9	3.8
	1103	4.4	4.2	4.2	4.5	4.9
	1104	3.7	4.0	3.9	3.6	3.9
	1105	4.1	4.2	4.4	4.4	4.2
	1106	4.1	4.2	4.2	4.2	4.4
	1107	4.4	4.2	4.4	4.2	4.3
	1108	6.0	6.4	6.6	6.7	6.9
	1109	4.1	3.8	4.0	4.0	4.2
	1110	3.5	3.9	3.7	3.9	3.8
	1111	4.3	4.4	4.4	4.4	4.3
	1112	3.8	3.8	4.0	4.0	3.9
	1113	4.3	4.4	4.6	4.7	4.7
	1114					
	1115	4.8	4.1	4.7	4.5	4.5
	1116	4.0	3.9	3.9	4.1	4.1
	1117	4.1	4.0	4.1	4.0	4.1
	1118	4.3	4.1	4.3	4.2	4.5
	1119	4.1	4.4	4.5	4.4	4.6
	1120	4.5	4.3	4.6	4.5	4.4
	1121	3.5	3.5	3.3	3.5	3.5
	1122	4.4	4.5	4.5	4.4	4.4
	1123	3.9	3.8	3.8	4.1	4.1
	1124	3.8	3.5	3.6	4.0	3.7
	1125	4.2	4.0	4.2	4.3	4.4

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
300 ppm	1201	3.4	3.3	3.8	3.9	3.8	3.7	4.0
	1202	4.5	4.1	4.0	4.4	4.5	4.5	4.5
	1203	4.1	3.6	3.8	4.1	4.0	4.0	3.8
	1204	3.7	3.4	3.6	3.7	3.8	3.8	3.8
	1205	3.8	3.8	4.1	4.2	4.0	4.1	4.1
	1206	3.9	3.8	4.2	4.1	4.1	4.2	4.1
	1207	3.3	3.6	3.7	3.8	3.7	3.7	3.7
	1208	3.6	3.7	4.0	4.0	4.0	4.0	3.9
	1209	3.8	4.0	4.2	4.1	4.0	3.8	3.8
	1210	3.5	3.8	4.0	4.2	4.2	4.0	4.2
	1211	4.1	4.1	4.3	4.2	4.3	4.2	4.2
	1212	4.1	4.0	4.1	4.1	4.1	3.9	4.0
	1213	3.5	3.3	3.5	3.7	3.7	3.9	3.9
	1214	3.8	3.8	4.0	4.1	3.9	4.2	3.9
	1215	3.8	3.8	4.0	4.2	4.2	4.2	4.0
	1216	3.6	3.6	3.8	3.9	4.0	3.9	4.0
	1217	3.7	3.9	4.0	4.0	4.2	4.0	4.1
	1218	4.3	4.1	4.1	4.1	4.2	4.2	3.9
	1219	4.0	4.3	4.3	4.3	4.4	4.4	4.3
	1220	4.1	4.1	4.4	4.3	4.2	4.3	4.4
	1221	3.7	3.8	3.9	4.3	4.1	4.1	4.2
	1222	4.0	4.2	4.4	4.6	4.3	4.2	4.3
	1223	3.9	4.0	4.1	4.1	4.0	4.0	4.0
	1224	4.1	4.2	4.2	4.1	4.4	4.3	4.3
	1225	3.5	3.8	3.9	4.0	4.0	3.9	4.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
300 ppm	1201	3.7	3.7	3.8	3.9	3.8	3.7	4.1
	1202	4.2	4.4	4.5	4.3	4.1	4.1	4.4
	1203	4.1	4.1	4.1	4.1	4.3	4.2	4.2
	1204	3.8	3.9	3.9	3.8	3.8	3.8	4.0
	1205	4.2	4.2	4.1	4.2	4.3	4.2	4.5
	1206	4.3	4.1	3.9	4.1	4.0	4.0	4.0
	1207	4.0	3.5	3.8	3.7	3.9	3.9	3.7
	1208	4.0	3.8	4.0	4.0	3.7	3.7	3.7
	1209	4.1	4.1	3.9	4.0	4.1	3.9	4.0
	1210	4.1	4.0	4.2	4.0	3.9	4.2	4.1
	1211	4.2	4.3	4.3	4.3	4.0	4.1	4.0
	1212	4.0	4.0	3.8	4.0	3.8	3.8	4.0
	1213	3.8	3.9	3.9	3.9	3.8	3.8	3.8
	1214	4.1	4.4	4.2	4.2	4.3	4.1	4.1
	1215	4.0	4.1	4.0	4.1	4.0	4.2	4.2
	1216	3.8	3.7	3.8	3.8	3.7	3.8	3.8
	1217	4.0	4.0	3.7	3.8	4.1	4.0	4.0
	1218	4.4	4.5	4.4	4.0	4.1	4.6	4.6
	1219	4.3	4.4	4.3	4.2	4.0	4.2	4.5
	1220	4.4	4.7	4.5	4.8	4.7	4.7	4.8
	1221	4.2	4.2	4.1	4.0	4.3	4.1	4.3
	1222	3.6	4.0	4.1	4.3	3.9	4.1	4.3
	1223	4.1	4.2	4.0	4.2	3.9	4.0	4.2
	1224	4.2	4.2	4.0	4.3	3.9	4.1	4.2
	1225	4.0	3.9	3.9	3.7	3.8	3.7	3.6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
300 ppm	1201	4.1	3.5	1.8				
	1202	4.1	4.3	4.0	4.1	4.3	4.3	4.4
	1203	4.1	4.2	4.3	4.2	4.2	4.5	4.3
	1204	4.1	3.9	3.7	3.7	3.9	4.0	4.0
	1205	4.3	4.0	4.5	4.4	4.4	4.8	4.7
	1206	4.0	4.0	4.3	4.3	4.4	4.4	4.6
	1207	3.6	3.6	3.7	3.5	3.8	3.7	3.9
	1208	3.8	3.8	4.0	3.6	3.9	3.9	4.0
	1209	4.0	3.8	4.0	4.0	4.1	4.1	4.2
	1210	4.1	3.6	4.0	3.9	4.0	4.0	4.1
	1211	4.2	4.1	4.1	3.9	4.3	4.4	4.2
	1212	3.9	4.0	3.9	3.7	4.2	4.0	4.4
	1213	3.8	3.6	3.7	3.8	3.9	4.1	4.0
	1214	4.1	4.2	4.4	4.2	4.4	4.4	4.4
	1215	4.4	4.1	4.4	4.2	4.4	4.3	4.5
	1216	3.9	3.8	3.9	3.9	4.0	3.9	4.1
	1217	4.0	4.0	3.9	3.9	4.1	4.3	4.2
	1218	4.5	4.8	5.1	5.1	5.6	6.0	5.4
	1219	4.5	4.5	4.4	4.5	4.5	4.5	4.6
	1220	4.9	4.4	4.7	4.5	4.7	4.7	5.0
	1221	4.4	4.3	4.4	4.2	4.6	4.7	5.0
	1222	4.0	3.6	4.4	4.2	3.7	4.4	4.2
	1223	4.1	4.0	4.1	3.9	4.2	4.6	4.4
	1224	4.3	4.0	4.2	4.2	4.1	4.4	4.5
	1225	3.6	3.6	3.6	3.6	3.9	4.0	3.9



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
300 ppm	1201					
	1202	4.7	4.3	4.5	4.6	4.3
	1203	4.3	4.3	4.4	4.4	4.4
	1204	3.8	3.8	4.0	3.8	3.8
	1205	4.4	4.5	4.6	4.4	4.3
	1206	4.4	4.6	4.7	4.5	4.8
	1207	4.1	3.8	4.1	3.9	4.0
	1208	3.9	3.9	4.0	4.0	4.2
	1209	4.3	4.3	4.1	4.3	4.1
	1210	4.3	4.1	4.0	4.3	4.2
	1211	4.3	4.2	4.2	4.4	4.3
	1212	3.8	3.8	3.9	4.4	4.4
	1213	3.9	4.1	4.2	3.9	4.1
	1214	4.5	4.4	4.7	4.8	4.7
	1215	4.3	4.4	4.8	4.9	4.8
	1216	4.1	4.0	4.1	4.1	4.0
	1217	4.4	4.2	4.4	4.2	4.5
	1218					
	1219	4.8	4.8	4.8	4.6	4.8
	1220	4.9	4.7	5.3	5.0	4.9
	1221	4.9	5.0	4.4	4.7	4.7
	1222	4.5	4.3			
	1223	4.3	4.5	4.3	4.3	4.3
	1224	4.3	4.4	4.2	4.5	4.5
	1225	3.9	3.8	2.2	5.1	4.9

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
1000 ppm	1301	3.8	3.6	4.0	3.9	4.0	3.8	4.1
	1302	3.5	3.7	4.0	4.1	4.0	4.0	4.1
	1303	3.6	3.6	4.2	4.2	4.1	4.4	4.3
	1304	3.5	3.8	4.0	4.1	3.9	4.0	3.9
	1305	3.7	3.7	4.0	3.7	3.8	3.8	3.9
	1306	3.6	4.0	4.1	4.1	4.1	4.1	4.1
	1307	3.5	3.6	3.8	3.9	3.9	3.8	3.9
	1308	3.9	4.0	4.0	4.1	4.0	4.0	4.1
	1309	3.8	4.1	4.2	3.8	4.1	4.1	4.1
	1310	4.0	3.9	4.1	4.3	4.2	4.4	4.5
	1311	3.7	3.8	3.8	4.0	3.8	3.9	3.9
	1312	3.7	3.9	4.1	4.0	3.8	4.0	4.0
	1313	3.2	3.8	3.8	3.9	3.8	3.9	3.8
	1314	3.8	3.8	3.9	4.0	4.0	4.2	4.3
	1315	3.5	4.1	4.3	4.0	4.0	4.2	4.1
	1316	3.7	4.1	3.9	4.0	3.8	3.9	3.9
	1317	3.3	3.8	3.8	3.7	3.6	3.7	3.7
	1318	2.9	3.7	3.7	4.0	4.0	4.0	4.0
	1319	3.7	3.8	4.4	4.1	4.0	4.0	4.0
	1320	3.5	3.8	3.8	3.8	3.7	4.0	3.9
	1321	3.9	3.6	3.9	4.0	4.0	4.0	4.0
	1322	3.3	3.7	4.1	4.1	4.0	4.0	4.0
	1323	3.4	3.6	3.8	3.8	3.8	4.2	3.8
	1324	4.4	4.6	4.8	4.9	4.7	5.1	4.8
	1325	3.4	3.9	3.7	4.0	3.9	4.0	4.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
1000 ppm	1301	4.1	3.9	4.1	3.9	4.0	3.9	4.2
	1302	4.0	3.8	4.0	3.9	4.0	3.8	4.0
	1303	4.6	4.3	4.4	4.3	4.4	4.3	4.4
	1304	4.1	3.9	4.2	4.0	4.0	3.8	4.3
	1305	3.9	3.8	3.9	3.6	3.9	4.1	4.0
	1306	4.1	4.0	4.1	4.0	4.1	3.9	4.2
	1307	3.8	3.9	4.1	4.1	4.1	3.8	4.2
	1308	3.9	3.8	3.8	3.7	3.9	3.7	4.1
	1309	4.0	4.1	4.3	4.2	4.1	4.1	4.1
	1310	4.5	4.2	4.2	4.6	4.2	4.2	4.4
	1311	3.9	3.8	3.9	3.7	3.8	3.7	4.0
	1312	3.9	3.9	3.9	4.0	4.1	4.1	4.0
	1313	3.9	3.6	3.8	3.8	3.8	3.9	4.0
	1314	4.3	4.2	4.0	4.1	4.1	4.0	4.2
	1315	3.9	4.1	4.1	4.2	4.1	4.2	4.1
	1316	3.8	3.8	3.9	4.0	3.9	4.0	3.9
	1317	3.7	3.6	3.8	3.8	3.8	3.9	4.0
	1318	3.7	4.0	4.0	4.0	3.8	3.9	4.0
	1319	4.1	3.9	3.9	3.7	4.0	3.7	3.9
	1320	3.8	3.8	3.8	3.9	4.1	3.9	4.1
	1321	3.8	4.0	4.1	4.0	4.2	3.8	4.6
	1322	4.1	4.0	4.0	4.0	4.0	4.0	4.1
	1323	4.1	4.1	3.6	4.0	3.9	3.9	4.2
	1324	4.8	4.6	4.8	4.6	4.7	4.5	4.6
	1325	4.1	4.1	4.0	4.1	4.0	4.1	4.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
1000 ppm	1301	3.9	4.0	4.1	3.8	3.9	3.7	2.5
	1302	4.0	3.9	4.0	3.9	4.0	4.1	4.1
	1303	4.1	4.1	4.3	4.4	4.3	4.3	4.4
	1304	4.0	4.1	3.7	4.0	4.0	3.8	
	1305	4.0	3.9	4.0	3.9	4.0	3.8	2.3
	1306	4.0	3.9	4.3	4.0	4.3	4.2	4.4
	1307	3.8	3.9	4.0	4.0	4.1	3.4	
	1308	3.8	3.8	3.7	3.8	4.0	4.2	4.1
	1309	3.4	3.5					
	1310	4.1	4.6	4.7	4.1	4.2	4.8	4.2
	1311	3.9	3.8	3.7	3.9	4.0	4.0	
	1312	4.0	3.9	4.0	3.5	3.5	5.1	5.2
	1313	4.2	3.9	3.9	4.1	4.3	4.2	
	1314	4.2	4.1	4.1	4.4	4.3	4.4	4.5
	1315	4.1	4.1	3.9	4.2	4.1	4.2	4.4
	1316	4.0	3.7	3.9	3.8	3.9	4.0	3.9
	1317	3.9	3.7	3.7	3.9	4.0	4.4	4.3
	1318	4.1	3.7					
	1319	3.6	3.8	3.6	4.0	3.9	3.9	3.7
	1320	3.9	3.9	4.1	3.9	4.2	4.1	4.0
	1321	4.3	4.0	4.2	3.9	4.2	4.2	4.4
	1322	4.0	3.7	4.0	4.0	4.0	4.1	4.2
	1323	3.9	3.7	4.2	3.7	4.1	4.0	4.1
	1324	4.5	4.5	4.7	4.5	4.7	4.9	4.9
	1325	4.3	4.0	4.0	4.1	4.2	4.1	4.2

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
1000 ppm	1301					
	1302	3.1				
	1303	4.5				
	1304					
	1305	2.7				
	1306	4.3	4.3	4.4	4.2	
	1307					
	1308	4.4	4.2	4.6	4.4	4.4
	1309					
	1310	4.4	3.8			
	1311					
	1312	5.6	5.2	5.0	5.4	4.5
	1313					
	1314	4.4	4.3	4.3	4.2	
	1315	4.2	4.1			
	1316	1.9				
	1317	4.3	4.3	4.6	4.4	
	1318					
	1319	3.7	3.9	4.0	3.8	3.0
	1320	4.0	4.0			
	1321	4.6	4.5	4.4	4.6	4.4
	1322	4.2	4.1	4.3	4.2	4.1
	1323	4.1	4.1	4.1	4.1	4.1
	1324	4.9	4.7	4.9	4.8	4.9
	1325	4.2	4.1	4.0	3.9	4.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Posi. Control	1401	3.4	3.7	3.9	3.7	3.8	3.5	3.6
	1402	4.1	4.0	4.1	3.8	3.9	4.2	4.2
	1403	4.0	4.0	3.9	4.0	3.8	4.1	3.6
	1404	3.0	3.4	3.1	3.3	3.5	3.3	3.6
	1405	3.6	3.8	3.5	3.8	3.7	3.8	3.7
	1406	3.5	3.5	3.7	3.7	3.9	3.8	3.4
	1407	3.0	3.3	3.6	3.5	3.6	3.5	3.7
	1408	3.6	3.8	3.6	3.6	3.7	3.6	3.6
	1409	3.4	3.8	4.0	4.0	3.8	4.1	4.0
	1410	3.6	3.6	3.6	3.6	3.6	3.6	3.6
	1411	3.6	3.9	3.8	3.8	3.8	3.8	3.8
	1412	3.5	3.6	3.7	3.7	3.8	3.7	3.8
	1413	3.8	3.8	3.8	3.8	3.8	3.8	3.8
	1414	3.9	3.4	3.7	3.7	3.6	3.8	3.6
	1415	4.4	4.3	3.5	3.7	3.8	3.7	3.7
	1416	3.4	4.1	3.6	3.5	3.6	3.3	3.5
	1417	3.2	3.3	3.7	3.7	3.6	3.9	3.7
	1418	3.8	3.6	3.4	3.7	3.8	3.9	3.8
	1419	3.8	3.7	4.1	4.3	3.9	4.1	4.1
	1420	4.0	4.0	3.8	4.1	4.3	4.2	4.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Posi. Control	1401	3.6	3.7	3.3	3.5	3.3	3.1	3.8
	1402	4.1	3.6	3.8	3.4	3.7	3.8	5.4
	1403	3.7	3.7	3.7	3.6	3.6	2.4	
	1404	3.5	3.6	3.5	3.2	3.3	3.1	3.0
	1405	4.1	3.6	3.7	3.9	3.6	1.7	
	1406	3.5	3.7	3.4	3.6	3.5	3.5	3.6
	1407	3.5	3.3	3.5	3.5	3.4	3.3	3.4
	1408	3.6	3.9	3.5	3.7	3.4	3.7	2.9
	1409	3.9	3.6	3.7	4.1	3.7	3.8	4.0
	1410	3.7	3.4	3.6	3.4	3.2	3.3	3.4
	1411	3.8	3.7	3.8	3.7	3.8	3.6	3.7
	1412	3.5	3.8	3.7	3.4	3.4	3.5	3.2
	1413	3.5	3.7	3.5	3.3	3.3	3.5	3.4
	1414	3.4	3.3	3.5	3.1	4.3	4.1	4.1
	1415	3.6	3.7	3.8	3.8	3.5	3.5	3.5
	1416	3.7	3.5	3.7	3.5	3.4	3.2	3.3
	1417	3.6	3.4	3.5	3.0	3.2	2.5	2.7
	1418	3.7	3.7	3.9	3.7	3.6	3.4	3.4
	1419	3.9	3.9	4.2	4.2	4.1	4.1	4.0
	1420	4.3	3.7	4.1	3.8	3.9	3.7	3.9

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Posi. Control	1401	4.1	4.1	4.0	4.3	4.2	4.4	5.1
	1402	4.2	4.0	3.8	3.4	2.8	5.2	
	1403							
	1404	2.8	2.8	2.8	3.1	2.7	2.2	
	1405							
	1406	3.7	3.3	3.7	3.6	3.9	3.7	3.9
	1407	3.2	3.4	3.3	3.3	3.5	3.8	4.6
	1408							
	1409	2.7						
	1410	3.4	3.4	3.3	3.4	3.6	3.5	4.0
	1411	3.5	3.6	3.6	3.6	3.7	3.8	3.8
	1412	3.6	3.1	3.3	3.5	3.6	3.7	3.7
	1413	3.3	2.9	4.4	4.7			
	1414	3.9	4.1	4.8	5.0	5.0	5.1	5.6
	1415	3.4	3.4	3.4	3.8	5.0	5.3	5.6
	1416	3.0	3.1	2.9	2.5	4.1	3.6	3.8
	1417	2.8	2.9	2.9	2.6	2.8	3.0	2.8
1418	3.4	3.4	3.6	3.5	3.6	3.8	3.8	
1419	4.2	3.9	3.8	2.5	2.4			
1420	4.2	4.0	4.3	3.9	4.1	3.8	3.9	



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Posi. Control	1401	5.0	5.9	5.8	5.9	6.1
	1402					
	1403					
	1404					
	1405					
	1406	3.9	4.0	3.8	3.6	3.9
	1407	5.3	5.5	5.3	5.9	5.4
	1408					
	1409					
	1410	4.9	5.4	5.2	5.3	5.1
	1411	3.8	3.8	3.7	3.7	3.9
	1412	3.7	4.3	4.5	5.1	4.6
	1413					
	1414	4.1				
	1415	5.8	6.0	6.0	7.0	5.7
	1416	4.2	4.1	4.3	5.7	4.5
	1417					
1418	3.8	3.8	3.8	3.8	3.9	
1419						
1420	4.2	4.9	4.2	4.2	4.4	

**APPENDIX 7-2**

**FOOD CONSUMPTION CHANGES (INDIVIDUAL) : FEMALE**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	2001	3.4	3.7	3.8	4.1	4.1	4.0	4.2
	2002	3.1	2.9	3.4	3.5	3.8	3.5	3.8
	2003	3.3	3.3	3.9	3.8	3.3	3.9	4.0
	2004	3.5	3.4	3.5	3.2	3.5	4.2	3.9
	2005	3.2	2.7	3.9	3.5	3.1	3.7	3.7
	2006	3.5	3.6	4.1	4.3	4.3	4.2	4.5
	2007	4.1	3.2	3.6	3.9	4.0	3.5	3.8
	2008	3.4	3.1	3.4	3.7	3.7	4.0	4.2
	2009	3.1	3.4	3.1	3.3	3.6	4.0	3.9
	2010	3.4	3.2	3.4	3.9	3.6	4.0	3.9
	2011	3.3	3.8	2.8	3.5	3.9	3.4	3.9
	2012	3.9	3.4	3.8	3.9	3.8	4.5	4.2
	2013	4.2	3.3	3.4	3.8	4.0	3.9	4.2
	2014	3.4	3.1	3.4	3.5	3.8	3.7	4.0
	2015	4.0	3.9	3.8	3.4	3.4	3.9	4.0
	2016	3.6	3.3	3.8	3.2	3.3	3.5	3.3
	2017	3.3	3.0	3.2	3.1	3.3	3.4	3.3
	2018	3.4	3.8	4.0	4.3	4.4	4.3	4.0
	2019	3.2	3.4	3.4	3.0	3.2	3.3	3.2
	2020	4.3	3.5	3.9	3.7	3.6	3.6	3.7
	2021	3.4	3.5	3.5	3.7	3.5	3.4	3.4
	2022	3.8	3.6	3.5	3.9	3.6	3.6	3.8
	2023	3.5	3.6	3.8	3.9	4.0	3.7	3.9
	2024	3.8	3.8	3.5	3.9	3.6	3.9	3.6
	2025	3.5	3.1	3.3	3.5	3.5	3.5	3.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	2001	3.9	3.9	4.1	3.7	3.8	3.4	3.8
	2002	3.6	3.7	3.6	3.7	3.3	3.4	3.6
	2003	4.0	3.7	4.0	4.1	3.3	3.4	3.9
	2004	3.6	3.7	4.0	3.5	4.0	3.4	4.0
	2005	3.9	3.6	3.3	3.5	3.8	3.4	3.3
	2006	4.3	4.4	4.0	3.9	4.1	3.6	4.5
	2007	3.6	3.6	3.4	3.4	3.5	3.5	3.3
	2008	3.8	3.9	3.3	3.9	3.9	3.6	3.7
	2009	3.8	3.7	3.9	3.5	3.5	3.7	3.5
	2010	3.6	3.9	3.7	3.5	3.9	3.4	3.5
	2011	3.8	3.8	4.0	3.7	3.8	3.4	3.8
	2012	3.0	3.8	4.6	5.5	5.0	5.9	5.7
	2013	4.0	4.0	3.8	3.9	3.6	3.7	3.9
	2014	3.6	3.5	3.6	3.5	3.2	3.5	3.3
	2015	4.1	3.7	3.2	3.5	3.8	3.4	3.6
	2016	3.4	3.5	3.4	3.5	3.6	3.3	3.6
	2017	3.6	3.6	3.4	3.2	3.2	3.0	3.0
	2018	3.9	3.9	3.8	3.8	3.9	4.0	3.3
	2019	3.5	3.5	3.2	3.4	3.1	3.3	3.1
	2020	3.8	3.7	4.1	3.9	3.3	3.6	3.6
	2021	3.4	3.4	3.3	3.1	3.2	3.3	3.3
	2022	3.6	3.7	3.3	3.5	3.7	3.2	3.7
	2023	3.6	3.6	3.7	3.5	3.8	3.4	3.7
	2024	3.8	3.5	3.2	3.5	3.6	3.2	3.3
	2025	3.5	3.2	3.3	3.4	3.0	3.2	3.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	2001	3.8	3.5	3.7	3.5	3.6	3.8	3.8
	2002	3.4	3.5	3.5	3.5	3.5	4.0	3.8
	2003	3.7	3.4	3.9	3.9	4.1	4.0	3.9
	2004	3.5	3.3	3.5	3.3	3.5	3.7	3.8
	2005	3.7	3.3	3.2	3.5	3.8	4.0	3.7
	2006	3.7	3.5	3.9	3.6	3.9	4.1	3.7
	2007	3.4	3.2	3.9	3.5	3.9	3.9	3.7
	2008	3.7	3.6	3.3	3.4	3.6	3.9	3.8
	2009	3.7	3.6	4.1	3.5	4.0	3.7	3.9
	2010	3.6	3.5	3.7	3.6	3.8	3.8	4.2
	2011	3.7	3.6	3.9	3.7	3.9	4.1	4.3
	2012	5.7	5.9	5.9	5.9	6.0	6.3	
	2013	3.7	3.7	3.6	3.6	4.1	3.9	3.7
	2014	3.6	3.9	3.2	3.7	3.5	4.0	3.8
	2015	3.1	3.4	3.6	3.3	3.5	3.7	3.6
	2016	3.5	3.6	3.6	3.7	3.6	3.9	3.7
	2017	3.1	3.1	3.3	3.3	3.3	3.3	3.4
	2018	3.8	3.9	3.9	3.8	3.9	3.9	3.8
	2019	3.4	3.4	3.3	3.4	3.5	3.9	3.6
	2020	3.9	3.5	3.6	3.7	3.6	3.8	4.0
	2021	3.5	3.3	3.3	3.3	3.3	3.6	3.3
	2022	3.3	3.8	3.3	3.5	3.7	3.9	3.8
	2023	3.9	3.7	3.8	3.7	3.7	4.0	4.1
	2024	3.5	3.7	3.5	3.4	3.8	4.1	3.8
	2025	3.1	3.2	3.3	3.4	3.2	3.5	3.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	2001	3.9	3.9	3.8	4.1	3.9
	2002	3.7	4.0	3.7	3.7	3.8
	2003	4.1	4.2	3.8	3.9	4.3
	2004	3.7	3.7	3.5	3.4	3.7
	2005	3.9	3.5	3.4	3.4	3.8
	2006	4.1	3.7	3.4	3.8	4.1
	2007	4.2	3.7	3.9	3.8	4.3
	2008	3.7	3.8	3.7		
	2009	3.7	3.9	3.8	3.8	4.0
	2010	3.8	3.8	3.8	3.7	4.1
	2011	4.1	3.8	3.9	4.1	4.3
	2012					
	2013	4.0	3.6	3.8	3.6	3.6
	2014	3.5	3.6	3.5	3.5	3.8
	2015	3.9	3.8	3.5	3.7	3.6
	2016	3.9	3.4	3.6	3.5	3.8
	2017	3.3	3.4	3.1	3.3	3.4
	2018	3.8	3.9	4.0	4.0	4.2
	2019	4.0	3.8	3.6	3.7	3.6
	2020	4.1	4.0	3.8	3.8	3.9
	2021	3.6	3.6	3.4	3.6	3.5
	2022	3.8	3.8	3.5	3.4	3.8
	2023	3.7	3.7	3.9	3.8	4.1
	2024	3.7	3.9	3.5	3.9	3.8
	2025	3.4	3.5	3.1	3.5	3.6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
100 ppm	2101	3.7	3.6	3.9	3.8	3.7	3.7	4.0
	2102	3.5	3.2	3.1	3.7	4.1	3.9	4.1
	2103	3.7	3.2	3.6	3.0	2.2		
	2104	4.0	3.5	3.9	3.8	3.9	3.5	3.8
	2105	3.7	3.9	3.1	3.2	3.9	4.1	3.7
	2106	3.6	3.6	4.2	4.3	4.2	4.2	4.1
	2107	3.9	3.9	3.8	3.8	3.6	3.8	4.2
	2108	3.1	3.0	3.8	3.5	3.6	3.9	3.6
	2109	3.0	2.7	3.3	3.5	3.6	4.0	3.6
	2110	4.0	3.7	3.5	3.6	3.7	3.9	3.7
	2111	3.8	3.3	3.8	3.0	3.4	3.7	3.1
	2112	3.6	3.4	3.7	3.4	3.7	3.7	3.8
	2113	3.5	3.5	2.9	3.6	3.8	3.9	4.0
	2114	3.5	3.0	3.7	3.4	3.5	3.6	3.6
	2115	3.4	3.7	3.6	3.1	3.7	3.7	3.8
	2116	3.7	3.1	3.5	3.9	4.1	4.2	4.0
	2117	3.4	3.0	3.7	3.5	3.8	3.9	4.1
	2118	3.7	3.1	3.0	3.6	3.7	3.9	4.0
	2119	4.3	3.6	3.5	4.2	4.2	4.5	4.2
	2120	4.1	2.9	3.2	3.7	3.5	3.7	3.6
	2121	3.8	3.7	3.4	3.9	3.9	4.3	4.0
	2122	3.3	3.6	3.4	3.4	3.5	3.9	3.8
	2123	3.3	2.9	3.8	4.0	3.8	4.1	3.8
	2124	3.6	3.4	3.2	3.3	3.6	3.2	3.3
	2125	3.9	3.2	3.7	4.1	4.2	4.4	4.2

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
100 ppm	2101	3.9	3.9	3.9	3.8	3.9	3.7	4.2
	2102	3.8	3.8	3.8	3.7	3.8	3.6	3.8
	2103							
	2104	3.7	3.5	3.7	3.8	3.8	3.7	3.7
	2105	4.0	3.5	4.0	3.8	3.6	3.8	3.4
	2106	3.9	4.1	4.0	3.8	3.9	3.8	4.0
	2107	3.8	4.2	4.0	3.9	3.9	3.9	3.8
	2108	3.8	3.6	3.9	3.7	3.6	3.5	3.7
	2109	3.8	3.5	3.4	3.1	3.7	3.2	3.9
	2110	3.9	3.6	3.8	3.5	3.5	3.4	3.7
	2111	3.7	3.6	4.0	3.8	3.4	3.9	3.5
	2112	3.7	4.1	3.6	3.6	3.7	3.6	3.7
	2113	4.0	4.1	3.7	3.9	3.5	3.7	3.7
	2114	3.8	3.8	3.6	3.4	3.6	3.1	3.4
	2115	3.9	3.8	3.9	3.8	3.7	3.7	3.7
	2116	3.7	3.7	3.6	3.8	3.9	3.8	3.7
	2117	3.6	3.8	3.6	3.9	3.8	4.0	3.7
	2118	3.9	3.8	3.6	3.7	3.7	3.7	3.9
	2119	4.6	4.1	3.9	4.0	3.7	4.5	4.0
	2120	3.7	3.5	3.2	3.6	3.4	3.2	3.3
	2121	4.0	3.8	3.9	3.6	3.9	3.7	3.5
	2122	4.0	3.7	3.7	3.4	3.5	3.8	3.5
	2123	4.1	3.7	3.9	3.8	3.8	3.8	3.8
	2124	3.8	3.6	3.7	3.7	3.3	3.2	3.5
	2125	4.2	4.3	4.2	4.2	4.1	4.0	4.2



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
100 ppm	2101	3.7	3.7	3.9	3.6	4.1	3.9	4.2
	2102	3.8	3.8	3.3	3.4	3.7	3.5	3.8
	2103							
	2104	3.8	3.5	3.6	4.0	3.9	4.2	3.9
	2105	3.8	4.0	4.0	3.8	3.7	3.9	4.2
	2106	4.0	4.0	4.2	4.0	4.0	4.1	4.2
	2107	4.1	3.7	3.8	4.0	4.1	4.1	4.0
	2108	4.0	3.6	3.8	3.9	3.9	3.8	3.9
	2109	3.0	2.6	3.4	3.3	3.5	3.3	3.5
	2110	3.6	3.8	3.6	3.7	3.8	3.9	3.7
	2111	3.4	3.7	3.7	3.6	3.9	3.7	4.2
	2112	4.2	3.9	3.9	4.0	3.6	3.2	3.7
	2113	3.9	3.8	3.8	4.0	4.1	4.0	4.1
	2114	3.5	3.3	3.5	3.3	3.4	3.9	3.8
	2115	3.9	3.9	3.6	3.8	4.1	3.8	3.9
	2116	3.7	4.0	3.8	3.6	4.0	3.9	4.2
	2117	3.8	3.8	3.8	3.7	4.0	4.2	4.1
	2118	3.8	3.8	4.2	3.9	3.8	3.9	3.9
	2119	3.8	4.0	4.3	4.1	4.1	4.6	4.0
	2120	3.7	3.5	3.6	3.5	3.6	3.7	3.6
	2121	3.8	3.5	3.6	4.0	3.6	3.8	3.9
	2122	3.8	3.7	3.8	3.7	3.7	4.0	4.1
	2123	4.0	4.0	4.1	3.9	3.9	4.3	3.9
	2124	3.3	3.5	3.3	3.4	3.7	3.8	3.6
	2125	4.1	4.1	4.2	4.3	4.2	4.4	4.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
100 ppm	2101	4.1	4.0	4.1	4.1	4.2
	2102	3.9	3.6	3.6	3.8	3.7
	2103					
	2104	3.9	3.9	4.2	3.7	4.1
	2105	4.0	3.7	3.6	3.7	4.0
	2106	4.1	4.3	4.0	3.9	4.0
	2107	4.1	4.1	4.0	4.0	4.1
	2108	3.8	3.7	3.8	3.7	4.0
	2109	3.4	3.4	3.4	3.3	3.5
	2110	3.8	3.9	3.7	3.9	3.9
	2111	4.1	3.8	3.7	4.1	3.8
	2112	3.9	3.8	3.6	3.5	3.9
	2113	3.9	3.9	4.2	3.8	4.0
	2114	3.8	3.7	3.6	3.7	3.8
	2115	3.8	3.9	3.6	3.9	3.9
	2116	3.9	4.1	3.7	4.1	4.2
	2117	4.1	3.9	3.7	4.1	3.8
	2118	4.2	3.6	3.9	3.9	4.2
	2119	4.1	4.4	4.2	4.1	4.3
	2120	3.6	3.6	3.7	3.6	3.7
	2121	3.9	3.8	3.7	3.6	3.8
	2122	3.8	4.0	3.9	4.0	4.2
	2123	4.1	4.0	3.9	4.2	4.1
	2124	3.7	3.5	3.6	3.5	3.4
	2125	4.2	4.4	4.2	4.4	4.4

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
300 ppm	2201	3.1	3.3	3.7	3.7	3.8	4.0	3.8
	2202	3.5	3.8	3.6	4.1	3.8	4.1	3.9
	2203	3.3	3.3	3.9	3.7	3.9	4.0	3.8
	2204	3.5	3.6	3.0	3.1	3.1	3.6	3.8
	2205	3.0	3.3	3.8	3.9	4.2	4.2	4.1
	2206	3.3	3.3	4.2	4.1	3.8	3.5	4.0
	2207	3.6	3.7	4.1	4.0	4.4	4.5	4.5
	2208	3.3	3.1	3.6	3.5	3.7	4.0	4.0
	2209	3.3	3.2	3.3	3.6	3.7	3.8	4.0
	2210	3.6	2.8	3.4	3.6	3.6	3.7	4.0
	2211	3.7	3.2	3.6	3.8	3.7	3.7	3.8
	2212	3.6	2.9	3.3	3.6	3.9	3.9	3.9
	2213	3.5	2.8	3.7	3.7	3.9	4.1	4.0
	2214	3.2	3.5	3.5	3.8	3.5	3.6	3.7
	2215	3.7	3.5	3.8	4.0	4.0	4.1	4.1
	2216	4.0	3.9	3.9	4.4	4.2	4.2	4.4
	2217	3.5	3.6	4.3	4.5	4.3	4.7	4.2
	2218	2.5	3.4	3.8	3.9	3.9	4.0	3.9
	2219	3.7	3.8	4.1	4.4	4.5	4.6	4.5
	2220	3.5	3.4	3.6	3.9	3.8	3.7	3.9
	2221	3.6	3.5	4.2	4.1	4.1	3.7	4.1
	2222	3.9	3.1	3.4	4.0	3.8	3.8	3.9
	2223	3.5	3.7	4.0	4.1	4.1	4.2	4.5
	2224	3.9	3.6	3.6	3.8	4.1	4.1	4.2
	2225	2.9	3.2	3.6	4.1	3.6	3.8	4.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
300 ppm	2201	3.8	3.9	3.9	3.7	3.8	3.6	4.0
	2202	4.2	4.1	4.0	3.7	3.9	3.7	3.8
	2203	4.1	3.9	4.1	3.8	3.8	3.5	3.8
	2204	3.9	3.8	3.4	3.5	3.7	3.6	3.8
	2205	4.2	4.0	4.0	3.9	3.9	3.9	3.9
	2206	4.2	4.0	3.9	3.7	3.7	3.7	4.2
	2207	4.2	4.0	4.1	3.8	3.9	3.8	4.0
	2208	3.8	3.6	4.0	3.5	3.8	3.4	3.8
	2209	3.7	3.7	3.8	3.7	3.7	3.6	3.8
	2210	3.6	3.9	3.9	3.6	4.0	4.1	3.6
	2211	3.5	3.6	3.8	3.6	3.6	3.5	3.6
	2212	3.9	3.8	3.9	3.6	3.8	3.8	3.7
	2213	4.0	3.8	3.7	3.7	4.8	3.4	3.8
	2214	3.5	3.9	3.6	3.7	3.5	3.7	3.7
	2215	3.9	3.7	3.6	3.8	3.6	3.4	3.7
	2216	4.1	4.3	4.1	3.9	4.2	4.0	4.5
	2217	4.4	4.2	4.6	4.4	4.4	4.2	4.3
	2218	3.8	4.0	3.7	3.7	3.6	3.7	3.7
	2219	3.9	4.4	4.1	4.1	4.4	4.2	4.3
	2220	3.8	3.7	3.7	3.7	3.6	3.7	3.5
	2221	4.0	4.2	4.1	4.0	3.9	4.1	3.7
	2222	3.8	3.7	3.5	3.6	3.8	3.7	3.9
	2223	4.2	3.8	4.1	4.1	4.0	4.0	4.2
	2224	4.2	3.9	3.8	3.9	4.0	3.8	3.9
	2225	4.5	4.5	4.8	4.4	4.6	4.7	4.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
300 ppm	2201	3.8	3.8	3.7	3.7	3.8	4.1	4.1
	2202	3.6	3.9	3.9	4.0	4.1	4.0	4.2
	2203	3.7	3.8	3.8	4.2	4.3	4.1	4.1
	2204	3.9	3.6	3.6	3.6	3.8	3.7	3.9
	2205	4.0	4.1	4.1	4.0	4.2	3.9	4.0
	2206	3.7	4.1	4.0	4.0	3.9	3.9	3.9
	2207	3.8	3.9	4.2	3.7	3.7	4.1	3.9
	2208	3.5	3.6	3.7	3.7	4.0	3.6	3.9
	2209	3.7	3.6	3.8	3.7	4.1	4.0	4.1
	2210	3.7	3.7	3.8	4.0	4.1	4.5	4.1
	2211	3.7	3.5	3.6	3.8	3.8	4.0	4.0
	2212	3.7	3.7	3.9	3.9	3.8	3.9	4.0
	2213	3.7	3.9	3.9	4.1	4.1	3.9	4.1
	2214	3.7	3.6	3.5	3.8	3.8	3.9	3.9
	2215	3.9	3.8	3.9	3.7	3.9	3.9	3.9
	2216	4.0	4.2	4.3	4.1	4.6	4.3	4.5
	2217	4.2	4.2	4.3	4.6	4.1	4.2	4.0
	2218	3.9	4.0	4.0	4.2	4.2	4.1	3.7
	2219	4.3	4.4	4.5	4.4	4.2	4.2	4.5
	2220	3.9	3.6	4.0	3.9	4.1	4.3	3.9
	2221	3.9	3.8	4.0	3.9	4.2	4.2	4.2
	2222	3.7	3.4	3.7	3.8	4.1	4.1	4.0
	2223	4.3	4.1	4.4	4.5	4.5	4.8	4.5
	2224	3.9	3.6	3.8	3.7	3.9	3.8	3.9
	2225	4.9	4.7	4.9	4.7	4.9	4.8	4.9

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
300 ppm	2201	3.7	4.1	3.9	4.1	4.1
	2202	4.2	3.8	3.9	4.1	4.1
	2203	4.1	4.1	3.9	3.9	4.1
	2204	3.8	3.9	4.0	4.1	4.0
	2205	4.0	4.1	4.0	4.3	4.0
	2206	3.5	3.8	4.1	3.9	3.8
	2207	3.9	3.9	4.1	3.9	4.3
	2208	3.9	3.8	3.7	3.7	3.9
	2209	3.9	4.2	4.1	4.0	4.4
	2210	4.2	4.0	4.3	4.1	4.4
	2211	4.3	3.8	4.2	4.4	4.1
	2212	4.2	4.0	3.9	4.2	4.1
	2213	4.1	3.7	4.2	3.6	4.0
	2214	3.9	3.8	3.7	3.8	3.9
	2215	4.1	3.9	3.8	4.1	4.0
	2216	4.6	4.1	4.5	4.5	4.6
	2217	4.0	4.2	4.0	4.1	4.4
	2218	3.9	4.0	3.7	3.9	3.9
	2219	4.3	4.3	4.5	4.3	4.5
	2220	3.9	3.9	3.8	4.1	4.2
	2221	4.1	4.0	4.3	4.3	4.5
	2222	4.0	3.8	4.2	4.0	4.0
	2223	4.8	4.5	4.8	4.8	4.6
	2224	3.9	3.8	3.9	3.8	4.1
	2225	5.0	4.8	5.0	5.2	5.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
1000 ppm	2301	3.3	3.5	3.8	3.9	3.9	4.3	3.8
	2302	3.5	3.4	3.7	4.0	3.9	4.0	4.0
	2303							
	2304	2.9	3.6	4.0	3.6	4.0	3.8	3.6
	2305	1.7	3.8	3.5	3.8	3.9	4.0	3.7
	2306	3.2	3.6	4.2	4.5	4.3	4.4	4.3
	2307	3.6	3.6	4.0	4.0	4.1	4.1	4.3
	2308	3.1	3.8	3.7	4.1	3.8	4.1	4.1
	2309	3.6	3.7	4.1	4.2	4.3	4.1	4.2
	2310	1.8	3.8	3.4	3.5	3.7	3.7	3.8
	2311	3.0	3.6	4.1	4.2	3.9	4.2	4.1
	2312	3.3	3.6	4.3	3.7	4.1	4.1	4.0
	2313	3.3	3.5	3.9	4.1	4.2	4.4	4.3
	2314	3.3	3.5	4.0	4.0	3.9	3.9	4.1
	2315	3.3	3.4	3.8	4.1	3.8	3.9	3.7
	2316	3.8	3.7	4.0	4.1	4.0	4.2	4.2
	2317	3.4	3.4	3.9	3.9	4.0	4.1	4.0
	2318	3.0	3.4	4.0	4.0	4.0	4.0	4.1
	2319	3.4	3.1	3.8	3.6	3.7	3.7	4.0
	2320	3.3	3.3	3.9	4.3	4.0	4.4	4.2
	2321	3.3	3.1	3.8	3.8	3.7	3.9	3.9
	2322	3.6	4.0	4.3	3.8	3.9	3.9	4.2
	2323	2.9	3.2	3.8	3.9	4.0	4.1	4.0
	2324	3.6	3.6	4.1	4.2	4.2	4.1	4.6
	2325	1.3	4.3	3.5	4.0	4.0	4.1	4.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
1000 ppm	2301	4.3	3.8	4.3	4.0	4.0	4.0	4.0
	2302	3.9	3.8	4.0	3.7	3.8	3.9	3.8
	2303							
	2304	4.0	4.0	4.1	3.9	3.9	3.6	4.3
	2305	4.1	3.9	3.8	3.8	3.9	3.8	4.1
	2306	4.4	4.2	4.5	4.6	4.2	4.2	4.5
	2307	4.1	4.1	4.4	4.1	4.0	4.0	4.1
	2308	4.1	4.3	4.4	4.2	4.4	4.5	4.3
	2309	4.2	4.2	4.1	4.2	3.9	4.1	4.1
	2310	3.6	3.9	3.6	3.7	3.8	3.5	3.9
	2311	4.1	4.0	4.2	3.9	3.8	4.0	4.4
	2312	4.3	4.1	4.1	4.5	4.3	4.5	4.4
	2313	4.2	4.3	4.3	4.0	4.5	4.4	4.3
	2314	3.8	3.9	4.1	3.8	4.0	4.1	4.3
	2315	4.0	3.9	4.2	4.1	4.0	3.9	3.9
	2316	4.2	4.2	4.2	4.1	4.2	4.1	4.2
	2317	4.1	3.7	4.0	4.3	4.0	3.8	4.1
	2318	4.0	3.7	3.8	3.9	3.8	4.0	4.4
	2319	4.1	3.8	3.7	3.9	3.9	3.9	4.1
	2320	4.7	4.4	4.3	4.2	4.0		
	2321	4.0	3.7	4.0	3.8	4.0	3.9	4.1
	2322	4.0	4.2	3.9	4.2	4.2	4.0	4.5
	2323	4.2	4.1	4.4	4.3	4.3	4.0	4.3
	2324	4.6	4.3	4.6	4.1	4.5	4.4	4.3
	2325	4.1	4.1	4.0	4.1	4.0	3.8	4.2



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
1000 ppm	2301	4.0	4.0	3.9	4.2	4.3	4.3	4.2
	2302	3.7	4.1	4.8	4.2	4.5	4.4	4.3
	2303							
	2304	4.1	4.1	4.4	4.6	4.4	4.2	4.7
	2305	4.4	4.2	4.3	4.2	4.5	4.3	4.2
	2306	4.5	4.5	4.7	4.6	4.9	4.3	4.9
	2307	3.8	3.8	4.1	4.5	4.0	5.2	4.4
	2308	4.5	4.4	4.5	4.7	4.7	4.5	4.5
	2309	4.4	4.3	4.4	4.2	5.0	4.7	4.9
	2310	4.1	4.0	3.4				
	2311	4.2	4.1	4.1	4.5	4.4	4.7	4.6
	2312	4.2	4.6	4.5	4.3	4.8	4.6	4.4
	2313	4.2	4.5	4.6	4.5	4.3	5.2	5.1
	2314	4.2	3.8	4.4	4.6	4.5	4.7	4.7
	2315	3.8	3.9	3.9	4.1	4.0	4.2	4.3
	2316	4.3	4.1	4.4	4.3	4.2	4.6	4.6
	2317	4.0	3.9	3.9	4.0	4.5	4.3	4.1
	2318	3.8	3.6	4.0	4.1	4.3	4.6	3.6
	2319	4.0	3.9	4.5	4.1	4.4	4.2	4.5
	2320							
	2321	4.2	3.9	3.8	3.9	4.1	4.2	4.4
	2322	4.3	4.5	3.9	4.4	4.5	4.7	4.7
	2323	4.3	4.1	4.4	4.5	4.8	5.4	5.6
	2324	4.5	4.6	4.8	4.9	4.9	5.9	6.5
	2325	4.2	4.0	4.1	4.4	4.4	4.1	5.1

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
1000 ppm	2301	4.4	4.3	4.4	3.5	
	2302	4.5	4.1	4.7	4.3	
	2303					
	2304	4.6	3.9	3.2		
	2305	4.4	3.9	4.2	4.4	4.4
	2306	5.0	4.5	3.5		
	2307	4.2	4.3	3.6	4.7	4.8
	2308	4.5	4.5	5.2	4.8	4.0
	2309	4.9	4.9	4.6	4.7	4.7
	2310					
	2311	4.8	4.3	4.9	4.4	3.3
	2312	4.6				
	2313	5.1	5.1	5.0	5.2	4.8
	2314	4.5	4.3	5.2	4.9	5.0
	2315	4.3	4.1	4.2	4.3	4.4
	2316	4.8	5.0	5.2	5.0	4.7
	2317	4.1	4.8	4.4	3.9	
	2318	3.5				
	2319	4.6	4.4	4.6	4.9	
	2320					
	2321	4.8	4.8	4.9	4.8	4.6
	2322	4.8	2.8			
	2323	5.4	5.4	5.3	4.8	
	2324					
	2325	4.9	3.4			

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Posi. Control	2401	3.3	3.5	3.6	3.7	3.8	3.9	3.9
	2402	3.5	3.7	3.9	3.6	4.0	4.1	3.6
	2403	3.3	3.9	4.2	3.6	3.7	3.9	3.5
	2404	3.5	4.0	3.9	2.6	4.5	3.8	4.3
	2405	2.8	3.4	3.2	3.7	3.3	2.8	3.0
	2406	3.8	4.0	4.0	2.6	3.2	3.4	3.6
	2407	2.9	3.4	2.8	3.1	3.5	3.3	3.5
	2408	3.1	3.8	3.8	4.0	4.2	4.0	3.8
	2409	3.1	3.8	3.7	2.9	3.2	3.6	3.4
	2410	2.9	3.6	3.5	3.7	3.4	3.2	3.4
	2411	3.2	3.4	3.6	3.3	3.7	3.6	4.0
	2412	3.1	3.7	3.6	3.5	3.8	3.8	3.9
	2413	3.4	3.4	3.9	4.0	4.1	4.2	4.1
	2414	2.9	3.4	3.1	3.8	3.5	4.0	3.9
	2415	3.1	3.5	3.3	3.5	3.3	3.4	3.1
	2416	3.6	4.1	3.6	3.6	2.9	4.3	3.8
	2417	3.2	3.4	3.7	3.5	3.9	3.7	3.7
	2418	3.8	4.4	3.6	4.2	4.2	4.2	4.0
	2419	2.7	2.9	3.3	3.5	3.7	3.8	3.8
	2420	2.8	3.4	3.3	3.0	3.5	3.6	3.6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Posi. Control	2401	3.6	3.2	3.7	3.3	3.2	3.2	3.2
	2402	3.8	3.6	3.5	3.6	2.1	2.2	
	2403	3.7	3.4	3.3	3.3	3.1	4.6	5.3
	2404	3.5	3.3	4.2	3.6	3.3	2.8	3.1
	2405	3.2	2.9	2.9	2.1			
	2406	3.6	2.6					
	2407	3.6	3.2	3.5	3.2	3.5	3.3	3.3
	2408	3.7	3.5	3.8	3.6	3.6	3.4	3.8
	2409	3.7	3.6	3.7	3.5	3.4	2.5	
	2410	3.1	3.6	3.0	3.6	3.1	3.4	2.3
	2411	3.6	1.9					
	2412	4.2	3.0	3.5	3.5	3.5	3.2	2.8
	2413	4.0	3.8	3.9	3.4	3.5	3.3	3.3
	2414	4.2	3.7	3.7	3.5			
	2415	3.3	3.2	3.1	2.9	3.5	3.0	
	2416	3.5	3.7	2.6	3.2	3.4	3.5	3.4
	2417	3.8	3.1					
	2418	3.8	4.0	4.3	4.1	5.3	6.0	5.8
	2419	3.9	3.7	3.8	3.8	4.1	3.7	2.4
	2420	3.6	3.2	3.9	3.5	3.4	3.1	3.3

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)						
		15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Posi. Control	2401	3.5	3.6	3.8	4.7			
	2402							
	2403							
	2404	3.2	3.3	3.8	3.5	3.7	2.9	4.5
	2405							
	2406							
	2407	3.2	3.1	3.1	2.0			
	2408	3.6	3.3	2.7	2.9			
	2409							
	2410	1.8						
	2411							
	2412	2.2						
	2413	4.3	3.5	3.4	2.7			
	2414							
2415								
2416	3.6	3.5	3.3	3.5	3.8	3.7	2.1	
2417								
2418	7.9	8.0	7.6	4.0	7.7	6.6	5.9	
2419								
2420	2.7	2.1						

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (INDIVIDUAL)  
 ALL ANIMALS

Group Name	Animal ID-NO.	Administration week-day(effective)				
		22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Posi. Control	2401					
	2402					
	2403					
	2404	4.8				
	2405					
	2406					
	2407					
	2408					
	2409					
	2410					
	2411					
	2412					
	2413					
	2414					
	2415					
2416	2.7	2.8	2.9	2.9	3.0	
2417						
2418	8.1	6.7	7.9	7.6	5.2	
2419						
2420						

APPENDIX 8-1

HEMATOLOGY (INDIVIDUAL) : MALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH Pg	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
Control	1001	9.63	14.0	42.4	44.0	14.5	33.0	1186
	1002	10.16	14.7	45.2	44.5	14.5	32.5	1609
	1003	10.01	14.1	43.9	43.9	14.1	32.1	1027
	1004	10.60	14.4	45.0	42.5	13.6	32.0	921
	1005	9.86	14.4	45.0	45.6	14.6	32.0	1587
	1006	10.11	14.3	44.9	44.4	14.1	31.8	1494
	1007	10.06	14.6	44.3	44.0	14.5	33.0	1511
	1008	10.52	15.1	46.5	44.2	14.4	32.5	1462
	1009	10.04	14.4	43.9	43.7	14.3	32.8	1496
	1010	10.65	14.8	46.1	43.3	13.9	32.1	1455
	1011	10.18	14.7	44.3	43.5	14.4	33.2	1359
	1012	9.95	14.2	44.3	44.5	14.3	32.1	1601
	1013	10.17	14.4	44.4	43.7	14.2	32.4	1526
	1014	9.99	14.4	44.7	44.7	14.4	32.2	1434
	1015	10.50	14.6	45.7	43.5	13.9	31.9	1488
	1016	10.46	14.8	45.6	43.6	14.1	32.5	1461
	1017	9.73	14.4	44.1	45.3	14.8	32.7	1005
	1018	9.77	13.8	43.0	44.0	14.1	32.1	1479
	1019	9.71	14.2	43.6	44.9	14.6	32.6	1551
	1020	9.98	14.2	43.4	43.5	14.2	32.7	1387
	1021	9.96	14.2	44.3	44.5	14.3	32.1	1424
	1022	10.07	14.4	44.1	43.8	14.3	32.7	1214
	1023	9.76	14.1	44.2	45.3	14.4	31.9	1426
	1024	10.59	15.3	46.4	43.8	14.4	33.0	1369
	1025	10.03	14.3	44.8	44.7	14.3	31.9	1379



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

---

Group Name	Animal ID-NO	RETICULOCYTE %
Control	1001	3.5
	1002	3.7
	1003	4.3
	1004	4.3
	1005	3.6
	1006	4.0
	1007	4.3
	1008	3.8
	1009	3.2
	1010	3.1
	1011	3.2
	1012	3.7
	1013	3.8
	1014	3.8
	1015	3.2
	1016	3.9
	1017	4.2
	1018	3.9
	1019	3.6
	1020	3.4
	1021	3.6
	1022	3.7
	1023	3.7
	1024	3.2
	1025	3.7

---

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 10 <sup>3</sup> /μl	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
Control	1001	3.59	28.1	59.6	12.3	0.0	0.0
	1002	2.99	14.1	79.9	4.3	1.7	0.0
	1003	3.07	17.6	77.5	4.6	0.3	0.0
	1004	5.38	18.4	75.8	4.5	1.3	0.0
	1005	4.46	11.2	85.9	2.5	0.4	0.0
	1006	2.09	13.4	83.7	2.9	0.0	0.0
	1007	4.66	13.1	82.6	3.2	1.1	0.0
	1008	1.85	20.6	75.1	3.8	0.5	0.0
	1009	2.69	16.3	79.6	4.1	0.0	0.0
	1010	3.83	7.8	87.5	3.9	0.8	0.0
	1011	3.93	7.4	89.3	2.8	0.5	0.0
	1012	4.18	8.6	87.1	3.3	1.0	0.0
	1013	2.56	13.3	81.6	4.3	0.8	0.0
	1014	1.91	7.3	88.5	4.2	0.0	0.0
	1015	2.49	11.7	85.5	2.4	0.4	0.0
	1016	5.83	7.9	88.7	2.4	1.0	0.0
	1017	8.39	10.3	79.0	7.9	2.7	0.1
	1018	2.98	13.1	82.9	3.7	0.3	0.0
	1019	2.98	13.0	82.6	3.7	0.7	0.0
	1020	2.99	14.4	83.3	2.3	0.0	0.0
	1021	2.39	8.7	86.2	3.8	1.3	0.0
	1022	3.35	17.0	80.6	2.1	0.3	0.0
	1023	3.62	16.5	79.0	3.9	0.6	0.0
	1024	2.42	10.3	87.2	2.1	0.4	0.0
	1025	2.80	9.0	87.1	2.5	1.4	0.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH Pg	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
100 ppm	1101	10.21	15.3	46.9	45.9	15.0	32.6	1165
	1102	10.78	15.8	48.9	45.4	14.7	32.3	1348
	1103	10.38	15.5	46.9	45.2	14.9	33.0	1290
	1104	10.04	15.2	45.2	45.0	15.1	33.6	1417
	1105	10.01	15.0	45.7	45.7	15.0	32.8	1392
	1106	10.30	15.6	47.7	46.3	15.1	32.7	1236
	1107	10.36	15.5	46.0	44.4	15.0	33.7	1115
	1108	7.93	12.3	40.9	51.6	15.5	30.1	2297
	1109	10.38	15.2	46.0	44.3	14.6	33.0	1108
	1110	10.67	15.7	47.2	44.2	14.7	33.3	1246
	1111	10.64	15.4	47.4	44.5	14.5	32.5	1223
	1112	10.48	15.2	46.1	44.0	14.5	33.0	1267
	1113	9.43	14.5	43.6	46.2	15.4	33.3	1071
	1115	9.47	14.2	42.4	44.8	15.0	33.5	923
	1116	10.10	15.1	45.4	45.0	15.0	33.3	1358
	1117	9.99	14.9	46.0	46.0	14.9	32.4	1458
	1118	10.69	15.8	48.1	45.0	14.8	32.8	1360
	1119	9.50	13.9	42.2	44.4	14.6	32.9	1030
	1120	10.79	15.6	47.4	43.9	14.5	32.9	1233
	1121	10.24	15.1	46.2	45.1	14.7	32.7	1324
	1122	10.20	15.2	46.0	45.1	14.9	33.0	1264
	1123	10.46	15.3	46.4	44.4	14.6	33.0	1364
	1124	9.86	15.0	44.5	45.1	15.2	33.7	1546
	1125	10.38	15.3	46.3	44.6	14.7	33.0	1486

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 5

---

Group Name	Animal ID-NO	RETICULOCYTE %
100 ppm	1101	2.8
	1102	3.2
	1103	2.9
	1104	2.8
	1105	3.2
	1106	3.1
	1107	3.0
	1108	15.0
	1109	2.8
	1110	2.6
	1111	2.6
	1112	2.9
	1113	4.3
	1115	3.9
	1116	3.2
	1117	3.9
	1118	3.5
	1119	3.8
	1120	3.0
	1121	3.2
	1122	2.9
	1123	2.8
	1124	3.0
	1125	2.5

---

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 1 0 <sup>3</sup> /μl	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
100 ppm	1101	4.64	16.4	76.3	5.8	1.5	0.0
	1102	1.69	14.8	82.8	2.4	0.0	0.0
	1103	6.22	14.0	81.8	3.4	0.8	0.0
	1104	2.25	25.8	71.1	3.1	0.0	0.0
	1105	5.39	10.3	84.2	4.6	0.9	0.0
	1106	6.11	8.5	86.9	2.8	1.8	0.0
	1107	5.42	7.9	86.7	3.9	1.3	0.2
	1108	13.66	64.9	26.9	7.7	0.4	0.1
	1109	3.18	15.1	78.0	6.0	0.9	0.0
	1110	5.30	9.1	87.2	2.8	0.9	0.0
	1111	6.80	8.3	84.4	5.3	1.9	0.1
	1112	3.75	9.1	84.3	3.7	2.9	0.0
	1113	5.22	13.4	82.0	4.0	0.6	0.0
	1115	3.25	19.1	73.8	6.5	0.6	0.0
	1116	5.93	8.7	85.2	4.7	1.2	0.2
	1117	2.40	9.6	86.7	3.3	0.4	0.0
	1118	5.50	7.6	88.2	2.4	1.8	0.0
	1119	2.87	20.2	72.5	7.0	0.3	0.0
	1120	4.49	8.4	86.2	3.8	1.6	0.0
	1121	2.62	11.4	86.3	1.9	0.4	0.0
	1122	3.94	9.4	84.8	4.3	1.5	0.0
	1123	4.31	8.2	86.5	3.0	2.3	0.0
	1124	1.89	9.5	88.9	1.6	0.0	0.0
	1125	4.08	10.4	82.8	3.9	2.9	0.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV f l	MCH p g	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl	
300 ppm	1202	10.66	16.3	48.7	45.7	15.3	33.5	761	
	1203	11.26	17.7	53.7	47.7	15.7	33.0	1140	
	1204	11.10	17.9	53.0	47.7	16.1	33.8	1156	
	1205	10.83	16.6	49.9	46.1	15.3	33.3	1386	
	1206	10.86	17.0	51.7	47.6	15.7	32.9	1170	
	1207	10.99	17.1	51.4	46.8	15.6	33.3	1128	
	1208	10.69	16.6	49.1	45.9	15.5	33.8	1387	
	1209	10.37	17.0	49.9	48.1	16.4	34.1	1109	
	1210	11.52	18.1	54.2	47.0	15.7	33.4	1088	
	1211	11.22	17.1	50.6	45.1	15.2	33.8	1098	
	1212	10.74	17.4	51.3	47.8	16.2	33.9	1312	
	1213	10.18	15.7	47.6	46.8	15.4	33.0	1218	
	1214	11.49	18.0	53.1	46.2	15.7	33.9	1041	
	1215	11.46	17.8	52.4	45.7	15.5	34.0	1047	
	1216	10.88	16.9	50.8	46.7	15.5	33.3	1666	
	1217	10.22	16.0	48.0	47.0	15.7	33.3	770	
	1219	9.34	15.7	47.1	50.4	16.8	33.3	1339	
	1220	10.69	16.9	50.3	47.1	15.8	33.6	1023	
	1221	10.88	16.8	50.8	46.7	15.4	33.1	1153	
	1223	9.11	14.5	43.7	48.0	15.9	33.2	571	
	1224	11.14	17.7	51.8	46.5	15.9	34.2	1278	
	1225	10.76	16.8	50.7	47.1	15.6	33.1	1842	
	1000 ppm	1308	8.76	15.6	46.0	52.5	17.8	33.9	701
		1312	11.08	18.3	57.0	51.4	16.5	32.1	1119
		1319	9.94	17.3	52.0	52.3	17.4	33.3	441
1321		8.10	14.2	42.8	52.8	17.5	33.2	874	
1322		8.80	15.3	46.3	52.6	17.4	33.0	774	
1323		8.33	14.4	43.8	52.6	17.3	32.9	412	
1324		8.94	15.5	47.2	52.8	17.3	32.8	861	
1325		9.56	16.1	48.3	50.5	16.8	33.3	720	

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 8

---

Group Name	Animal ID-NO	RETICULOCYTE %
300 ppm	1202	3.0
	1203	2.4
	1204	2.1
	1205	2.3
	1206	2.5
	1207	1.9
	1208	2.4
	1209	2.0
	1210	1.9
	1211	2.2
	1212	1.8
	1213	3.3
	1214	2.5
	1215	3.2
	1216	3.1
	1217	3.4
	1219	3.5
1220	2.5	
1221	2.2	
1223	3.6	
1224	2.7	
1225	2.4	
1000 ppm	1308	1.5
	1312	2.2
	1319	3.8
	1321	3.6
	1322	1.1
	1323	6.1
	1324	3.0
1325	2.5	

---

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 1 0 <sup>9</sup> /μℓ	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
300 ppm	1202	3.00	12.7	82.3	3.0	2.0	0.0
	1203	4.38	11.4	82.9	3.9	1.8	0.0
	1204	4.15	14.7	80.7	3.9	0.7	0.0
	1205	8.48	34.2	51.9	11.3	2.6	0.0
	1206	5.07	8.7	84.8	3.9	2.6	0.0
	1207	3.92	10.2	86.2	2.8	0.8	0.0
	1208	4.06	10.6	86.5	2.7	0.2	0.0
	1209	3.33	14.4	79.3	4.5	1.8	0.0
	1210	9.00	10.0	83.7	4.2	2.0	0.1
	1211	6.34	9.2	83.9	3.9	3.0	0.0
	1212	5.49	4.7	92.0	2.7	0.4	0.2
	1213	4.61	19.5	76.6	3.7	0.2	0.0
	1214	4.49	12.1	81.3	5.3	1.3	0.0
	1215	3.02	9.9	84.8	5.0	0.3	0.0
	1216	5.29	12.7	80.7	4.5	2.1	0.0
	1217	7.31	9.3	80.8	6.6	3.3	0.0
	1219	2.59	10.8	85.3	3.1	0.8	0.0
	1220	5.79	10.2	84.1	4.1	1.6	0.0
	1221	4.37	18.6	75.3	5.0	1.1	0.0
	1223	9.17	12.3	79.2	6.7	1.7	0.1
1224	6.98	4.9	90.7	2.3	2.1	0.0	
1225	2.90	13.5	83.1	3.1	0.3	0.0	
1000 ppm	1308	1.21	15.7	77.7	5.8	0.8	0.0
	1312	1.53	36.5	59.5	3.3	0.7	0.0
	1319	1.69	36.7	56.2	7.1	0.0	0.0
	1321	1.77	49.2	42.9	7.3	0.6	0.0
	1322	1.43	12.6	83.9	2.8	0.7	0.0
	1323	4.59	23.8	70.8	3.7	1.7	0.0
	1324	2.17	25.3	68.7	4.6	1.4	0.0
	1325	2.02	34.1	61.4	4.0	0.5	0.0



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH pg	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
Posi. Control	1401	2.14	2.5	13.1	61.2	11.7	19.1	1637
	1406	4.98	6.6	27.7	55.6	13.3	23.8	1583
	1407	2.50	3.5	17.0	68.0	14.0	20.6	1183
	1410	2.71	3.4	16.6	61.3	12.5	20.5	1364
	1411	7.43	11.1	36.3	48.9	14.9	30.6	1452
	1412	3.84	3.6	18.1	47.1	9.4	19.9	1792
	1415	1.97	2.5	13.1	66.5	12.7	19.1	1264
	1416	2.01	2.7	14.1	70.1	13.4	19.1	768
	1418	4.69	6.6	26.0	55.4	14.1	25.4	2136
	1420	4.62	5.4	24.2	52.4	11.7	22.3	1565

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 11

---

Group Name	Animal ID-NO	RETICULOCYTE %
Posi. Control	1401	73.5
	1406	42.5
	1407	67.7
	1410	67.8
	1411	13.4
	1412	51.6
	1415	79.7
	1416	67.9
	1418	49.4
	1420	63.6

---

(HCL072)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 1 0 <sup>3</sup> /μl	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
Posi. Control	1401	13.01	87.2	8.9	3.4	0.4	0.1
	1406	4.68	22.1	72.2	5.1	0.4	0.2
	1407	7.22	77.1	16.5	6.2	0.1	0.1
	1410	11.69	64.6	28.5	6.5	0.4	0.0
	1411	2.90	6.2	90.0	2.8	1.0	0.0
	1412	5.12	81.2	13.1	4.9	0.6	0.2
	1415	11.24	63.0	29.2	7.6	0.2	0.0
	1416	5.61	56.6	23.2	19.4	0.4	0.4
	1418	4.43	24.6	71.1	4.3	0.0	0.0
	1420	9.24	21.5	72.8	5.3	0.3	0.1

APPENDIX 8-2

HEMATOLOGY (INDIVIDUAL) : FEMALE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH Pg	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
Control	2001	-	-	-	-	-	-	-
	2002	10.37	15.2	45.6	44.0	14.7	33.3	1477
	2003	10.27	15.9	46.7	45.5	15.5	34.0	931
	2004	10.12	15.2	45.1	44.6	15.0	33.7	946
	2005	10.45	14.8	45.7	43.7	14.2	32.4	1194
	2006	9.85	14.5	43.7	44.4	14.7	33.2	955
	2007	10.18	14.7	44.5	43.7	14.4	33.0	1260
	2009	10.92	15.5	47.2	43.2	14.2	32.8	1245
	2010	11.07	16.0	48.3	43.6	14.5	33.1	1258
	2011	10.48	15.0	45.7	43.6	14.3	32.8	1295
	2013	9.94	14.8	44.1	44.4	14.9	33.6	910
	2014	9.80	14.6	43.8	44.7	14.9	33.3	939
	2015	10.62	15.0	45.3	42.7	14.1	33.1	1217
	2016	9.88	14.4	43.5	44.0	14.6	33.1	1366
	2017	10.74	15.6	46.9	43.7	14.5	33.3	1349
	2018	10.37	14.8	45.5	43.9	14.3	32.5	1287
	2019	10.52	15.1	45.7	43.4	14.4	33.0	1311
	2020	9.61	14.4	43.1	44.8	15.0	33.4	917
	2021	10.33	14.5	44.5	43.1	14.0	32.6	1261
	2022	10.64	15.1	46.9	44.1	14.2	32.2	1250
	2023	10.49	14.8	45.3	43.2	14.1	32.7	1345
	2024	10.74	15.9	47.6	44.3	14.8	33.4	1293
	2025	10.74	15.4	46.5	43.3	14.3	33.1	1315

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 14

---

Group Name	Animal ID-NO	RETICULOCYTE %
Control	2001	-
	2002	3.4
	2003	4.0
	2004	4.1
	2005	4.5
	2006	3.8
	2007	3.6
	2009	3.4
	2010	3.8
	2011	3.7
	2013	3.6
	2014	3.8
	2015	3.8
	2016	3.9
	2017	3.8
	2018	3.3
	2019	3.3
	2020	2.9
	2021	4.1
	2022	3.7
	2023	3.1
	2024	3.4
	2025	2.9

---

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 1 0 <sup>3</sup> /μl	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
Control	2001	-	-	-	-	-	-
	2002	1.83	12.1	86.3	1.1	0.5	0.0
	2003	4.40	20.0	78.2	1.6	0.2	0.0
	2004	4.34	14.1	82.9	2.1	0.9	0.0
	2005	5.31	9.2	86.1	2.8	1.9	0.0
	2006	3.48	14.3	80.5	2.6	2.6	0.0
	2007	3.63	11.6	86.2	1.9	0.3	0.0
	2009	2.14	12.6	86.0	1.4	0.0	0.0
	2010	1.88	18.1	80.3	1.6	0.0	0.0
	2011	2.74	17.1	81.4	1.5	0.0	0.0
	2013	6.06	15.5	82.2	2.0	0.3	0.0
	2014	1.94	19.1	76.8	3.6	0.5	0.0
	2015	1.95	22.5	74.4	3.1	0.0	0.0
	2016	2.16	19.9	77.3	2.8	0.0	0.0
	2017	2.15	9.8	87.4	1.4	1.4	0.0
	2018	2.63	8.7	89.4	1.9	0.0	0.0
	2019	1.92	20.8	77.1	1.6	0.5	0.0
	2020	3.79	14.3	79.4	5.5	0.8	0.0
	2021	2.12	13.6	84.0	2.4	0.0	0.0
	2022	2.11	15.6	81.5	2.4	0.0	0.5
	2023	3.60	12.5	85.0	2.2	0.3	0.0
	2024	3.80	6.5	91.1	2.1	0.3	0.0
	2025	1.89	9.0	89.4	1.6	0.0	0.0

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV f l	MCH p g	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
100 ppm	2101	9.62	15.2	45.2	47.0	15.8	33.6	1117
	2102	10.31	15.5	46.4	45.0	15.0	33.4	1381
	2104	10.13	15.4	47.0	46.4	15.2	32.8	1088
	2105	10.24	15.4	45.5	44.4	15.0	33.8	1233
	2106	9.89	15.5	45.6	46.1	15.7	34.0	817
	2107	10.45	15.4	46.7	44.7	14.7	33.0	1123
	2108	10.15	15.1	44.8	44.1	14.9	33.7	1092
	2109	10.78	16.0	49.4	45.8	14.8	32.4	1213
	2110	10.50	15.3	46.4	44.2	14.6	33.0	1001
	2111	10.55	16.0	47.0	44.5	15.2	34.0	1325
	2112	10.69	15.6	47.8	44.7	14.6	32.6	1106
	2113	10.28	15.6	45.9	44.6	15.2	34.0	1023
	2114	10.18	15.2	45.7	44.9	14.9	33.3	1315
	2115	9.56	15.1	44.7	46.8	15.8	33.8	980
	2116	10.74	15.9	47.4	44.1	14.8	33.5	1243
	2117	10.65	15.8	47.1	44.2	14.8	33.5	1060
	2118	10.41	15.9	47.2	45.3	15.3	33.7	1465
	2119	10.51	15.6	46.6	44.3	14.8	33.5	1352
	2120	10.69	15.5	46.4	43.4	14.5	33.4	1195
	2121	9.39	14.6	43.8	46.6	15.5	33.3	879
	2122	10.66	15.9	47.4	44.5	14.9	33.5	1275
	2123	10.21	15.4	46.1	45.2	15.1	33.4	1157
	2124	10.46	15.5	47.1	45.0	14.8	32.9	1216
	2125	10.63	16.1	48.1	45.2	15.1	33.5	1068



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 17

---

Group Name	Animal ID-NO	RETICULOCYTE %
100 ppm	2101	2.6
	2102	3.0
	2104	2.7
	2105	3.4
	2106	2.9
	2107	3.1
	2108	3.1
	2109	3.2
	2110	3.5
	2111	2.3
	2112	2.6
	2113	3.3
	2114	3.1
	2115	3.4
	2116	3.4
	2117	3.6
	2118	3.8
	2119	3.7
	2120	3.4
	2121	4.0
	2122	2.4
	2123	2.4
	2124	3.3
	2125	2.5

---

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 10 <sup>3</sup> /μl	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
100 ppm	2101	3.86	9.4	87.0	2.8	0.8	0.0
	2102	1.25	24.0	74.4	1.6	0.0	0.0
	2104	3.28	18.3	75.6	5.2	0.9	0.0
	2105	4.47	9.2	87.7	2.0	1.1	0.0
	2106	7.43	9.7	82.9	4.0	3.1	0.3
	2107	3.79	9.2	88.4	1.6	0.8	0.0
	2108	1.87	10.2	86.1	3.7	0.0	0.0
	2109	2.77	10.5	87.7	1.8	0.0	0.0
	2110	2.18	13.7	83.5	2.3	0.5	0.0
	2111	3.47	10.7	87.3	1.4	0.6	0.0
	2112	3.62	7.1	90.9	1.7	0.3	0.0
	2113	1.55	19.4	78.7	1.9	0.0	0.0
	2114	1.41	14.9	83.0	2.1	0.0	0.0
	2115	1.81	21.0	76.2	2.8	0.0	0.0
	2116	1.74	16.7	81.6	1.7	0.0	0.0
	2117	3.40	17.6	80.9	1.2	0.3	0.0
	2118	2.56	11.4	85.9	2.3	0.4	0.0
	2119	1.72	21.5	75.6	2.9	0.0	0.0
	2120	1.98	12.1	86.4	1.5	0.0	0.0
	2121	3.89	13.3	82.3	3.9	0.5	0.0
	2122	2.72	19.2	79.0	1.8	0.0	0.0
	2123	3.13	13.1	82.4	4.5	0.0	0.0
	2124	4.27	7.4	89.5	1.9	1.2	0.0
	2125	1.88	12.8	85.1	2.1	0.0	0.0

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV f l	MCH p g	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
300 ppm	2201	10.37	16.0	48.0	46.3	15.4	33.3	997
	2202	9.33	15.2	45.2	48.4	16.3	33.6	685
	2203	10.69	16.8	50.5	47.2	15.7	33.3	1139
	2204	10.58	17.1	50.4	47.6	16.2	33.9	1097
	2205	11.25	17.4	52.3	46.5	15.5	33.3	1026
	2206	10.24	16.5	48.6	47.5	16.1	34.0	900
	2207	11.08	17.1	51.0	46.0	15.4	33.5	880
	2208	9.34	15.0	44.3	47.4	16.1	33.9	1196
	2209	10.69	17.1	50.5	47.2	16.0	33.9	1027
	2210	10.71	17.1	50.3	47.0	16.0	34.0	1074
	2211	10.23	16.8	49.5	48.4	16.4	33.9	898
	2212	10.81	16.8	49.2	45.5	15.5	34.1	1014
	2213	10.11	16.2	47.5	47.0	16.0	34.1	1088
	2214	10.54	16.5	48.8	46.3	15.7	33.8	1113
	2215	10.26	16.0	48.1	46.9	15.6	33.3	1140
	2216	11.14	17.2	50.9	45.7	15.4	33.8	997
	2217	9.77	15.6	45.7	46.8	16.0	34.1	2343
	2218	10.49	16.3	48.8	46.5	15.5	33.4	1058
	2219	9.73	15.5	45.7	47.0	15.9	33.9	750
	2220	10.71	16.6	49.5	46.2	15.5	33.5	1262
	2221	10.61	16.5	49.9	47.0	15.6	33.1	894
	2222	10.47	16.6	49.0	46.8	15.9	33.9	1133
	2223	10.65	17.0	50.3	47.2	16.0	33.8	1149
	2224	9.14	15.5	46.0	50.3	17.0	33.7	646
	2225	8.31	13.3	38.9	46.8	16.0	34.2	1010
1000 ppm	2305	8.01	14.1	41.3	51.6	17.6	34.1	521
	2307	6.70	11.1	34.2	51.0	16.6	32.5	300
	2308	9.46	16.3	47.0	49.7	17.2	34.7	694
	2309	8.12	14.1	40.4	49.8	17.4	34.9	392
	2311	-	-	-	-	-	-	-
	2313	9.00	15.6	45.9	51.0	17.3	34.0	469
	2314	8.77	15.1	44.6	50.9	17.2	33.9	669
	2315	8.87	15.1	46.0	51.9	17.0	32.8	650
	2316	9.59	16.5	49.3	51.4	17.2	33.5	649
	2321	9.00	15.5	45.6	50.7	17.2	34.0	587

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 20

---

Group Name	Animal ID-NO	RETICULOCYTE %
300 ppm	2201	1.9
	2202	2.9
	2203	2.1
	2204	1.9
	2205	1.5
	2206	1.6
	2207	1.9
	2208	2.2
	2209	1.4
	2210	1.5
	2211	1.7
	2212	1.5
	2213	3.0
	2214	3.2
	2215	2.8
	2216	2.9
	2217	2.8
	2218	3.4
	2219	3.6
	2220	3.7
2221	2.5	
2222	2.2	
2223	1.8	
2224	4.0	
2225	2.2	
1000 ppm	2305	3.9
	2307	3.8
	2308	1.6
	2309	0.8
	2311	-
	2313	3.3
	2314	2.9
	2315	4.8
	2316	3.6
	2321	4.9

---

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO.	WBC 1 0 <sup>3</sup> /μℓ	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
300 ppm	2201	5.58	7.4	88.0	3.2	1.4	0.0
	2202	5.20	12.5	81.2	4.6	1.7	0.0
	2203	4.58	15.1	77.1	7.4	0.4	0.0
	2204	2.35	16.1	79.6	3.4	0.9	0.0
	2205	7.66	8.0	85.8	4.4	1.7	0.1
	2206	7.63	8.4	87.4	3.1	1.0	0.1
	2207	4.11	7.6	87.8	4.4	0.2	0.0
	2208	2.52	9.5	86.5	4.0	0.0	0.0
	2209	3.19	11.8	82.8	3.8	1.6	0.0
	2210	5.47	12.6	82.8	3.3	1.3	0.0
	2211	2.14	21.5	76.2	2.3	0.0	0.0
	2212	6.22	9.3	87.3	2.6	0.8	0.0
	2213	2.88	14.3	84.7	1.0	0.0	0.0
	2214	1.62	19.1	79.0	1.9	0.0	0.0
	2215	1.53	19.6	76.5	3.9	0.0	0.0
	2216	2.02	11.8	84.2	3.5	0.5	0.0
	2217	3.01	10.0	86.7	3.0	0.3	0.0
	2218	2.84	9.4	87.0	3.2	0.4	0.0
	2219	4.63	18.1	76.7	4.8	0.4	0.0
	2220	2.53	9.1	88.9	2.0	0.0	0.0
	2221	5.47	8.8	87.6	2.7	0.9	0.0
	2222	1.91	16.7	81.2	2.1	0.0	0.0
	2223	5.13	9.4	87.3	2.1	1.2	0.0
	2224	6.75	12.5	81.6	3.7	2.2	0.0
	2225	0.52	21.2	76.9	1.9	0.0	0.0
1000 ppm	2305	8.03	6.3	87.0	4.5	2.1	0.1
	2307	16.78	17.7	53.0	28.3	0.2	0.8
	2308	3.88	30.1	65.5	3.6	0.8	0.0
	2309	5.60	9.2	82.0	7.7	0.4	0.7
	2311	-	-	-	-	-	-
	2313	6.83	5.0	89.6	4.4	1.0	0.0
	2314	7.45	12.2	81.1	5.4	1.2	0.1
	2315	4.01	15.8	80.0	3.7	0.5	0.0
	2316	4.05	10.4	83.2	5.2	1.2	0.0
	2321	3.09	13.3	83.5	2.9	0.3	0.0

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 22

Group Name	Animal ID-NO	RED BLOOD CELL 1 0 <sup>6</sup> /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH Pg	MCHC g/dl	PLATELET 1 0 <sup>3</sup> /μl
Posi. Control	2416 2418	5.57 3.01	5.7 3.4	27.8 19.0	49.9 63.1	10.2 11.3	20.5 17.9	2471 1011

(HCL072)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 23

---

Group Name	Animal ID-NO	RETICULOCYTE %
Posi. Control	2416	65.4
	2418	83.7

---

(HCL072)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 24

Group Name	Animal ID-NO.	WBC 10 <sup>3</sup> /μl	Differential NEUTRO	WBC (%) LYMPHO	MONO	EOSINO	BASO
Posi. Control	2416 2418	2.02 9.30	61.3 61.4	4.5 28.1	33.7 8.9	0.5 1.4	0.0 0.2

(HCL072)

BAIS 6



APPENDIX 9-1

BIOCHEMISTRY (INDIVIDUAL) : MALE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Control	1001	5.0	2.9	1.4	0.11	154	88	48
	1002	5.5	3.2	1.4	0.11	195	89	40
	1003	4.9	2.9	1.5	0.17	174	61	43
	1004	4.9	2.9	1.5	0.14	138	60	56
	1005	5.3	3.2	1.5	0.11	197	94	48
	1006	5.6	3.3	1.4	0.11	210	90	30
	1007	5.7	3.5	1.6	0.10	222	101	33
	1008	5.6	3.5	1.7	0.11	200	96	28
	1009	5.4	3.2	1.5	0.09	167	89	39
	1010	5.2	3.2	1.6	0.09	194	90	48
	1011	5.3	3.3	1.6	0.11	174	92	45
	1012	5.4	3.1	1.3	0.10	263	95	38
	1013	5.5	3.4	1.6	0.09	213	94	31
	1014	5.5	3.4	1.6	0.09	171	98	45
	1015	5.4	3.3	1.6	0.10	181	82	31
	1016	5.2	3.3	1.7	0.09	210	78	39
	1017	4.7	2.9	1.6	0.16	233	71	45
	1018	5.0	3.1	1.6	0.09	208	92	47
	1019	5.4	3.3	1.6	0.11	177	84	32
	1020	5.1	3.3	1.8	0.09	196	82	40
	1021	5.1	3.1	1.5	0.11	152	85	50
	1022	5.2	3.2	1.6	0.10	157	84	52
	1023	5.1	3.1	1.5	0.10	206	85	40
	1024	5.0	3.0	1.5	0.12	138	70	36
	1025	5.2	3.1	1.5	0.12	205	91	44

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	1001	196	56	15	355	160	0.3	88
	1002	192	52	17	209	193	0.2	89
	1003	136	107	15	236	227	0.4	112
	1004	125	169	23	344	239	0.1	158
	1005	203	47	15	182	191	0.0	63
	1006	195	45	15	221	197	0.1	72
	1007	203	46	14	218	261	0.0	51
	1008	198	58	15	208	230	0.2	68
	1009	190	80	21	218	183	0.0	110
	1010	190	61	20	235	223	0.0	116
	1011	203	56	16	194	235	0.3	65
	1012	192	48	17	193	197	0.8	62
	1013	193	49	18	183	204	0.0	58
	1014	199	55	17	222	236	0.1	86
	1015	176	74	22	432	231	0.1	137
	1016	179	45	14	162	223	0.3	56
	1017	157	112	18	192	243	0.5	132
	1018	204	75	18	366	194	0.1	263
	1019	185	55	15	259	217	0.0	78
	1020	179	56	17	159	193	0.1	68
	1021	183	54	18	188	197	0.3	62
	1022	191	54	16	229	207	0.3	69
	1023	193	58	18	236	181	0.2	83
	1024	160	61	18	301	247	0.1	88
	1025	186	56	19	223	183	0.2	79

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

REPORT TYPE : A1

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

PAGE : 3

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHURUS mg/dl
Control	1001	31.5	152	4.1	120	8.8	4.9
	1002	29.5	151	4.1	119	8.8	5.9
	1003	30.7	149	4.1	115	8.9	6.4
	1004	30.5	152	4.8	121	9.1	7.4
	1005	34.0	150	4.4	118	8.6	5.2
	1006	25.3	151	4.2	121	9.0	4.4
	1007	30.1	151	4.0	116	8.9	4.5
	1008	35.7	152	3.6	118	8.7	5.8
	1009	29.4	153	3.8	120	8.6	5.4
	1010	29.9	149	4.2	117	8.7	4.5
	1011	26.5	151	4.2	118	8.7	4.1
	1012	28.1	150	3.6	118	9.0	4.3
	1013	31.3	152	3.8	118	8.6	5.0
	1014	30.4	153	3.6	118	8.4	5.3
	1015	28.4	153	3.9	122	8.4	5.4
	1016	33.5	150	3.9	119	8.4	4.4
	1017	30.9	147	4.2	115	8.6	5.4
	1018	27.9	152	3.7	121	8.3	4.6
	1019	30.3	151	4.3	117	8.7	4.6
	1020	31.4	151	3.8	118	8.6	5.3
	1021	37.0	150	4.1	116	8.9	5.7
	1022	33.9	152	4.0	120	8.8	6.1
	1023	31.9	150	4.3	118	8.7	4.9
	1024	37.8	151	4.4	121	8.8	4.8
	1025	31.6	151	3.5	118	8.6	5.2

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
100 ppm	1101	5.2	3.2	1.6	0.10	195	75	66
	1102	5.4	3.3	1.6	0.12	207	81	34
	1103	5.3	3.1	1.4	0.11	215	91	96
	1104	5.6	3.4	1.5	0.11	156	89	46
	1105	5.3	3.2	1.5	0.11	244	90	68
	1106	5.3	3.2	1.5	0.12	218	92	41
	1107	5.4	3.4	1.7	0.10	208	92	51
	1108	4.6	2.2	0.9	0.09	95	85	19
	1109	5.3	3.3	1.6	0.10	182	81	51
	1110	5.3	3.2	1.5	0.12	197	88	43
	1111	5.4	3.2	1.5	0.11	236	102	56
	1112	5.5	3.3	1.5	0.11	222	85	47
	1113	5.0	3.0	1.5	0.17	159	53	35
	1115	4.8	2.9	1.5	0.14	188	62	38
	1116	5.4	3.2	1.5	0.11	209	106	63
	1117	5.3	3.2	1.5	0.12	217	93	42
	1118	5.2	3.1	1.5	0.12	215	86	55
	1119	4.9	2.9	1.5	0.15	153	59	62
	1120	5.4	3.3	1.6	0.09	244	89	46
	1121	5.3	3.4	1.8	0.11	181	79	36
	1122	5.2	3.2	1.6	0.09	191	85	70
	1123	5.2	3.2	1.6	0.12	194	82	74
	1124	5.4	3.5	1.8	0.11	173	90	31
	1125	5.0	3.1	1.6	0.12	248	82	57

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
100 ppm	1101	165	89	36	256	222	0.0	126
	1102	170	48	14	192	190	0.1	54
	1103	188	51	18	219	212	0.0	103
	1104	200	84	19	245	209	0.2	136
	1105	184	56	16	252	176	0.1	97
	1106	187	46	15	188	180	0.0	60
	1107	194	68	18	224	180	0.0	89
	1108	79	114	51	398	121	0.2	467
	1109	170	81	22	255	196	0.3	107
	1110	176	63	26	193	183	0.4	76
	1111	201	60	25	230	183	0.3	73
	1112	170	61	19	230	185	0.3	145
	1113	129	95	15	223	224	0.1	67
	1115	145	124	16	246	229	0.1	150
	1116	227	59	18	185	168	0.1	59
	1117	188	71	24	275	204	0.2	85
	1118	179	59	17	247	203	0.0	69
	1119	134	168	21	328	200	0.0	145
	1120	181	59	25	176	201	0.0	66
	1121	170	57	19	180	208	0.5	84
	1122	185	64	18	351	194	0.4	91
	1123	183	44	15	166	227	0.0	64
	1124	193	59	17	202	200	0.0	72
	1125	180	53	16	253	204	0.0	76

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHRUS mg/dl
100 ppm	1101	27.9	151	4.1	123	8.9	4.8
	1102	26.3	150	4.1	123	8.6	5.8
	1103	26.0	151	4.5	122	9.2	6.8
	1104	30.2	154	3.8	124	8.9	7.4
	1105	26.3	148	4.2	121	8.8	3.9
	1106	29.2	151	4.3	124	9.0	5.2
	1107	26.6	151	3.8	118	8.6	4.3
	1108	88.8	160	4.7	132	8.6	10.8
	1109	24.0	152	4.0	121	8.7	5.4
	1110	27.9	149	4.4	119	8.9	4.3
	1111	25.6	149	4.2	119	8.9	4.2
	1112	28.3	150	4.1	121	9.0	4.7
	1113	25.2	149	4.1	116	8.3	5.8
	1115	25.8	149	4.0	117	8.2	6.3
	1116	24.0	150	4.2	119	8.4	3.6
	1117	28.8	150	3.7	120	8.5	4.5
	1118	25.7	151	3.8	121	8.4	4.3
	1119	24.3	149	4.0	114	8.6	5.3
	1120	26.5	150	3.8	116	8.9	4.6
	1121	26.3	151	3.5	119	8.8	5.8
	1122	31.7	150	3.7	120	8.9	5.6
	1123	31.5	149	4.5	118	9.0	4.1
	1124	27.5	152	3.8	121	9.0	4.4
	1125	33.6	148	3.7	116	8.9	4.5

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
300 ppm	1202	4.4	2.7	1.6	0.24	191	42	32
	1203	5.1	3.0	1.4	0.10	279	84	67
	1204	5.4	3.2	1.5	0.13	243	82	59
	1205	5.2	2.8	1.2	0.08	249	113	74
	1206	5.0	3.1	1.6	0.15	298	90	76
	1207	5.4	3.4	1.7	0.11	223	83	42
	1208	6.0	3.6	1.5	0.10	208	106	45
	1209	5.1	3.2	1.7	0.10	225	81	69
	1210	5.3	3.2	1.5	0.12	226	81	71
	1211	5.1	3.1	1.5	0.12	248	87	60
	1212	5.3	3.2	1.5	0.11	198	86	48
	1213	5.0	2.8	1.3	0.14	178	100	50
	1214	5.1	3.1	1.5	0.12	208	84	87
	1215	5.2	3.2	1.6	0.11	187	73	59
	1216	5.2	3.2	1.6	0.15	246	93	57
	1217	4.8	2.9	1.5	0.24	216	63	41
	1219	5.5	3.2	1.4	0.10	245	100	54
	1220	5.3	3.2	1.5	0.13	229	83	54
	1221	5.0	3.0	1.5	0.12	179	56	29
	1223	4.6	2.9	1.7	0.20	207	57	40
1224	5.3	3.3	1.6	0.18	256	92	64	
1225	5.2	3.0	1.4	0.14	226	86	34	
1000 ppm	1308	4.9	3.1	1.7	0.13	192	74	52
	1312	5.4	3.0	1.3	0.09	211	117	37
	1319	5.0	3.2	1.8	0.18	165	91	36
	1321	5.0	2.7	1.2	0.10	187	81	41
	1322	5.3	3.3	1.6	0.14	210	77	48
	1323	4.3	2.7	1.7	0.22	174	48	22
	1324	5.2	3.0	1.4	0.13	139	104	36
	1325	5.0	3.2	1.8	0.16	230	75	44



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
300 ppm	1202	98	87	16	288	225	0.1	84
	1203	171	66	39	296	187	0.1	62
	1204	172	57	16	353	200	0.1	97
	1205	225	100	49	314	142	0.4	97
	1206	176	46	14	247	186	0.0	67
	1207	173	60	15	217	217	0.1	66
	1208	227	47	14	172	170	0.2	69
	1209	166	70	19	345	194	0.0	105
	1210	179	60	20	234	197	0.2	89
	1211	184	52	18	195	200	0.1	55
	1212	190	56	18	208	326	0.2	65
	1213	210	76	18	298	128	0.0	122
	1214	178	53	17	241	197	0.1	79
	1215	157	67	20	265	221	0.0	71
	1216	198	71	19	215	177	0.1	153
	1217	149	148	21	316	208	0.2	97
	1219	202	44	13	248	182	0.4	53
	1220	177	62	17	221	186	0.0	74
	1221	125	74	18	302	196	0.4	105
	1223	132	138	19	266	191	0.1	131
1224	189	48	14	252	203	0.0	68	
1225	194	47	17	358	279	0.5	74	
1000 ppm	1308	154	110	23	896	239	0.0	89
	1312	203	336	36	4236	202	0.1	86
	1319	158	188	30	2822	222	0.6	151
	1321	170	81	27	319	174	0.2	70
	1322	166	100	17	678	229	0.1	71
	1323	97	177	45	372	217	0.3	61
	1324	182	154	21	2865	172	0.1	98
	1325	159	96	17	726	218	0.0	67

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHRUS mg/dl
300 ppm	1202	19.1	148	4.7	125	8.6	5.1
	1203	20.8	149	4.3	129	8.6	4.3
	1204	21.4	150	4.2	129	8.6	5.2
	1205	27.6	148	4.2	128	9.0	4.0
	1206	24.4	149	4.2	128	8.6	4.7
	1207	29.6	150	3.8	120	8.7	4.7
	1208	25.4	151	3.5	120	9.1	4.1
	1209	23.1	151	3.8	123	8.5	5.9
	1210	29.8	147	4.2	120	9.0	4.6
	1211	27.4	149	4.3	124	8.9	4.0
	1212	23.4	151	3.7	121	8.8	4.2
	1213	23.2	148	3.6	110	8.0	5.8
	1214	31.4	150	4.0	120	8.7	5.3
	1215	24.8	150	4.0	120	8.5	4.8
	1216	23.7	147	4.0	118	8.2	3.9
	1217	28.6	148	4.1	119	8.3	4.5
	1219	26.3	149	4.0	115	9.1	4.2
	1220	26.9	148	3.9	117	8.5	4.3
	1221	24.4	150	3.7	121	8.6	5.7
	1223	22.3	147	4.2	118	8.6	4.2
1224	26.0	148	3.9	116	9.1	4.2	
1225	27.0	150	3.5	121	8.7	5.0	
1000 ppm	1308	24.0	151	3.5	129	8.4	5.0
	1312	24.5	153	4.2	124	9.6	8.2
	1319	39.7	152	4.5	121	9.4	6.8
	1321	25.0	150	3.7	122	9.0	5.5
	1322	19.8	149	3.5	121	8.6	5.7
	1323	19.6	148	4.0	119	8.4	4.1
	1324	33.6	151	4.1	124	9.3	4.7
	1325	19.7	150	3.7	121	8.9	4.4

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 10

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Posi. Control	1401	2.6	1.4	1.2	0.07	142	92	128
	1406	4.4	2.2	1.0	0.24	174	92	86
	1407	3.4	1.8	1.1	0.12	23	105	20
	1410	3.1	1.6	1.1	0.09	166	82	117
	1411	4.7	2.9	1.6	0.09	218	90	42
	1412	2.6	1.5	1.4	0.08	39	107	20
	1415	2.8	1.4	1.0	0.09	23	102	28
	1416	3.1	1.6	1.1	0.07	89	92	36
	1418	4.7	2.5	1.1	0.07	225	113	52
	1420	4.2	2.4	1.3	0.09	254	111	101

(HCL075)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 11

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Posi. Control	1401	167	44	40	142	66	0.1	124
	1406	210	54	14	500	92	1.2	190
	1407	136	113	58	322	127	0.3	292
	1410	163	59	33	149	84	0.0	118
	1411	193	44	14	182	147	0.5	59
	1412	137	258	176	582	108	0.0	1912
	1415	137	77	40	191	344	0.4	211
	1416	134	115	51	500	239	0.3	370
	1418	246	56	17	218	104	0.3	110
	1420	264	69	26	200	106	0.0	109

(HCL075)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : MALE

REPORT TYPE : A1

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

PAGE : 12

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHURUS mg/dl
Posi. Control	1401	70.8	147	5.3	119	8.6	10.2
	1406	30.8	158	4.8	120	9.4	6.6
	1407	68.6	155	4.9	129	8.7	8.9
	1410	49.5	151	4.5	121	8.5	8.6
	1411	34.9	151	3.7	118	8.9	5.1
	1412	97.6	156	5.3	119	9.2	6.6
	1415	87.2	156	6.8	130	8.8	11.6
	1416	72.0	161	6.3	133	8.7	10.6
	1418	52.6	152	3.4	121	9.1	6.2
	1420	38.3	150	4.2	119	8.7	6.7

(HCL075)

BAIS 6

**APPENDIX 9-2**

**BIOCHEMISTRY (INDIVIDUAL) : FEMALE**

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Control	2001	-	-	-	-	-	-	-
	2002	5.4	3.4	1.7	0.14	190	74	30
	2003	5.3	3.2	1.5	0.19	138	65	42
	2004	5.0	3.1	1.6	0.17	179	62	42
	2005	5.2	3.2	1.6	0.11	250	74	32
	2006	4.8	2.9	1.5	0.24	214	53	29
	2007	5.2	3.3	1.7	0.08	198	79	31
	2009	5.6	3.8	2.1	0.14	232	80	22
	2010	5.7	3.5	1.6	0.09	207	79	39
	2011	5.1	3.3	1.8	0.10	227	77	25
	2013	5.0	3.1	1.6	0.14	186	42	25
	2014	5.0	3.2	1.8	0.16	174	45	23
	2015	5.3	3.4	1.8	0.12	168	67	28
	2016	5.3	3.4	1.8	0.10	176	69	30
	2017	5.3	3.3	1.6	0.12	202	70	24
	2018	5.3	3.3	1.6	0.09	230	81	27
	2019	5.2	3.3	1.7	0.10	170	73	33
	2020	4.7	3.0	1.8	0.15	160	47	26
	2021	5.2	3.4	1.9	0.09	196	71	27
	2022	5.6	3.6	1.8	0.16	190	98	40
	2023	5.0	3.2	1.8	0.10	216	60	30
	2024	5.5	3.3	1.5	0.11	205	75	29
	2025	5.5	3.4	1.6	0.11	229	66	34

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	2001	-	-	-	-	-	-	-
	2002	159	47	19	119	339	0.2	46
	2003	139	93	16	260	383	0.1	96
	2004	132	78	13	212	329	0.1	55
	2005	163	41	15	233	302	0.2	59
	2006	117	74	15	193	363	0.6	66
	2007	163	51	16	182	269	0.4	56
	2009	152	52	14	234	324	1.2	218
	2010	163	63	17	191	399	0.0	52
	2011	167	57	16	137	308	0.3	60
	2013	103	130	23	230	394	0.2	62
	2014	100	115	20	274	378	0.2	368
	2015	149	58	20	147	362	0.2	71
	2016	152	55	17	134	348	0.7	60
	2017	160	51	20	318	285	0.0	77
	2018	170	49	15	179	318	0.4	54
	2019	159	64	20	184	318	0.2	63
	2020	100	98	20	278	343	0.0	56
	2021	149	50	17	118	327	0.2	50
	2022	180	60	16	190	514	0.4	88
	2023	142	50	15	117	403	0.2	52
	2024	168	57	20	193	334	0.3	56
	2025	148	58	20	137	332	0.3	63



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHURUS mg/dl
Control	2001	-	-	-	-	-	-
	2002	19.6	150	3.9	118	8.7	6.1
	2003	24.1	152	3.9	119	8.8	6.3
	2004	20.0	148	4.3	117	8.8	6.7
	2005	21.5	147	4.1	116	8.8	4.4
	2006	19.2	148	4.2	115	8.8	5.2
	2007	21.8	148	3.5	116	8.9	4.6
	2009	28.2	152	3.2	110	8.6	5.6
	2010	22.5	151	3.7	118	8.8	6.2
	2011	22.3	151	3.5	119	8.8	3.5
	2013	25.1	151	3.7	116	8.2	5.6
	2014	22.2	149	3.6	114	8.2	6.8
	2015	25.0	149	3.6	117	9.0	5.2
	2016	31.9	154	3.3	121	8.4	7.7
	2017	19.7	150	4.1	117	8.5	3.6
	2018	26.6	150	3.8	121	8.6	3.6
	2019	21.7	150	3.5	118	8.8	4.5
	2020	23.5	149	4.1	115	8.6	5.5
	2021	35.4	151	3.5	120	9.1	7.2
	2022	27.0	154	3.4	110	8.6	7.2
	2023	28.8	148	3.8	116	9.0	4.2
	2024	27.4	149	3.6	117	9.3	4.2
	2025	25.5	151	3.3	118	9.0	5.7

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
100 ppm	2101	5.3	3.3	1.6	0.11	204	67	42
	2102	5.5	3.5	1.8	0.11	191	66	32
	2104	5.3	3.3	1.6	0.12	217	76	56
	2105	5.1	3.2	1.7	0.11	215	71	50
	2106	4.9	3.0	1.6	0.21	181	50	20
	2107	5.2	3.4	1.9	0.10	205	77	36
	2108	5.2	3.4	1.9	0.10	215	85	53
	2109	5.4	3.4	1.7	0.14	186	64	36
	2110	5.3	3.3	1.6	0.09	149	77	35
	2111	5.2	3.3	1.7	0.11	253	74	40
	2112	5.3	3.4	1.8	0.11	238	77	44
	2113	5.3	3.4	1.8	0.11	204	71	25
	2114	5.4	3.4	1.7	0.10	182	62	27
	2115	4.9	3.1	1.7	0.20	160	42	27
	2116	5.4	3.7	2.2	0.10	220	76	30
	2117	5.4	3.4	1.7	0.10	214	77	32
	2118	5.4	3.4	1.7	0.11	239	77	29
	2119	5.6	3.6	1.8	0.12	203	78	17
	2120	5.5	3.6	1.9	0.10	207	82	27
	2121	4.9	3.1	1.7	0.15	162	43	27
	2122	5.6	3.5	1.7	0.11	199	73	31
	2123	5.0	3.2	1.8	0.10	188	69	40
	2124	5.2	3.4	1.9	0.10	244	75	34
	2125	5.5	3.4	1.6	0.13	170	70	28

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
100 ppm	2101	139	55	20	208	325	0.0	86
	2102	139	57	16	138	315	0.1	61
	2104	159	79	27	273	278	0.2	72
	2105	163	52	15	237	243	0.2	62
	2106	111	85	19	206	316	0.4	66
	2107	162	51	15	172	278	0.0	50
	2108	182	74	18	203	374	0.1	95
	2109	142	58	20	192	316	0.8	72
	2110	150	68	21	234	219	0.0	66
	2111	160	52	18	149	341	0.1	48
	2112	171	60	19	192	371	0.1	59
	2113	155	63	15	204	254	0.2	77
	2114	131	62	20	184	288	0.2	66
	2115	100	133	20	256	386	0.9	91
	2116	158	57	17	162	329	0.5	52
	2117	169	58	19	182	317	0.2	67
	2118	161	51	16	216	337	0.2	59
	2119	161	55	17	166	1251	0.7	75
	2120	165	50	16	224	328	0.2	59
	2121	86	98	17	308	292	0.0	72
	2122	154	46	14	120	350	0.2	44
	2123	158	63	18	193	368	0.7	67
	2124	165	50	16	123	312	0.5	49
	2125	155	93	27	237	329	0.2	94

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHRUS mg/dl
100 ppm	2101	25.1	148	3.8	120	8.9	4.9
	2102	21.8	151	3.8	124	8.7	4.4
	2104	17.2	151	3.9	124	8.8	5.7
	2105	16.6	148	4.2	120	8.4	3.4
	2106	21.7	148	4.4	119	8.9	4.6
	2107	19.8	148	3.4	117	8.9	4.4
	2108	20.8	151	3.6	120	9.0	4.7
	2109	21.0	150	3.2	110	8.2	5.4
	2110	25.9	152	4.1	122	8.6	6.3
	2111	22.1	149	3.5	121	8.8	3.7
	2112	21.1	148	3.4	118	8.9	3.3
	2113	25.9	148	3.3	115	8.4	5.1
	2114	22.6	151	3.4	119	8.4	6.0
	2115	24.8	152	3.6	118	8.3	7.3
	2116	19.9	151	3.3	118	8.5	6.0
	2117	27.3	149	3.7	118	8.9	3.8
	2118	25.0	148	3.4	119	8.4	3.6
	2119	25.2	149	3.4	117	8.9	6.1
	2120	29.6	149	3.9	117	8.8	4.8
	2121	22.1	150	3.5	118	8.5	6.1
	2122	27.0	149	3.5	117	9.0	5.8
	2123	24.3	149	3.7	118	8.8	3.5
	2124	20.1	148	3.6	116	8.9	3.4
	2125	22.7	150	3.4	119	8.9	3.8

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
300 ppm	2201	5.2	3.2	1.6	0.10	213	70	46
	2202	4.7	3.0	1.8	0.18	192	40	27
	2203	5.6	3.4	1.5	0.10	178	82	56
	2204	5.4	3.3	1.6	0.14	213	64	41
	2205	5.3	3.3	1.6	0.13	224	73	48
	2206	5.1	3.2	1.7	0.14	197	62	48
	2207	5.4	3.4	1.7	0.09	196	77	39
	2208	5.3	3.3	1.6	0.12	187	71	42
	2209	5.3	3.3	1.6	0.12	172	67	54
	2210	5.5	3.4	1.6	0.11	207	72	52
	2211	5.4	3.4	1.7	0.10	177	76	40
	2212	5.0	3.2	1.8	0.12	194	71	47
	2213	5.4	3.4	1.7	0.10	226	69	25
	2214	5.6	3.5	1.7	0.11	221	75	27
	2215	5.3	3.5	1.9	0.12	147	76	33
	2216	5.3	3.4	1.8	0.11	208	69	38
	2217	5.5	3.5	1.8	0.13	216	71	32
	2218	5.3	3.4	1.8	0.12	226	79	34
	2219	5.1	3.2	1.7	0.16	221	48	20
	2220	5.5	3.3	1.5	0.10	184	84	22
	2221	5.2	3.3	1.7	0.16	305	74	62
	2222	5.6	3.6	1.8	0.12	229	79	29
	2223	5.4	3.4	1.7	0.12	257	73	40
	2224	4.8	3.0	1.7	0.24	176	40	20
	2225	4.9	3.2	1.9	0.11	102	50	10
1000 ppm	2305	4.7	2.9	1.6	0.12	193	67	36
	2307	5.1	3.4	2.0	0.15	198	85	94
	2308	5.0	3.2	1.8	0.18	262	70	32
	2309	5.0	3.2	1.8	0.13	218	61	60
	2311	-	-	-	-	-	-	-
	2313	5.1	3.2	1.7	0.11	194	68	58
	2314	5.3	3.2	1.5	0.13	136	87	58
	2315	5.5	3.5	1.8	0.12	222	86	53
	2316	5.6	3.4	1.5	0.11	217	81	40
	2321	5.3	3.4	1.8	0.12	179	72	49

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
300 ppm	2201	142	55	31	245	256	0.2	39
	2202	95	108	18	261	407	0.0	95
	2203	169	69	33	289	356	0.1	59
	2204	140	66	31	259	318	0.0	83
	2205	158	55	18	213	346	0.2	64
	2206	147	55	17	222	324	0.0	57
	2207	155	91	25	295	299	0.0	85
	2208	145	72	26	268	315	0.1	75
	2209	142	81	21	318	264	0.0	106
	2210	150	72	23	364	306	0.0	736
	2211	164	106	33	294	923	0.1	85
	2212	162	59	22	224	330	0.1	59
	2213	150	49	20	215	295	0.0	57
	2214	154	51	17	189	294	0.1	67
	2215	158	102	23	288	377	0.1	133
	2216	154	63	23	255	331	0.3	79
	2217	162	59	19	218	378	0.3	78
	2218	178	63	19	200	311	0.1	60
	2219	113	110	22	300	387	0.2	88
	2220	164	52	16	154	321	0.0	50
	2221	160	43	15	302	276	0.0	79
	2222	163	61	17	201	401	0.5	63
	2223	156	48	17	236	349	0.3	56
	2224	91	136	30	296	462	0.5	80
	2225	94	180	38	409	495	0.5	723
1000 ppm	2305	135	80	26	1504	254	0.1	68
	2307	185	127	52	1288	301	0.3	72
	2308	146	65	20	419	432	0.3	203
	2309	134	65	38	794	261	0.3	61
	2311	-	-	-	-	-	-	-
	2313	146	48	27	261	402	0.2	41
	2314	185	113	21	1230	250	0.0	66
	2315	167	41	20	253	608	0.2	78
	2316	163	71	49	306	490	0.2	70
	2321	158	63	23	342	521	0.4	59

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 21

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHRUS mg/dl
300 ppm	2201	18.0	147	4.2	126	8.8	3.9
	2202	18.1	150	4.2	123	8.5	5.0
	2203	18.0	150	4.0	126	8.7	5.0
	2204	18.6	149	4.2	128	8.6	4.9
	2205	19.4	149	4.1	126	8.9	3.4
	2206	20.7	148	4.5	127	8.5	3.6
	2207	19.8	150	3.9	123	9.0	5.0
	2208	20.1	150	3.6	121	8.8	4.7
	2209	17.6	151	3.5	123	8.8	5.0
	2210	20.1	148	3.4	121	9.0	5.0
	2211	21.7	150	3.4	123	8.7	3.8
	2212	20.4	149	3.5	122	8.8	3.2
	2213	24.5	148	3.4	119	8.7	4.2
	2214	26.2	149	3.6	121	8.4	3.8
	2215	23.9	152	3.6	122	8.6	5.1
	2216	23.6	149	3.5	120	8.7	6.6
	2217	24.9	149	3.6	119	8.6	3.6
	2218	20.7	149	3.4	119	8.5	3.2
	2219	23.3	147	3.4	113	9.0	5.2
	2220	26.1	149	3.6	120	9.1	4.2
	2221	25.3	147	4.1	116	8.8	5.8
	2222	23.8	149	3.4	119	9.1	4.7
	2223	23.1	148	3.7	117	9.0	3.7
	2224	21.2	148	4.3	117	8.6	4.0
	2225	52.3	148	3.2	118	8.4	7.5
1000 ppm	2305	17.9	150	4.0	131	8.9	4.5
	2307	27.2	149	3.9	124	9.5	5.9
	2308	27.5	147	4.0	120	9.2	6.7
	2309	21.9	149	3.6	125	8.9	5.9
	2311	-	-	-	-	-	-
	2313	24.6	147	3.5	120	8.6	4.9
	2314	25.0	148	3.7	120	8.9	5.4
	2315	23.8	149	3.7	121	8.8	6.3
	2316	25.0	150	3.3	122	8.7	5.5
	2321	23.3	148	3.4	117	9.1	4.9

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 22

Group Name	Animal ID-NO	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Posi. Control	2416	4.7	2.8	1.5	0.11	163	141	20
	2418	4.3	2.5	1.4	0.15	144	152	118

(HCL075)

BAIS 6



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 23

Group Name	Animal ID-NO	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Posi. Control	2416 2418	212 211	127 61	31 29	473 249	274 141	2.2 0.4	487 138

(HCL075)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
MEASURE. TIME : 1  
SEX : FEMALE

BIOCHEMISTRY (INDIVIDUAL)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 24

Group Name	Animal ID-NO	UREANITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHRUS mg/dl
Posi. Control	2416	56.7	152	3.9	115	8.9	8.9
	2418	39.4	155	4.6	120	9.9	7.0

(HCL075)

BAIS 6

APPENDIX 10-1

GROSS FINDINGS (INDIVIDUAL) : MALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 1

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1001	SCHEDULED	027-1	mediastinum	mass, 5, mm
1002	SCHEDULED	027-1		NON-REMARKABLE
1003	SCHEDULED	027-1	spleen	black zone
1004	SCHEDULED	027-1		NON-REMARKABLE
1005	SCHEDULED	027-1	spleen	black zone
1006	SCHEDULED	027-1		NON-REMARKABLE
1007	SCHEDULED	027-2		NON-REMARKABLE
1008	SCHEDULED	027-2		NON-REMARKABLE
1009	SCHEDULED	027-2	stomach	forestomach:white zone
1010	SCHEDULED	027-2	spleen	black zone
			stomach	glandular stomach:red zone
1011	SCHEDULED	027-2		NON-REMARKABLE
1012	SCHEDULED	027-2		NON-REMARKABLE
1013	SCHEDULED	027-3		NON-REMARKABLE
1014	SCHEDULED	027-3		NON-REMARKABLE
1015	SCHEDULED	027-3		NON-REMARKABLE
1016	SCHEDULED	027-3		NON-REMARKABLE
1017	SCHEDULED	027-3		NON-REMARKABLE
1018	SCHEDULED	027-3	spleen	black zone
1019	SCHEDULED	027-4		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 2

---

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ_____	Findings_____
1020	SCHEDULED	027-4		NON-REMARKABLE
1021	SCHEDULED	027-4		NON-REMARKABLE
1022	SCHEDULED	027-4		NON-REMARKABLE
1023	SCHEDULED	027-4		NON-REMARKABLE
1024	SCHEDULED	027-4		NON-REMARKABLE
1025	SCHEDULED	027-4		NON-REMARKABLE

---

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : 100 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 3

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1101	SCHEDULED	027-1		NON-REMARKABLE
1102	SCHEDULED	027-1		NON-REMARKABLE
1103	SCHEDULED	027-1		NON-REMARKABLE
1104	SCHEDULED	027-1		NON-REMARKABLE
1105	SCHEDULED	027-1		NON-REMARKABLE
1106	SCHEDULED	027-1	spleen	black zone
1107	SCHEDULED	027-2		NON-REMARKABLE
1108	SCHEDULED	027-2	skin/app spleen	erosion enlarged
1109	SCHEDULED	027-2	spleen	black zone
1110	SCHEDULED	027-2		NON-REMARKABLE
1111	SCHEDULED	027-2		NON-REMARKABLE
1112	SCHEDULED	027-2		NON-REMARKABLE
1113	SCHEDULED	027-3		NON-REMARKABLE
1114	MORIBUND	013-7	lung heart thoracic ca	red zone hypertrophy pleural fluid, red, moderate
1115	SCHEDULED	027-3		NON-REMARKABLE
1116	SCHEDULED	027-3		NON-REMARKABLE
1117	SCHEDULED	027-3		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : 100 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 4

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1118	SCHEDULED	027-3		NON-REMARKABLE
1119	SCHEDULED	027-4	spleen	black zone
			stomach	glandular stomach:ulcer
1120	SCHEDULED	027-4	liver	scarred//nodule, 5, mm
1121	SCHEDULED	027-4	spleen	black zone
1122	SCHEDULED	027-4		NON-REMARKABLE
1123	SCHEDULED	027-4		NON-REMARKABLE
1124	SCHEDULED	027-4		NON-REMARKABLE
1125	SCHEDULED	027-4		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : 300 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 5

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1201	MORIBUND	018-2	spleen	black zone
1202	SCHEDULED	027-1	stomach	glandular stomach:black zone
			testis	small
1203	SCHEDULED	027-1	testis	small
1204	SCHEDULED	027-1	testis	small
1205	SCHEDULED	027-1	stomach	glandular stomach:red zone
			testis	small
1206	SCHEDULED	027-1	testis	small
1207	SCHEDULED	027-2	testis	small
1208	SCHEDULED	027-2	testis	small
1209	SCHEDULED	027-2	spleen	black zone
			testis	small
1210	SCHEDULED	027-2	testis	small
1211	SCHEDULED	027-2	testis	small
1212	SCHEDULED	027-2	testis	small
1213	SCHEDULED	027-3	testis	small
1214	SCHEDULED	027-3	testis	small
1215	SCHEDULED	027-3	testis	small
1216	SCHEDULED	027-3	testis	small
1217	SCHEDULED	027-3	testis	small

( ) : Comment



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : 300 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 6

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1218	MORIBUND	022-1	skin/app	erosion, hemorrhage
			spleen	enlarged
			testis	small
1219	SCHEDULED	027-4	testis	small
1220	SCHEDULED	027-4	testis	small
1221	SCHEDULED	027-4	spleen	black zone
			testis	small
1222	MORIBUND	024-7	thymus	enlarged, 10, mm
			spleen	enlarged
			liver	enlarged
			testis	small
1223	SCHEDULED	027-4	testis	small
1224	SCHEDULED	027-4	testis	small
1225	SCHEDULED	027-4	lung	red zone
			testis	small

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 7

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1301	MORIBUND	022-7	testis	small
			other	lower jaw:nodule, 5, mm, hard
1302	MORIBUND	023-2	lung	red zone
			thymus	enlarged, 10, mm
			testis	small
			thoracic ca	pleural fluid, transparent, moderate
1303	MORIBUND	023-7	thymus	enlarged, 15, mm
			testis	small
			thoracic ca	pleural fluid, transparent, moderate
1304	MORIBUND	021-2	thymus	enlarged, 15, mm
			spleen	enlarged
			stomach	forestomach:nodule, white, 2, mm
			testis	small
			pleura	thick
1305	DEAD	023-1	lymph node	enlarged, 5, mm
			urin bladd	urine:marked retention
			testis	small
			periph nerv	thick, trigeminal nerve
1306	MORIBUND	026-7	thymus	enlarged, 17, mm
			testis	small

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 8

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1307	MORIBUND	021-1	thymus	enlarged, 13, mm
			testis	small
			pleura	thick
			thoracic ca	pleural fluid, transparent, slight
1308	SCHEDULED	027-2	thymus	enlarged, red, 10, mm
			stomach	forestomach:white zone
			testis	small
1309	MORIBUND	017-7	lung	white zone
			thymus	enlarged, 22, mm
			heart	white
			testis	small
			pleura	thick
1310	MORIBUND	024-1	lung	red zone
			thymus	enlarged, white, 10, mm
			stomach	forestomach:white zone
			testis	small
			thoracic ca	pleural fluid, transparent, moderate
1311	MORIBUND	021-7	lung	red zone
			thymus	enlarged, 15, mm
			spleen	enlarged

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 9

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1312	SCHEDULED	027-2	testis	small
			pleura	thick
			thoracic ca	pleural fluid, transparent, marked
			lung	red zone
			thymus	enlarged, 14, mm
1313	MORIBUND	021-3	testis	small
			thoracic ca	pleural fluid, red, marked
			thymus	enlarged, 15, mm
1314	MORIBUND	026-5	testis	small
			thoracic ca	pleural fluid, transparent, marked
			thymus	enlarged, 15, mm//red zone
			spleen	enlarged
			pleura	thick
1315	MORIBUND	024-7	thoracic ca	pleural fluid, transparent, moderate
			thymus	enlarged, white, 12, mm
			testis	small
			thoracic ca	pleural fluid, red, slight
1316	DEAD	023-3	thymus	enlarged, 15, mm
			testis	small

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 10

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1317	MORIBUND	026-3	thoracic ca	pleural fluid, white, slight
			thymus	enlarged, 15, mm
			testis	small
1318	MORIBUND	017-7	thoracic ca	pleural fluid, red, moderate
			thymus	enlarged, 10, mm
			eye	white
1319	SCHEDULED	027-4	thoracic ca	pleural fluid, transparent, slight
			thymus	enlarged, 12, mm
			spleen	cyst
			stomach	forestomach: white zone
			testis	small
1320	MORIBUND	024-7	thoracic ca	pleural fluid, transparent, slight
			thymus	enlarged, red, 10, mm
			stomach	forestomach: white zone
			testis	small
1321	SCHEDULED	027-4	thoracic ca	pleural fluid, red, moderate
			testis	small
			testis	small
1322	SCHEDULED	027-4	testis	small
1323	SCHEDULED	027-4	testis	small
1324	SCHEDULED	027-4	thymus	enlarged, 12, mm

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 11

---

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1325	SCHEDULED	027-4	testis	small
			thymus	enlarged, 8, mm
			stomach	forestomach:white zone
			testis	small

---

( ):Comment

(HPT045)

BAIS6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 12

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1401	SCHEDULED	027-1	skin/app	erosion
			spleen	enlarged//white zone
			small intes	nodule, 6, mm
			semin ves	small
			whole body	anemic
1402	MORIBUND	021-5	thymus	enlarged, 10, mm
			spleen	enlarged
			stomach	forestomach: nodule, 5, mm, 2, mm
			liver	white zone
			kidney	white zone
1403	MORIBUND	014-6	whole body	anemic
			lung	red zone
			thymus	enlarged, 18, mm
1404	MORIBUND	021-1	thoracic ca	pleural fluid, transparent, moderate
			thymus	enlarged, 18, mm
			spleen	enlarged
1405	MORIBUND	014-4	small intes	invagination
			pleura	thick
			thoracic ca	pleural fluid, transparent, moderate
			lung	red zone

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 13

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
			thymus	enlarged, 16, mm
			kidney	white zone
1406	SCHEDULED	027-1	spleen	enlarged
1407	SCHEDULED	027-1	skin/app	scab
			spleen	enlarged//nodule, 7, mm
			stomach	forestomach:white zone
			liver	white zone
			testis	small
1408	DEAD	015-7	thymus	enlarged, 17, mm
			spleen	black zone
			pleura	thick
			thoracic ca	pleural fluid, transparent, slight
1409	MORIBUND	016-7	lung	red zone
			thymus	enlarged, 16, mm
			pleura	thick, white
			thoracic ca	pleural fluid, transparent, moderate
1410	SCHEDULED	027-2	spleen	enlarged
			whole body	anemic
1411	SCHEDULED	027-2	spleen	black zone
1412	SCHEDULED	027-1	thymus	enlarged, 10, mm

( ) : Comment



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 14

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1413	MORIBUND	019-7	spleen	enlarged
			stomach	forestomach:white zone
			whole body	anemic
			lung	red zone
1414	MORIBUND	023-2	thymus	enlarged, 12, mm
			spleen	enlarged//black zone
			thoracic ca	pleural fluid, transparent, slight
			spleen	enlarged//white zone
1415	SCHEDULED	027-2	heart	hypertrophy
			whole body	anemic
			spleen	enlarged
1416	SCHEDULED	027-2	small intes	stenosed
			whole body	anemic
			lymph node	enlarged, 5, -, 8, mm, 20, *, 5, mm
1417	MORIBUND	021-5	spleen	enlarged
			thymus	atrophic
			spleen	white zone
1418	SCHEDULED	027-3	testis	small
			spleen	enlarged
			kidney	hydronephrosis

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 15

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
1419	MORIBUND	020-3	whole body	anemic
			lymph node	enlarged, 5, mm
			thymus	enlarged, 15, mm
1420	SCHEDULED	027-3	thoracic ca	pleural fluid, transparent, moderate
			spleen	enlarged
			small intes	white zone
			whole body	anemic

( ) : Comment

**APPENDIX 10-2**

**GROSS FINDINGS (INDIVIDUAL) : FEMALE**

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 16

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2001	SCHEDULED	027-1	kidney	red zone
2002	SCHEDULED	027-1		NON-REMARKABLE
2003	SCHEDULED	027-1	stomach	glandular stomach:white zone
2004	SCHEDULED	027-1		NON-REMARKABLE
2005	SCHEDULED	027-1		NON-REMARKABLE
2006	SCHEDULED	027-1		NON-REMARKABLE
2007	SCHEDULED	027-2		NON-REMARKABLE
2008	MORIBUND	025-6	thymus	enlarged, 16, mm
			thoracic ca	pleural fluid, transparent, moderate
2009	SCHEDULED	027-2	spleen	black zone
2010	SCHEDULED	027-2		NON-REMARKABLE
2011	SCHEDULED	027-2		NON-REMARKABLE
2012	MORIBUND	021-3	skin/app	ulcer
			spleen	enlarged
			whole body	anemic
2013	SCHEDULED	027-3		NON-REMARKABLE
2014	SCHEDULED	027-3		NON-REMARKABLE
2015	SCHEDULED	027-3	stomach	glandular stomach:white zone
2016	SCHEDULED	027-3		NON-REMARKABLE
2017	SCHEDULED	027-3		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 17

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2018	SCHEDULED	027-3		NON-REMARKABLE
2019	SCHEDULED	027-4		NON-REMARKABLE
2020	SCHEDULED	027-4	stomach	glandular stomach:white zone
2021	SCHEDULED	027-4	liver	nodule, 4, mm
			kidney	absence
2022	SCHEDULED	027-4		NON-REMARKABLE
2023	SCHEDULED	027-4		NON-REMARKABLE
2024	SCHEDULED	027-4		NON-REMARKABLE
2025	SCHEDULED	027-4		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : 100 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 18

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2101	SCHEDULED	027-1		NON-REMARKABLE
2102	SCHEDULED	027-1		NON-REMARKABLE
2103	MORIBUND	006-4	thymus	enlarged, 15, mm
			kidney	white zone
			pleura	thick
			thoracic ca	pleural fluid, transparent, slight
2104	SCHEDULED	027-1		NON-REMARKABLE
2105	SCHEDULED	027-1		NON-REMARKABLE
2106	SCHEDULED	027-1		NON-REMARKABLE
2107	SCHEDULED	027-2		NON-REMARKABLE
2108	SCHEDULED	027-2	stomach	glandular stomach:red zone
2109	SCHEDULED	027-2		NON-REMARKABLE
2110	SCHEDULED	027-2		NON-REMARKABLE
2111	SCHEDULED	027-2		NON-REMARKABLE
2112	SCHEDULED	027-2		NON-REMARKABLE
2113	SCHEDULED	027-3	spleen	black zone
2114	SCHEDULED	027-3		NON-REMARKABLE
2115	SCHEDULED	027-3		NON-REMARKABLE
2116	SCHEDULED	027-3		NON-REMARKABLE
2117	SCHEDULED	027-3		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : 100 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 19

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2118	SCHEDULED	027-3		NON-REMARKABLE
2119	SCHEDULED	027-4		NON-REMARKABLE
2120	SCHEDULED	027-4		NON-REMARKABLE
2121	SCHEDULED	027-4		NON-REMARKABLE
2122	SCHEDULED	027-4		NON-REMARKABLE
2123	SCHEDULED	027-4	spleen	black zone
2124	SCHEDULED	027-4		NON-REMARKABLE
2125	SCHEDULED	027-4		NON-REMARKABLE

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : 300 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 20

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2201	SCHEDULED	027-1		NON-REMARKABLE
2202	SCHEDULED	027-1		NON-REMARKABLE
2203	SCHEDULED	027-1		NON-REMARKABLE
2204	SCHEDULED	027-1		NON-REMARKABLE
2205	SCHEDULED	027-1		NON-REMARKABLE
2206	SCHEDULED	027-1	spleen	black zone
2207	SCHEDULED	027-2	stomach	glandular stomach:red zone
2208	SCHEDULED	027-2		NON-REMARKABLE
2209	SCHEDULED	027-2		NON-REMARKABLE
2210	SCHEDULED	027-2		NON-REMARKABLE
2211	SCHEDULED	027-2		NON-REMARKABLE
2212	SCHEDULED	027-2		NON-REMARKABLE
2213	SCHEDULED	027-3		NON-REMARKABLE
2214	SCHEDULED	027-3		NON-REMARKABLE
2215	SCHEDULED	027-3		NON-REMARKABLE
2216	SCHEDULED	027-3		NON-REMARKABLE
2217	SCHEDULED	027-3		NON-REMARKABLE
2218	SCHEDULED	027-3		NON-REMARKABLE
2219	SCHEDULED	027-4		NON-REMARKABLE
2220	SCHEDULED	027-4	stomach	glandular stomach:white zone

( ) : Comment



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : 300 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 21

---

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2221	SCHEDULED	027-4	brain	red zone
2222	SCHEDULED	027-4		NON-REMARKABLE
2223	SCHEDULED	027-4		NON-REMARKABLE
2224	SCHEDULED	027-4		NON-REMARKABLE
2225	SCHEDULED	027-4	lung	white zone

---

( ) : Comment

(HPT045)

BAIS6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 22

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2301	MORIBUND	026-5	urin bladd	urine:marked retention
			spinal cord	red zone
2302	MORIBUND	026-5	thymus	enlarged, 12, mm
			thoracic ca	pleural fluid, red, slight
2303	MORIBUND	001-7		NON-REMARKABLE
2304	MORIBUND	025-1	thymus	enlarged, white, 10, mm
			stomach	forestomach:white zone, multiple
			liver	cyst, red
			eye	turbid
			thoracic ca	pleural fluid, transparent, moderate
2305	SCHEDULED	027-1	thymus	enlarged, red, 12, mm
			spleen	enlarged
2306	MORIBUND	025-4	thymus	enlarged, white, 15, mm
			spleen	enlarged
			stomach	forestomach:ulcer
			liver	enlarged
			thoracic ca	pleural fluid, transparent, moderate
2307	SCHEDULED	027-2	lung	white zone
			spleen	enlarged
			stomach	forestomach:white zone

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 23

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2308	SCHEDULED	027-2	stomach	forestomach:white zone,multiple
2309	SCHEDULED	027-2	spleen	enlarged
			stomach	forestomach:white zone
2310	MORIBUND	018-7	thymus	enlarged, 12, mm
			thoracic ca	pleural fluid, transparent, slight
2311	SCHEDULED	027-2	thymus	enlarged, 8, mm
			spleen	enlarged//white zone
			heart	hypertrophy
			liver	nodule, red, 7, mm, 5, mm
2312	MORIBUND	023-6	thymus	red zone//enlarged, 15, mm
			spleen	enlarged
			thoracic ca	pleural fluid, transparent, moderate
2313	SCHEDULED	027-3		NON-REMARKABLE
2314	SCHEDULED	027-3	thymus	enlarged, red, 10, mm
2315	SCHEDULED	027-3		NON-REMARKABLE
2316	SCHEDULED	027-3	stomach	forestomach:white zone
2317	MORIBUND	026-1	thymus	enlarged, 15, mm
			thoracic ca	pleural fluid, transparent, slight
2318	MORIBUND	023-4	lymph node	enlarged, 15, mm
			thymus	enlarged, 12, mm

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 24

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
			spleen	enlarged
			thoracic ca	pleural fluid, transparent, moderate
2319	MORIBUND	026-3	muscle	mass, 25, mm, adhesion, rib
2320	DEAD	013-7	spleen	enlarged
2321	SCHEDULED	027-4	liver	red zone
2322	MORIBUND	024-2	lung	red zone
			thymus	enlarged, 13, mm
			spleen	enlarged
			liver	red zone
			ovary	small
			thoracic ca	pleural fluid, transparent, slight
2323	MORIBUND	026-2	lung	red zone
			thymus	enlarged, white, 10, mm
			spleen	enlarged
			liver	enlarged
			thoracic ca	pleural fluid, red, moderate
2324	MORIBUND	022-1	subcutis	mass, ulcer, soft, 30, mm
			spleen	enlarged
2325	MORIBUND	024-2	thymus	enlarged, 15, mm
			spleen	enlarged

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : 1000 ppm

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 25

---

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ_____	Findings_____
			thoracic ca	pleural fluid, transparent, moderate

---

( ) : Comment

(HPT045)

BAIS6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 26

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
2401	DEAD	019-1	lymph node	enlarged, 4, mm
			thymus	enlarged, 12, mm
			spleen	enlarged
			peritoneum	nodule, mesenterium, red, soft, 22, mm
			abdominal c	ascites, red, marked
			whole body	anemic
2402	MORIBUND	014-4	lung	red zone, multiple
			thymus	enlarged, 15, mm
			spleen	enlarged
			thoracic ca	pleural fluid, red, slight
2403	MORIBUND	015-5	thymus	enlarged, 13, mm
			spleen	enlarged
			thoracic ca	pleural fluid, transparent, slight
			whole body	anemic
2404	MORIBUND	023-4	lymph node	enlarged, 5, mm
			thymus	enlarged, 10, mm
			spleen	enlarged
			thoracic ca	pleural fluid, transparent, slight
			whole body	anemic
2405	MORIBUND	012-1	spleen	enlarged

( ) : Comment

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 27

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
			whole body	anemic
2406	MORIBUND	010-2	thymus	enlarged, 10, mm
			spleen	enlarged
			stomach	forestomach:ulcer, perforation
			liver	white zone
			thoracic ca	pleural fluid, red, slight
2407	MORIBUND	019-6	lung	red zone
			thymus	enlarged, 13, mm
			thoracic ca	pleural fluid, transparent, moderate
2408	MORIBUND	019-1	lymph node	enlarged, 5, mm, 6, mm
			thymus	enlarged, 17, mm
			spleen	enlarged
			thoracic ca	pleural fluid, white, moderate
			whole body	anemic
2409	MORIBUND	014-1	thymus	enlarged, 16, mm
			thoracic ca	pleural fluid, red, moderate
2410	MORIBUND	016-6	lung	red zone
			thymus	enlarged, 15, mm
2411	DEAD	010-4	lung	red
			thymus	enlarged, 15, mm

( ) : Comment

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

PAGE : 28

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
			spleen	enlarged
			liver	enlarged
			kidney	white, red zone
2412	MORIBUND	016-4	spleen	enlarged
			whole body	anemic
2413	MORIBUND	019-7	thymus	enlarged, 12, mm
			spleen	enlarged
			thoracic ca	pleural fluid, white, slight
2414	MORIBUND	012-7	thymus	enlarged, 17, mm
			spleen	enlarged//black zone
2415	MORIBUND	014-7	lung	red zone
			thymus	enlarged, 15, mm
			spleen	black zone
			thoracic ca	pleural fluid, transparent, moderate
2416	SCHEDULED	027-2	thymus	enlarged, 10, mm
			spleen	enlarged
2417	MORIBUND	010-4	thymus	enlarged, 8, mm
			spleen	enlarged
2418	SCHEDULED	027-3	spleen	enlarged
			stomach	forestomach:white zone

( ) : Comment



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE

GROUP NAME : Posi. Control

GROSS FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 29

Animal ID-NO.	Death Information	Time of Examination Week-Day	Organ	Findings
			pituitary	white zone
			whole body	anemic
2419	MORIBUND	015-2	thymus	enlarged, 16, mm
			spleen	black zone
			thoracic ca	pleural fluid, transparent, moderate
2420	DEAD	017-3	thymus	enlarged, white, 15, mm
			thoracic ca	pleural fluid, transparent, slight

( ) : Comment

APPENDIX 11-1

ORGAN WEIGHT, ABSOLUTE (INDIVIDUAL) : MALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight	ADRENALS	TESTES	HEART	LUNGS
Control	1001	27-1 SCHEDULED	30.2	0.011	0.229	0.140	0.202
	1002	27-1 SCHEDULED	30.3	0.011	0.220	0.157	0.147
	1003	27-1 SCHEDULED	30.7	0.010	0.190	0.202	0.155
	1004	27-1 SCHEDULED	35.2	0.014	0.230	0.172	0.174
	1005	27-1 SCHEDULED	30.7	0.011	0.215	0.160	0.146
	1006	27-1 SCHEDULED	28.1	0.010	0.233	0.162	0.146
	1007	27-2 SCHEDULED	35.8	0.012	0.244	0.157	0.155
	1008	27-2 SCHEDULED	26.9	0.012	0.221	0.137	0.138
	1009	27-2 SCHEDULED	29.5	0.018	0.246	0.153	0.146
	1010	27-2 SCHEDULED	28.8	0.012	0.234	0.144	0.151
	1011	27-2 SCHEDULED	28.8	0.012	0.220	0.142	0.158
	1012	27-2 SCHEDULED	32.2	0.010	0.240	0.144	0.148
	1013	27-3 SCHEDULED	33.3	0.011	0.213	0.176	0.147
	1014	27-3 SCHEDULED	31.0	0.009	0.230	0.153	0.139
	1015	27-3 SCHEDULED	32.9	0.010	0.226	0.154	0.149
	1016	27-3 SCHEDULED	29.0	0.011	0.224	0.139	0.145
	1017	27-3 SCHEDULED	36.4	0.010	0.154	0.201	0.198
	1018	27-3 SCHEDULED	28.8	0.010	0.213	0.168	0.148
	1019	27-4 SCHEDULED	31.7	0.010	0.253	0.159	0.168
	1020	27-4 SCHEDULED	28.1	0.015	0.231	0.138	0.144
	1021	27-4 SCHEDULED	31.3	0.008	0.213	0.142	0.139
	1022	27-4 SCHEDULED	27.5	0.007	0.212	0.150	0.143
	1023	27-4 SCHEDULED	26.2	0.004	0.235	0.129	0.138
	1024	27-4 SCHEDULED	29.4	0.009	0.240	0.156	0.170
	1025	27-4 SCHEDULED	30.2	0.010	0.231	0.148	0.153

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 2

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	1001	0.383	0.072	1.276	0.458
	1002	0.435	0.069	1.266	0.461
	1003	0.488	0.098	1.054	0.493
	1004	0.510	0.099	1.141	0.490
	1005	0.419	0.061	1.296	0.464
	1006	0.415	0.066	1.236	0.461
	1007	0.421	0.084	1.461	0.483
	1008	0.385	0.057	1.183	0.459
	1009	0.406	0.063	1.352	0.482
	1010	0.380	0.059	1.288	0.463
	1011	0.412	0.070	1.317	0.499
	1012	0.395	0.082	1.333	0.456
	1013	0.438	0.085	1.374	0.448
	1014	0.414	0.099	1.389	0.455
	1015	0.431	0.063	1.381	0.465
	1016	0.378	0.061	1.231	0.452
	1017	0.562	0.116	1.256	0.485
	1018	0.414	0.063	1.304	0.467
	1019	0.431	0.061	1.284	0.475
	1020	0.401	0.071	1.295	0.484
	1021	0.469	0.073	1.343	0.454
	1022	0.444	0.058	1.255	0.463
	1023	0.378	0.057	1.233	0.472
	1024	0.441	0.064	1.373	0.482
	1025	0.448	0.073	1.369	0.451

(HCL041)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight	ADRENALS	TESTES	HEART	LUNGS
100 ppm	1101	27-1 SCHEDULED	32.4	0.010	0.194	0.129	0.156
	1102	27-1 SCHEDULED	27.6	0.014	0.204	0.149	0.151
	1103	27-1 SCHEDULED	36.5	0.013	0.215	0.152	0.170
	1104	27-1 SCHEDULED	28.7	0.010	0.204	0.154	0.136
	1105	27-1 SCHEDULED	36.2	0.016	0.227	0.165	0.164
	1106	27-1 SCHEDULED	30.6	0.011	0.205	0.147	0.152
	1107	27-2 SCHEDULED	35.6	0.012	0.221	0.159	0.153
	1108	27-2 SCHEDULED	21.2	0.010	0.179	0.167	0.152
	1109	27-2 SCHEDULED	34.0	0.011	0.182	0.152	0.152
	1110	27-2 SCHEDULED	28.3	0.012	0.223	0.145	0.167
	1111	27-2 SCHEDULED	35.6	0.010	0.211	0.163	0.182
	1112	27-2 SCHEDULED	31.9	0.008	0.202	0.151	0.155
	1113	27-3 SCHEDULED	29.7	0.019	0.159	0.182	0.156
	1115	27-3 SCHEDULED	29.0	0.009	0.166	0.181	0.163
	1116	27-3 SCHEDULED	32.3	0.007	0.214	0.152	0.158
	1117	27-3 SCHEDULED	35.2	0.013	0.136	0.156	0.162
	1118	27-3 SCHEDULED	34.1	0.010	0.212	0.160	0.147
	1119	27-4 SCHEDULED	31.5	0.007	0.185	0.173	0.154
	1120	27-4 SCHEDULED	36.0	0.009	0.232	0.170	0.165
	1121	27-4 SCHEDULED	25.3	0.009	0.192	0.126	0.129
	1122	27-4 SCHEDULED	33.4	0.009	0.210	0.157	0.163
	1123	27-4 SCHEDULED	31.3	0.008	0.210	0.143	0.166
	1124	27-4 SCHEDULED	28.4	0.008	0.214	0.143	0.163
	1125	27-4 SCHEDULED	32.5	0.011	0.201	0.183	0.172

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 4

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
100 ppm	1101	0.369	0.064	1.300	0.461
	1102	0.382	0.062	1.118	0.457
	1103	0.405	0.089	1.488	0.459
	1104	0.411	0.067	1.263	0.474
	1105	0.426	0.079	1.460	0.466
	1106	0.405	0.077	1.330	0.467
	1107	0.422	0.092	1.419	0.481
	1108	0.452	0.247	1.199	0.443
	1109	0.416	0.077	1.404	0.461
	1110	0.399	0.065	1.216	0.478
	1111	0.446	0.085	1.434	0.469
	1112	0.381	0.061	1.299	0.452
	1113	0.502	0.086	0.988	0.505
	1115	0.509	0.085	1.016	0.501
	1116	0.412	0.088	1.334	0.457
	1117	0.415	0.091	1.423	0.470
	1118	0.418	0.071	1.427	0.462
	1119	0.545	0.073	1.061	0.471
	1120	0.448	0.085	1.557	0.464
	1121	0.333	0.058	1.078	0.450
	1122	0.394	0.073	1.341	0.466
	1123	0.386	0.060	1.280	0.450
	1124	0.427	0.057	1.260	0.476
	1125	0.406	0.071	1.449	0.474

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight	ADRENALS	TESTES	HEART	LUNGS
300 ppm	1202	27-1 SCHEDULED	29.1	0.013	0.049	0.160	0.175
	1203	27-1 SCHEDULED	36.1	0.023	0.067	0.162	0.138
	1204	27-1 SCHEDULED	30.8	0.021	0.070	0.156	0.161
	1205	27-1 SCHEDULED	30.1	0.010	0.057	0.150	0.169
	1206	27-1 SCHEDULED	35.7	0.011	0.095	0.161	0.175
	1207	27-2 SCHEDULED	31.0	0.013	0.083	0.150	0.160
	1208	27-2 SCHEDULED	27.8	0.010	0.061	0.151	0.144
	1209	27-2 SCHEDULED	34.0	0.010	0.083	0.169	0.164
	1210	27-2 SCHEDULED	31.4	0.014	0.061	0.134	0.163
	1211	27-2 SCHEDULED	33.3	0.025	0.065	0.173	0.177
	1212	27-2 SCHEDULED	29.5	0.013	0.091	0.147	0.161
	1213	27-3 SCHEDULED	28.5	0.010	0.061	0.160	0.146
	1214	27-3 SCHEDULED	31.6	0.015	0.053	0.150	0.148
	1215	27-3 SCHEDULED	30.8	0.010	0.057	0.141	0.153
	1216	27-3 SCHEDULED	32.0	0.009	0.105	0.147	0.155
	1217	27-3 SCHEDULED	29.7	0.009	0.050	0.169	0.161
	1219	27-4 SCHEDULED	37.9	0.009	0.117	0.171	0.184
	1220	27-4 SCHEDULED	32.6	0.007	0.081	0.157	0.158
	1221	27-4 SCHEDULED	29.2	0.010	0.055	0.153	0.153
	1223	27-4 SCHEDULED	29.6	0.020	0.064	0.183	0.181
1224	27-4 SCHEDULED	36.2	0.007	0.089	0.164	0.160	
1225	27-4 SCHEDULED	24.4	0.009	0.056	0.131	0.179	
1000 ppm	1308	27-2 SCHEDULED	26.2	0.009	0.052	0.159	0.146
	1312	27-2 SCHEDULED	24.2	0.011	0.055	0.139	0.175
	1319	27-4 SCHEDULED	22.2	0.009	0.045	0.186	0.163
	1321	27-4 SCHEDULED	24.8	0.009	0.056	0.148	0.157
	1322	27-4 SCHEDULED	25.4	0.009	0.055	0.162	0.146
	1323	27-4 SCHEDULED	25.1	0.008	0.047	0.174	0.173
	1324	27-4 SCHEDULED	27.6	0.009	0.060	0.170	0.165
	1325	27-4 SCHEDULED	26.4	0.008	0.062	0.170	0.151

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 6

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
300 ppm	1202	0.483	0.076	0.903	0.487
	1203	0.380	0.091	1.381	0.455
	1204	0.404	0.090	1.230	0.467
	1205	0.424	0.119	1.395	0.463
	1206	0.419	0.081	1.397	0.472
	1207	0.385	0.081	1.259	0.464
	1208	0.366	0.073	1.241	0.448
	1209	0.413	0.088	1.442	0.476
	1210	0.373	0.080	1.358	0.458
	1211	0.457	0.075	1.417	0.490
	1212	0.397	0.084	1.281	0.476
	1213	0.364	0.090	1.235	0.453
	1214	0.399	0.081	1.404	0.432
	1215	0.397	0.069	1.282	0.452
	1216	0.402	0.069	1.347	0.451
	1217	0.484	0.085	0.962	0.507
	1219	0.442	0.108	1.576	0.474
	1220	0.431	0.076	1.398	0.460
	1221	0.398	0.078	1.252	0.463
	1223	0.519	0.097	1.095	0.497
1224	0.422	0.072	1.514	0.459	
1225	0.365	0.082	1.120	0.450	
1000 ppm	1308	0.406	0.084	1.351	0.437
	1312	0.356	0.089	1.167	0.439
	1319	0.352	0.116	1.108	0.411
	1321	0.385	0.107	1.332	0.434
	1322	0.400	0.152	1.310	0.432
	1323	0.508	0.106	0.986	0.465
	1324	0.416	0.088	1.401	0.455
	1325	0.417	0.065	1.334	0.426

(HCL041)

BAIS 6



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 7

Group Name	Animal ID-NO.	Death Information		Body Weight	ADRENALS	TESTES	HEART	LUNGS
Posi. Control	1401	27-1	SCHEDULED	28.2	0.008	0.204	0.235	0.173
	1406	27-1	SCHEDULED	30.8	0.010	0.208	0.173	0.173
	1407	27-1	SCHEDULED	23.6	0.007	0.130	0.194	0.156
	1410	27-2	SCHEDULED	26.7	0.008	0.194	0.248	0.169
	1411	27-2	SCHEDULED	30.1	0.008	0.218	0.161	0.143
	1412	27-1	SCHEDULED	25.1	0.010	0.172	0.143	0.141
	1415	27-2	SCHEDULED	23.0	0.008	0.156	0.238	0.156
	1416	27-2	SCHEDULED	23.7	0.008	0.144	0.195	0.148
	1418	27-3	SCHEDULED	27.4	0.009	0.225	0.174	0.145
	1420	27-3	SCHEDULED	29.9	0.008	0.237	0.173	0.166

(HCL041)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 8

---

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Posi. Control	1401	0.423	0.836	2.287	0.449
	1406	0.411	0.428	1.534	0.464
	1407	0.357	0.723	1.304	0.425
	1410	0.391	0.573	1.887	0.456
	1411	0.398	0.145	1.310	0.447
	1412	0.308	0.234	1.192	0.450
	1415	0.328	0.748	1.437	0.425
	1416	0.300	1.109	1.719	0.427
	1418	0.521	0.358	1.479	0.449
	1420	0.449	0.480	1.613	0.460

---

(HCL041)

BAIS 6

APPENDIX 11-2

ORGAN WEIGHT, ABSOLUTE (INDIVIDUAL) : FEMALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight	ADRENALS	OVARIES	HEART	LUNGS
Control	2001	27-1 SCHEDULED	25.4	0.017	0.036	0.132	0.171
	2002	27-1 SCHEDULED	23.8	0.014	0.030	0.130	0.136
	2003	27-1 SCHEDULED	21.5	0.014	0.023	0.148	0.140
	2004	27-1 SCHEDULED	23.4	0.017	0.028	0.154	0.149
	2005	27-1 SCHEDULED	23.0	0.014	0.030	0.131	0.146
	2006	27-1 SCHEDULED	23.7	0.018	0.034	0.158	0.163
	2007	27-2 SCHEDULED	26.5	0.014	0.035	0.129	0.152
	2009	27-2 SCHEDULED	21.3	0.011	0.031	0.122	0.134
	2010	27-2 SCHEDULED	22.5	0.015	0.021	0.124	0.143
	2011	27-2 SCHEDULED	22.9	0.016	0.024	0.122	0.145
	2013	27-3 SCHEDULED	22.5	0.018	0.029	0.157	0.187
	2014	27-3 SCHEDULED	22.2	0.015	0.030	0.146	0.157
	2015	27-3 SCHEDULED	23.8	0.012	0.048	0.132	0.146
	2016	27-3 SCHEDULED	23.3	0.012	0.032	0.131	0.149
	2017	27-3 SCHEDULED	21.5	0.017	0.031	0.122	0.137
	2018	27-3 SCHEDULED	22.7	0.015	0.027	0.110	0.141
	2019	27-4 SCHEDULED	23.2	0.017	0.038	0.122	0.145
	2020	27-4 SCHEDULED	23.2	0.012	0.028	0.148	0.145
	2021	27-4 SCHEDULED	21.9	0.016	0.023	0.122	0.132
	2022	27-4 SCHEDULED	24.5	0.015	0.032	0.129	0.150
	2023	27-4 SCHEDULED	22.1	0.014	0.031	0.131	0.149
	2024	27-4 SCHEDULED	22.1	0.015	0.024	0.125	0.142
	2025	27-4 SCHEDULED	21.4	0.014	0.025	0.115	0.133

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 10

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	2001	0.367	0.080	1.206	0.505
	2002	0.324	0.077	1.062	0.476
	2003	0.349	0.081	0.755	0.481
	2004	0.377	0.084	0.826	0.494
	2005	0.330	0.088	1.053	0.453
	2006	0.391	0.074	0.840	0.500
	2007	0.331	0.083	1.187	0.484
	2009	0.295	0.074	0.957	0.468
	2010	0.332	0.082	1.075	0.481
	2011	0.335	0.066	1.134	0.487
	2013	0.403	0.088	0.905	0.538
	2014	0.365	0.070	0.749	0.480
	2015	0.332	0.077	1.092	0.481
	2016	0.345	0.076	1.001	0.467
	2017	0.317	0.068	0.968	0.462
	2018	0.341	0.078	1.016	0.457
	2019	0.340	0.078	1.115	0.498
	2020	0.442	0.081	0.880	0.510
	2021		0.096	1.051	0.458
	2022	0.360	0.074	1.184	0.509
	2023	0.334	0.066	1.063	0.481
	2024	0.322	0.096	1.038	0.463
	2025	0.301	0.062	1.035	0.472

(HCL041)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight	ADRENALS	OVARIES	HEART	LUNGS
100 ppm	2101	27-1 SCHEDULED	25.6	0.014	0.021	0.133	0.142
	2102	27-1 SCHEDULED	23.1	0.013	0.023	0.115	0.135
	2104	27-1 SCHEDULED	28.6	0.020	0.030	0.126	0.135
	2105	27-1 SCHEDULED	24.2	0.018	0.028	0.134	0.152
	2106	27-1 SCHEDULED	25.0	0.017	0.024	0.152	0.178
	2107	27-2 SCHEDULED	26.1	0.015	0.037	0.150	0.156
	2108	27-2 SCHEDULED	22.5	0.014	0.037	0.140	0.148
	2109	27-2 SCHEDULED	21.6	0.013	0.025	0.109	0.130
	2110	27-2 SCHEDULED	24.3	0.013	0.029	0.133	0.150
	2111	27-2 SCHEDULED	24.1	0.014	0.028	0.131	0.150
	2112	27-2 SCHEDULED	21.9	0.012	0.029	0.119	0.142
	2113	27-3 SCHEDULED	23.6	0.019	0.031	0.139	0.164
	2114	27-3 SCHEDULED	23.1	0.025	0.037	0.128	0.156
	2115	27-3 SCHEDULED	21.9	0.016	0.024	0.144	0.147
	2116	27-3 SCHEDULED	24.1	0.015	0.028	0.124	0.144
	2117	27-3 SCHEDULED	21.5	0.013	0.026	0.129	0.132
	2118	27-3 SCHEDULED	23.2	0.013	0.029	0.118	0.137
	2119	27-4 SCHEDULED	26.2	0.013	0.027	0.131	0.156
	2120	27-4 SCHEDULED	23.6	0.017	0.031	0.135	0.158
	2121	27-4 SCHEDULED	24.1	0.015	0.029	0.165	0.155
	2122	27-4 SCHEDULED	23.8	0.015	0.025	0.127	0.143
	2123	27-4 SCHEDULED	24.4	0.016	0.029	0.159	0.180
	2124	27-4 SCHEDULED	22.1	0.014	0.024	0.129	0.143
	2125	27-4 SCHEDULED	22.1	0.014	0.026	0.123	0.148

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 12

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
100 ppm	2101	0.336	0.095	1.122	0.467
	2102	0.321	0.077	1.021	0.472
	2104	0.346	0.086	1.190	0.470
	2105	0.328	0.071	1.074	0.474
	2106	0.427	0.092	0.845	0.501
	2107	0.346	0.088	1.209	0.497
	2108	0.348	0.079	1.119	0.476
	2109	0.293	0.069	0.978	0.452
	2110	0.338	0.097	1.199	0.478
	2111	0.340	0.075	1.114	0.472
	2112	0.310	0.069	1.042	0.467
	2113	0.348	0.076	1.036	0.481
	2114	0.319	0.075	1.095	0.469
	2115	0.385	0.072	0.744	0.508
	2116	0.336	0.071	1.093	0.470
	2117	0.315	0.077	1.054	0.461
	2118	0.314	0.070	1.124	0.461
	2119	0.366	0.073	1.141	0.528
	2120	0.335	0.068	1.100	0.486
	2121	0.412	0.095	0.825	0.492
	2122	0.335	0.093	1.049	0.472
	2123	0.357	0.091	1.188	0.480
	2124	0.338	0.079	1.045	0.469
	2125	0.337	0.079	1.066	0.478

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight	ADRENALS	OVARIES	HEART	LUNGS
300 ppm	2201	27-1 SCHEDULED	24.8	0.014	0.023	0.128	0.149
	2202	27-1 SCHEDULED	23.4	0.011	0.027	0.172	0.151
	2203	27-1 SCHEDULED	24.7	0.016	0.030	0.136	0.166
	2204	27-1 SCHEDULED	22.3	0.012	0.050	0.134	0.148
	2205	27-1 SCHEDULED	23.5	0.015	0.033	0.119	0.148
	2206	27-1 SCHEDULED	22.5	0.016	0.021	0.127	0.139
	2207	27-2 SCHEDULED	23.6	0.013	0.024	0.132	0.168
	2208	27-2 SCHEDULED	22.4	0.013	0.022	0.134	0.142
	2209	27-2 SCHEDULED	26.2	0.015	0.029	0.137	0.149
	2210	27-2 SCHEDULED	25.3	0.013	0.015	0.143	0.146
	2211	27-2 SCHEDULED	21.6	0.015	0.020	0.138	0.138
	2212	27-2 SCHEDULED	22.8	0.012	0.025	0.128	0.144
	2213	27-3 SCHEDULED	23.6	0.016	0.028	0.137	0.140
	2214	27-3 SCHEDULED	23.8	0.016	0.029	0.129	0.141
	2215	27-3 SCHEDULED	23.7	0.011	0.035	0.139	0.148
	2216	27-3 SCHEDULED	25.6	0.014	0.028	0.150	0.148
	2217	27-3 SCHEDULED	22.4	0.014	0.026	0.147	0.142
	2218	27-3 SCHEDULED	23.1	0.014	0.030	0.134	0.144
	2219	27-4 SCHEDULED	24.8	0.015	0.024	0.187	0.181
	2220	27-4 SCHEDULED	23.0	0.015	0.033	0.131	0.145
	2221	27-4 SCHEDULED	26.5	0.021	0.026	0.137	0.153
	2222	27-4 SCHEDULED	24.2	0.013	0.027	0.130	0.143
	2223	27-4 SCHEDULED	28.4	0.014	0.025	0.156	0.163
	2224	27-4 SCHEDULED	22.7	0.012	0.011	0.123	0.163
	2225	27-4 SCHEDULED	19.9	0.012	0.021	0.134	0.134
1000 ppm	2305	27-1 SCHEDULED	24.4	0.011	0.048	0.144	0.154
	2307	27-2 SCHEDULED	25.5	0.014	0.017	0.154	0.192
	2308	27-2 SCHEDULED	21.1	0.013	0.012	0.173	0.152
	2309	27-2 SCHEDULED	24.0	0.012	0.015	0.156	0.147
	2313	27-3 SCHEDULED	26.8	0.017	0.019	0.178	0.178
	2314	27-3 SCHEDULED	25.1	0.010	0.012	0.147	0.148
	2315	27-3 SCHEDULED	23.2	0.012	0.024	0.135	0.149
	2316	27-3 SCHEDULED	24.2	0.013	0.021	0.156	0.164
	2321	27-4 SCHEDULED	23.6	0.011	0.033	0.161	0.157



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
300 ppm	2201	0.326	0.103	1.151	0.482
	2202	0.416	0.086	0.851	0.492
	2203	0.331	0.104	1.262	0.486
	2204	0.313	0.075	1.090	0.474
	2205	0.313	0.091	1.093	0.461
	2206	0.319	0.080	1.107	0.461
	2207	0.355	0.106	1.177	0.475
	2208	0.328	0.088	1.197	0.476
	2209	0.353	0.112	1.238	0.477
	2210	0.346	0.098	1.241	0.469
	2211	0.339	0.083	1.101	0.476
	2212	0.340	0.105	1.115	0.469
	2213	0.324	0.104	1.124	0.472
	2214	0.319	0.071	1.070	0.459
	2215	0.365	0.088	1.173	0.481
	2216	0.339	0.092	1.237	0.490
	2217	0.345	0.065	1.006	0.475
	2218	0.336	0.082	1.112	0.463
	2219	0.462	0.092	0.973	0.495
	2220	0.337	0.095	1.055	0.453
	2221	0.371	0.092	1.187	0.502
	2222	0.352	0.095	1.093	0.465
	2223	0.404	0.101	1.358	0.492
	2224	0.413	0.110	0.810	0.490
	2225	0.328	0.057	0.815	0.469
1000 ppm	2305	0.362	0.203	1.376	0.444
	2307	0.377	1.055	1.719	0.451
	2308	0.406	0.094	1.367	0.477
	2309	0.388	0.250	1.476	0.469
	2313	0.426	0.177	1.448	0.458
	2314	0.406	0.123	1.357	0.457
	2315	0.407	0.153	1.361	0.449
	2316	0.414	0.156	1.465	0.468
	2321	0.408	0.135	1.429	0.459

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 15

Group Name	Animal ID-NO.	Death Information		Body Weight	ADRENALS	OVARIES	HEART	LUNGS
Posi. Control	2416	27-2	SCHEDULED	17.1	0.008	0.014	0.117	0.128
	2418	27-3	SCHEDULED	19.0	0.009	0.011	0.231	0.150

(HCL041)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT: ABSOLUTE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 16

---

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Posi. Control	2416	0.293	0.343	0.970	0.441
	2418	0.313	0.752	1.421	0.434

---

(HCL041)

BAIS 6

APPENDIX 12-1

ORGAN WEIGHT, RELATIVE (INDIVIDUAL) : MALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS
Control	1001	27-1 SCHEDULED	30.2	0.036	0.758	0.464	0.669
	1002	27-1 SCHEDULED	30.3	0.036	0.726	0.518	0.485
	1003	27-1 SCHEDULED	30.7	0.033	0.619	0.658	0.505
	1004	27-1 SCHEDULED	35.2	0.040	0.653	0.489	0.494
	1005	27-1 SCHEDULED	30.7	0.036	0.700	0.521	0.476
	1006	27-1 SCHEDULED	28.1	0.036	0.829	0.577	0.520
	1007	27-2 SCHEDULED	35.8	0.034	0.682	0.439	0.433
	1008	27-2 SCHEDULED	26.9	0.045	0.822	0.509	0.513
	1009	27-2 SCHEDULED	29.5	0.061	0.834	0.519	0.495
	1010	27-2 SCHEDULED	28.8	0.042	0.813	0.500	0.524
	1011	27-2 SCHEDULED	28.8	0.042	0.764	0.493	0.549
	1012	27-2 SCHEDULED	32.2	0.031	0.745	0.447	0.460
	1013	27-3 SCHEDULED	33.3	0.033	0.640	0.529	0.441
	1014	27-3 SCHEDULED	31.0	0.029	0.742	0.494	0.448
	1015	27-3 SCHEDULED	32.9	0.030	0.687	0.468	0.453
	1016	27-3 SCHEDULED	29.0	0.038	0.772	0.479	0.500
	1017	27-3 SCHEDULED	36.4	0.027	0.423	0.552	0.544
	1018	27-3 SCHEDULED	28.8	0.035	0.740	0.583	0.514
	1019	27-4 SCHEDULED	31.7	0.032	0.798	0.502	0.530
	1020	27-4 SCHEDULED	28.1	0.053	0.822	0.491	0.512
	1021	27-4 SCHEDULED	31.3	0.026	0.681	0.454	0.444
	1022	27-4 SCHEDULED	27.5	0.025	0.771	0.545	0.520
	1023	27-4 SCHEDULED	26.2	0.015	0.897	0.492	0.527
	1024	27-4 SCHEDULED	29.4	0.031	0.816	0.531	0.578
	1025	27-4 SCHEDULED	30.2	0.033	0.765	0.490	0.507

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 2

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	1001	1.268	0.238	4.225	1.517
	1002	1.436	0.228	4.178	1.521
	1003	1.590	0.319	3.433	1.606
	1004	1.449	0.281	3.241	1.392
	1005	1.365	0.199	4.221	1.511
	1006	1.477	0.235	4.399	1.641
	1007	1.176	0.235	4.081	1.349
	1008	1.431	0.212	4.398	1.706
	1009	1.376	0.214	4.583	1.634
	1010	1.319	0.205	4.472	1.608
	1011	1.431	0.243	4.573	1.733
	1012	1.227	0.255	4.140	1.416
	1013	1.315	0.255	4.126	1.345
	1014	1.335	0.319	4.481	1.468
	1015	1.310	0.191	4.198	1.413
	1016	1.303	0.210	4.245	1.559
	1017	1.544	0.319	3.451	1.332
	1018	1.438	0.219	4.528	1.622
	1019	1.360	0.192	4.050	1.498
	1020	1.427	0.253	4.609	1.722
	1021	1.498	0.233	4.291	1.450
	1022	1.615	0.211	4.564	1.684
	1023	1.443	0.218	4.706	1.802
	1024	1.500	0.218	4.670	1.639
	1025	1.483	0.242	4.533	1.493

(HCL043)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS
100 ppm	1101	27-1 SCHEDULED	32.4	0.031	0.599	0.398	0.481
	1102	27-1 SCHEDULED	27.6	0.051	0.739	0.540	0.547
	1103	27-1 SCHEDULED	36.5	0.036	0.589	0.416	0.466
	1104	27-1 SCHEDULED	28.7	0.035	0.711	0.537	0.474
	1105	27-1 SCHEDULED	36.2	0.044	0.627	0.456	0.453
	1106	27-1 SCHEDULED	30.6	0.036	0.670	0.480	0.497
	1107	27-2 SCHEDULED	35.6	0.034	0.621	0.447	0.430
	1108	27-2 SCHEDULED	21.2	0.047	0.844	0.788	0.717
	1109	27-2 SCHEDULED	34.0	0.032	0.535	0.447	0.447
	1110	27-2 SCHEDULED	28.3	0.042	0.788	0.512	0.590
	1111	27-2 SCHEDULED	35.6	0.028	0.593	0.458	0.511
	1112	27-2 SCHEDULED	31.9	0.025	0.633	0.473	0.486
	1113	27-3 SCHEDULED	29.7	0.064	0.535	0.613	0.525
	1115	27-3 SCHEDULED	29.0	0.031	0.572	0.624	0.562
	1116	27-3 SCHEDULED	32.3	0.022	0.663	0.471	0.489
	1117	27-3 SCHEDULED	35.2	0.037	0.386	0.443	0.460
	1118	27-3 SCHEDULED	34.1	0.029	0.622	0.469	0.431
	1119	27-4 SCHEDULED	31.5	0.022	0.587	0.549	0.489
	1120	27-4 SCHEDULED	36.0	0.025	0.644	0.472	0.458
	1121	27-4 SCHEDULED	25.3	0.036	0.759	0.498	0.510
	1122	27-4 SCHEDULED	33.4	0.027	0.629	0.470	0.488
	1123	27-4 SCHEDULED	31.3	0.026	0.671	0.457	0.530
	1124	27-4 SCHEDULED	28.4	0.028	0.754	0.504	0.574
	1125	27-4 SCHEDULED	32.5	0.034	0.618	0.563	0.529

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 4

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
100 ppm	1101	1.139	0.198	4.012	1.423
	1102	1.384	0.225	4.051	1.656
	1103	1.110	0.244	4.077	1.258
	1104	1.432	0.233	4.401	1.652
	1105	1.177	0.218	4.033	1.287
	1106	1.324	0.252	4.346	1.526
	1107	1.185	0.258	3.986	1.351
	1108	2.132	1.165	5.656	2.090
	1109	1.224	0.226	4.129	1.356
	1110	1.410	0.230	4.297	1.689
	1111	1.253	0.239	4.028	1.317
	1112	1.194	0.191	4.072	1.417
	1113	1.690	0.290	3.327	1.700
	1115	1.755	0.293	3.503	1.728
	1116	1.276	0.272	4.130	1.415
	1117	1.179	0.259	4.043	1.335
	1118	1.226	0.208	4.185	1.355
	1119	1.730	0.232	3.368	1.495
	1120	1.244	0.236	4.325	1.289
	1121	1.316	0.229	4.261	1.779
	1122	1.180	0.219	4.015	1.395
	1123	1.233	0.192	4.089	1.438
	1124	1.504	0.201	4.437	1.676
	1125	1.249	0.218	4.458	1.458



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS
300 ppm	1202	27-1 SCHEDULED	29.1	0.045	0.168	0.550	0.601
	1203	27-1 SCHEDULED	36.1	0.064	0.186	0.449	0.382
	1204	27-1 SCHEDULED	30.8	0.068	0.227	0.506	0.523
	1205	27-1 SCHEDULED	30.1	0.033	0.189	0.498	0.561
	1206	27-1 SCHEDULED	35.7	0.031	0.266	0.451	0.490
	1207	27-2 SCHEDULED	31.0	0.042	0.268	0.484	0.516
	1208	27-2 SCHEDULED	27.8	0.036	0.219	0.543	0.518
	1209	27-2 SCHEDULED	34.0	0.029	0.244	0.497	0.482
	1210	27-2 SCHEDULED	31.4	0.045	0.194	0.427	0.519
	1211	27-2 SCHEDULED	33.3	0.075	0.195	0.520	0.532
	1212	27-2 SCHEDULED	29.5	0.044	0.308	0.498	0.546
	1213	27-3 SCHEDULED	28.5	0.035	0.214	0.561	0.512
	1214	27-3 SCHEDULED	31.6	0.047	0.168	0.475	0.468
	1215	27-3 SCHEDULED	30.8	0.032	0.185	0.458	0.497
	1216	27-3 SCHEDULED	32.0	0.028	0.328	0.459	0.484
	1217	27-3 SCHEDULED	29.7	0.030	0.168	0.569	0.542
	1219	27-4 SCHEDULED	37.9	0.024	0.309	0.451	0.485
	1220	27-4 SCHEDULED	32.6	0.021	0.248	0.482	0.485
	1221	27-4 SCHEDULED	29.2	0.034	0.188	0.524	0.524
	1223	27-4 SCHEDULED	29.6	0.068	0.216	0.618	0.611
1224	27-4 SCHEDULED	36.2	0.019	0.246	0.453	0.442	
1225	27-4 SCHEDULED	24.4	0.037	0.230	0.537	0.734	
1000 ppm	1308	27-2 SCHEDULED	26.2	0.034	0.198	0.607	0.557
	1312	27-2 SCHEDULED	24.2	0.045	0.227	0.574	0.723
	1319	27-4 SCHEDULED	22.2	0.041	0.203	0.838	0.734
	1321	27-4 SCHEDULED	24.8	0.036	0.226	0.597	0.633
	1322	27-4 SCHEDULED	25.4	0.035	0.217	0.638	0.575
	1323	27-4 SCHEDULED	25.1	0.032	0.187	0.693	0.689
	1324	27-4 SCHEDULED	27.6	0.033	0.217	0.616	0.598
	1325	27-4 SCHEDULED	26.4	0.030	0.235	0.644	0.572

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 6

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
300 ppm	1202	1.660	0.261	3.103	1.674
	1203	1.053	0.252	3.825	1.260
	1204	1.312	0.292	3.994	1.516
	1205	1.409	0.395	4.635	1.538
	1206	1.174	0.227	3.913	1.322
	1207	1.242	0.261	4.061	1.497
	1208	1.317	0.263	4.464	1.612
	1209	1.215	0.259	4.241	1.400
	1210	1.188	0.255	4.325	1.459
	1211	1.372	0.225	4.255	1.471
	1212	1.346	0.285	4.342	1.614
	1213	1.277	0.316	4.333	1.589
	1214	1.263	0.256	4.443	1.367
	1215	1.289	0.224	4.162	1.468
	1216	1.256	0.216	4.209	1.409
	1217	1.630	0.286	3.239	1.707
	1219	1.166	0.285	4.158	1.251
	1220	1.322	0.233	4.288	1.411
	1221	1.363	0.267	4.288	1.586
	1223	1.753	0.328	3.699	1.679
1224	1.166	0.199	4.182	1.268	
1225	1.496	0.336	4.590	1.844	
1000 ppm	1308	1.550	0.321	5.156	1.668
	1312	1.471	0.368	4.822	1.814
	1319	1.586	0.523	4.991	1.851
	1321	1.552	0.431	5.371	1.750
	1322	1.575	0.598	5.157	1.701
	1323	2.024	0.422	3.928	1.853
	1324	1.507	0.319	5.076	1.649
	1325	1.580	0.246	5.053	1.614

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS
Posi. Control	1401	27-1 SCHEDULED	28.2	0.028	0.723	0.833	0.613
	1406	27-1 SCHEDULED	30.8	0.032	0.675	0.562	0.562
	1407	27-1 SCHEDULED	23.6	0.030	0.551	0.822	0.661
	1410	27-2 SCHEDULED	26.7	0.030	0.727	0.929	0.633
	1411	27-2 SCHEDULED	30.1	0.027	0.724	0.535	0.475
	1412	27-1 SCHEDULED	25.1	0.040	0.685	0.570	0.562
	1415	27-2 SCHEDULED	23.0	0.035	0.678	1.035	0.678
	1416	27-2 SCHEDULED	23.7	0.034	0.608	0.823	0.624
	1418	27-3 SCHEDULED	27.4	0.033	0.821	0.635	0.529
	1420	27-3 SCHEDULED	29.9	0.027	0.793	0.579	0.555

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 8

---

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Posi. Control	1401	1.500	2.965	8.110	1.592
	1406	1.334	1.390	4.981	1.506
	1407	1.513	3.064	5.525	1.801
	1410	1.464	2.146	7.067	1.708
	1411	1.322	0.482	4.352	1.485
	1412	1.227	0.932	4.749	1.793
	1415	1.426	3.252	6.248	1.848
	1416	1.266	4.679	7.253	1.802
	1418	1.901	1.307	5.398	1.639
	1420	1.502	1.605	5.395	1.538

---

(HCL043)

BAIS 6

APPENDIX 12-2

ORGAN WEIGHT, RELATIVE (INDIVIDUAL) : FEMALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information		Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS
Control	2001	27-1	SCHEDULED	25.4	0.067	0.142	0.520	0.673
	2002	27-1	SCHEDULED	23.8	0.059	0.126	0.546	0.571
	2003	27-1	SCHEDULED	21.5	0.065	0.107	0.688	0.651
	2004	27-1	SCHEDULED	23.4	0.073	0.120	0.658	0.637
	2005	27-1	SCHEDULED	23.0	0.061	0.130	0.570	0.635
	2006	27-1	SCHEDULED	23.7	0.076	0.143	0.667	0.688
	2007	27-2	SCHEDULED	26.5	0.053	0.132	0.487	0.574
	2009	27-2	SCHEDULED	21.3	0.052	0.146	0.573	0.629
	2010	27-2	SCHEDULED	22.5	0.067	0.093	0.551	0.636
	2011	27-2	SCHEDULED	22.9	0.070	0.105	0.533	0.633
	2013	27-3	SCHEDULED	22.5	0.080	0.129	0.698	0.831
	2014	27-3	SCHEDULED	22.2	0.068	0.135	0.658	0.707
	2015	27-3	SCHEDULED	23.8	0.050	0.202	0.555	0.613
	2016	27-3	SCHEDULED	23.3	0.052	0.137	0.562	0.639
	2017	27-3	SCHEDULED	21.5	0.079	0.144	0.567	0.637
	2018	27-3	SCHEDULED	22.7	0.066	0.119	0.485	0.621
	2019	27-4	SCHEDULED	23.2	0.073	0.164	0.526	0.625
	2020	27-4	SCHEDULED	23.2	0.052	0.121	0.638	0.625
	2021	27-4	SCHEDULED	21.9	0.073	0.105	0.557	0.603
	2022	27-4	SCHEDULED	24.5	0.061	0.131	0.527	0.612
	2023	27-4	SCHEDULED	22.1	0.063	0.140	0.593	0.674
	2024	27-4	SCHEDULED	22.1	0.068	0.109	0.566	0.643
	2025	27-4	SCHEDULED	21.4	0.065	0.117	0.537	0.621

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 10

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	2001	1.445	0.315	4.748	1.988
	2002	1.361	0.324	4.462	2.000
	2003	1.623	0.377	3.512	2.237
	2004	1.611	0.359	3.530	2.111
	2005	1.435	0.383	4.578	1.970
	2006	1.650	0.312	3.544	2.110
	2007	1.249	0.313	4.479	1.826
	2009	1.385	0.347	4.493	2.197
	2010	1.476	0.364	4.778	2.138
	2011	1.463	0.288	4.952	2.127
	2013	1.791	0.391	4.022	2.391
	2014	1.644	0.315	3.374	2.162
	2015	1.395	0.324	4.588	2.021
	2016	1.481	0.326	4.296	2.004
	2017	1.474	0.316	4.502	2.149
	2018	1.502	0.344	4.476	2.013
	2019	1.466	0.336	4.806	2.147
	2020	1.905	0.349	3.793	2.198
	2021		0.438	4.799	2.091
	2022	1.469	0.302	4.833	2.078
	2023	1.511	0.299	4.810	2.176
	2024	1.457	0.434	4.697	2.095
	2025	1.407	0.290	4.836	2.206

(HCL043)

BAIS 6

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS
100 ppm	2101	27-1 SCHEDULED	25.6	0.055	0.082	0.520	0.555
	2102	27-1 SCHEDULED	23.1	0.056	0.100	0.498	0.584
	2104	27-1 SCHEDULED	28.6	0.070	0.105	0.441	0.472
	2105	27-1 SCHEDULED	24.2	0.074	0.116	0.554	0.628
	2106	27-1 SCHEDULED	25.0	0.068	0.096	0.608	0.712
	2107	27-2 SCHEDULED	26.1	0.057	0.142	0.575	0.598
	2108	27-2 SCHEDULED	22.5	0.062	0.164	0.622	0.658
	2109	27-2 SCHEDULED	21.6	0.060	0.116	0.505	0.602
	2110	27-2 SCHEDULED	24.3	0.053	0.119	0.547	0.617
	2111	27-2 SCHEDULED	24.1	0.058	0.116	0.544	0.622
	2112	27-2 SCHEDULED	21.9	0.055	0.132	0.543	0.648
	2113	27-3 SCHEDULED	23.6	0.081	0.131	0.589	0.695
	2114	27-3 SCHEDULED	23.1	0.108	0.160	0.554	0.675
	2115	27-3 SCHEDULED	21.9	0.073	0.110	0.658	0.671
	2116	27-3 SCHEDULED	24.1	0.062	0.116	0.515	0.598
	2117	27-3 SCHEDULED	21.5	0.060	0.121	0.600	0.614
	2118	27-3 SCHEDULED	23.2	0.056	0.125	0.509	0.591
	2119	27-4 SCHEDULED	26.2	0.050	0.103	0.500	0.595
	2120	27-4 SCHEDULED	23.6	0.072	0.131	0.572	0.669
	2121	27-4 SCHEDULED	24.1	0.062	0.120	0.685	0.643
	2122	27-4 SCHEDULED	23.8	0.063	0.105	0.534	0.601
	2123	27-4 SCHEDULED	24.4	0.066	0.119	0.652	0.738
	2124	27-4 SCHEDULED	22.1	0.063	0.109	0.584	0.647
	2125	27-4 SCHEDULED	22.1	0.063	0.118	0.557	0.670



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 12

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
100 ppm	2101	1.313	0.371	4.383	1.824
	2102	1.390	0.333	4.420	2.043
	2104	1.210	0.301	4.161	1.643
	2105	1.355	0.293	4.438	1.959
	2106	1.708	0.368	3.380	2.004
	2107	1.326	0.337	4.632	1.904
	2108	1.547	0.351	4.973	2.116
	2109	1.356	0.319	4.528	2.093
	2110	1.391	0.399	4.934	1.967
	2111	1.411	0.311	4.622	1.959
	2112	1.416	0.315	4.758	2.132
	2113	1.475	0.322	4.390	2.038
	2114	1.381	0.325	4.740	2.030
	2115	1.758	0.329	3.397	2.320
	2116	1.394	0.295	4.535	1.950
	2117	1.465	0.358	4.902	2.144
	2118	1.353	0.302	4.845	1.987
	2119	1.397	0.279	4.355	2.015
	2120	1.419	0.288	4.661	2.059
	2121	1.710	0.394	3.423	2.041
	2122	1.408	0.391	4.408	1.983
	2123	1.463	0.373	4.869	1.967
	2124	1.529	0.357	4.729	2.122
	2125	1.525	0.357	4.824	2.163

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	Death Information	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS
300 ppm	2201	27-1 SCHEDULED	24.8	0.056	0.093	0.516	0.601
	2202	27-1 SCHEDULED	23.4	0.047	0.115	0.735	0.645
	2203	27-1 SCHEDULED	24.7	0.065	0.121	0.551	0.672
	2204	27-1 SCHEDULED	22.3	0.054	0.224	0.601	0.664
	2205	27-1 SCHEDULED	23.5	0.064	0.140	0.506	0.630
	2206	27-1 SCHEDULED	22.5	0.071	0.093	0.564	0.618
	2207	27-2 SCHEDULED	23.6	0.055	0.102	0.559	0.712
	2208	27-2 SCHEDULED	22.4	0.058	0.098	0.598	0.634
	2209	27-2 SCHEDULED	26.2	0.057	0.111	0.523	0.569
	2210	27-2 SCHEDULED	25.3	0.051	0.059	0.565	0.577
	2211	27-2 SCHEDULED	21.6	0.069	0.093	0.639	0.639
	2212	27-2 SCHEDULED	22.8	0.053	0.110	0.561	0.632
	2213	27-3 SCHEDULED	23.6	0.068	0.119	0.581	0.593
	2214	27-3 SCHEDULED	23.8	0.067	0.122	0.542	0.592
	2215	27-3 SCHEDULED	23.7	0.046	0.148	0.586	0.624
	2216	27-3 SCHEDULED	25.6	0.055	0.109	0.586	0.578
	2217	27-3 SCHEDULED	22.4	0.062	0.116	0.656	0.634
	2218	27-3 SCHEDULED	23.1	0.061	0.130	0.580	0.623
	2219	27-4 SCHEDULED	24.8	0.060	0.097	0.754	0.730
	2220	27-4 SCHEDULED	23.0	0.065	0.143	0.570	0.630
	2221	27-4 SCHEDULED	26.5	0.079	0.098	0.517	0.577
	2222	27-4 SCHEDULED	24.2	0.054	0.112	0.537	0.591
	2223	27-4 SCHEDULED	28.4	0.049	0.088	0.549	0.574
	2224	27-4 SCHEDULED	22.7	0.053	0.048	0.542	0.718
	2225	27-4 SCHEDULED	19.9	0.060	0.106	0.673	0.673
1000 ppm	2305	27-1 SCHEDULED	24.4	0.045	0.197	0.590	0.631
	2307	27-2 SCHEDULED	25.5	0.055	0.067	0.604	0.753
	2308	27-2 SCHEDULED	21.1	0.062	0.057	0.820	0.720
	2309	27-2 SCHEDULED	24.0	0.050	0.063	0.650	0.612
	2313	27-3 SCHEDULED	26.8	0.063	0.071	0.664	0.664
	2314	27-3 SCHEDULED	25.1	0.040	0.048	0.586	0.590
	2315	27-3 SCHEDULED	23.2	0.052	0.103	0.582	0.642
	2316	27-3 SCHEDULED	24.2	0.054	0.087	0.645	0.678
	2321	27-4 SCHEDULED	23.6	0.047	0.140	0.682	0.665

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
300 ppm	2201	1.315	0.415	4.641	1.944
	2202	1.778	0.368	3.637	2.103
	2203	1.340	0.421	5.109	1.968
	2204	1.404	0.336	4.888	2.126
	2205	1.332	0.387	4.651	1.962
	2206	1.418	0.356	4.920	2.049
	2207	1.504	0.449	4.987	2.013
	2208	1.464	0.393	5.344	2.125
	2209	1.347	0.427	4.725	1.821
	2210	1.368	0.387	4.905	1.854
	2211	1.569	0.384	5.097	2.204
	2212	1.491	0.461	4.890	2.057
	2213	1.373	0.441	4.763	2.000
	2214	1.340	0.298	4.496	1.929
	2215	1.540	0.371	4.949	2.030
	2216	1.324	0.359	4.832	1.914
	2217	1.540	0.290	4.491	2.121
	2218	1.455	0.355	4.814	2.004
	2219	1.863	0.371	3.923	1.996
	2220	1.465	0.413	4.587	1.970
	2221	1.400	0.347	4.479	1.894
	2222	1.455	0.393	4.517	1.921
	2223	1.423	0.356	4.782	1.732
	2224	1.819	0.485	3.568	2.159
	2225	1.648	0.286	4.095	2.357
1000 ppm	2305	1.484	0.832	5.639	1.820
	2307	1.478	4.137	6.741	1.769
	2308	1.924	0.445	6.479	2.261
	2309	1.617	1.042	6.150	1.954
	2313	1.590	0.660	5.403	1.709
	2314	1.618	0.490	5.406	1.821
	2315	1.754	0.659	5.866	1.935
	2316	1.711	0.645	6.054	1.934
	2321	1.729	0.572	6.055	1.945

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 15

Group Name	Animal ID-NO.	Death Information		Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS
Posi. Control	2416	27-2	SCHEDULED	17.1	0.047	0.082	0.684	0.749
	2418	27-3	SCHEDULED	19.0	0.047	0.058	1.216	0.789

(HCL043)

BAIS 6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

PAGE : 16

Group Name	Animal ID-NO.	KIDNEYS	SPLEEN	LIVER	BRAIN
Posi. Control	2416	1.713	2.006	5.673	2.579
	2418	1.647	3.958	7.479	2.284

(HCL043)

BAIS 6

APPENDIX 13-1

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL) : MALE

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Control

PAGE : 1

Animal	Death Info.	Week-Day	Organ	Findings
1001	SCHEDULED	27-1	lung heart liver gall bladd pleura mediastinum NON-REMARKABLE	metastasis:mediastinum tumor, 2+, histiocytic sarcoma metastasis:mediastinum tumor, 1+, histiocytic sarcoma inflammatory cell nest, 1+ degeneration:focal, 1+ metastasis:mediastinum tumor, 1+, histiocytic sarcoma histiocytic sarcoma, 0' skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, tongue, salivary gl, esophagus, stomach, small intes, large intes, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1002	SCHEDULED	27-1	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1003	SCHEDULED	27-1	spleen NON-REMARKABLE	deposit of melanin, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1004	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1005	SCHEDULED	27-1	spleen NON-REMARKABLE	deposit of melanin, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1006	SCHEDULED	27-1	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1007	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1008	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1009	SCHEDULED	27-2	lung NON-REMARKABLE	bronchiolar-alveolar cell hyperplasia, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1010	SCHEDULED	27-2	spleen stomach NON-REMARKABLE	deposit of melanin, 1+ erosion:glandular stomach, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, small intes, large intes,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Control

Animal	Death Info.	Week-Day	Organ	Findings
1010	SCHEDULED	27-2		liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1011	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1012	SCHEDULED	27-2	liver testis NON-REMARKABLE	inflammatory cell nest, 1+ tubular atrophy, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1013	SCHEDULED	27-3	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1014	SCHEDULED	27-3	nasal cavit NON-REMARKABLE	eosinophilic change:olfactory epithelium, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1015	SCHEDULED	27-3	liver semin ves NON-REMARKABLE	inflammatory cell nest, 2+ dilatation, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1016	SCHEDULED	27-3	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1017	SCHEDULED	27-3	spleen liver testis NON-REMARKABLE	extramedullary hematopoiesis, 1+ inflammatory cell nest, 1+ tubular atrophy, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1018	SCHEDULED	27-3	lung spleen NON-REMARKABLE	inflammatory infiltration, 1+, focal deposit of melanin, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1019	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context



STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

GROUP NAME : Control

Animal	Death Info.	Week-Day	Organ	Findings
1020	SCHEDULED	27-4	stomach NON-REMARKABLE	erosion:glandular stomach, 1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd,pancreas,kidney,urin bladd,pituitary, thyroid,parathyroid,adrenal, testis,epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1021	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd,pancreas,kidney,urin bladd,pituitary, thyroid,parathyroid,adrenal, testis,epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1022	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd,pancreas,kidney,urin bladd,pituitary, thyroid,parathyroid,adrenal, testis,epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1023	SCHEDULED	27-4	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd,pancreas,kidney,urin bladd,pituitary, thyroid,parathyroid,adrenal, testis,epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1024	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd,pancreas,kidney,urin bladd,pituitary, thyroid,parathyroid,adrenal, testis,epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1025	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd,pancreas,kidney,urin bladd,pituitary, thyroid,parathyroid,adrenal, testis,epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

(BI0290)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

GROUP NAME : 100 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1101	SCHEDULED	27-1	liver pancreas NON-REMARKABLE	inflammatory cell nest, 1+ vacuolic change, 1+, acinar cell skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1102	SCHEDULED	27-1	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1103	SCHEDULED	27-1	Harder gl NON-REMARKABLE	hyperplasia, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, muscle, bone
1104	SCHEDULED	27-1	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1105	SCHEDULED	27-1	lung NON-REMARKABLE	osseous metaplasia, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1106	SCHEDULED	27-1	spleen Harder gl NON-REMARKABLE	deposit of melanin, 1+ hyperplasia, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, muscle, bone
1107	SCHEDULED	27-2	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1108	SCHEDULED	27-2	skin/app bone marrow thymus spleen stomach NON-REMARKABLE	erosion, 2+ increased hemotopoiesis: granulocyte/monocyte, 1+ atrophy, 1+ extramedullary hematopoiesis, 2+ erosion: glandular stomach, 2+ nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1109	SCHEDULED	27-2	spleen NON-REMARKABLE	deposit of melanin, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1110	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
(B10290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 100 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1110	SCHEDULED	27-2		large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1111	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1112	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1113	SCHEDULED	27-3	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1114	MORIBUND	13-7	lung thymus spleen heart kidney semin ves NON-REMARKABLE	pneumonia: NOS, 2+, hemorrhage atrophy, 1+ extramedullary hematopoiesis, 2+ hemorrhage, 1+ deposit of brown pigment: proximal tubule, 1+ inflammatory infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
			Cause of Death	pneumonia
1115	SCHEDULED	27-3	heart NON-REMARKABLE	inflammatory infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1116	SCHEDULED	27-3	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1117	SCHEDULED	27-3	liver testis NON-REMARKABLE	inflammatory cell nest, 1+ tubular atrophy, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1118	SCHEDULED	27-3	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1119	SCHEDULED	27-4	lung spleen	hemorrhage, 1+ deposit of melanin, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 100 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1119	SCHEDULED	27-4	stomach testis NON-REMARKABLE	erosion:glandular stomach, 2+ degeneration:seminiferous epithelium, 1+ skin/app,nasal cavit,nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1120	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1121	SCHEDULED	27-4	spleen NON-REMARKABLE	deposit of melanin, 1+ skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1122	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1123	SCHEDULED	27-4	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1124	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1125	SCHEDULED	27-4	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

(B10290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1201	MORIBUND	18-2	thymus spleen stomach testis epididymis NON-REMARKABLE	atrophy, 1+ deposit of melanin, 1+ ulcer:forestomach, 1+ tubular atrophy, 1+ debris of spermatic elements, 1+//decreased:sperma, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death no microscopical confirmation
1202	SCHEDULED	27-1	stomach testis epididymis NON-REMARKABLE	erosion:glandular stomach, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1203	SCHEDULED	27-1	small intes liver testis epididymis NON-REMARKABLE	inflammation, 1+ inflammatory cell nest, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1204	SCHEDULED	27-1	testis epididymis NON-REMARKABLE	tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1205	SCHEDULED	27-1	stomach liver testis epididymis NON-REMARKABLE	erosion:glandular stomach, 1+ inflammatory cell nest, 2+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1206	SCHEDULED	27-1	liver testis epididymis NON-REMARKABLE	inflammatory cell nest, 1+ tubular atrophy, 1+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1207	SCHEDULED	27-2	testis epididymis NON-REMARKABLE	tubular atrophy, 1+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes,

( ) : Comment      1+ :Slight      2+ :Moderate      3+ :Marked      4+ :Severe      ' ' :Context  
 (BI0290)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1207	SCHEDULED	27-2		large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1208	SCHEDULED	27-2	testis epididymis NON-REMARKABLE	tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1209	SCHEDULED	27-2	spleen liver adrenal testis epididymis NON-REMARKABLE	deposit of melanin, 1+ inflammatory cell nest, 1+ hyperplasia:cortical cell, 1+ tubular atrophy, 1+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1210	SCHEDULED	27-2	liver testis epididymis NON-REMARKABLE	inflammatory cell nest, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1211	SCHEDULED	27-2	testis epididymis NON-REMARKABLE	tubular atrophy, 2+ debris of spermatic elements, 1+//decreased:sperma, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1212	SCHEDULED	27-2	lung testis epididymis NON-REMARKABLE	hemorrhage, 1+ tubular atrophy, 1+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1213	SCHEDULED	27-3	small intes testis epididymis NON-REMARKABLE	lymphocytic infiltration, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1214	SCHEDULED	27-3	small intes liver testis epididymis	inflammation, 1+ inflammatory cell nest, 2+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1214	SCHEDULED	27-3	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1215	SCHEDULED	27-3	liver testis epididymis NON-REMARKABLE	inflammatory cell nest, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1216	SCHEDULED	27-3	testis epididymis NON-REMARKABLE	tubular atrophy, 1+ debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1217	SCHEDULED	27-3	liver testis epididymis NON-REMARKABLE	inflammatory cell nest, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1218	MORIBUND	22-1	skin/app lung spleen testis epididymis NON-REMARKABLE  Cause of Death	erosion, 2+ inflammatory infiltration, 1+ extramedullary hematopoiesis, 3+ tubular atrophy, 3+ debris of spermatic elements, 1+//decreased:sperma, 1+ nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone integumentary system lesion
1219	SCHEDULED	27-4	lung liver testis epididymis NON-REMARKABLE	inflammatory infiltration, 1+ inflammatory cell nest, 1+ tubular atrophy, 1+ debris of spermatic elements, 1+//decreased:sperma, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1220	SCHEDULED	27-4	stomach liver testis epididymis NON-REMARKABLE	erosion:glandular stomach, 1+ inflammatory cell nest, 1+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1221	SCHEDULED	27-4	spleen small intes testis epididymis NON-REMARKABLE	deposit of melanin, 1+ adenocarcinoma, '0' tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1222	MORIBUND	24-7	lung bone marrow lymph node thymus spleen liver kidney testis epididymis pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ tubular atrophy, 2+ decreased:sperma, 1+//debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1223	SCHEDULED	27-4	stomach small intes testis epididymis NON-REMARKABLE	erosion:glandular stomach, 1+ lymphocytic infiltration, 1+ tubular atrophy, 3+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1224	SCHEDULED	27-4	testis epididymis NON-REMARKABLE	tubular atrophy, 1+ decreased:sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1225	SCHEDULED	27-4	lung kidney testis epididymis NON-REMARKABLE	inflammatory infiltration, 1+, focal inflammatory infiltration, 1+ tubular atrophy, 2+ decreased:sperma, 2+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (B10290)



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1301	MORIBUND	22-7	bone marrow thymus spleen salivary gl testis epididymis muscle NON-REMARKABLE	atrophy:focal,1+//deposit of hemosiderin,1+ atrophy,1+ atrophy,1+//deposit of hemosiderin,1+ acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ tubular atrophy,3+ debris of spermatic elements,1+//decreased:sperma,2+ rhabdomyosarcoma,'4', lower jaw skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, lymph node,heart,tongue,esophagus,stomach,small intes,large intes,liver,gall bladd,pancreas, kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,semin ves,prostate,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,bone
			Cause of Death	tumor death:muscle
1302	MORIBUND	23-2	lung thymus heart salivary gl liver testis epididymis pleura NON-REMARKABLE	leukemic cell infiltration,2+ malignant lymphoma,'4' leukemic cell infiltration,1+ acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ leukemic cell infiltration,1+ tubular atrophy,3+ debris of spermatic elements,1+//decreased:sperma,2+ leukemic cell infiltration,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,bone marrow,lymph node,spleen,tongue,esophagus,stomach,small intes,large intes,gall bladd, pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,semin ves,prostate,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl, muscle,bone
			Cause of Death	tumor death:malignant lymphoma
1303	MORIBUND	23-7	lung bone marrow thymus heart salivary gl kidney testis epididymis pleura NON-REMARKABLE	leukemic cell infiltration,2+ deposit of hemosiderin,1+ malignant lymphoma,'4' leukemic cell infiltration,1+ acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ leukemic cell infiltration,1+ tubular atrophy,3+ decreased:sperma,2+//debris of spermatic elements,1+ leukemic cell infiltration,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lymph node,spleen,tongue,esophagus,stomach,small intes,large intes,liver,gall bladd,pancreas, urin bladd,pituitary,thyroid,parathyroid,adrenal,semin ves,prostate,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone
			Cause of Death	tumor death:malignant lymphoma
1304	MORIBUND	21-2	lung bone marrow thymus spleen heart salivary gl stomach liver kidney pituitary testis epididymis	leukemic cell infiltration,2+ leukemic cell infiltration,1+ malignant lymphoma,'4' leukemic cell infiltration,2+ leukemic cell infiltration,1+ acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ ulcer:forestomach,2+ leukemic cell infiltration,1+ leukemic cell infiltration,1+ leukemic cell infiltration,1+ tubular atrophy,3+ decreased:sperma,1+

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ-Findings
1304	MORIBUND	21-2	pleura NON-REMARKABLE Cause of Death leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1305	DEAD	23-1	nasal cavit lung bone marrow lymph node thymus spleen salivary gl urin bladd pituitary testis epididymis spinal cord periph nerv NON-REMARKABLE Cause of Death eosinophilic change:respiratory epithelium, 1+//eosinophilic change:olfactory epithelium, 1+ bronchiolar-alveolar adenoma, '1' decreased hematopoiesis, 1+//deposit of hemosiderin, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ dilatation, 1+ leukemic cell infiltration, 2+ tubular atrophy, 3+ debris of spermatic elements, 1+//decreased:sperma, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ skin/app, nasopharynx, larynx, trachea, heart, tongue, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1306	MORIBUND	26-7	lung bone marrow lymph node thymus spleen heart salivary gl liver kidney testis epididymis pleura NON-REMARKABLE Cause of Death leukemic cell infiltration, 2+ deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1307	MORIBUND	21-1	lung bone marrow thymus heart salivary gl stomach kidney testis epididymis pleura NON-REMARKABLE leukemic cell infiltration, 2+ leukemic cell infiltration, 1+//atrophy:focal, 2+ malignant lymphoma, '4' leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ ulcer:forestomach, 1+ regeneration:proximal tubule, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, spleen, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, urin bladd,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1307	MORIBUND	21-1	Cause of Death	pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1308	SCHEDULED	27-2	lung bone marrow thymus spleen salivary gl stomach kidney testis epididymis bone NON-REMARKABLE	hemorrhage, 1+ deposit of hemosiderin, 1+ malignant lymphoma, '0' extramedullary hematopoiesis, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ regeneration:proximal tubule, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
1309	MORIBUND	17-7	lung thymus spleen heart salivary gl testis epididymis pleura NON-REMARKABLE	metastasis:thymus tumor, 2+, histiocytic sarcoma histiocytic sarcoma, '4' extramedullary hematopoiesis, 1+ metastasis:thymus tumor, 2+, histiocytic sarcoma acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ metastasis:thymus tumor, 2+, histiocytic sarcoma skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
			Cause of Death	tumor death:thymus
1310	MORIBUND	24-1	lung bone marrow thymus spleen heart salivary gl stomach testis epididymis pleura NON-REMARKABLE	leukemic cell infiltration, 2+ deposit of hemosiderin, 1+ malignant lymphoma, '4' deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 2+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ leukemic cell infiltration, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
			Cause of Death	tumor death:malignant lymphoma
1311	MORIBUND	21-7	nasal cavit lung bone marrow thymus spleen heart	malformation, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1311	MORIBUND	21-7	salivary gl stomach liver testis epididymis pleura NON-REMARKABLE Cause of Death	acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ ulcer:forestomach,1+//hyperplasia:forestomach,2+ leukemic cell infiltration,1+ tubular atrophy,3+ decreased:sperma,2+//debris of spermatic elements,1+ leukemic cell infiltration,2+ skin/app,nasopharynx,larynx,trachea,lymph node,tongue,esophagus,small intes,large intes,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,semin ves,prostate,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone tumor death:malignant lymphoma
1312	SCHEDULED	27-2	nasal cavit lung bone marrow thymus spleen heart salivary gl stomach liver testis epididymis pleura NON-REMARKABLE	eosinophilic change:olfactory epithelium,1+ leukemic cell infiltration,2+ leukemic cell infiltration,1+ malignant lymphoma,'0' deposit of hemosiderin,1+ leukemic cell infiltration,1+,fibrosis:focal acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ hyperplasia:forestomach,2+ leukemic cell infiltration,1+ tubular atrophy,3+ decreased:sperma,2+//debris of spermatic elements,1+ leukemic cell infiltration,1+ skin/app,nasopharynx,larynx,trachea,lymph node,tongue,esophagus,small intes,large intes,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,semin ves,prostate,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone
1313	MORIBUND	21-3	nasal cavit lung bone marrow thymus spleen heart salivary gl stomach liver kidney testis epididymis pleura NON-REMARKABLE Cause of Death	eosinophilic change:olfactory epithelium,1+ leukemic cell infiltration,2+ deposit of hemosiderin,1+ malignant lymphoma,'4' extramedullary hematopoiesis,2+ leukemic cell infiltration,1+ acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ hyperplasia:forestomach,1+ leukemic cell infiltration,1+ leukemic cell infiltration,1+ tubular atrophy,3+ decreased:sperma,2+ leukemic cell infiltration,2+ skin/app,nasopharynx,larynx,trachea,lymph node,tongue,esophagus,small intes,large intes,gall bladd,pancreas,urin bladd,pituitary,thyroid,parathyroid,adrenal,semin ves,prostate,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone tumor death:malignant lymphoma
1314	MORIBUND	26-5	lung bone marrow thymus spleen heart salivary gl liver	leukemic cell infiltration,2+ deposit of hemosiderin,1+ malignant lymphoma,'4' extramedullary hematopoiesis,2+ leukemic cell infiltration,1+ acinar cell hyperplasia:submaxillary gland,1+//acinar cell hyperplasia:sublingual gland,1+ endothelial cell hyperplasia,1+//extramedullary hematopoiesis,1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

PAGE : 15

Animal	Death Info.	Week-Day	Organ	Findings
1314	MORIBUND	26-5	kidney testis epididymis pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1315	MORIBUND	24-7	lung bone marrow thymus spleen heart salivary gl liver kidney testis epididymis pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ deposit of hemosiderin, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ tubular atrophy, 3+ decreased:sperma, 2+ leukemic cell infiltration, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1316	DEAD	23-3	lung bone marrow thymus heart salivary gl testis epididymis pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ deposit of hemosiderin, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, spleen, tongue, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1317	MORIBUND	26-3	lung bone marrow thymus spleen heart salivary gl testis epididymis pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ deposit of hemosiderin, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1318	MORIBUND	17-7	lung	leukemic cell infiltration, 2+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1318	MORIBUND	17-7	bone marrow thymus heart salivary gl stomach kidney pituitary testis epididymis eye pleura NON-REMARKABLE	leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 1+ leukemic cell infiltration, 1+ Rathke pouch, 1+ tubular atrophy, 3+ decreased: sperma, 2+//debris of spermatic elements, 1+ ulcer: cornea, 1+ leukemic cell infiltration, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, spleen, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, urin bladd, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, Harder gl, muscle, bone Cause of Death tumor death: malignant lymphoma
1319	SCHEDULED	27-4	lung bone marrow thymus spleen heart salivary gl stomach kidney testis epididymis pleura NON-REMARKABLE	leukemic cell infiltration, 2+ deposit of hemosiderin, 1+ malignant lymphoma, '0' cyst, 1+//deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 2+ leukemic cell infiltration, 1+ tubular atrophy, 3+ decreased: sperma, 2+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1320	MORIBUND	24-7	nasal cavit lung bone marrow thymus spleen heart salivary gl stomach liver kidney pituitary testis epididymis eye pleura NON-REMARKABLE	eosinophilic change: respiratory epithelium, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ tubular atrophy, 3+ decreased: sperma, 2+//debris of spermatic elements, 1+ ulcer: cornea, 1+ leukemic cell infiltration, 2+ skin/app, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, Harder gl, muscle, bone Cause of Death tumor death: malignant lymphoma
1321	SCHEDULED	27-4	nasal cavit	esthesioneuroepithelioma, '0', vomeronasal organ

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
1321	SCHEDULED	27-4	lung bone marrow thymus spleen salivary gl stomach liver testis epididymis NON-REMARKABLE	hemorrhage, 1+ deposit of hemosiderin, 1+ atrophy, 1+ extramedullary hematopoiesis, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ inflammatory cell nest, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ skin/app, nasopharynx, larynx, trachea, lymph node, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1322	SCHEDULED	27-4	bone marrow thymus spleen salivary gl testis epididymis NON-REMARKABLE	deposit of hemosiderin, 1+ malignant lymphoma, '0' leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, heart, tongue, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1323	SCHEDULED	27-4	bone marrow thymus salivary gl stomach liver testis epididymis bone NON-REMARKABLE	deposit of hemosiderin, 1+ malignant lymphoma, '0' acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 2+//erosion:glandular stomach, 1+ angiectasis, 2+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, spleen, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
1324	SCHEDULED	27-4	bone marrow thymus spleen heart salivary gl liver testis epididymis NON-REMARKABLE	deposit of hemosiderin, 1+ malignant lymphoma, '0' deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ extramedullary hematopoiesis, 1+ tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1325	SCHEDULED	27-4	lung bone marrow thymus spleen salivary gl stomach	osseous metaplasia, 1+ deposit of hemosiderin, 1+ malignant lymphoma, '0' deposit of hemosiderin, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 2+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

GROUP NAME : 1000 ppm

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

Animal	Death Info.	Week-Day	Organ	Findings
1325	SCHEDULED	27-4	testis epididymis NON-REMARKABLE	tubular atrophy, 3+ decreased:sperma, 2+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
( ):Comment      1+ :Slight      2+ :Moderate      3+ :Marked      4+ :Severe      ' ':Context				
(B10290)				BAS6



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
1401	SCHEDULED	27-1	skin/app thymus spleen heart stomach small intes liver semin ves NON-REMARKABLE	ulcer, 2+ atrophy, 1+ extramedullary hematopoiesis, 3+//thrombus, 1+ thrombus, 1+ hyperplasia:forestomach, 1+ adenocarcinoma, '0' inflammatory infiltration, 1+ atrophy, 1+ nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, tongue, salivary gl, esophagus, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1402	MORIBUND	21-5	lung bone marrow thymus spleen heart stomach small intes liver kidney testis epididymis NON-REMARKABLE Cause of Death	inflammatory infiltration, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ leukemic cell infiltration, 1+ squamous cell papilloma, '1' adenocarcinoma, '1' leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ multinucleated giant cell formation, 1+//tubular atrophy, 1+ debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1403	MORIBUND	14-6	lung thymus spleen heart NON-REMARKABLE Cause of Death	leukemic cell infiltration, 1+//osseous metaplasia, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1404	MORIBUND	21-1	lung bone marrow thymus spleen heart small intes epididymis pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ leukemic cell infiltration, 1+ adenocarcinoma, '1' debris of spermatic elements, 1+ leukemic cell infiltration, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1405	MORIBUND	14-4	lung bone marrow	leukemic cell infiltration, 2+//bronchiolar-alveolar cell hyperplasia, 1+ leukemic cell infiltration, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
1405	MORIBUND	14-4	thymus spleen heart stomach liver kidney epididymis pleura adipose NON-REMARKABLE Cause of Death	malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+//erosion:forestomach, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ debris of spermatic elements, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1406	SCHEDULED	27-1	spleen heart stomach small intes NON-REMARKABLE	extramedullary hematopoiesis, 2+ inflammatory infiltration, 1+, focal ulcer:glandular stomach, 3+ adenocarcinoma, '0' skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, tongue, salivary gl, esophagus, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1407	SCHEDULED	27-1	skin/app lymph node thymus spleen stomach small intes liver testis epididymis NON-REMARKABLE	ulcer, 2+ thrombus, 1+ atrophy, 1+ extramedullary hematopoiesis, 3+//thrombus, 1+ hyperplasia:forestomach, 2+ adenocarcinoma, '0' necrosis:focal, 1+//biliary cyst, 1+ mineralization, 1+//tubular atrophy, 1+ decreased:sperma, 1+//debris of spermatic elements, 1+ nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, heart, tongue, salivary gl, esophagus, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1408	DEAD	15-7	lung bone marrow thymus spleen heart pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' deposit of hemosiderin, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
1409	MORIBUND	16-7	lung bone marrow thymus spleen stomach	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ ulcer:glandular stomach, 1+//hyperplasia:forestomach, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
1409	MORIBUND	16-7	pleura NON-REMARKABLE	leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death:malignant lymphoma
1410	SCHEDULED	27-2	thymus spleen stomach small intes NON-REMARKABLE	atrophy, 1+ extramedullary hematopoiesis, 3+ hyperplasia:forestomach, 1+ adenocarcinoma, '0' skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, heart, tongue, salivary gl, esophagus, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1411	SCHEDULED	27-2	nasal cavit spleen small intes pituitary NON-REMARKABLE	eosinophilic change:olfactory epithelium, 1+ extramedullary hematopoiesis, 1+ adenocarcinoma, '0' cystic degeneration:anterior lobe, 1+ skin/app, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1412	SCHEDULED	27-1	lung thymus spleen stomach small intes testis epididymis NON-REMARKABLE	atelectasis, 2+//inflammatory infiltration, 1+ malignant lymphoma, '0' extramedullary hematopoiesis, 2+ hyperplasia:forestomach, 1+//ulcer:forestomach, 1+ adenocarcinoma, '0' tubular atrophy, 1+ debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, heart, tongue, salivary gl, esophagus, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1413	MORIBUND	19-7	lung bone marrow thymus spleen heart stomach small intes kidney epididymis pleura NON-REMARKABLE	atelectasis, 1+//leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 2+ adenocarcinoma, '1' leukemic cell infiltration, 1+ debris of spermatic elements, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, large intes, liver, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death:malignant lymphoma
1414	MORIBUND	23-2	lung thymus spleen	inflammatory infiltration, 1+ inflammation, 1+ extramedullary hematopoiesis, 3+//thrombus, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
1414	MORIBUND	23-2	heart small intes liver testis epididymis NON-REMARKABLE	dilatation, 1+ adenocarcinoma, '4' necrosis: focal, 1+//inflammatory infiltration, 1+ degeneration: seminiferous epithelium, 1+ debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, salivary gl, esophagus, stomach, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death: small intestine
1415	SCHEDULED	27-2	lung thymus spleen heart stomach small intes liver NON-REMARKABLE	inflammatory infiltration, 1+ atrophy, 1+ extramedullary hematopoiesis, 3+ thrombus, 1+ hyperplasia: forestomach, 2+ adenocarcinoma, '0' inflammatory infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, salivary gl, esophagus, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1416	SCHEDULED	27-2	bone marrow lymph node thymus spleen small intes liver kidney urin bladd epididymis prostate muscle NON-REMARKABLE	leukemic cell infiltration, 1+ malignant lymphoma, '0' leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ adenocarcinoma, '0' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, heart, tongue, salivary gl, esophagus, stomach, large intes, gall bladd, pancreas, pituitary, thyroid, parathyroid, adrenal, testis, semin ves, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, bone
1417	MORIBUND	21-5	lung thymus spleen stomach small intes liver testis epididymis NON-REMARKABLE	inflammatory infiltration, 1+ atrophy, 1+ extramedullary hematopoiesis, 3+//thrombus, 2+ hyperplasia: forestomach, 2+ adenocarcinoma, '4' extramedullary hematopoiesis, 1+ tubular atrophy, 1+ decreased: sperma, 1+//debris of spermatic elements, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, heart, tongue, salivary gl, esophagus, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death: small intestine
1418	SCHEDULED	27-3	spleen stomach small intes	extramedullary hematopoiesis, 3+ adenocarcinoma, '0' adenoma, '0'

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
1418	SCHEDULED	27-3	kidney NON-REMARKABLE	hydronephrosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, large intes, liver, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
1419	MORIBUND	20-3	lung bone marrow lymph node thymus spleen heart small intes testis Harder gl NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ adenocarcinoma, '1' degeneration: seminiferous epithelium, 1+ hyperplasia, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, muscle, bone tumor death: malignant lymphoma
1420	SCHEDULED	27-3	spleen small intes urin bladd NON-REMARKABLE	extramedullary hematopoiesis, 3+ adenocarcinoma, '0' lymphocytic infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, pituitary, thyroid, parathyroid, adrenal, testis, epididymis, semin ves, prostate, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

(B10290)

**APPENDIX 13-2**

**HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL) : FEMALE**

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Control

Animal	Death Info.	Week-Day	Organ	Findings
2001	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2002	SCHEDULED	27-1	pituitary NON-REMARKABLE	cystic degeneration: anterior lobe, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2003	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2004	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2005	SCHEDULED	27-1	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2006	SCHEDULED	27-1	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2007	SCHEDULED	27-2	bone marrow NON-REMARKABLE	deposit of hemosiderin, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2008	MORIBUND	25-6	lung bone marrow thymus spleen heart stomach liver ovary vagina NON-REMARKABLE	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ hyperplasia: forestomach, 1+//erosion: forestomach, 1+ inflammatory cell nest, 2+ leukemic cell infiltration, 1+ atrophy: epithelium, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
			Cause of Death	tumor death: malignant lymphoma
2009	SCHEDULED	27-2	spleen ovary NON-REMARKABLE	deposit of melanin, 1+ ovarian cyst, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Control

Animal	Death Info.	Week-Day	Organ	Findings
2009	SCHEDULED	27-2		large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2010	SCHEDULED	27-2	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2011	SCHEDULED	27-2	pituitary NON-REMARKABLE	cystic degeneration: anterior lobe, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2012	MORIBUND	21-3	skin/app thymus spleen ovary uterus vagina NON-REMARKABLE	ulcer, 2+ atrophy, 1+ extramedullary hematopoiesis, 3+ hyperplasia, 1+, interstitial atrophy, 1+ atrophy: epithelium, 1+ nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
			Cause of Death	integumentary system lesion
2013	SCHEDULED	27-3	lung liver NON-REMARKABLE	inflammatory infiltration, 1+, perivascular inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2014	SCHEDULED	27-3	liver ovary NON-REMARKABLE	inflammatory cell nest, 1+ ovarian cyst, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2015	SCHEDULED	27-3	stomach NON-REMARKABLE	erosion: glandular stomach, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2016	SCHEDULED	27-3	lung NON-REMARKABLE	inflammatory infiltration, 1+, perivascular skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2017	SCHEDULED	27-3	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Control

Animal	Death Info.	Week-Day	Organ	Findings
2018	SCHEDULED	27-3	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2019	SCHEDULED	27-4	liver urin bladd NON-REMARKABLE	inflammatory cell nest, 1+ lymphocytic infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2020	SCHEDULED	27-4	stomach liver NON-REMARKABLE	erosion:glandular stomach, 2+ inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2021	SCHEDULED	27-4	liver kidney NON-REMARKABLE	herniation, 1+ aplasia, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2022	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2023	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2024	SCHEDULED	27-4	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2025	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (B10290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 100 ppm

Animal	Death Info.	Week-Day	Organ-Findings	
2101	SCHEDULED	27-1	pituitary NON-REMARKABLE	cystic degeneration:anterior lobe, 1+ skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd,pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2102	SCHEDULED	27-1	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd,pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2103	MORIBUND	6-4	lung bone marrow thymus spleen heart liver kidney pituitary ovary uterus vagina pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ atrophy, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2104	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2105	SCHEDULED	27-1	pituitary NON-REMARKABLE	cystic degeneration:anterior lobe, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2106	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2107	SCHEDULED	27-2	ovary NON-REMARKABLE	ovarian cyst, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2108	SCHEDULED	27-2	stomach liver adrenal bone	erosion:glandular stomach, 1+ inflammatory cell nest, 1+ acesory cortical nodule, 1+ osteosclerosis, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 100 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2108	SCHEDULED	27-2	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2109	SCHEDULED	27-2	liver NON-REMARKABLE	inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2110	SCHEDULED	27-2	liver vagina NON-REMARKABLE	inflammatory cell nest, 1+ mucification:epithelium, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2111	SCHEDULED	27-2	nasal cavit NON-REMARKABLE	eosinophilic change:olfactory epithelium, 1+//eosinophilic change:respiratory epithelium, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2112	SCHEDULED	27-2	nasal cavit bone NON-REMARKABLE	eosinophilic change:olfactory epithelium, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2113	SCHEDULED	27-3	spleen liver NON-REMARKABLE	deposit of melanin, 1+ inflammatory cell nest, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2114	SCHEDULED	27-3	urin bladd NON-REMARKABLE	lymphocytic infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2115	SCHEDULED	27-3	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2116	SCHEDULED	27-3	lung NON-REMARKABLE	inflammatory infiltration, 1+, perivascular skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2117	SCHEDULED	27-3	pituitary NON-REMARKABLE	cystic degeneration:anterior lobe, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 100 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2117	SCHEDULED	27-3		eye, Harder gl, muscle, bone
2118	SCHEDULED	27-3	bone marrow bone NON-REMARKABLE	deposit of hemosiderin, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2119	SCHEDULED	27-4	kidney bone NON-REMARKABLE	hyaline cast, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2120	SCHEDULED	27-4	pituitary parathyroid NON-REMARKABLE	cystic degeneration: anterior lobe, 1+ cyst, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2121	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2122	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2123	SCHEDULED	27-4	bone marrow spleen NON-REMARKABLE	deposit of hemosiderin, 1+ deposit of melanin, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, lymph node, thymus, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2124	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2125	SCHEDULED	27-4	NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context				
(B10290)				

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2201	SCHEDULED	27-1	lung liver NON-REMARKABLE	vacuolic change:bronchial epithelium,1+ inflammatory cell nest,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,bone marrow,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,stomach,small intes, large intes,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,ovary,uterus,vagina,mammary gl,brain,spinal cord, periph nerv,eye,Harder gl,muscle,bone
2202	SCHEDULED	27-1	liver pituitary ovary NON-REMARKABLE	inflammatory cell nest,1+ cystic degeneration:anterior lobe,1+ atrophy,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lung,bone marrow,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,stomach,small intes, large intes,gall bladd,pancreas,kidney,urin bladd,thyroid,parathyroid,adrenal,uterus,vagina,mammary gl,brain,spinal cord,periph nerv,eye, Harder gl,muscle,bone
2203	SCHEDULED	27-1	liver NON-REMARKABLE	inflammatory cell nest,2+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lung,bone marrow,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,stomach,small intes, large intes,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,ovary,uterus,vagina,mammary gl,brain,spinal cord, periph nerv,eye,Harder gl,muscle,bone
2204	SCHEDULED	27-1	lung adrenal NON-REMARKABLE	vacuolic change:bronchial epithelium,1+ accesory cortical nodule,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,bone marrow,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,stomach,small intes, large intes,liver,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,ovary,uterus,vagina,mammary gl,brain,spinal cord, periph nerv,eye,Harder gl,muscle,bone
2205	SCHEDULED	27-1	liver pituitary NON-REMARKABLE	inflammatory cell nest,1+ cystic degeneration:anterior lobe,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lung,bone marrow,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,stomach,small intes, large intes,gall bladd,pancreas,kidney,urin bladd,thyroid,parathyroid,adrenal,ovary,uterus,vagina,mammary gl,brain,spinal cord,periph nerv,eye, Harder gl,muscle,bone
2206	SCHEDULED	27-1	lung bone marrow spleen ovary NON-REMARKABLE	vacuolic change:bronchial epithelium,1+ deposit of hemosiderin,1+ deposit of melanin,1+ atrophy,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lymph node,thymus,heart,tongue,salivary gl,esophagus,stomach,small intes,large intes,liver, gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,uterus,vagina,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl, muscle,bone
2207	SCHEDULED	27-2	stomach ovary NON-REMARKABLE	erosion:glandular stomach,1+ atrophy,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lung,bone marrow,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,small intes, large intes,liver,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,uterus,vagina,mammary gl,brain,spinal cord, periph nerv,eye,Harder gl,muscle,bone
2208	SCHEDULED	27-2	bone marrow liver pituitary NON-REMARKABLE	deposit of hemosiderin,1+ inflammatory cell nest,1+ cystic degeneration:anterior lobe,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,lung,lymph node,thymus,spleen,heart,tongue,salivary gl,esophagus,stomach,small intes,large intes, gall bladd,pancreas,kidney,urin bladd,thyroid,parathyroid,adrenal,ovary,uterus,vagina,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2208	SCHEDULED	27-2		muscle, bone
2209	SCHEDULED	27-2	nasal cavit NON-REMARKABLE	eosinophilic change:respiratory epithelium,1+ skin/app,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2210	SCHEDULED	27-2	liver NON-REMARKABLE	inflammatory cell nest,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2211	SCHEDULED	27-2	adrenal bone NON-REMARKABLE	focal fatty change:cortex,1+ osteosclerosis,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2212	SCHEDULED	27-2	stomach liver NON-REMARKABLE	hyperplasia:forestomach,1+ inflammatory cell nest,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2213	SCHEDULED	27-3	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2214	SCHEDULED	27-3	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2215	SCHEDULED	27-3	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2216	SCHEDULED	27-3	uterus NON-REMARKABLE	cystic endometrial hyperplasia,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2217	SCHEDULED	27-3	lung bone marrow pituitary NON-REMARKABLE	eosinophilic crystalline pneumonia,1+ deposit of hemosiderin,1+ cystic degeneration:anterior lobe,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2218	SCHEDULED	27-3	NON-REMARKABLE	skin/app,nasal cavit,nasopharynx,larynx,trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes,

( ) : Comment      1+ :Slight      2+ :Moderate      3+ :Marked      4+ :Severe      ' ' :Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 300 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2218	SCHEDULED	27-3		large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2219	SCHEDULED	27-4	stomach liver bone NON-REMARKABLE	hyperplasia:forestomach, 1+ inflammatory cell nest, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2220	SCHEDULED	27-4	liver adrenal NON-REMARKABLE	inflammatory cell nest, 1+ focal fatty change:cortex, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, ovary, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2221	SCHEDULED	27-4	liver brain NON-REMARKABLE	inflammatory cell nest, 1+ glioblastoma, '0' skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, ovary, uterus, vagina, mammary gl, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2222	SCHEDULED	27-4	ovary NON-REMARKABLE	atrophy, 1+, with, lutenum cyst skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2223	SCHEDULED	27-4	ovary NON-REMARKABLE	atrophy, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2224	SCHEDULED	27-4	liver ovary NON-REMARKABLE	inflammatory cell nest, 1+ atrophy, 1+, with, ovarian cyst skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2225	SCHEDULED	27-4	lung bone marrow ovary NON-REMARKABLE	bronchiolar-alveolar adenoma, '0' deposit of hemosiderin, 1+ ovarian cyst, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, thymus, spleen, heart, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2301	MORIBUND	26-5	thymus salivary gl stomach liver ovary uterus spinal cord bone NON-REMARKABLE	atrophy, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 3+ inflammatory cell nest, 1+ atrophy, 2+ atrophy, 1+ hemorrhage, 2+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, spleen, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, vagina, mammary gl, brain, periph nerv, eye, Harder gl, muscle Cause of Death central nervous system lesion
2302	MORIBUND	26-5	lung thymus spleen heart salivary gl stomach liver ovary uterus vagina eye bone NON-REMARKABLE	leukemic cell infiltration, 2+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+//deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ extramedullary hematopoiesis, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+ keratitis, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, Harder gl, muscle Cause of Death tumor death:malignant lymphoma
2303	MORIBUND	1-7	thymus salivary gl liver ovary uterus vagina eye NON-REMARKABLE	atrophy, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ inflammatory cell nest, 1+ atrophy, 1+ atrophy, 1+ atrophy:epithelium, 1+ keratitis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, spleen, heart, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, Harder gl, muscle, bone Cause of Death no microscopical confirmation
2304	MORIBUND	25-1	lung thymus spleen heart salivary gl stomach liver kidney ovary uterus	leukemic cell infiltration, 2+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ hemangioma, '1' leukemic cell infiltration, 1+ atrophy, 2+ atrophy, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2304	MORIBUND	25-1	vagina bone NON-REMARKABLE	atrophy:epithelium, 1+, with mucification:epithelium osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
			Cause of Death	tumor death:malignant lymphoma
2305	SCHEDULED	27-1	lung thymus spleen salivary gl stomach liver ovary uterus vagina bone pleura NON-REMARKABLE	leukemic cell infiltration, 2+ malignant lymphoma, '0' leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ angiectasis, 1+//inflammatory cell nest, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2306	MORIBUND	25-4	lung bone marrow thymus spleen heart salivary gl stomach liver kidney ovary vagina bone NON-REMARKABLE	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 3+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ atrophy, 2+ atrophy:epithelium, 1+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
			Cause of Death	tumor death:malignant lymphoma
2307	SCHEDULED	27-2	lung bone marrow lymph node thymus spleen salivary gl stomach liver ovary uterus vagina bone NON-REMARKABLE	eosinophilic crystalline pneumonia, 2+//leukemic cell infiltration, 1+ deposit of hemosiderin, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '0' acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 2+ leukemic cell infiltration, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary,

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2307	SCHEDULED	27-2		thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2308	SCHEDULED	27-2	spleen salivary gl stomach ovary uterus bone NON-REMARKABLE	deposit of hemosiderin, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 3+ atrophy, 2+ atrophy, 1+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2309	SCHEDULED	27-2	thymus spleen salivary gl stomach ovary uterus vagina bone NON-REMARKABLE	malignant lymphoma, '0' leukemic cell infiltration, 2+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 2+ atrophy, 2+ atrophy, 1+ atrophy: epithelium, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2310	MORIBUND	18-7	lung bone marrow thymus heart salivary gl liver kidney ovary uterus bone NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+//atrophy, 2+ atrophy, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, spleen, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle tumor death: malignant lymphoma
2311	SCHEDULED	27-2	nasal cavit lung bone marrow thymus spleen heart salivary gl stomach liver adrenal ovary uterus vagina	inflammation: transitional epithelium, 1+ inflammatory infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ thrombus, 2+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 1+//erosion: glandular stomach, 1+ leukemic cell infiltration, 2+//angiectasis, 1+ leukemic cell infiltration, 1+ atrophy, 2+ atrophy, 1+ atrophy: epithelium, 1+

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2311	SCHEDULED	27-2	bone NON-REMARKABLE	osteosclerosis, 1+ skin/app, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2312	MORIBUND	23-6	lung bone marrow thymus spleen heart salivary gl stomach liver pituitary ovary uterus vagina bone NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle tumor death:malignant lymphoma
2313	SCHEDULED	27-3	spleen salivary gl stomach pituitary ovary uterus vagina bone NON-REMARKABLE	deposit of hemosiderin, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ cystic degeneration:anterior lobe, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2314	SCHEDULED	27-3	lung bone marrow thymus spleen salivary gl stomach liver ovary uterus vagina bone NON-REMARKABLE	inflammation:focal, 1+ deposit of hemosiderin, 1+ malignant lymphoma, '0' deposit of hemosiderin, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ inflammatory cell nest, 1+ atrophy, 1+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2315	SCHEDULED	27-3	spleen salivary gl stomach	extramedullary hematopoiesis, 1+//deposit of hemosiderin, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2315	SCHEDULED	27-3	pituitary ovary bone NON-REMARKABLE	cystic degeneration:anterior lobe, 1+ atrophy, 2+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2316	SCHEDULED	27-3	spleen heart salivary gl stomach liver kidney ovary uterus vagina bone NON-REMARKABLE	extramedullary hematopoiesis, 1+//deposit of hemosiderin, 1+ endothelial cell hyperplasia, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ ulcer:forestomach, 1+//hyperplasia:forestomach, 2+ inflammatory cell nest, 1+ hyaline cast, 1+ atrophy, 1+, with, ovarian cyst//ovarian cyst, 1+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, tongue, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2317	MORIBUND	26-1	lung bone marrow thymus spleen heart salivary gl stomach liver ovary uterus vagina bone pleura NON-REMARKABLE	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' deposit of hemosiderin, 1+ leukemic cell infiltration, 2+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 1+ atrophy, 1+, with, ovarian cyst//ovarian cyst, 1+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 2+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
			Cause of Death	tumor death:malignant lymphoma
2318	MORIBUND	23-4	skin/app lung bone marrow lymph node thymus spleen heart salivary gl liver urin bladd pituitary ovary uterus	leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ atrophy, 1+, with, hemorrhage leukemic cell infiltration, 1+

( ) :Comment      1+ :Slight      2+ :Moderate      3+ :Marked      4+ :Severe      ' ' :Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2318	MORIBUND	23-4	vagina bone pleura NON-REMARKABLE	leukemic cell infiltration, 1+ osteosclerosis, 1+ leukemic cell infiltration, 1+ nasal cavit, nasopharynx, larynx, trachea, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle Cause of Death tumor death: malignant lymphoma
2319	MORIBUND	26-3	subcutis thymus spleen salivary gl stomach ovary vagina bone NON-REMARKABLE	sarcoma: NOS, '4' atrophy, 1+ extramedullary hematopoiesis, 1+//deposit of hemosiderin, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 2+ atrophy, 2+ atrophy: epithelium, 1+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, heart, tongue, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle Cause of Death tumor death: subcutis
2320	DEAD	13-7	nasal cavit lung thymus spleen salivary gl liver adrenal ovary uterus vagina NON-REMARKABLE	malformation, 2+ hemorrhage, 2+//leukemic cell infiltration, 2+ inflammation, 1+ malignant lymphoma, '4' acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ leukemic cell infiltration, 2+ mineralization: cortex, 1+ atrophy, 1+ atrophy, 1+ atrophy: epithelium, 1+ skin/app, nasopharynx, larynx, trachea, bone marrow, lymph node, heart, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death: malignant lymphoma
2321	SCHEDULED	27-4	thymus spleen heart salivary gl stomach liver ovary uterus bone NON-REMARKABLE	malignant lymphoma, '0' extramedullary hematopoiesis, 1+//deposit of hemosiderin, 1+ endothelial cell hyperplasia, 1+ acinar cell hyperplasia: submaxillary gland, 1+//acinar cell hyperplasia: sublingual gland, 1+ hyperplasia: forestomach, 2+ hemorrhage, 1+ atrophy, 2+ atrophy, 1+ osteosclerosis, 2+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
2322	MORIBUND	24-2	lung bone marrow thymus spleen	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2322	MORIBUND	24-2	heart salivary gl liver ovary uterus vagina bone pleura NON-REMARKABLE	leukemic cell infiltration, 1+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ leukemic cell infiltration, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+, with, mucification:epithelium osteosclerosis, 2+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, stomach, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle Cause of Death tumor death:malignant lymphoma
2323	MORIBUND	26-2	lung bone marrow thymus spleen heart salivary gl stomach liver kidney pituitary thyroid ovary uterus vagina bone pleura NON-REMARKABLE	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+ osteosclerosis, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle Cause of Death tumor death:malignant lymphoma
2324	MORIBUND	22-1	skin/app nasal cavit spleen salivary gl stomach liver ovary uterus vagina bone NON-REMARKABLE	basal cell carcinoma, '4' inflammation:transitional epithelium, 1+ extramedullary hematopoiesis, 2+ acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+ hyperplasia:forestomach, 1+ extramedullary hematopoiesis, 1+ atrophy, 2+ atrophy, 1+ atrophy:epithelium, 1+, with, mucification:epithelium osteosclerosis, 1+ nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle Cause of Death tumor death:skin/appendag
2325	MORIBUND	24-2	lung bone marrow thymus	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4'

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : 1000 ppm

Animal	Death Info.	Week-Day	Organ	Findings
2325	MORIBUND	24-2	spleen	extramedullary hematopoiesis, 1+//deposit of hemosiderin, 1+
			heart	leukemic cell infiltration, 1+
			salivary gl	acinar cell hyperplasia:submaxillary gland, 1+//acinar cell hyperplasia:sublingual gland, 1+
			stomach	hyperplasia:forestomach, 1+
			liver	leukemic cell infiltration, 1+
			ovary	atrophy, 2+
			uterus	atrophy, 1+
			vagina	atrophy:epithelium, 1+
			bone	osteosclerosis, 1+
			pleura	leukemic cell infiltration, 1+
			NON-REMARKABLE	skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle
			Cause of Death	tumor death:malignant lymphoma
<p>( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context</p>				
(BI0290)				BAIS6

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE      GROUP NAME : Posi. Control

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Animal	Death Info.	Week-Day	Organ	Findings
2401	DEAD	19-1	lung bone marrow lymph node thymus spleen heart stomach liver pancreas pituitary adrenal ovary uterus vagina peritoneum NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ malignant lymphoma, '4' extramedullary hematopoiesis, 3+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 1+ ductal adenocarcinoma, '1' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+//atrophy, 1+ leukemic cell infiltration, 1+ atrophy:epithelium, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, kidney, urin bladd, thyroid, parathyroid, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2402	MORIBUND	14-4	lung bone marrow thymus spleen heart stomach liver kidney adrenal ovary uterus vagina pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+//hemorrhage, 1+ leukemic cell infiltration, 2+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2403	MORIBUND	15-5	lung bone marrow thymus spleen heart urin bladd ovary uterus vagina pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+//bronchiolar-alveolar adenoma, '1' leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ necrosis:focal, 1+ mineralization, 1+ leukemic cell infiltration, 2+ atrophy, 1+ atrophy:epithelium, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context



STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
2404	MORIBUND	23-4	nasal cavit lung bone marrow lymph node thymus spleen heart stomach small intes liver kidney pituitary adrenal ovary uterus vagina NON-REMARKABLE Cause of Death	leukemic cell infiltration,1+ leukemic cell infiltration,2+ leukemic cell infiltration,1+ leukemic cell infiltration,2+ malignant lymphoma,'4' leukemic cell infiltration,2+ leukemic cell infiltration,1+ hyperplasia:forestomach,1+ adenocarcinoma,'1' leukemic cell infiltration,2+ leukemic cell infiltration,1+ cystic degeneration:anterior lobe,1+ leukemic cell infiltration,1+ leukemic cell infiltration,2+ leukemic cell infiltration,2+ leukemic cell infiltration,1+ skin/app,nasopharynx,larynx,trachea,tongue,salivary gl,esophagus,large intes,gall bladd,pancreas,urin bladd,thyroid,parathyroid,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone tumor death:malignant lymphoma
2405	MORIBUND	12-1	lung thymus spleen uterus vagina NON-REMARKABLE Cause of Death	inflammatory infiltration,1+ atrophy,1+ extramedullary hematopoiesis,2+ atrophy,1+ atrophy:epithelium,1+ skin/app,nasal cavit,nasopharynx,larynx,trachea,bone marrow,lymph node,heart,tongue,salivary gl,esophagus,stomach,small intes,large intes,liver,gall bladd,pancreas,kidney,urin bladd,pituitary,thyroid,parathyroid,adrenal,ovary,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone no microscopical confirmation
2406	MORIBUND	10-2	nasal cavit lung bone marrow thymus spleen heart stomach liver kidney pleura NON-REMARKABLE Cause of Death	eosinophilic change:olfactory epithelium,1+ leukemic cell infiltration,2+ leukemic cell infiltration,1+ malignant lymphoma,'4' extramedullary hematopoiesis,2+ leukemic cell infiltration,1+ hyperplasia:forestomach,1+ leukemic cell infiltration,1+ leukemic cell infiltration,1+ leukemic cell infiltration,1+ skin/app,nasopharynx,larynx,trachea,lymph node,tongue,salivary gl,esophagus,small intes,large intes,gall bladd,pancreas,urin bladd,pituitary,thyroid,parathyroid,adrenal,ovary,uterus,vagina,mammary gl,brain,spinal cord,periph nerv,eye,Harder gl,muscle,bone tumor death:malignant lymphoma
2407	MORIBUND	19-6	lung bone marrow lymph node thymus spleen	leukemic cell infiltration,2+ leukemic cell infiltration,1+ leukemic cell infiltration,1+ malignant lymphoma,'4' extramedullary hematopoiesis,2+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
2407	MORIBUND	19-6	heart stomach liver ovary pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2408	MORIBUND	19-1	lung bone marrow lymph node thymus spleen heart stomach ovary pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ leukemic cell infiltration, 2+ hyperplasia:forestomach, 2+ atrophy, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2409	MORIBUND	14-1	thymus spleen heart small intes ovary pleura NON-REMARKABLE Cause of Death	malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ adenocarcinoma, '1' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2410	MORIBUND	16-6	lung lymph node thymus spleen heart stomach liver adrenal ovary uterus vagina pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 1+ hyperplasia:cortical cell, 1+, zona glomerulosa leukemic cell infiltration, 2+ atrophy, 1+ atrophy:epithelium, 1+, with, mucification:epithelium leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2411	DEAD	10-4	nasal cavit	leukemic cell infiltration, 1+

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
REPORT TYPE : A1  
SEX : FEMALE      GROUP NAME : Posi. Control

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
ALL ANIMALS (0- 27W)

Animal	Death Info.	Week-Day	Organ	Findings
2411	DEAD	10-4	lung bone marrow lymph node thymus spleen heart stomach liver kidney urin bladd pituitary adrenal ovary uterus vagina pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 3+//hemorrhage, 3+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasopharynx, larynx, trachea, tongue, salivary gl, esophagus, small intes, large intes, gall bladd, pancreas, thyroid, parathyroid, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2412	MORIBUND	16-4	nasal cavit lung bone marrow lymph node thymus spleen heart liver kidney ovary uterus vagina NON-REMARKABLE Cause of Death	leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ decreased hematopoiesis, 2+ leukemic cell infiltration, 2+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ leukemic cell infiltration, 2+ skin/app, nasopharynx, larynx, trachea, tongue, salivary gl, esophagus, stomach, small intes, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2413	MORIBUND	19-7	nasal cavit lung bone marrow thymus spleen heart ovary uterus vagina pleura NON-REMARKABLE Cause of Death	eosinophilic change:respiratory epithelium, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ atrophy, 1+ atrophy:epithelium, 1+ leukemic cell infiltration, 1+ skin/app, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
2414	MORIBUND	12-7	lung bone marrow thymus spleen heart small intes liver kidney ovary uterus vagina pleura NON-REMARKABLE	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ leukemic cell infiltration, 1+ adenocarcinoma, '1' leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ leukemic cell infiltration, 2+ atrophy, 1+ atrophy:epithelium, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, large intes, gall bladd, pancreas, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death:malignant lymphoma
2415	MORIBUND	14-7	lung bone marrow thymus spleen heart stomach adrenal ovary uterus pleura NON-REMARKABLE	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' deposit of melanin, 1+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ focal fatty change:cortex, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone Cause of Death tumor death:malignant lymphoma
2416	SCHEDULED	27-2	lung thymus spleen small intes ovary uterus vagina pleura NON-REMARKABLE	leukemic cell infiltration, 2+ malignant lymphoma, '0' extramedullary hematopoiesis, 2+ adenocarcinoma, '0' leukemic cell infiltration, 1+ atrophy, 1+ leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, bone marrow, lymph node, heart, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2417	MORIBUND	10-4	nasal cavit bone marrow thymus spleen small intes ovary NON-REMARKABLE	eosinophilic change:olfactory epithelium, 1+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ adenocarcinoma, '1' leukemic cell infiltration, 1+ skin/app, nasopharynx, larynx, trachea, lung, lymph node, heart, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (BI0290)

STUDY NO. : 0944  
 ANIMAL : B6.129S2-Trp53tm1Tyj/J  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS (INDIVIDUAL)  
 ALL ANIMALS (0- 27W)

GROUP NAME : Posi. Control

Animal	Death Info.	Week-Day	Organ	Findings
2417	MORIBUND	10-4	Cause of Death	tumor death:malignant lymphoma
2418	SCHEDULED	27-3	spleen stomach pituitary ovary uterus vagina NON-REMARKABLE	extramedullary hematopoiesis, 2+//thrombus, 1+ hyperplasia:forestomach, 1+ ectasia of sinus, 1+ lymphocytic infiltration, 1+ atrophy, 1+ atrophy:epithelium, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lung, bone marrow, lymph node, thymus, heart, tongue, salivary gl, esophagus, small intes, large intes, liver, gall bladd, pancreas, kidney, urin bladd, thyroid, parathyroid, adrenal, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone
2419	MORIBUND	15-2	subcutis lung bone marrow thymus spleen heart small intes ovary NON-REMARKABLE Cause of Death	epidermal cyst, 1+ leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 2+ leukemic cell infiltration, 2+ adenocarcinoma, '1' leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, stomach, large intes, liver, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, uterus, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma
2420	DEAD	17-3	lung bone marrow thymus spleen heart stomach small intes liver ovary uterus pleura NON-REMARKABLE Cause of Death	leukemic cell infiltration, 2+ leukemic cell infiltration, 1+ malignant lymphoma, '4' extramedullary hematopoiesis, 1+ leukemic cell infiltration, 1+ hyperplasia:forestomach, 1+ adenocarcinoma, '1' leukemic cell infiltration, 1+ leukemic cell infiltration, 1+ atrophy, 1+ leukemic cell infiltration, 1+ skin/app, nasal cavit, nasopharynx, larynx, trachea, lymph node, tongue, salivary gl, esophagus, large intes, gall bladd, pancreas, kidney, urin bladd, pituitary, thyroid, parathyroid, adrenal, vagina, mammary gl, brain, spinal cord, periph nerv, eye, Harder gl, muscle, bone tumor death:malignant lymphoma

( ) : Comment      1+ : Slight      2+ : Moderate      3+ : Marked      4+ : Severe      ' ' : Context  
 (B10290)

APPENDIX 14-1

CAUSE OF DEATH (INDIVIDUAL) : MALE

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
SEX : MALE      GROUP NAME :      100 ppm

COUSE OF DEATH (INDIVIDUAL)

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
1114	MORBUND	13-7	(1)	pneumonia

(BI0080)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

SEX : MALE

GROUP NAME : 300 ppm

COUSE OF DEATH (INDIVIDUAL)

PAGE : 2

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
1201	MORIBUND	18-2	(1)	no microscopical confirmation
1218	MORIBUND	22-1	(1)	integumentary system lesion
1222	MORIBUND	24-7	(1)	tumor death:malignant lymphoma

(B10080)

BAIS6



STUDY NO. : 0944

COUSE OF DEATH (INDIVIDUAL)

ANIMAL : B6.129S2-Trp53tm1Tyj/J

SEX : MALE GROUP NAME : 1000 ppm

PAGE : 3

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
1301	MORIBUND	22-7	(1)	tumor death:muscle
1302	MORIBUND	23-2	(1)	tumor death:malignant lymphoma
1303	MORIBUND	23-7	(1)	tumor death:malignant lymphoma
1304	MORIBUND	21-2	(1)	tumor death:malignant lymphoma
1305	DEAD	23-1	(1)	tumor death:malignant lymphoma
1306	MORIBUND	26-7	(1)	tumor death:malignant lymphoma
1307	MORIBUND	21-1	(1)	tumor death:malignant lymphoma
1309	MORIBUND	17-7	(1)	tumor death:thymus
1310	MORIBUND	24-1	(1)	tumor death:malignant lymphoma
1311	MORIBUND	21-7	(1)	tumor death:malignant lymphoma
1313	MORIBUND	21-3	(1)	tumor death:malignant lymphoma
1314	MORIBUND	26-5	(1)	tumor death:malignant lymphoma
1315	MORIBUND	24-7	(1)	tumor death:malignant lymphoma
1316	DEAD	23-3	(1)	tumor death:malignant lymphoma
1317	MORIBUND	26-3	(1)	tumor death:malignant lymphoma
1318	MORIBUND	17-7	(1)	tumor death:malignant lymphoma
1320	MORIBUND	24-7	(1)	tumor death:malignant lymphoma

(B10080)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

SEX : MALE

GROUP NAME : Posi. Control

COUSE OF DEATH (INDIVIDUAL)

PAGE : 4

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
1402	MORIBUND	21-5	(1)	tumor death:malignant lymphoma
1403	MORIBUND	14-6	(1)	tumor death:malignant lymphoma
1404	MORIBUND	21-1	(1)	tumor death:malignant lymphoma
1405	MORIBUND	14-4	(1)	tumor death:malignant lymphoma
1408	DEAD	15-7	(1)	tumor death:malignant lymphoma
1409	MORIBUND	16-7	(1)	tumor death:malignant lymphoma
1413	MORIBUND	19-7	(1)	tumor death:malignant lymphoma
1414	MORIBUND	23-2	(1)	tumor death:small intestine
1417	MORIBUND	21-5	(1)	tumor death:small intestine
1419	MORIBUND	20-3	(1)	tumor death:malignant lymphoma

(B10080)

BAIS6

**APPENDIX 14-2**

**CAUSE OF DEATH (INDIVIDUAL) : FEMALE**

STUDY NO. : 0944  
ANIMAL : B6.129S2-Trp53tm1Tyj/J  
SEX : FEMALE      GROUP NAME : Control

COUSE OF DEATH (INDIVIDUAL)

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
2008	MORIBUND	25-6	(1)	tumor death:malignant lymphoma
2012	MORIBUND	21-3	(1)	integumentary system lesion

(BI0080)

BAIS6

STUDY NO. : 0944

ANIMAL : B6.129S2-Trp53tm1Tyj/J

SEX : FEMALE

GROUP NAME :

100 ppm

COUSE OF DEATH (INDIVIDUAL)

PAGE : 6

---

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
2103	MORBUND	6-4	(1)	tumor death:malignant lymphoma

---

(BI0080)

BAIS6

STUDY NO. : 0944

COUSE OF DEATH (INDIVIDUAL)

ANIMAL : B6.129S2-Trp53tm1Tyj/J

SEX : FEMALE GROUP NAME : 1000 ppm

PAGE : 7

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
2301	MORIBUND	26-5	(1)	central nervous system lesion
2302	MORIBUND	26-5	(1)	tumor death:malignant lymphoma
2303	MORIBUND	1-7	(1)	no microscopical confirmation
2304	MORIBUND	25-1	(1)	tumor death:malignant lymphoma
2306	MORIBUND	25-4	(1)	tumor death:malignant lymphoma
2310	MORIBUND	18-7	(1)	tumor death:malignant lymphoma
2312	MORIBUND	23-6	(1)	tumor death:malignant lymphoma
2317	MORIBUND	26-1	(1)	tumor death:malignant lymphoma
2318	MORIBUND	23-4	(1)	tumor death:malignant lymphoma
2319	MORIBUND	26-3	(1)	tumor death:subcutis
2320	DEAD	13-7	(1)	tumor death:malignant lymphoma
2322	MORIBUND	24-2	(1)	tumor death:malignant lymphoma
2323	MORIBUND	26-2	(1)	tumor death:malignant lymphoma
2324	MORIBUND	22-1	(1)	tumor death:skin/appendage
2325	MORIBUND	24-2	(1)	tumor death:malignant lymphoma

(B10080)

BAIS6

STUDY NO. : 0944

COUSE OF DEATH (INDIVIDUAL)

ANIMAL : B6.129S2-Trp53tm1Tyj/J

SEX : FEMALE      GROUP NAME : Posi. Control

PAGE : 8

Animal ID-NO.	Death Information	Time of Examination (Week-Day)	Time of Sacrifice	Couse of Death
2401	DEAD	19-1	(1)	tumor death:malignant lymphoma
2402	MORIBUND	14-4	(1)	tumor death:malignant lymphoma
2403	MORIBUND	15-5	(1)	tumor death:malignant lymphoma
2404	MORIBUND	23-4	(1)	tumor death:malignant lymphoma
2405	MORIBUND	12-1	(1)	no microscopical confirmation
2406	MORIBUND	10-2	(1)	tumor death:malignant lymphoma
2407	MORIBUND	19-6	(1)	tumor death:malignant lymphoma
2408	MORIBUND	19-1	(1)	tumor death:malignant lymphoma
2409	MORIBUND	14-1	(1)	tumor death:malignant lymphoma
2410	MORIBUND	16-6	(1)	tumor death:malignant lymphoma
2411	DEAD	10-4	(1)	tumor death:malignant lymphoma
2412	MORIBUND	16-4	(1)	tumor death:malignant lymphoma
2413	MORIBUND	19-7	(1)	tumor death:malignant lymphoma
2414	MORIBUND	12-7	(1)	tumor death:malignant lymphoma
2415	MORIBUND	14-7	(1)	tumor death:malignant lymphoma
2417	MORIBUND	10-4	(1)	tumor death:malignant lymphoma
2419	MORIBUND	15-2	(1)	tumor death:malignant lymphoma
2420	DEAD	17-3	(1)	tumor death:malignant lymphoma

(BI0080)

BAIS6